[
    {
        "name": "Davis",
        "sentences": [
            "n engl j med 381;2 nejm.org July 11, 2019121The authors\u2122 full names, academic degrees, and affiliations are listed in the Appendix.",
            "Address reprint requests to Dr. Davis at Level 2, 5 Arnold St., Box Hill, VIC 3128, Australia, or at  ian .",
            "davis@  monash .",
            "edu.",
            "* A full list of the investigators in the ENZAMET Trial is provided in the Supple-mentary Appendix, available at NEJM.org.This article was published on June 2, 2019, and updated on June 11, 2019, at NEJM.org.N\u02dcEngl\u02dcJ\u02dcMed\u02dc2019;381:121-31.DOI:\u02dc10.1056/NEJMoa1903835Copyright \u00a9 2019 Massachusetts Medical Society.BACKGROUNDEnzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer.",
            "It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive pros-tate cancer.METHODSIn this open-label, randomized, phase 3 trial, we assigned patients to receive tes-tosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group).",
            "The primary end point was overall survival.",
            "Secondary end points included progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free survival, and adverse events.RESULTSA total of 1125 men underwent randomization; the median follow-up was 34 months.",
            "There were 102 deaths in the enzalutamide group and 143 deaths in the standard-care group (hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.86; P = 0.002).",
            "Kaplan\u0152Meier estimates of overall survival at 3 years were 80% (based on 94 events) in the enzalutamide group and 72% (based on 130 events) in the standard-care group.",
            "Better results with enzalutamide were also seen in PSA progression-free survival (174 and 333 events, respectively; hazard ratio, 0.39; P<0.001) and in clinical progression-free survival (167 and 320 events, respectively; hazard ratio, 0.40; P<0.001).",
            "Treat-ment discontinuation due to adverse events was more frequent in the enzalutamide group than in the standard-care group (33 events and 14 events, respectively).",
            "Fa-tigue was more common in the enzalutamide group; seizures occurred in 7 patients in the enzalutamide group (1%) and in no patients in the standard-care group.CONCLUSIONSEnzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression.",
            "The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetax-el.",
            "(Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; ClinicalTrials.gov num-ber, NCT02446405; and EU Clinical Trials Register number, 2014 - 003190 - 42.",
            ")ABSTRACTEnzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerI.D.",
            "Davis, A.J.",
            "Martin, M.R.",
            "Stockler, S. Begbie, K.N.",
            "Chi, S. Chowdhury, X. Coskinas, M. Frydenberg, W.E.",
            "Hague, L.G.",
            "Horvath, A.M. Joshua, N.J. Lawrence, G. Marx, J. McCaffrey, R. McDermott, M. McJannett, S.A. North, F. Parnis, W. Parulekar, D.W. Pook, M.N.",
            "Reaume, S.K.",
            "Sandhu, A. Tan, T.H.",
            "Tan, A. Thomson, E. Tu, F. Vera-Badillo, S.G. Williams, S. Yip, A.Y.",
            "Zhang, R.R.",
            "Zielinski, and C.J.",
            "Sweeney, for the ENZAMET Trial Investigators and the Australian  and New Zealand Urogenital and Prostate Cancer Trials Group*  Original Articlen engl j med 381;2 nejm.org July 11, 2019122The new england journal of medicineSeveral randomized trials have es-tablished the benefits of adding docetaxel or abiraterone to testosterone suppression in men with metastatic, hormone-sensitive pros-tate cancer.1-10 The survival benefits associated with docetaxel early in the course of treatment, particularly in men with high-volume metastatic disease,7 are substantially larger than the survival benefits associated with using docetaxel later af-ter castration resistance has developed.11-13 The addition of abiraterone to testosterone suppression also improved overall survival in hormone-sensi-tive prostate cancer, regardless of the burden of metastatic disease.9,10 A recent post hoc compari-son indicated that men who were given abiraterone or docetaxel early in the course of treatment had similar outcomes with respect to overall survival.14Enzalutamide is an orally administered, small-molecule inhibitor of the androgen receptor that is designed to overcome acquired resistance to first-generation nonsteroidal antiandrogens, in-cluding bicalutamide, nilutamide, and flutamide.",
            "Previous trials have shown that enzalutamide improved overall survival in castration-resistant prostate cancer, regardless of whether it was used before or after docetaxel chemotherapy.15,16We hypothesized that adding enzalutamide to first-line therapy would delay the emergence of castration resistance and thereby improve overall survival.",
            "In the ENZAMET (Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer) trial, our aim was to determine the effects of adding enzalutamide to first-line treatment that included testosterone suppression with or without early docetaxel.MethodsTrial DesignThe primary objective of this multinational, open-label, randomized, phase 3 trial was to determine the effects of early enzalutamide treatment on overall survival in men with metastatic, hormone-sensitive prostate cancer.",
            "Secondary objectives were to determine the effects on progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free sur-vival (based on imaging, symptoms, signs, or changes in therapy), and adverse events.",
            "Effects on health-related quality of life, resource use, and incremental cost-effectiveness will be reported separately.Patients and TreatmentEligible patients had prostatic adenocarcinoma with metastases on computed tomography (CT), bone scanning with technetium-99, or both and a score of 2 or less on the Eastern Cooperative Oncology Group (ECOG) performance-status scale, which ranges from 0 (no disability) to 5 (death).",
            "Testosterone suppression was initiated up to 12 weeks before randomization.",
            "Previous adjuvant testosterone suppression for up to 24 months was allowed if the treatment had been completed at least 12 months earlier.",
            "The trial protocol and Supplementary Appendix are available with the full text of this article at NEJM.org.Eligible patients were randomly assigned in a 1:1 ratio to receive enzalutamide (at a dose of 160 mg daily) or a standard nonsteroidal antian-drogen drug (bicalutamide, nilutamide, or flu-tamide) (standard-care group) until the occur-rence of clinical disease progression or prohibitive toxic effects.",
            "In the two groups, background ther-apy included continuous testosterone suppression.",
            "After the enrollment of 88 patients (mainly from Australia and New Zealand), the early adminis-tration of docetaxel with testosterone suppression was permitted in protocol version 2 (as revised on November 2014) as a stratification factor before randomization, according to evidence showing improved survival with this approach.1 The deci-sion to initiate early treatment with docetaxel was left up to the individual patients and their physi-cians.",
            "If docetaxel was administered, the regimen consisted of 75 mg per square meter of body-surface area, without prednisone or prednisolone, given every 3 weeks for a maximum of six cycles.",
            "Up to two cycles of docetaxel were permitted be-fore randomization.The central randomization system implement-ed minimization with a random component.",
            "Ran-domization was stratified according to the volume of disease (high [defined as the presence of vis-ceral metastases or at least four bone lesions with at least one lesion located beyond the vertebral bodies and pelvis] or low), planned use of early docetaxel (yes or no), planned use of bone anti-resorptive therapy (yes or no), the score on the Adult Comorbidity Evaluation 27 (ACE-27)17 (with n engl j med 381;2 nejm.org July 11, 2019123Enzalutamide with Standard Therapy in Prostate Cancercoexisting conditions rated as 0 [none] or 1 [mild] vs. 2 [moderate] or 3 [severe or multiple condi-tions]), and trial site.Trial OversightThe trial was led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney.",
            "Regional sponsorship and coordination was performed by Cancer Trials Ireland in Ireland and the United Kingdom, the Canadian Cancer Trials Group in Canada, and the Dana\u0152Farber Cancer Institute in the United States.",
            "The trial was designed by the ANZUP investigators.",
            "Data were collected and analyzed by the NHMRC Clinical Trials Centre.",
            "The authors were solely responsible for the writ-ing of the manuscript.Astellas Pharma provided enzalutamide and financial support for trial conduct; representa-tives of the company reviewed drafts of the pro-tocol and trial report but were not otherwise in-volved in any aspects of the trial design, data accrual, data analysis, or manuscript preparation.",
            "Testosterone suppression, standard antiandrogen drugs, docetaxel, and all subsequent treatments were accessed according to local standard prac-tice.",
            "The authors vouch for the accuracy and completeness of the reported data and for the fidelity of the trial to the protocol.An independent data and safety monitoring committee reviewed the progress and results of the trial.",
            "The trial was conducted in accordance with the principles of Good Clinical Practice guidelines and the Declaration of Helsinki.",
            "The protocol was independently reviewed and ap-proved as required at each participating institu-tion.",
            "All the patients provided written informed consent.End PointsThe primary end point of overall survival was measured as the interval from randomization to death from any cause or to the date at which the patient was last known to be alive.",
            "The second-ary end point of PSA progression-free survival was measured as the interval from randomiza-tion to the earliest event of PSA progression ac-cording to the criteria of the Prostate Cancer Working Group 2 (a confirmed relative increase in the PSA level from the nadir value by \u02dc25% and by \u02dc2 ng per milliliter),18 clinical progres-sion, death from any cause, or the last known date of follow-up without PSA progression.",
            "The secondary end point of clinical progression was defined as the earliest sign of radiographic pro-gression according to the criteria of the Prostate Cancer Working Group 2 for bone lesions and the Response Evaluation Criteria in Solid Tu-mors, version 1.1,19 for soft-tissue lesions; the development of symptoms attributable to cancer progression; or the initiation of another antican-cer treatment for prostate cancer.",
            "Imaging by means of CT and bone scanning was recom-mended to confirm clinical suspicion of pro-gressive disease.",
            "Imaging reports (but not the images themselves) were reviewed centrally.",
            "Ad-verse events were graded according to the Na-tional Cancer Institute Common Terminology Criteria for Adverse Events, version 4.02.",
            "Ad-verse-event data were collected during the treat-ment period, with a final safety assessment performed 30 to 42 days after the cessation of the trial regimen.Statistical AnalysisWe determined that the enrollment of 1100 pa-tients (with 470 deaths) would provide a power of at least 80% to detect a 25% lower hazard of death in the enzalutamide group than in the standard-care group (hazard ratio, 0.75), with a two-sided type I error rate of 0.05.",
            "In these cal-culations, we assumed a 3-year survival rate of 65% in the standard-care group on the basis of two previous studies of enzalutamide in men with metastatic, castration-resistant prostate cancer.15,16 Protocol versions 1 and 2 called for an interim analysis of overall survival after the occurrence of 67% of the prespecified 470 deaths with the use of the Lan\u0152DeMets alpha-spending function.",
            "Protocol version 3, which was written after external evidence became available for improved overall survival with early abiraterone treatment,8,9 added interim analyses of overall survival after the occurrence of 50% and 80% of the prespecified 470 deaths.",
            "The trial executive committee made these decisions without any knowledge of outcomes in each treatment group.n engl j med 381;2 nejm.org July 11, 2019124The new england journal of medicineEfficacy analyses were based on the inten-tion-to-treat principle and included all the pa-tients who had undergone randomization.",
            "The relevant follow-up times of patients who did not have an event were included in time-to-event analysis as censored observations.",
            "These analy-ses included patients who were lost to follow-up or who withdrew consent for continued follow-up after the date of consent withdrawal.",
            "Patients who had undergone randomization and received a dose of any trial drug were included in analy-ses of drug exposure and safety.We used the Kaplan\u0152Meier method to sum-marize time-to-event end points and to calculate event probabilities at 3 years.",
            "An unadjusted log-rank test was used for the primary comparison of randomly assigned trial groups.",
            "We used Cox proportional-hazards regression to estimate haz-ard ratios, their 95% confidence intervals, and interactions between group assignment and pre-specified baseline characteristics.",
            "The propor-tional-hazards assumption was tested.",
            "All P val-ues and confidence intervals are two-sided.We prespecified that consistency of the treat-ment effect would be evaluated across the fol-lowing subgroups: Gleason score (\u02da7 vs. 8 to 10); age at trial entry (<70 years or \u02dc70 years); ECOG performance status score (0 vs. 1 or 2); the pres-ence or absence of visceral metastases in the lung, liver, or other organs; volume of disease (high or low); planned use or nonuse of early docetaxel treatment; planned use or nonuse of bone anti-resorptive therapy; the ACE-27 comorbidity score (0 or 1 vs. 2 or 3); prior local treatment (radiation, surgery, or neither); and geographic region (Aus-tralia or New Zealand vs. North America vs. Ire-land or United Kingdom).",
            "We prespecified that the effects of enzalutamide according to the volume of disease and the use of early docetaxel treatment were of particular interest.",
            "We used the Benjamini\u0152Hochberg method to account for multiple comparisons associated with subgroup analyses.ResultsPatientsFrom March 2014 through March 2017, we as-signed 1125 men to receive either enzalutamide (563 patients) or standard care (562 patients) at 83 sites (Fig.",
            "S1 and Table S1 in the Supplemen-tary Appendix).",
            "A total of 14 patients \u0160 2 who were lost to follow-up and 12 who withdrew con-sent for continued follow-up \u0160 were included in the time-to-event analyses with censored times as appropriate.CharacteristicEnzalutamide\u02dc(N\u02dc=\u02dc563)Standard\u02dcCare\u02dc(N\u02dc=\u02dc562)Age \u0160 yrMean68.9\u00b18.168.8\u00b18.3Median (IQR)69.2 (63.2\u015274.5)69.0 (63.6\u015274.5)Region \u0160 no.",
            "(%)Australia324 (58)321 (57)Canada97 (17)107 (19)Ireland39 (7)43 (8)New Zealand20 (4)19 (3)United Kingdom63 (11)50 (9)United States20 (4)22 (4)Planned use of early docetaxel  \u0160 no.",
            "(%)254 (45)249 (44)Volume of disease \u0160 no.",
            "(%)High291 (52)297 (53)Low272 (48)265 (47)Visceral metastases \u0160 no.",
            "(%)62 (11)67 (12)No.",
            "of months since diagnosis  of metastasisMean2.9\u00b16.93.1\u00b17.2Median (IQR)1.9 (0.9\u01522.8)1.9 (1.0\u01522.8)Gleason score \u0160 no.",
            "(%)\u0192\u02dc7152 (27)163 (29)8\u015210335 (60)321 (57)Missing data76 (13)78 (14)Previous therapy \u0160 no.",
            "(%)Adjuvant androgen-deprivation therapy58 (10)40 (7)Antiandrogen therapy\u2044285 (51)316 (56)LHRHA\u2044411 (73)418 (74)Bilateral orchiectomy5 (1)8 (1)Docetaxel\u204495 (17)83 (15)*  Plus\u0152minus values are means \u00b1SD.",
            "Patients in the standard-care group re-ceived standard nonsteroidal antiandrogen therapy.",
            "Patients in the two groups also received testosterone suppression.",
            "Additional details are provided in Table S2 in the Supplementary Appendix.",
            "Percentages may not total 100 be-cause of rounding.",
            "IQR denotes interquartile range, and LHRHA luteinizing-hormone\u0152releasing hormone agonist or antagonist.\u0192  Gleason scores for the histologic pattern of carcinoma range from 2 to 10, with higher scores indicating a higher-grade tumor.\u2044  This therapy was initiated within 12 weeks before randomization.Table\u02dc1.\u02dcCharacteristics\u02dcof\u02dcthe\u02dcPatients\u02dcat\u02dcBaseline.",
            "*n engl j med 381;2 nejm.org July 11, 2019125Enzalutamide with Standard Therapy in Prostate CancerThe baseline characteristics of all the patients are summarized in Table 1 and detailed in the Supplementary Appendix.",
            "High-volume disease was present in 52% of the patients in the two groups.",
            "Early docetaxel treatment was planned in 45% of the patients (including in 61% of those with high-volume disease and in 27% of those with low-volume disease) but was not adminis-tered to 22 patients, 11 in each of the randomly assigned treatment groups.",
            "The full planned course of six cycles of docetaxel was given to 159 of 243 patients (65%) in the enzalutamide group and 181 of 238 (76%) in the standard-care group.Overall SurvivalThe first interim analysis of the primary end point occurred on February 28, 2019, after the occurrence of 235 deaths.",
            "On March 7, 2019, the independent data and safety monitoring com-mittee recommended that the unblinded results be provided to the trial executive committee so that plans for definitive analyses could be imple-mented.",
            "The observed P value of 0.0016 met the rejection boundary of 0.0031 for the null hypoth-esis that was specified for this interim analysis.",
            "The results that are reported here include 10 additional deaths (for a total of 245) after a re-view to ascertain the survival status of all the patients as of February 28, 2019, after a median follow-up of 34 months.At the time of this analysis, there were 102 deaths in the enzalutamide group and 143 deaths in the standard-care group (hazard ratio for death, 0.67; 95% confidence interval [CI], 0.52 to 0.86; P = 0.002) (Fig.",
            "1A).",
            "The results were unaf-fected by adjustments for geographical region, volume of disease, use of early docetaxel treat-ment, bone antiresorptive therapy, and coexisting conditions.",
            "The median survival time was not yet estimable in either trial group.",
            "The Kaplan\u0152Meier estimates of overall survival at 3 years were 80% (based on 94 events) in the enzalutamide group and 72% (based on 130 events) in the standard-care group.Progression-free SurvivalThe effects of enzalutamide on PSA progression-free survival and clinical progression-free survival were larger than its effect on overall survival.",
            "For PSA progression-free survival, there were 174 events in the enzalutamide group and 333 events in the standard-care group (rate of event-free survival at 3 years, 67% and 37% respectively; hazard ratio, 0.39; 95% CI, 0.33 to 0.47; P<0.001) (Fig.",
            "1B).",
            "For clinical progression-free survival, there were 167 events in the enzalutamide group and 320 events in the standard-care group (rate of event-free survival at 3 years, 68% and 41%, respectively; hazard ratio, 0.40; 95% CI, 0.33 to 0.49; P<0.001) (Fig.",
            "1C).",
            "P values for analyses of the between-group difference in PSA progres-sion-free survival and clinical progression-free survival remained highly significant after adjust-ment for multiple comparisons.Subgroup AnalysesThe effects of enzalutamide on overall survival were smaller among the patients in the stratified subgroups with respect to bone antiresorptive therapy, planned early docetaxel treatment, and high-volume disease (Fig.",
            "2, and Table S3 in the Supplementary Appendix).",
            "After adjustment for multiple comparisons, P values for heterogeneity of the treatment effect of enzalutamide were 0.14 for volume of disease, 0.14 for early docetax-el treatment, and 0.06 for the use of bone anti-resorptive therapy.We anticipated that the smaller number of deaths would limit the reliability of subgroup analyses of overall survival.",
            "Thus, we specified in the analysis plan that subgroup analyses of progression-free survival would also be per-formed to take advantage of the larger number of events for this secondary end point.",
            "The ef-fects of enzalutamide on clinical progression-free survival were noted in all predefined sub-groups, including those with early docetaxel treatment (Fig.",
            "3, and Fig.",
            "S2 in the Supplemen-tary Appendix).",
            "The analyses of treatment effects on clinical progression-free survival according to the volume of disease and planned early docetax-el treatment showed consistently smaller effects of enzalutamide in patients with high-volume disease and in those with early docetaxel treat-ment.",
            "However, P values for heterogeneity of the treatment effect of enzalutamide were no longer significant after adjustment for multiple com-parisons (Figs.",
            "S2, S3, and S4 in the Supplemen-tary Appendix).Subsequent Anticancer TherapiesTreatment after progression was initiated at the discretion of the patients and their physicians.",
            "The number of patients who received anticancer n engl j med 381;2 nejm.org July 11, 2019126The new england journal of medicinetherapies after the trial regimen was 113 in the enzalutamide group and 275 in the standard-care group, a finding that was commensurate with the higher incidence of clinical progression in the standard-care group.",
            "Among the patients who had clinical progression, 112 of 167 (67%) in the enzalutamide group and 271 of 320 (85%) in the standard-care group received one or more subsequent life-prolonging therapies (Table S4 in the Supplementary Appendix).Treatment DurationAt 3 years, the percentage of patients who were still receiving a trial regimen was 62% in the enzalutamide group and 34% in the standard-care group (Table S5 in the Supplementary Appen-dix).",
            "Disease progression or death was the rea-son for discontinuation in 133 of 201 patients (66%) in the enzalutamide group and in 251 of 356 (71%) in the standard-care group who discon-tinued treatment.",
            "Discontinuation for reasons other than disease progression occurred in 68 of 563 patients (12%) and 105 of 558 patients (19%) in the respective groups.",
            "Early docetaxel treat-ment was administered in 227 of 487 patients (47%) who subsequently had clinical progression and in 91 of 203 (45%) who died from prostate cancer.",
            "Of the patients who died from prostate cancer without receiving subsequent therapy, ear-ly docetaxel treatment was administered in 13 of 28 (46%) in the enzalutamide group and in 3 of 13 (23%) in the standard-care group.Adverse EventsAdverse events during the follow-up period were consistent with the stage of disease, the age of the patients, and known safety profiles of the trial regimen (Table 2; and Tables S6, S7, and S8 in the Supplementary Appendix).",
            "During the first 6 months, adverse events of grades 1 to 3 were reported by more patients in the enzalutamide group than in the standard-care group (Table S8 in the Supplementary Appendix).The number of patients with febrile neutro-penia was similar in the two treatment groups (37 with enzalutamide and 32 with standard care), and all but 2 of these events (67 of 69) occurred during early docetaxel treatment.",
            "Seizures oc-curred more frequently in patients in the enzalu-tamide group (7 vs. 0).",
            "Six patients discontinued enzalutamide because of seizure; 1 discontinued enzalutamide because of clinical progression be-fore the seizure event.",
            "Fatigue of any grade was Figure\u02dc1.\u02dcOverall\u02dcSurvival,\u02dcPSA\u02dcProgression-free\u02dcSurvival,\u02dcand\u02dcClinical\u02dc\u02dcProgression-free\u02dcSurvival.Among the patients who received enzalutamide and those who received standard nonsteroidal antiandrogen therapy (standard-care group), shown are Kaplan\u0152Meier curves for overall survival (Panel A), progression-free survival as determined by the prostate-specific antigen (PSA) level (Panel B), and clinical progression-free survival as determined by results on imaging, symptoms, signs, or changes in therapy (Panel C).\u02dc\u02da\u02da\u02db\u02dd\u02d9\u02dd\u02dd\u02da\u02da\u02da\u02c6\u02dc\u02d9\u02dc\u02c7\u02d9\u02d8\u02d8\u02c7\u02d8\u02dd\u02c6\u02d9\u02dd\u02dd\u02c7\u02dd\u02dd\u02dc\u02dd\u02d8\u02dc\u02dd\u02d9\u02db\u02dd\u02da\u02dc\u02d8\u02c7\u02da\u02d8\u02dd\u02d9\u02dc\u02db\u02d8\u02d8\u02dd\u02d8\u02d9\u02dc\u02da\u02c6\u02c7\u02c6\u02dc\u02da\u02da\u02db\u02dd\u02d9\u02dd\u02dd\u02da\u02da\u02da\u02c6\u02dc\u02d9\u02dc\u02c7\u02d9\u02d8\u02d8\u02c7\u02dd\u02c6\u02d9\u02d8\u02c7\u02c6\u02dd\u02da\u02da\u02d8\u02dd\u02dd\u02d8\u02dc\u02dc\u02dc\u02d8\u02c6\u02db\u02c7\u02dc\u02c6\u02dc\u02dc\u02db\u02d8\u02d9\u02db\u02db\u02d8\u02d8\u02dc\u02da\u02da\u02db\u02dd\u02d9\u02dd\u02dd\u02da\u02da\u02da\u02c6\u02dc\u02d9\u02dc\u02c7\u02d9\u02d8\u02d8\u02c7\u02dd\u02c6\u02d9\u02dd\u02d8\u02db\u02dd\u02dc\u02d9\u02dd\u02da\u02db\u02d8\u02dc\u02c7\u02d8\u02c6\u02c7\u02d8\u02d9\u02d8\u02d9\u02db\u02d9\u02dc\u02dd\u02c6\u02d9\u02c7\u02d8\u02dc\u02c7\u02d9\u02dc\u02db\u02d8\u02d9\u02c7\u02d8\u02dd\u02dan engl j med 381;2 nejm.org July 11, 2019127Enzalutamide with Standard Therapy in Prostate Cancermore common with enzalutamide than with stan-dard care (465 patients and 363 patients, respec-tively).",
            "Grade 2 (clinically significant) fatigue was reported in 142 patients (25%) in the enzalutamide group and in 80 (14%) in the standard-care group.Adverse events that occurred during the first 6 months among the patients who received early docetaxel treatment are shown in Table S8 in the Supplementary Appendix.",
            "Among those who re-ceived early docetaxel treatment, grade 2 periph-eral sensory neuropathy was reported in 24 of 254 patients (9%) in the enzalutamide group and in 7 of 246 (3%) in the standard-care group.",
            "Among those who did not receive early docetax-el treatment, grade 2 peripheral neuropathy was reported in none of 309 patients in the enzalu-tamide group and in 2 of 312 (1%) in the stan-dard-care group; grade 3 peripheral sensory neu-ropathy with docetaxel occurred in 3 patients in the enzalutamide group and in 1 in the stan-dard-care group.There were 385 serious adverse events reported in 235 patients in the enzalutamide group and 297 in 189 patients in the standard-care group.",
            "Figure\u02dc2.\u02dcSubgroup\u02dcAnalysis\u02dcof\u02dcOverall\u02dcSurvival.Shown are the results of subgroup analysis of overall survival in 10 key subgroups of patients in the enzalutamide group and the standard-care group.",
            "Hazard ratios and 95% confidence intervals are provided.",
            "The size of the gray shaded boxes is proportional to the number of events in the subgroup.",
            "The dashed vertical line indicates the overall hazard ratio in all the patients.",
            "Scores on the Eastern Coopera-tive Oncology Group (ECOG) performance-status scale range from 0 (no disability) to 5 (death).",
            "Scores on the Adult Comorbidity Evalu-ation 27 (ACE-27) are 0 (none) or 1 (mild) vs. 2 (moderate) or 3 (severe).\u02dc\u02da\u02db\u02dd\u02da\u02dc\u02d9\u02da\u02dc\u0192\u2019\u02dc\u02dc\u02da\u02db\u2019\u02d8\u201e\u02dc\u02da\u201d\u02d9\u201a\u02dc\u02da\u2044\u02db\u2122\u02dc\u02da\u2019\u02d9\u02d8\u201e\u02dc\u02da\ufb01\u2019\u201a\u02dd\u02da\u02dc\ufb02\u2122\u02dc\u02da\u02db\u201d\u02d8\u201e\u02dc\u02da\ufb01\u2019\u201a\u02dc\u02da\u2044\ufb02\u2122\u02dc\u02da\u02db\u02d9\u02d8\u201e\u02dc\u02da\ufb01\u2019\u201a\u02dc\u02da\u2044\u02d9\u2122\u02dd\u02da\u02dc\u201d\u02d8\u201e\u02dc\u02da\u201d\ufb01\u201a\u02d9\u02da\u02dc\u02d9\u2122\u02dc\u02da\u02db\u02db\u02d8\u201e\u02dc\u02da\ufb01\u2019\u201a\u02dc\u02da\ufb02\u02d9\u2122\u02dc\u02da\u201d\u02db\u02d8\u201e\u02dc\u02da\u0161\ufb02\u201a\u02dc\u02da\u2044\u02dd\u2122\u02dc\u02da\u2044\u02dd\u02d8\u201e\u02dc\u02da\u201d\u02db\u201a\u02dd\u02da\u02dd\u201d\u2122\u02dc\u02da\u2019\u02dc\u02d8\u201e\u02dc\u02da\u201d\u02dc\u201a\u02dc\u02da\ufb02\u02db\u2122\u02dc\u02da\u201d\ufb02\u02d8\u201e\u02dc\u02da\u0161\u02dc\u201a\u02dd\u02da\u02dd\u02db\u2122\u02dc\u02da\u02db\u02db\u02d8\u201e\u02dc\u02da\ufb01\u201d\u201a\u02dc\u02da\ufb02\u2044\u2122\u02dc\u02da\u2019\u02d9\u02d8\u201e\u02dc\u02da\ufb01\u02dd\u201a\u02dd\u02da\u02d9\u201d\u2122\u02dd\u02da\u02dc\ufb01\u02d8\u201e\u02dc\u02da\u201d\u2019\u201a\u02dd\u02da\u2044\u2044\u2122\u02dc\u02da\u201d\ufb02\u02d8\u201e\u02dc\u02da\ufb01\u201d\u201a\u02dc\u02da\u2019\u2019\u2122\u02dc\u02da\u201d\u2044\u02d8\u201e\u02dc\u02da\ufb01\u02d9\u201a\u02dc\u02da\u2044\u02dd\u2122\u02dd\u02da\u2019\u2019\u02d8\u201e\u02dc\u02da\u2044\u0161\u201a\u0161\u02da\u2019\u2019\u2122\u02dc\u02da\u2019\u0161\u02d8\u201e\u02dc\u02da\ufb01\u02db\u201a\u02dd\u02da\u02dd\u02db\u2122\u02dc\u02da\u02db\u201d\u02d8\u201e\u02dc\u02da\ufb01\u2044\u201a\u02dc\u02da\u2044\u2044\u2122\u02dc\u02da\u201d\u0161\u02d8\u201e\u02dc\u02da\u0161\u2019\u201a\u02dc\u02da\u2019\u201d\u2122\u02dc\u02da\ufb02\u02dc\u02d8\u201e\u02dc\u02da\u02db\u02d9\u201a\u02dd\u02da\u0161\u02dd\u2122\u02dc\u02da\ufb01\u0161\u02d8\u201e\u02dc\u02da\u02d9\u02db\u201a\u02dc\u02da\u2019\u02d9\u2122\u02dc\u02da\u02d9\u02dc\u02da\u2044\u02dc\u02d8\u201e\u02dc\u02da\u201d\ufb02\u201a\u02dd\u02da\u02dc\u2019\u2122\u02dd\ufb01\u0161\u0141\u201d\u02db\u02d9\u02d8\u02d8\u02d8\u02d8\ufb01\u02db\u0141\u02d9\u02db\u201d\u02d8\u02d8\ufb02\u2019\u0141\u02d9\ufb02\u2019\u02d8\u02d8\u201d\u201d\u0141\u02d9\ufb01\ufb02\u02d8\u02d8\u2044\u2044\u0141\u0161\u02dd\u0161\u02d8\u02d8\ufb01\u02d9\u0141\u02dd\ufb01\u0161\u02dd\u02dc\u02dd\u0141\ufb01\u02dd\ufb02\u02dd\u02dd\u0141\u201d\u2044\u02dd\u0161\u02d9\u0141\u201d\u02dc\ufb01\u02d9\u02d9\u0141\ufb02\u0161\u02d8\u02d8\u0161\u02dd\u0141\u02dd\u02d9\ufb02\u02d8\u02d8\ufb02\u02dc\u0141\u0161\ufb01\u02dc\u02d8\u02d8\u02d9\u0161\u0141\u02dd\u02db\u0161\u02d8\u02d8\u2044\ufb01\u0141\u0161\u02d9\u02dd\u02d8\u02d8\u201d\ufb02\u0141\u02dd\u201d\u2019\u02d8\u02d8\u2044\ufb01\u0141\ufb01\u02dc\u201d\u02d8\u02d8\u2019\ufb02\u0141\u02d9\u201d\u2019\u02d8\u02d8\u02db\ufb01\u0141\u0161\u02dc\u201d\u02dd\u2044\u0141\u02db\u2019\u02dd\u02d9\u201d\u0141\ufb01\ufb02\u201d\u02d8\u02d8\ufb01\ufb02\u0141\u02d9\u0161\u201d\u02d8\u02d8\ufb02\ufb01\u0141\u0161\u02d9\u2019\u02dd\u02dc\u02d9\u0141\u201d\u02db\u0161\u02d8\u02d8\u02d9\u02d9\u0141\u02d9\u2019\u02d9\u02d8\u02d8\u2044\u02dc\u0141\u02d9\ufb02\u02dd\u02d8\u02d8\u201d\u02d9\u0141\u02d9\u201d\ufb01\u02d8\u02d8\u201d\u02dc\u0141\u0161\u02dc\ufb02\u02d8\u02d8\u0161\u02dd\u0141\u02dd\ufb01\u02dd\u02d8\u02d8\u2019\u02dd\u0141\ufb01\u02d9\u02d9\u02dd\u2019\u0141\u201d\u201d\u02d8\u02d8\u2044\u201d\u0141\u201d\u02dc\u2044\u02d8\u02d8\u02d9\u02d9\u0141\u02dd\u02dc\u02d9\u02d8\u02d8\u02d9\u02dd\u0141\u02dd\u02dd\u2019\u02d8\u02d8\u201d\ufb02\u0141\u0161\ufb01\ufb01\u02d8\u02d8\u02dd\u0161\u0141\u02dd\u201d\u02d9\u02d8\u02d8\u02db\u02db\u0141\u0161\u0161\u201d\u02d8\u02d8\ufb01\ufb01\u0141\u02dd\u201d\u2044\u02d8\u02d8\u201d\u2044\u0141\ufb01\u02dc\u201d\u02d8\u02d8\ufb01\u2019\u0141\u02d9\u201d\u2019\u02d8\u02d8\u201d\u201d\u0141\u0161\u02dc\u02db\u02dd\u2044\u0141\u02db\u02d9\u02d8\u02d8\u2044\ufb01\u0141\u201d\u02dc\u02dd\u02d8\u02d8\u0161\ufb02\u0141\u02d9\u0161\u2044\u02d8\u02d8\u02db\u0161\u0141\u0161\u02d9\u201d\u02dc\u02da\u02dc\ufb01\u02dc\u02da\u02dc\ufb01\u02dc\u02da\u2019\u0161\u02dc\u02da\u02dc\u02dc\u02db\u02dc\u02da\u02d9\u201d\u02dc\u02da\u02db\u02db\u02dc\u02da\ufb02\u02db\u02dc\u02da\u02dd\u02db\u02dc\u02da\u02dd\u02db\u02dc\u02da\u2019\u02d9\u02dc\u02da\u02dd\ufb01\u02dc\u02da\u02dd\ufb01\u02dc\u02da\u2044\u02dd\u02dc\u02da\u02dc\u02db\u02dc\u02da\ufb01\u02d9\u02dc\u02da\u2044\u02dd\u02dc\u02da\ufb02\u02db\u02dc\u02da\u0161\u0161\u02dc\u02da\u0161\u0161\u02dc\u02da\u2044\u02ddn engl j med 381;2 nejm.org July 11, 2019128The new england journal of medicineThe larger number of serious adverse events as-sociated with enzalutamide was commensurate with the longer duration of trial treatment.",
            "The frequency of serious adverse events per person-year of exposure to a trial regimen was similar in the two groups (Table 2).DiscussionEnzalutamide was associated with longer overall survival and progression-free survival than stan-dard care with nonsteroidal antiandrogen therapy in men with metastatic, hormone-sensitive pros-tate cancer.",
            "All the patients received testosterone suppression, plus the addition of docetaxel when appropriate.",
            "The control group in this trial was treated with standard antiandrogen therapy to provide a stringent comparator.",
            "All the patients had access to further effective therapies if the cancer progressed, and a high proportion of the patients in the standard-care group received enzalutamide or abiraterone after disease pro-gression.",
            "The frequency of early docetaxel treat-ment was similar in the two groups.",
            "Thus, the Figure\u02dc3.\u02dcSubgroup\u02dcAnalysis\u02dcof\u02dcClinical\u02dcProgression-free\u02dcSurvival.Shown are the results of subgroup analysis of clinical progression-free survival in 10 key subgroups of patients in the enzalutamide group and standard-care group.",
            "Clinical progression-free survival was determined by results on imaging, symptoms, signs, or changes in therapy.\u02dc\u02da\u02db\u02dd\u02da\u02dc\u02d9\u02da\u02dc\u0192\u2019\u02dc\u02dc\u02da\u02d9\u02dd\u02dd\u2044\u201e\u02d9\u02db\u201d\u02dd\u2019\u201a\u201e\u0161\u02dd\u0161\u02dd\u201d\u2122\u201e\u02d9\u201d\u2019\u02d8\u02d8\u02db\u2019\u201e\u02dd\u02db\u0161\u02dd\u2122\u2019\u201e\u0161\u201a\u02dc\u02dd\u02db\u02dd\u201e\u0161\u02dc\u201d\u02d9\u02dd\u201a\u201e\u201a\u02dc\u201d\u02dd\u02dc\u02db\u201e\u02dd\u201d\u2019\u02dd\u201a\u02db\u201e\u02d9\u201a\u2122\u02d9\u0161\u02d9\u201e\u201a\u02dd\u2122\u0161\u201d\u201e\u201d\u2044\u02d9\u2044\u201d\u201e\u201d\u02dc\u201a\u201a\u2044\u201e\u2122\u0161\u02dd\u2122\u02dc\u201e\u0161\u02d9\u02dd\u201a\u02dd\u201e\u02db\u2019\u02d9\u2019\u2122\u201e\u201a\u2122\u201d\u0161\u02d9\u02dc\u201e\u201d\u02db\u02d9\u02dd\u02d9\u02dc\u201e\u02d9\u0161\u201d\u02d8\u02d8\u2019\u201d\u201e\u02dd\u02d9\u2122\u02d9\u02dc\u02d9\u201e\u02d9\u2122\u2019\u02d8\u02d8\u2044\u2044\u201e\u02dd\u201a\u0161\u02d8\u02d8\u201a\u02db\u201e\u02d9\u2019\u02d9\u02d8\u02d8\u2019\u02db\u201e\u0161\u02dc\u2122\u2019\u02dd\u201e\u02d9\u201d\u2019\u02d8\u02d8\u02d9\u201a\u201e\u02dd\u201d\u02d9\u02d8\u02d8\u2122\u2044\u201e\u0161\u201a\u201a\u02d8\u02d8\u2122\u02db\u201e\u0161\u02dc\u02db\u02dd\u02dc\u0161\u201e\u201a\u02dc\u201d\u02d8\u02d8\u02db\u201a\u201e\u02dd\u201d\u2044\u02d8\u02d8\u2122\u02dd\u201e\u02d9\u201d\u201a\u02dd\u02d9\u0161\u201e\u201a\u02d9\u02d9\u02d9\u02d9\u201e\u201d\u201d\u02dd\u201a\u201d\u201e\u201d\u02dc\u2044\u02d8\u02d8\u0161\u02db\u201e\u02dd\u02dc\u02d9\u02dd\u02dd\u02dc\u201e\u0161\u0161\u201d\u02d9\u02db\u201e\u02db\u02d9\u02dd\u201a\u02dd\u201e\u201d\u02dc\u02dd\u02dd\u02db\u2019\u201e\u201d\u02db\u0161\u02d8\u02d8\u02db\u201a\u201e\u02d9\u0161\u2044\u02d8\u02d8\u0161\u0161\u201e\u02dd\u02dd\u2019\u02dd\u02d9\u02dd\u201e\u02d9\u2122\u02dd\u02d8\u02d8\u201a\u201a\u201e\u02dd\u201a\u02dd\u02dc\u02da\u0161\u0161\u02d8\ufb01\u02dc\u02da\u02d9\u201d\ufb02\u02dc\u02da\u201a\u201a\u0141\u02dc\u02da\u0161\u2044\u02d8\ufb01\u02dc\u02da\u0161\u02dc\ufb02\u02dc\u02da\u201a\u2044\u0141\u02dc\u02da\u201a\u02dd\u02d8\ufb01\u02dc\u02da\u0161\u0161\ufb02\u02dc\u02da\u201d\u02dd\u0141\u02dc\u02da\u201d\u2019\u02d8\ufb01\u02dc\u02da\u0161\u201a\ufb02\u02dc\u02da\u2122\u2044\u0141\u02dc\u02da\u201d\u2122\u02d8\ufb01\u02dc\u02da\u0161\u2044\ufb02\u02dc\u02da\u2122\u02dd\u0141\u02dc\u02da\u201d\u2044\u02d8\ufb01\u02dc\u02da\u0161\u201d\ufb02\u02dc\u02da\u2122\u201d\u0141\u02dc\u02da\u201a\u02d9\u02d8\ufb01\u02dc\u02da\u0161\u02dd\ufb02\u02dc\u02da\u201d\u2019\u0141\u02dc\u02da\u0161\u02db\u02d8\ufb01\u02dc\u02da\u02d9\u201a\ufb02\u02dc\u02da\u201d\u201d\u0141\u02dc\u02da\u201a\u02dc\u02d8\ufb01\u02dc\u02da\u02d9\u2044\ufb02\u02dc\u02da\u201d\u2019\u0141\u02dc\u02da\u02dc\u201d\u02dc\u02da\u02dd\u2044\u02dc\u02da\u02dc\u02db\u02dc\u02da\u201d\u02db\u02dc\u02da\u2044\u2044\u02dc\u02da\u02dd\u2122\u02dc\u02da\u0161\u02db\u02dc\u02da\u02dd\u0161\u02dc\u02da\u02dc\u2019\u02dc\u02da\u0161\u02dc\u02d8\ufb01\u02dc\u02da\u02d9\u02d9\ufb02\u02dc\u02da\u201a\u0161\u0141\u02dc\u02da\u0161\u201a\u02d8\ufb01\u02dc\u02da\u02d9\u02db\ufb02\u02dc\u02da\u201a\u201a\u0141\u02dc\u02da\u0161\u0161\u02d8\ufb01\u02dc\u02da\u02d9\u02dd\ufb02\u02dc\u02da\u201d\u0161\u0141\u02dc\u02da\u0161\u2019\u02d8\ufb01\u02dc\u02da\u02d9\u2122\ufb02\u02dc\u02da\u201a\u2044\u0141\u02dc\u02da\u201a\u2019\u02d8\ufb01\u02dc\u02da\u0161\u2019\ufb02\u02dc\u02da\u02db\u02dd\u0141\u02dc\u02da\u201a\u201a\u02d8\ufb01\u02dc\u02da\u0161\u02d9\ufb02\u02dc\u02da\u02db\u02dc\u0141\u02dc\u02da\u201a\u2044\u02d8\ufb01\u02dc\u02da\u0161\u2019\ufb02\u02dc\u02da\u02db\u02d9\u0141\u02dc\u02da\u0161\u2122\u02d8\ufb01\u02dc\u02da\u0161\u02d9\ufb02\u02dc\u02da\u201a\u2019\u0141\u02dc\u02da\u201a\u02d9\u02d8\ufb01\u02dc\u02da\u0161\u0161\ufb02\u02dc\u02da\u201d\u0161\u0141\u02dc\u02da\u0161\u2044\u02d8\ufb01\u02dc\u02da\u0161\u02dd\ufb02\u02dc\u02da\u201a\u2019\u0141\u02dc\u02da\u201a\u02dc\u02d8\ufb01\u02dc\u02da\u0161\u0161\ufb02\u02dc\u02da\u201a\u2122\u0141\u02dc\u02da\u201a\u201d\u02d8\ufb01\u02dc\u02da\u0161\u02db\ufb02\u02dc\u02da\u201d\u2019\u0141\u02d9\u02dc\u02dc\u201e\u0161\u02d9\u2019\u02dd\u02dc\u0161\u201e\u0161\u02d9\u201d\u02dc\u02da\u2019\u2019\u02dc\u02da\u02d9\u0161\u02dc\u02da\u0161\u02dd\u02dc\u02da\u02d9\u0161\u02dc\u02da\u2019\u02dd\u02dc\u02da\u2044\u2044\u02dc\u02da\u0161\u02dd\u02dc\u02da\u201d\u02dd\u02dc\u02da\u0161\u02dd\u02dc\u02da\u02d9\u0161\u02dc\u02da\u2044\u02db\u02dc\u02da\u0161\u2122\u02d8\ufb01\u02dc\u02da\u0161\u02dd\ufb02\u02dc\u02da\u201d\u02dc\u0141n engl j med 381;2 nejm.org July 11, 2019129Enzalutamide with Standard Therapy in Prostate Cancerobserved benefits of early enzalutamide therapy are not explained by differences in access to or use of subsequent therapies.We found that adding early enzalutamide to testosterone suppression was associated with a higher frequency of toxic effects, especially periph-eral neuropathy associated with the concomitant use of docetaxel.",
            "Patients who were treated with enzalutamide reported more fatigue and more often discontinued therapy before disease progres-sion.",
            "Seven patients (1%) in this group had seizures, a known potential side effect of enzalutamide.Adverse\u02dcEventEnzalutamide\u02dc(N\u02dc=\u02dc563)Standard\u02dcCare\u02dc(N\u02dc=\u02dc558)Any adverse event \u0160 no.",
            "of patients (%)*Grade 140 (7)77 (14)Grade 2202 (36)230 (41)Grade 3277 (49)194 (35)Grade 438 (7)40 (7)Grade 56 (1)7 (1)Serious adverse eventNo.",
            "of patients (%)235 (42)189 (34)No.",
            "of events385297Rate during treatment exposure (95% CI) \u0160 no./yr\u01920.34 (0.29\u01520.40)0.33 (0.28\u01520.39)Adverse event leading to treatment discontinuation at any time  \u0160 no.",
            "of patients3314Grade 3 to 5 adverse event \u0160 no.",
            "of patients (%)\u2044Febrile neutropenia37 (7)32 (6)Hypertension43 (8)25 (4)Neutrophil count decreased31 (6)16 (3)Fatigue31 (6)4 (1)Syncope20 (4)6 (1)Surgical or medical procedure13 (2)10 (2)Anemia4 (1)5 (1)Fall6 (1)2 (<1)Thromboembolic event4 (1)4 (1)Acute coronary syndrome3 (1)4 (1)Myocardial infarction5 (1)2 (<1)Chest pain from cardiac cause3 (1)2 (<1)Stroke1 (<1)2 (<1)Seizure\u00a72 (<1)0Delirium01 (<1)*  When a patient had multiple events identified by a particular term, the worst grade is shown.\u0192  The rate of serious adverse events per year of treatment exposure was estimated with the use of a negative binomial  regression model.\u2044  These adverse events occurred in at least 2% of the patients in either group or were selected as being events of special interest.",
            "In the enzalutamide group, 6 grade 5 adverse events were reported: death from an unknown cause in 2 patients and 1 patient each with stroke, myocardial infarction, aspiration pneumonia, and acidosis.",
            "In the standard-care group, 7 grade 5 adverse events were reported: sepsis in 2 patients and 1 patient each with cardiac arrest, sudden death from an unknown cause, gastric hemorrhage, urinary tract infection, and symptomatic progression of prostate cancer.\u00a7  Seizure of any grade occurred in 7 patients in the enzalutamide group and in no patients in the standard-care group.Table\u02dc2.\u02dcAdverse\u02dcEvents.n engl j med 381;2 nejm.org July 11, 2019130The new england journal of medicineThe effect of enzalutamide on overall survival appeared to be smaller in the subgroup with early docetaxel treatment.",
            "However, this trial was neither designed nor powered to reliably analyze the results in this subgroup.",
            "The effects of enzalu-tamide on clinical progression-free survival, an earlier end point with considerably more events and consequently greater statistical reliability, remained substantial regardless of early docetax-el treatment.",
            "This finding indicates that longer follow-up is needed to determine the effects of enzalutamide on overall survival beyond 3 years in those with early docetaxel treatment.",
            "Our cur-rent data support the claim that early enzalu-tamide prolongs survival within 3 years in the entire trial population but provide limited sup-port that it prolongs overall survival within 3 years in patients who received early docetaxel treatment.The main limitations of this trial are conse-quences of the detection of evidence of benefit at the first planned interim analysis.",
            "This early analy-sis may have overestimated the eventual treatment benefit.20 There was no central review of actual imaging, but this factor would have no effect on the rate of death, the primary end point.",
            "The me-dian follow-up of 34 months is sufficient to pro-vide evidence about the effects within this interval but not beyond it.",
            "The sample size and number of events allow for strong conclusions about the effects of enzalutamide on survival in the entire trial population and the effects on progression-free survival in some subgroups; however, we cannot determine the effects on overall survival in any of the prespecified subgroups.In conclusion, in men with metastatic hor-mone-sensitive prostate cancer receiving testos-terone suppression, the addition of enzalutamide resulted in longer overall survival, PSA progres-sion-free survival, and clinical progression-free survival within 3 years than the use of standard nonsteroidal antiandrogen therapy.",
            "However, enzalutamide was associated with some additional toxic effects, including fatigue and a small risk of seizures.",
            "Among the patients who also received early docetaxel treatment, the addition of enzalu-tamide was associated with additional toxic ef-fects and longer progression-free survival but not longer overall survival.Supported by Astellas Scientific and Medical Affairs, a grant (704970) from the Canadian Cancer Society, the Support for Cancer Clinical Trials Program of Cancer Australia, and a prac-titioner fellowship (APP1102604) and program grants (1037786 and 1150467) from the National Health and Medical Research Council of the Australian Government Department of Health.Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.AppendixThe authors\u2122 full names and academic degrees are as follows: Ian D. Davis, M.B., B.S., Ph.D., Andrew J. Martin, Ph.D., Martin R. Stockler, M.B., B.S., Stephen Begbie, M.B., B.S., Kim N. Chi, M.D., Simon Chowdhury, M.B., B.S., Ph.D., Xanthi Coskinas, M.Med.Sc., Mark Frydenberg, M.B., B.S., Wendy E. Hague, M.B., B.S., Ph.D., Lisa G. Horvath, M.B., B.S., Ph.D., Anthony M. Joshua, M.B., B.S., Ph.D., Nicola J. Lawrence, M.B., Ch.B., Gavin Marx, M.B., B.S., John McCaffrey, M.B., B.Ch., Ray McDermott, M.D., Ph.D., Margaret McJannett, R.N., Scott A.",
            "North, M.D., Francis Parnis, M.B., B.S., Wendy Parulekar, M.D., David W. Pook, M.B., B.S., M.D., M. Neil Reaume, M.D., Shahneen K. Sandhu, M.B., B.S., Alvin Tan, M.B., Ch.B., T. Hsiang Tan, M.B., B.S., Alastair Thomson, B.M., Emily Tu, Ph.D., Francisco Vera-Badillo, M.D., Scott G. Williams, M.B., B.S., M.D., Sonia Yip, Ph.D., Alison Y. Zhang, M.B., B.S., Robert R. Zielinski, M.B., B.S., and Christopher J. Sweeney, M.B., B.S.The authors\u2122 affiliations are as follows: Monash University (I.D.D., M.F., D.W.P.",
            "), Eastern Health (I.D.D.",
            "), Australian Urology As-sociates (M.F.",
            "), Monash Health (D.W.P.",
            "), and the Peter MacCallum Cancer Centre and the University of Melbourne (S.K.S., S.G.W.",
            "), Melbourne, VIC, the National Health and Medical Research Council Clinical Trials Centre, University of Sydney (A.J.M., M.R.S., X.C., W.E.H., E.T., S.Y., A.Y.Z.",
            "), the Chris O\u2122Brien Lifehouse (M.R.S., L.G.H., A.Y.Z.",
            "), the University of Sydney (L.G.H., G.M.",
            "), Royal Prince Alfred Hospital (L.G.H.",
            "), Kinghorn Cancer Centre, St. Vincent\u2122s Hospital, and Garvan Institute of Medical Research (A.M.J.",
            "), Macquarie University (A.Y.Z.",
            "), and Western Sydney University (R.R.Z.",
            "), Sydney, Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW (M.R.S.",
            "), Port Macquarie Base Hospital and Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, NSW (S.B.",
            "), Sydney Adventist Hospital, Wahroonga, NSW (G.M.",
            "), the ANZUP Cancer Trials Group, Camperdown, NSW (M.M.",
            "), the Adelaide Cancer Centre and the University of Adelaide (F.P.)",
            "and the Royal Adelaide Hospital (T.H.T.",
            "), Adelaide, SA, and Orange Health Service, Central West Cancer Care Centre, Orange, NSW (R.R.Z.)",
            "\u0160 all in Australia; BC Cancer and the University of British Columbia, Vancou-ver (K.N.C.",
            "), the Cross Cancer Institute and the University of Alberta, Edmonton (S.A.N.",
            "), Canadian Cancer Trials Group, Queen\u2122s University (W.P., F.V.-B.",
            "), and the Kingston Health Sciences Center (F.V.-B.",
            "), Kingston, ON, and the University of Ottawa and the Ot-tawa Hospital Research Institute, Ottawa (M.N.R.)",
            "\u0160 all in Canada; Guy\u2122s and St. Thomas\u2122 NHS Foundation Trust Biomedical Research Centre, Cancer Research UK and King\u2122s College London, and Sarah Cannon Research UK, London (S.C.), and the Royal Cornwall Hospital, Truro (A. Thomson) \u0160 all in the United Kingdom; Auckland City Hospital, Auckland (N.J.L.",
            "), and the Waikato District Health Board, Hamilton (A. Tan) \u0160 both in New Zealand; Cancer Trials Ireland (J.M., R.M.",
            "), Mater Misericordiae University Hospital (J.M.",
            "), and St. Vincent\u2122s University Hospital and University College Dublin (R.M.D.)",
            "\u0160 all in Dublin; and Dana\u0152Farber Cancer Institute and Harvard Medical School (C.J.S.)",
            "\u0160 both in Boston.n engl j med 381;2 nejm.org July 11, 2019131Enzalutamide with Standard Therapy in Prostate CancerReferences1.",
            "Sweeney CJ, Chen Y-H, Carducci M, et al.",
            "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.",
            "N Engl J Med 2015; 373: 737-46.2.",
            "Kyriakopoulos CE, Chen YH, Carducci MA, et al.",
            "Chemohormonal therapy in metastatic hormone-sensitive prostate can-cer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial.",
            "J Clin Oncol 2018; 36: 1080-7.3.",
            "James ND, Sydes MR, Clarke NW, et al.",
            "Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multi-arm, multistage, platform randomised con-trolled trial.",
            "Lancet 2016; 387: 1163-77.4.",
            "Gravis G, Fizazi K, Joly F, et al.",
            "Andro-gen-deprivation therapy alone or with docetaxel in non-castrate metastatic pros-tate cancer (GETUG-AFU 15): a random-ised, open-label, phase 3 trial.",
            "Lancet Oncol 2013; 14: 149-58.5.",
            "Gravis G, Boher JM, Joly F, et al.",
            "Andro-gen-deprivation therapy (ADT) plus docetaxel versus ADT alone in metastat-ic non castrate prostate cancer: impact of metastatic burden and long-term sur-vival analysis of the randomized phase 3 GETUG-AFU15 trial.",
            "Eur Urol 2016; 70: 256-62.6.",
            "Vale CL, Burdett S, Rydzewska LHM, et al.",
            "Addition of docetaxel or bisphos-phonates to standard of care in men with localised or metastatic, hormone-sensi-tive prostate cancer: a systematic review and meta-analyses of aggregate data.",
            "Lancet Oncol 2016; 17: 243-56.7.",
            "Gravis G, Boher J-M, Chen Y-H, et al.",
            "Burden of metastatic castrate naive pros-tate cancer patients, to identify men more likely to benefit from early docetax-el: further analyses of CHAARTED and GETUG-AFU15 studies.",
            "Eur Urol 2018; 73: 847-55.8.",
            "Fizazi K, Tran N, Fein L, et al.",
            "Abi-raterone plus prednisone in metastatic, castration-sensitive prostate cancer.",
            "N Engl J Med 2017; 377: 352-60.9.",
            "James ND, de Bono JS, Spears MR, et al.",
            "Abiraterone for prostate cancer not previously treated with hormone therapy.",
            "N Engl J Med 2017; 377: 338-51.10.",
            "Hoyle AP, Ali SA, James ND, et al.",
            "Ef-fects of abiraterone acetate plus predni-sone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer.",
            "Ann Oncol 2018; 29: Suppl 8: LBA4.",
            "abstract.11.",
            "Tannock IF, de Wit R, Berry WR, et al.",
            "Docetaxel plus prednisone or mitoxan-trone plus prednisone for advanced pros-tate cancer.",
            "N Engl J Med 2004; 351: 1502-12.12.",
            "Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF.",
            "Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetax-el after mitoxantrone or vice versa.",
            "Ann Oncol 2008; 19: 1749-53.13.",
            "Prostate Cancer Trialists Collabora-tive Group.",
            "Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.",
            "Lancet 2000; 355: 1491-8.14.",
            "Sydes MR, Spears MR, Mason MD,  et al.",
            "Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage plat-form protocol.",
            "Ann Oncol 2018; 29: 1235-48.15.",
            "Scher HI, Fizazi K, Saad F, et al.",
            "In-creased survival with enzalutamide in pros-tate cancer after chemotherapy.",
            "N Engl J Med 2012; 367: 1187-97.16.",
            "Beer TM, Armstrong AJ, Rathkopf DE, et al.",
            "Enzalutamide in metastatic prostate cancer before chemotherapy.",
            "N Engl J Med 2014; 371: 424-33.17.",
            "Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic impor-tance of comorbidity in a hospital-based cancer registry.",
            "JAMA 2004; 291: 2441-7.18.",
            "Scher HI, Halabi S, Tannock I, et al.",
            "Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.",
            "J Clin On-col 2008; 26: 1148-59.19.",
            "Eisenhauer EA, Therasse P, Bogaerts J, et al.",
            "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).",
            "Eur J Cancer 2009; 45: 228-47.20.",
            "Pocock SJ, Hughes MD.",
            "Practical prob-lems in interim analyses, with particular regard to estimation.",
            "Control Clin Trials 1989; 10: Suppl: 209S-221S.Copyright \u00a9 2019 Massachusetts Medical Society.RECEIVE IMMEDIATE NOTIFICATION WHEN AN ARTICLE  IS PUBLISHED ONLINE FIRSTTo be notified by email when Journal articles  are published online first, sign up at NEJM.org."
        ],
        "words": [
            "n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019121The",
            "authors\u2122",
            "full",
            "names",
            ",",
            "academic",
            "degrees",
            ",",
            "and",
            "affiliations",
            "are",
            "listed",
            "in",
            "the",
            "Appendix",
            ".",
            "Address",
            "reprint",
            "requests",
            "to",
            "Dr.",
            "Davis",
            "at",
            "Level",
            "2",
            ",",
            "5",
            "Arnold",
            "St.",
            ",",
            "Box",
            "Hill",
            ",",
            "VIC",
            "3128",
            ",",
            "Australia",
            ",",
            "or",
            "at",
            "ian",
            ".",
            "davis",
            "@",
            "monash",
            ".",
            "edu",
            ".",
            "*",
            "A",
            "full",
            "list",
            "of",
            "the",
            "investigators",
            "in",
            "the",
            "ENZAMET",
            "Trial",
            "is",
            "provided",
            "in",
            "the",
            "Supple-mentary",
            "Appendix",
            ",",
            "available",
            "at",
            "NEJM.org.This",
            "article",
            "was",
            "published",
            "on",
            "June",
            "2",
            ",",
            "2019",
            ",",
            "and",
            "updated",
            "on",
            "June",
            "11",
            ",",
            "2019",
            ",",
            "at",
            "NEJM.org.N\u02dcEngl\u02dcJ\u02dcMed\u02dc2019",
            ";",
            "381:121-31.DOI",
            ":",
            "\u02dc10.1056/NEJMoa1903835Copyright",
            "\u00a9",
            "2019",
            "Massachusetts",
            "Medical",
            "Society.BACKGROUNDEnzalutamide",
            ",",
            "an",
            "androgen-receptor",
            "inhibitor",
            ",",
            "has",
            "been",
            "associated",
            "with",
            "improved",
            "overall",
            "survival",
            "in",
            "men",
            "with",
            "castration-resistant",
            "prostate",
            "cancer",
            ".",
            "It",
            "is",
            "not",
            "known",
            "whether",
            "adding",
            "enzalutamide",
            "to",
            "testosterone",
            "suppression",
            ",",
            "with",
            "or",
            "without",
            "early",
            "docetaxel",
            ",",
            "will",
            "improve",
            "survival",
            "in",
            "men",
            "with",
            "metastatic",
            ",",
            "hormone-sensitive",
            "pros-tate",
            "cancer.METHODSIn",
            "this",
            "open-label",
            ",",
            "randomized",
            ",",
            "phase",
            "3",
            "trial",
            ",",
            "we",
            "assigned",
            "patients",
            "to",
            "receive",
            "tes-tosterone",
            "suppression",
            "plus",
            "either",
            "open-label",
            "enzalutamide",
            "or",
            "a",
            "standard",
            "nonsteroidal",
            "antiandrogen",
            "therapy",
            "(",
            "standard-care",
            "group",
            ")",
            ".",
            "The",
            "primary",
            "end",
            "point",
            "was",
            "overall",
            "survival",
            ".",
            "Secondary",
            "end",
            "points",
            "included",
            "progression-free",
            "survival",
            "as",
            "determined",
            "by",
            "the",
            "prostate-specific",
            "antigen",
            "(",
            "PSA",
            ")",
            "level",
            ",",
            "clinical",
            "progression-free",
            "survival",
            ",",
            "and",
            "adverse",
            "events.RESULTSA",
            "total",
            "of",
            "1125",
            "men",
            "underwent",
            "randomization",
            ";",
            "the",
            "median",
            "follow-up",
            "was",
            "34",
            "months",
            ".",
            "There",
            "were",
            "102",
            "deaths",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "143",
            "deaths",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "hazard",
            "ratio",
            ",",
            "0.67",
            ";",
            "95",
            "%",
            "confidence",
            "interval",
            "[",
            "CI",
            "]",
            ",",
            "0.52",
            "to",
            "0.86",
            ";",
            "P",
            "=",
            "0.002",
            ")",
            ".",
            "Kaplan\u0152Meier",
            "estimates",
            "of",
            "overall",
            "survival",
            "at",
            "3",
            "years",
            "were",
            "80",
            "%",
            "(",
            "based",
            "on",
            "94",
            "events",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "72",
            "%",
            "(",
            "based",
            "on",
            "130",
            "events",
            ")",
            "in",
            "the",
            "standard-care",
            "group",
            ".",
            "Better",
            "results",
            "with",
            "enzalutamide",
            "were",
            "also",
            "seen",
            "in",
            "PSA",
            "progression-free",
            "survival",
            "(",
            "174",
            "and",
            "333",
            "events",
            ",",
            "respectively",
            ";",
            "hazard",
            "ratio",
            ",",
            "0.39",
            ";",
            "P",
            "<",
            "0.001",
            ")",
            "and",
            "in",
            "clinical",
            "progression-free",
            "survival",
            "(",
            "167",
            "and",
            "320",
            "events",
            ",",
            "respectively",
            ";",
            "hazard",
            "ratio",
            ",",
            "0.40",
            ";",
            "P",
            "<",
            "0.001",
            ")",
            ".",
            "Treat-ment",
            "discontinuation",
            "due",
            "to",
            "adverse",
            "events",
            "was",
            "more",
            "frequent",
            "in",
            "the",
            "enzalutamide",
            "group",
            "than",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "33",
            "events",
            "and",
            "14",
            "events",
            ",",
            "respectively",
            ")",
            ".",
            "Fa-tigue",
            "was",
            "more",
            "common",
            "in",
            "the",
            "enzalutamide",
            "group",
            ";",
            "seizures",
            "occurred",
            "in",
            "7",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "(",
            "1",
            "%",
            ")",
            "and",
            "in",
            "no",
            "patients",
            "in",
            "the",
            "standard-care",
            "group.CONCLUSIONSEnzalutamide",
            "was",
            "associated",
            "with",
            "significantly",
            "longer",
            "progression-free",
            "and",
            "overall",
            "survival",
            "than",
            "standard",
            "care",
            "in",
            "men",
            "with",
            "metastatic",
            ",",
            "hormone-sensitive",
            "prostate",
            "cancer",
            "receiving",
            "testosterone",
            "suppression",
            ".",
            "The",
            "enzalutamide",
            "group",
            "had",
            "a",
            "higher",
            "incidence",
            "of",
            "seizures",
            "and",
            "other",
            "toxic",
            "effects",
            ",",
            "especially",
            "among",
            "those",
            "treated",
            "with",
            "early",
            "docetax-el",
            ".",
            "(",
            "Funded",
            "by",
            "Astellas",
            "Scientific",
            "and",
            "Medical",
            "Affairs",
            "and",
            "others",
            ";",
            "ENZAMET",
            "(",
            "ANZUP",
            "1304",
            ")",
            "ANZCTR",
            "number",
            ",",
            "ACTRN12614000110684",
            ";",
            "ClinicalTrials.gov",
            "num-ber",
            ",",
            "NCT02446405",
            ";",
            "and",
            "EU",
            "Clinical",
            "Trials",
            "Register",
            "number",
            ",",
            "2014",
            "-",
            "003190",
            "-",
            "42",
            ".",
            ")",
            "ABSTRACTEnzalutamide",
            "with",
            "Standard",
            "First-Line",
            "Therapy",
            "in",
            "Metastatic",
            "Prostate",
            "CancerI.D",
            ".",
            "Davis",
            ",",
            "A.J",
            ".",
            "Martin",
            ",",
            "M.R",
            ".",
            "Stockler",
            ",",
            "S.",
            "Begbie",
            ",",
            "K.N",
            ".",
            "Chi",
            ",",
            "S.",
            "Chowdhury",
            ",",
            "X.",
            "Coskinas",
            ",",
            "M.",
            "Frydenberg",
            ",",
            "W.E",
            ".",
            "Hague",
            ",",
            "L.G",
            ".",
            "Horvath",
            ",",
            "A.M.",
            "Joshua",
            ",",
            "N.J.",
            "Lawrence",
            ",",
            "G.",
            "Marx",
            ",",
            "J.",
            "McCaffrey",
            ",",
            "R.",
            "McDermott",
            ",",
            "M.",
            "McJannett",
            ",",
            "S.A.",
            "North",
            ",",
            "F.",
            "Parnis",
            ",",
            "W.",
            "Parulekar",
            ",",
            "D.W.",
            "Pook",
            ",",
            "M.N",
            ".",
            "Reaume",
            ",",
            "S.K",
            ".",
            "Sandhu",
            ",",
            "A.",
            "Tan",
            ",",
            "T.H",
            ".",
            "Tan",
            ",",
            "A.",
            "Thomson",
            ",",
            "E.",
            "Tu",
            ",",
            "F.",
            "Vera-Badillo",
            ",",
            "S.G.",
            "Williams",
            ",",
            "S.",
            "Yip",
            ",",
            "A.Y",
            ".",
            "Zhang",
            ",",
            "R.R",
            ".",
            "Zielinski",
            ",",
            "and",
            "C.J",
            ".",
            "Sweeney",
            ",",
            "for",
            "the",
            "ENZAMET",
            "Trial",
            "Investigators",
            "and",
            "the",
            "Australian",
            "and",
            "New",
            "Zealand",
            "Urogenital",
            "and",
            "Prostate",
            "Cancer",
            "Trials",
            "Group",
            "*",
            "Original",
            "Articlen",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019122The",
            "new",
            "england",
            "journal",
            "of",
            "medicineSeveral",
            "randomized",
            "trials",
            "have",
            "es-tablished",
            "the",
            "benefits",
            "of",
            "adding",
            "docetaxel",
            "or",
            "abiraterone",
            "to",
            "testosterone",
            "suppression",
            "in",
            "men",
            "with",
            "metastatic",
            ",",
            "hormone-sensitive",
            "pros-tate",
            "cancer.1-10",
            "The",
            "survival",
            "benefits",
            "associated",
            "with",
            "docetaxel",
            "early",
            "in",
            "the",
            "course",
            "of",
            "treatment",
            ",",
            "particularly",
            "in",
            "men",
            "with",
            "high-volume",
            "metastatic",
            "disease,7",
            "are",
            "substantially",
            "larger",
            "than",
            "the",
            "survival",
            "benefits",
            "associated",
            "with",
            "using",
            "docetaxel",
            "later",
            "af-ter",
            "castration",
            "resistance",
            "has",
            "developed.11-13",
            "The",
            "addition",
            "of",
            "abiraterone",
            "to",
            "testosterone",
            "suppression",
            "also",
            "improved",
            "overall",
            "survival",
            "in",
            "hormone-sensi-tive",
            "prostate",
            "cancer",
            ",",
            "regardless",
            "of",
            "the",
            "burden",
            "of",
            "metastatic",
            "disease.9,10",
            "A",
            "recent",
            "post",
            "hoc",
            "compari-son",
            "indicated",
            "that",
            "men",
            "who",
            "were",
            "given",
            "abiraterone",
            "or",
            "docetaxel",
            "early",
            "in",
            "the",
            "course",
            "of",
            "treatment",
            "had",
            "similar",
            "outcomes",
            "with",
            "respect",
            "to",
            "overall",
            "survival.14Enzalutamide",
            "is",
            "an",
            "orally",
            "administered",
            ",",
            "small-molecule",
            "inhibitor",
            "of",
            "the",
            "androgen",
            "receptor",
            "that",
            "is",
            "designed",
            "to",
            "overcome",
            "acquired",
            "resistance",
            "to",
            "first-generation",
            "nonsteroidal",
            "antiandrogens",
            ",",
            "in-cluding",
            "bicalutamide",
            ",",
            "nilutamide",
            ",",
            "and",
            "flutamide",
            ".",
            "Previous",
            "trials",
            "have",
            "shown",
            "that",
            "enzalutamide",
            "improved",
            "overall",
            "survival",
            "in",
            "castration-resistant",
            "prostate",
            "cancer",
            ",",
            "regardless",
            "of",
            "whether",
            "it",
            "was",
            "used",
            "before",
            "or",
            "after",
            "docetaxel",
            "chemotherapy.15,16We",
            "hypothesized",
            "that",
            "adding",
            "enzalutamide",
            "to",
            "first-line",
            "therapy",
            "would",
            "delay",
            "the",
            "emergence",
            "of",
            "castration",
            "resistance",
            "and",
            "thereby",
            "improve",
            "overall",
            "survival",
            ".",
            "In",
            "the",
            "ENZAMET",
            "(",
            "Enzalutamide",
            "in",
            "First",
            "Line",
            "Androgen",
            "Deprivation",
            "Therapy",
            "for",
            "Metastatic",
            "Prostate",
            "Cancer",
            ")",
            "trial",
            ",",
            "our",
            "aim",
            "was",
            "to",
            "determine",
            "the",
            "effects",
            "of",
            "adding",
            "enzalutamide",
            "to",
            "first-line",
            "treatment",
            "that",
            "included",
            "testosterone",
            "suppression",
            "with",
            "or",
            "without",
            "early",
            "docetaxel.MethodsTrial",
            "DesignThe",
            "primary",
            "objective",
            "of",
            "this",
            "multinational",
            ",",
            "open-label",
            ",",
            "randomized",
            ",",
            "phase",
            "3",
            "trial",
            "was",
            "to",
            "determine",
            "the",
            "effects",
            "of",
            "early",
            "enzalutamide",
            "treatment",
            "on",
            "overall",
            "survival",
            "in",
            "men",
            "with",
            "metastatic",
            ",",
            "hormone-sensitive",
            "prostate",
            "cancer",
            ".",
            "Secondary",
            "objectives",
            "were",
            "to",
            "determine",
            "the",
            "effects",
            "on",
            "progression-free",
            "survival",
            "as",
            "determined",
            "by",
            "the",
            "prostate-specific",
            "antigen",
            "(",
            "PSA",
            ")",
            "level",
            ",",
            "clinical",
            "progression-free",
            "sur-vival",
            "(",
            "based",
            "on",
            "imaging",
            ",",
            "symptoms",
            ",",
            "signs",
            ",",
            "or",
            "changes",
            "in",
            "therapy",
            ")",
            ",",
            "and",
            "adverse",
            "events",
            ".",
            "Effects",
            "on",
            "health-related",
            "quality",
            "of",
            "life",
            ",",
            "resource",
            "use",
            ",",
            "and",
            "incremental",
            "cost-effectiveness",
            "will",
            "be",
            "reported",
            "separately.Patients",
            "and",
            "TreatmentEligible",
            "patients",
            "had",
            "prostatic",
            "adenocarcinoma",
            "with",
            "metastases",
            "on",
            "computed",
            "tomography",
            "(",
            "CT",
            ")",
            ",",
            "bone",
            "scanning",
            "with",
            "technetium-99",
            ",",
            "or",
            "both",
            "and",
            "a",
            "score",
            "of",
            "2",
            "or",
            "less",
            "on",
            "the",
            "Eastern",
            "Cooperative",
            "Oncology",
            "Group",
            "(",
            "ECOG",
            ")",
            "performance-status",
            "scale",
            ",",
            "which",
            "ranges",
            "from",
            "0",
            "(",
            "no",
            "disability",
            ")",
            "to",
            "5",
            "(",
            "death",
            ")",
            ".",
            "Testosterone",
            "suppression",
            "was",
            "initiated",
            "up",
            "to",
            "12",
            "weeks",
            "before",
            "randomization",
            ".",
            "Previous",
            "adjuvant",
            "testosterone",
            "suppression",
            "for",
            "up",
            "to",
            "24",
            "months",
            "was",
            "allowed",
            "if",
            "the",
            "treatment",
            "had",
            "been",
            "completed",
            "at",
            "least",
            "12",
            "months",
            "earlier",
            ".",
            "The",
            "trial",
            "protocol",
            "and",
            "Supplementary",
            "Appendix",
            "are",
            "available",
            "with",
            "the",
            "full",
            "text",
            "of",
            "this",
            "article",
            "at",
            "NEJM.org.Eligible",
            "patients",
            "were",
            "randomly",
            "assigned",
            "in",
            "a",
            "1:1",
            "ratio",
            "to",
            "receive",
            "enzalutamide",
            "(",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "daily",
            ")",
            "or",
            "a",
            "standard",
            "nonsteroidal",
            "antian-drogen",
            "drug",
            "(",
            "bicalutamide",
            ",",
            "nilutamide",
            ",",
            "or",
            "flu-tamide",
            ")",
            "(",
            "standard-care",
            "group",
            ")",
            "until",
            "the",
            "occur-rence",
            "of",
            "clinical",
            "disease",
            "progression",
            "or",
            "prohibitive",
            "toxic",
            "effects",
            ".",
            "In",
            "the",
            "two",
            "groups",
            ",",
            "background",
            "ther-apy",
            "included",
            "continuous",
            "testosterone",
            "suppression",
            ".",
            "After",
            "the",
            "enrollment",
            "of",
            "88",
            "patients",
            "(",
            "mainly",
            "from",
            "Australia",
            "and",
            "New",
            "Zealand",
            ")",
            ",",
            "the",
            "early",
            "adminis-tration",
            "of",
            "docetaxel",
            "with",
            "testosterone",
            "suppression",
            "was",
            "permitted",
            "in",
            "protocol",
            "version",
            "2",
            "(",
            "as",
            "revised",
            "on",
            "November",
            "2014",
            ")",
            "as",
            "a",
            "stratification",
            "factor",
            "before",
            "randomization",
            ",",
            "according",
            "to",
            "evidence",
            "showing",
            "improved",
            "survival",
            "with",
            "this",
            "approach.1",
            "The",
            "deci-sion",
            "to",
            "initiate",
            "early",
            "treatment",
            "with",
            "docetaxel",
            "was",
            "left",
            "up",
            "to",
            "the",
            "individual",
            "patients",
            "and",
            "their",
            "physi-cians",
            ".",
            "If",
            "docetaxel",
            "was",
            "administered",
            ",",
            "the",
            "regimen",
            "consisted",
            "of",
            "75",
            "mg",
            "per",
            "square",
            "meter",
            "of",
            "body-surface",
            "area",
            ",",
            "without",
            "prednisone",
            "or",
            "prednisolone",
            ",",
            "given",
            "every",
            "3",
            "weeks",
            "for",
            "a",
            "maximum",
            "of",
            "six",
            "cycles",
            ".",
            "Up",
            "to",
            "two",
            "cycles",
            "of",
            "docetaxel",
            "were",
            "permitted",
            "be-fore",
            "randomization.The",
            "central",
            "randomization",
            "system",
            "implement-ed",
            "minimization",
            "with",
            "a",
            "random",
            "component",
            ".",
            "Ran-domization",
            "was",
            "stratified",
            "according",
            "to",
            "the",
            "volume",
            "of",
            "disease",
            "(",
            "high",
            "[",
            "defined",
            "as",
            "the",
            "presence",
            "of",
            "vis-ceral",
            "metastases",
            "or",
            "at",
            "least",
            "four",
            "bone",
            "lesions",
            "with",
            "at",
            "least",
            "one",
            "lesion",
            "located",
            "beyond",
            "the",
            "vertebral",
            "bodies",
            "and",
            "pelvis",
            "]",
            "or",
            "low",
            ")",
            ",",
            "planned",
            "use",
            "of",
            "early",
            "docetaxel",
            "(",
            "yes",
            "or",
            "no",
            ")",
            ",",
            "planned",
            "use",
            "of",
            "bone",
            "anti-resorptive",
            "therapy",
            "(",
            "yes",
            "or",
            "no",
            ")",
            ",",
            "the",
            "score",
            "on",
            "the",
            "Adult",
            "Comorbidity",
            "Evaluation",
            "27",
            "(",
            "ACE-27",
            ")",
            "17",
            "(",
            "with",
            "n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019123Enzalutamide",
            "with",
            "Standard",
            "Therapy",
            "in",
            "Prostate",
            "Cancercoexisting",
            "conditions",
            "rated",
            "as",
            "0",
            "[",
            "none",
            "]",
            "or",
            "1",
            "[",
            "mild",
            "]",
            "vs.",
            "2",
            "[",
            "moderate",
            "]",
            "or",
            "3",
            "[",
            "severe",
            "or",
            "multiple",
            "condi-tions",
            "]",
            ")",
            ",",
            "and",
            "trial",
            "site.Trial",
            "OversightThe",
            "trial",
            "was",
            "led",
            "by",
            "the",
            "Australian",
            "and",
            "New",
            "Zealand",
            "Urogenital",
            "and",
            "Prostate",
            "Cancer",
            "Trials",
            "Group",
            "(",
            "ANZUP",
            ")",
            "and",
            "the",
            "National",
            "Health",
            "and",
            "Medical",
            "Research",
            "Council",
            "(",
            "NHMRC",
            ")",
            "Clinical",
            "Trials",
            "Centre",
            ",",
            "University",
            "of",
            "Sydney",
            ".",
            "Regional",
            "sponsorship",
            "and",
            "coordination",
            "was",
            "performed",
            "by",
            "Cancer",
            "Trials",
            "Ireland",
            "in",
            "Ireland",
            "and",
            "the",
            "United",
            "Kingdom",
            ",",
            "the",
            "Canadian",
            "Cancer",
            "Trials",
            "Group",
            "in",
            "Canada",
            ",",
            "and",
            "the",
            "Dana\u0152Farber",
            "Cancer",
            "Institute",
            "in",
            "the",
            "United",
            "States",
            ".",
            "The",
            "trial",
            "was",
            "designed",
            "by",
            "the",
            "ANZUP",
            "investigators",
            ".",
            "Data",
            "were",
            "collected",
            "and",
            "analyzed",
            "by",
            "the",
            "NHMRC",
            "Clinical",
            "Trials",
            "Centre",
            ".",
            "The",
            "authors",
            "were",
            "solely",
            "responsible",
            "for",
            "the",
            "writ-ing",
            "of",
            "the",
            "manuscript.Astellas",
            "Pharma",
            "provided",
            "enzalutamide",
            "and",
            "financial",
            "support",
            "for",
            "trial",
            "conduct",
            ";",
            "representa-tives",
            "of",
            "the",
            "company",
            "reviewed",
            "drafts",
            "of",
            "the",
            "pro-tocol",
            "and",
            "trial",
            "report",
            "but",
            "were",
            "not",
            "otherwise",
            "in-volved",
            "in",
            "any",
            "aspects",
            "of",
            "the",
            "trial",
            "design",
            ",",
            "data",
            "accrual",
            ",",
            "data",
            "analysis",
            ",",
            "or",
            "manuscript",
            "preparation",
            ".",
            "Testosterone",
            "suppression",
            ",",
            "standard",
            "antiandrogen",
            "drugs",
            ",",
            "docetaxel",
            ",",
            "and",
            "all",
            "subsequent",
            "treatments",
            "were",
            "accessed",
            "according",
            "to",
            "local",
            "standard",
            "prac-tice",
            ".",
            "The",
            "authors",
            "vouch",
            "for",
            "the",
            "accuracy",
            "and",
            "completeness",
            "of",
            "the",
            "reported",
            "data",
            "and",
            "for",
            "the",
            "fidelity",
            "of",
            "the",
            "trial",
            "to",
            "the",
            "protocol.An",
            "independent",
            "data",
            "and",
            "safety",
            "monitoring",
            "committee",
            "reviewed",
            "the",
            "progress",
            "and",
            "results",
            "of",
            "the",
            "trial",
            ".",
            "The",
            "trial",
            "was",
            "conducted",
            "in",
            "accordance",
            "with",
            "the",
            "principles",
            "of",
            "Good",
            "Clinical",
            "Practice",
            "guidelines",
            "and",
            "the",
            "Declaration",
            "of",
            "Helsinki",
            ".",
            "The",
            "protocol",
            "was",
            "independently",
            "reviewed",
            "and",
            "ap-proved",
            "as",
            "required",
            "at",
            "each",
            "participating",
            "institu-tion",
            ".",
            "All",
            "the",
            "patients",
            "provided",
            "written",
            "informed",
            "consent.End",
            "PointsThe",
            "primary",
            "end",
            "point",
            "of",
            "overall",
            "survival",
            "was",
            "measured",
            "as",
            "the",
            "interval",
            "from",
            "randomization",
            "to",
            "death",
            "from",
            "any",
            "cause",
            "or",
            "to",
            "the",
            "date",
            "at",
            "which",
            "the",
            "patient",
            "was",
            "last",
            "known",
            "to",
            "be",
            "alive",
            ".",
            "The",
            "second-ary",
            "end",
            "point",
            "of",
            "PSA",
            "progression-free",
            "survival",
            "was",
            "measured",
            "as",
            "the",
            "interval",
            "from",
            "randomiza-tion",
            "to",
            "the",
            "earliest",
            "event",
            "of",
            "PSA",
            "progression",
            "ac-cording",
            "to",
            "the",
            "criteria",
            "of",
            "the",
            "Prostate",
            "Cancer",
            "Working",
            "Group",
            "2",
            "(",
            "a",
            "confirmed",
            "relative",
            "increase",
            "in",
            "the",
            "PSA",
            "level",
            "from",
            "the",
            "nadir",
            "value",
            "by",
            "\u02dc25",
            "%",
            "and",
            "by",
            "\u02dc2",
            "ng",
            "per",
            "milliliter",
            ")",
            ",18",
            "clinical",
            "progres-sion",
            ",",
            "death",
            "from",
            "any",
            "cause",
            ",",
            "or",
            "the",
            "last",
            "known",
            "date",
            "of",
            "follow-up",
            "without",
            "PSA",
            "progression",
            ".",
            "The",
            "secondary",
            "end",
            "point",
            "of",
            "clinical",
            "progression",
            "was",
            "defined",
            "as",
            "the",
            "earliest",
            "sign",
            "of",
            "radiographic",
            "pro-gression",
            "according",
            "to",
            "the",
            "criteria",
            "of",
            "the",
            "Prostate",
            "Cancer",
            "Working",
            "Group",
            "2",
            "for",
            "bone",
            "lesions",
            "and",
            "the",
            "Response",
            "Evaluation",
            "Criteria",
            "in",
            "Solid",
            "Tu-mors",
            ",",
            "version",
            "1.1,19",
            "for",
            "soft-tissue",
            "lesions",
            ";",
            "the",
            "development",
            "of",
            "symptoms",
            "attributable",
            "to",
            "cancer",
            "progression",
            ";",
            "or",
            "the",
            "initiation",
            "of",
            "another",
            "antican-cer",
            "treatment",
            "for",
            "prostate",
            "cancer",
            ".",
            "Imaging",
            "by",
            "means",
            "of",
            "CT",
            "and",
            "bone",
            "scanning",
            "was",
            "recom-mended",
            "to",
            "confirm",
            "clinical",
            "suspicion",
            "of",
            "pro-gressive",
            "disease",
            ".",
            "Imaging",
            "reports",
            "(",
            "but",
            "not",
            "the",
            "images",
            "themselves",
            ")",
            "were",
            "reviewed",
            "centrally",
            ".",
            "Ad-verse",
            "events",
            "were",
            "graded",
            "according",
            "to",
            "the",
            "Na-tional",
            "Cancer",
            "Institute",
            "Common",
            "Terminology",
            "Criteria",
            "for",
            "Adverse",
            "Events",
            ",",
            "version",
            "4.02",
            ".",
            "Ad-verse-event",
            "data",
            "were",
            "collected",
            "during",
            "the",
            "treat-ment",
            "period",
            ",",
            "with",
            "a",
            "final",
            "safety",
            "assessment",
            "performed",
            "30",
            "to",
            "42",
            "days",
            "after",
            "the",
            "cessation",
            "of",
            "the",
            "trial",
            "regimen.Statistical",
            "AnalysisWe",
            "determined",
            "that",
            "the",
            "enrollment",
            "of",
            "1100",
            "pa-tients",
            "(",
            "with",
            "470",
            "deaths",
            ")",
            "would",
            "provide",
            "a",
            "power",
            "of",
            "at",
            "least",
            "80",
            "%",
            "to",
            "detect",
            "a",
            "25",
            "%",
            "lower",
            "hazard",
            "of",
            "death",
            "in",
            "the",
            "enzalutamide",
            "group",
            "than",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "hazard",
            "ratio",
            ",",
            "0.75",
            ")",
            ",",
            "with",
            "a",
            "two-sided",
            "type",
            "I",
            "error",
            "rate",
            "of",
            "0.05",
            ".",
            "In",
            "these",
            "cal-culations",
            ",",
            "we",
            "assumed",
            "a",
            "3-year",
            "survival",
            "rate",
            "of",
            "65",
            "%",
            "in",
            "the",
            "standard-care",
            "group",
            "on",
            "the",
            "basis",
            "of",
            "two",
            "previous",
            "studies",
            "of",
            "enzalutamide",
            "in",
            "men",
            "with",
            "metastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer.15,16",
            "Protocol",
            "versions",
            "1",
            "and",
            "2",
            "called",
            "for",
            "an",
            "interim",
            "analysis",
            "of",
            "overall",
            "survival",
            "after",
            "the",
            "occurrence",
            "of",
            "67",
            "%",
            "of",
            "the",
            "prespecified",
            "470",
            "deaths",
            "with",
            "the",
            "use",
            "of",
            "the",
            "Lan\u0152DeMets",
            "alpha-spending",
            "function",
            ".",
            "Protocol",
            "version",
            "3",
            ",",
            "which",
            "was",
            "written",
            "after",
            "external",
            "evidence",
            "became",
            "available",
            "for",
            "improved",
            "overall",
            "survival",
            "with",
            "early",
            "abiraterone",
            "treatment,8,9",
            "added",
            "interim",
            "analyses",
            "of",
            "overall",
            "survival",
            "after",
            "the",
            "occurrence",
            "of",
            "50",
            "%",
            "and",
            "80",
            "%",
            "of",
            "the",
            "prespecified",
            "470",
            "deaths",
            ".",
            "The",
            "trial",
            "executive",
            "committee",
            "made",
            "these",
            "decisions",
            "without",
            "any",
            "knowledge",
            "of",
            "outcomes",
            "in",
            "each",
            "treatment",
            "group.n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019124The",
            "new",
            "england",
            "journal",
            "of",
            "medicineEfficacy",
            "analyses",
            "were",
            "based",
            "on",
            "the",
            "inten-tion-to-treat",
            "principle",
            "and",
            "included",
            "all",
            "the",
            "pa-tients",
            "who",
            "had",
            "undergone",
            "randomization",
            ".",
            "The",
            "relevant",
            "follow-up",
            "times",
            "of",
            "patients",
            "who",
            "did",
            "not",
            "have",
            "an",
            "event",
            "were",
            "included",
            "in",
            "time-to-event",
            "analysis",
            "as",
            "censored",
            "observations",
            ".",
            "These",
            "analy-ses",
            "included",
            "patients",
            "who",
            "were",
            "lost",
            "to",
            "follow-up",
            "or",
            "who",
            "withdrew",
            "consent",
            "for",
            "continued",
            "follow-up",
            "after",
            "the",
            "date",
            "of",
            "consent",
            "withdrawal",
            ".",
            "Patients",
            "who",
            "had",
            "undergone",
            "randomization",
            "and",
            "received",
            "a",
            "dose",
            "of",
            "any",
            "trial",
            "drug",
            "were",
            "included",
            "in",
            "analy-ses",
            "of",
            "drug",
            "exposure",
            "and",
            "safety.We",
            "used",
            "the",
            "Kaplan\u0152Meier",
            "method",
            "to",
            "sum-marize",
            "time-to-event",
            "end",
            "points",
            "and",
            "to",
            "calculate",
            "event",
            "probabilities",
            "at",
            "3",
            "years",
            ".",
            "An",
            "unadjusted",
            "log-rank",
            "test",
            "was",
            "used",
            "for",
            "the",
            "primary",
            "comparison",
            "of",
            "randomly",
            "assigned",
            "trial",
            "groups",
            ".",
            "We",
            "used",
            "Cox",
            "proportional-hazards",
            "regression",
            "to",
            "estimate",
            "haz-ard",
            "ratios",
            ",",
            "their",
            "95",
            "%",
            "confidence",
            "intervals",
            ",",
            "and",
            "interactions",
            "between",
            "group",
            "assignment",
            "and",
            "pre-specified",
            "baseline",
            "characteristics",
            ".",
            "The",
            "propor-tional-hazards",
            "assumption",
            "was",
            "tested",
            ".",
            "All",
            "P",
            "val-ues",
            "and",
            "confidence",
            "intervals",
            "are",
            "two-sided.We",
            "prespecified",
            "that",
            "consistency",
            "of",
            "the",
            "treat-ment",
            "effect",
            "would",
            "be",
            "evaluated",
            "across",
            "the",
            "fol-lowing",
            "subgroups",
            ":",
            "Gleason",
            "score",
            "(",
            "\u02da7",
            "vs.",
            "8",
            "to",
            "10",
            ")",
            ";",
            "age",
            "at",
            "trial",
            "entry",
            "(",
            "<",
            "70",
            "years",
            "or",
            "\u02dc70",
            "years",
            ")",
            ";",
            "ECOG",
            "performance",
            "status",
            "score",
            "(",
            "0",
            "vs.",
            "1",
            "or",
            "2",
            ")",
            ";",
            "the",
            "pres-ence",
            "or",
            "absence",
            "of",
            "visceral",
            "metastases",
            "in",
            "the",
            "lung",
            ",",
            "liver",
            ",",
            "or",
            "other",
            "organs",
            ";",
            "volume",
            "of",
            "disease",
            "(",
            "high",
            "or",
            "low",
            ")",
            ";",
            "planned",
            "use",
            "or",
            "nonuse",
            "of",
            "early",
            "docetaxel",
            "treatment",
            ";",
            "planned",
            "use",
            "or",
            "nonuse",
            "of",
            "bone",
            "anti-resorptive",
            "therapy",
            ";",
            "the",
            "ACE-27",
            "comorbidity",
            "score",
            "(",
            "0",
            "or",
            "1",
            "vs.",
            "2",
            "or",
            "3",
            ")",
            ";",
            "prior",
            "local",
            "treatment",
            "(",
            "radiation",
            ",",
            "surgery",
            ",",
            "or",
            "neither",
            ")",
            ";",
            "and",
            "geographic",
            "region",
            "(",
            "Aus-tralia",
            "or",
            "New",
            "Zealand",
            "vs.",
            "North",
            "America",
            "vs.",
            "Ire-land",
            "or",
            "United",
            "Kingdom",
            ")",
            ".",
            "We",
            "prespecified",
            "that",
            "the",
            "effects",
            "of",
            "enzalutamide",
            "according",
            "to",
            "the",
            "volume",
            "of",
            "disease",
            "and",
            "the",
            "use",
            "of",
            "early",
            "docetaxel",
            "treatment",
            "were",
            "of",
            "particular",
            "interest",
            ".",
            "We",
            "used",
            "the",
            "Benjamini\u0152Hochberg",
            "method",
            "to",
            "account",
            "for",
            "multiple",
            "comparisons",
            "associated",
            "with",
            "subgroup",
            "analyses.ResultsPatientsFrom",
            "March",
            "2014",
            "through",
            "March",
            "2017",
            ",",
            "we",
            "as-signed",
            "1125",
            "men",
            "to",
            "receive",
            "either",
            "enzalutamide",
            "(",
            "563",
            "patients",
            ")",
            "or",
            "standard",
            "care",
            "(",
            "562",
            "patients",
            ")",
            "at",
            "83",
            "sites",
            "(",
            "Fig",
            ".",
            "S1",
            "and",
            "Table",
            "S1",
            "in",
            "the",
            "Supplemen-tary",
            "Appendix",
            ")",
            ".",
            "A",
            "total",
            "of",
            "14",
            "patients",
            "\u0160",
            "2",
            "who",
            "were",
            "lost",
            "to",
            "follow-up",
            "and",
            "12",
            "who",
            "withdrew",
            "con-sent",
            "for",
            "continued",
            "follow-up",
            "\u0160",
            "were",
            "included",
            "in",
            "the",
            "time-to-event",
            "analyses",
            "with",
            "censored",
            "times",
            "as",
            "appropriate.CharacteristicEnzalutamide\u02dc",
            "(",
            "N\u02dc=\u02dc563",
            ")",
            "Standard\u02dcCare\u02dc",
            "(",
            "N\u02dc=\u02dc562",
            ")",
            "Age",
            "\u0160",
            "yrMean68.9\u00b18.168.8\u00b18.3Median",
            "(",
            "IQR",
            ")",
            "69.2",
            "(",
            "63.2\u015274.5",
            ")",
            "69.0",
            "(",
            "63.6\u015274.5",
            ")",
            "Region",
            "\u0160",
            "no",
            ".",
            "(",
            "%",
            ")",
            "Australia324",
            "(",
            "58",
            ")",
            "321",
            "(",
            "57",
            ")",
            "Canada97",
            "(",
            "17",
            ")",
            "107",
            "(",
            "19",
            ")",
            "Ireland39",
            "(",
            "7",
            ")",
            "43",
            "(",
            "8",
            ")",
            "New",
            "Zealand20",
            "(",
            "4",
            ")",
            "19",
            "(",
            "3",
            ")",
            "United",
            "Kingdom63",
            "(",
            "11",
            ")",
            "50",
            "(",
            "9",
            ")",
            "United",
            "States20",
            "(",
            "4",
            ")",
            "22",
            "(",
            "4",
            ")",
            "Planned",
            "use",
            "of",
            "early",
            "docetaxel",
            "\u0160",
            "no",
            ".",
            "(",
            "%",
            ")",
            "254",
            "(",
            "45",
            ")",
            "249",
            "(",
            "44",
            ")",
            "Volume",
            "of",
            "disease",
            "\u0160",
            "no",
            ".",
            "(",
            "%",
            ")",
            "High291",
            "(",
            "52",
            ")",
            "297",
            "(",
            "53",
            ")",
            "Low272",
            "(",
            "48",
            ")",
            "265",
            "(",
            "47",
            ")",
            "Visceral",
            "metastases",
            "\u0160",
            "no",
            ".",
            "(",
            "%",
            ")",
            "62",
            "(",
            "11",
            ")",
            "67",
            "(",
            "12",
            ")",
            "No",
            ".",
            "of",
            "months",
            "since",
            "diagnosis",
            "of",
            "metastasisMean2.9\u00b16.93.1\u00b17.2Median",
            "(",
            "IQR",
            ")",
            "1.9",
            "(",
            "0.9\u01522.8",
            ")",
            "1.9",
            "(",
            "1.0\u01522.8",
            ")",
            "Gleason",
            "score",
            "\u0160",
            "no",
            ".",
            "(",
            "%",
            ")",
            "\u0192\u02dc7152",
            "(",
            "27",
            ")",
            "163",
            "(",
            "29",
            ")",
            "8\u015210335",
            "(",
            "60",
            ")",
            "321",
            "(",
            "57",
            ")",
            "Missing",
            "data76",
            "(",
            "13",
            ")",
            "78",
            "(",
            "14",
            ")",
            "Previous",
            "therapy",
            "\u0160",
            "no",
            ".",
            "(",
            "%",
            ")",
            "Adjuvant",
            "androgen-deprivation",
            "therapy58",
            "(",
            "10",
            ")",
            "40",
            "(",
            "7",
            ")",
            "Antiandrogen",
            "therapy\u2044285",
            "(",
            "51",
            ")",
            "316",
            "(",
            "56",
            ")",
            "LHRHA\u2044411",
            "(",
            "73",
            ")",
            "418",
            "(",
            "74",
            ")",
            "Bilateral",
            "orchiectomy5",
            "(",
            "1",
            ")",
            "8",
            "(",
            "1",
            ")",
            "Docetaxel\u204495",
            "(",
            "17",
            ")",
            "83",
            "(",
            "15",
            ")",
            "*",
            "Plus\u0152minus",
            "values",
            "are",
            "means",
            "\u00b1SD",
            ".",
            "Patients",
            "in",
            "the",
            "standard-care",
            "group",
            "re-ceived",
            "standard",
            "nonsteroidal",
            "antiandrogen",
            "therapy",
            ".",
            "Patients",
            "in",
            "the",
            "two",
            "groups",
            "also",
            "received",
            "testosterone",
            "suppression",
            ".",
            "Additional",
            "details",
            "are",
            "provided",
            "in",
            "Table",
            "S2",
            "in",
            "the",
            "Supplementary",
            "Appendix",
            ".",
            "Percentages",
            "may",
            "not",
            "total",
            "100",
            "be-cause",
            "of",
            "rounding",
            ".",
            "IQR",
            "denotes",
            "interquartile",
            "range",
            ",",
            "and",
            "LHRHA",
            "luteinizing-hormone\u0152releasing",
            "hormone",
            "agonist",
            "or",
            "antagonist.\u0192",
            "Gleason",
            "scores",
            "for",
            "the",
            "histologic",
            "pattern",
            "of",
            "carcinoma",
            "range",
            "from",
            "2",
            "to",
            "10",
            ",",
            "with",
            "higher",
            "scores",
            "indicating",
            "a",
            "higher-grade",
            "tumor.\u2044",
            "This",
            "therapy",
            "was",
            "initiated",
            "within",
            "12",
            "weeks",
            "before",
            "randomization.Table\u02dc1.\u02dcCharacteristics\u02dcof\u02dcthe\u02dcPatients\u02dcat\u02dcBaseline",
            ".",
            "*",
            "n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019125Enzalutamide",
            "with",
            "Standard",
            "Therapy",
            "in",
            "Prostate",
            "CancerThe",
            "baseline",
            "characteristics",
            "of",
            "all",
            "the",
            "patients",
            "are",
            "summarized",
            "in",
            "Table",
            "1",
            "and",
            "detailed",
            "in",
            "the",
            "Supplementary",
            "Appendix",
            ".",
            "High-volume",
            "disease",
            "was",
            "present",
            "in",
            "52",
            "%",
            "of",
            "the",
            "patients",
            "in",
            "the",
            "two",
            "groups",
            ".",
            "Early",
            "docetaxel",
            "treatment",
            "was",
            "planned",
            "in",
            "45",
            "%",
            "of",
            "the",
            "patients",
            "(",
            "including",
            "in",
            "61",
            "%",
            "of",
            "those",
            "with",
            "high-volume",
            "disease",
            "and",
            "in",
            "27",
            "%",
            "of",
            "those",
            "with",
            "low-volume",
            "disease",
            ")",
            "but",
            "was",
            "not",
            "adminis-tered",
            "to",
            "22",
            "patients",
            ",",
            "11",
            "in",
            "each",
            "of",
            "the",
            "randomly",
            "assigned",
            "treatment",
            "groups",
            ".",
            "The",
            "full",
            "planned",
            "course",
            "of",
            "six",
            "cycles",
            "of",
            "docetaxel",
            "was",
            "given",
            "to",
            "159",
            "of",
            "243",
            "patients",
            "(",
            "65",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "181",
            "of",
            "238",
            "(",
            "76",
            "%",
            ")",
            "in",
            "the",
            "standard-care",
            "group.Overall",
            "SurvivalThe",
            "first",
            "interim",
            "analysis",
            "of",
            "the",
            "primary",
            "end",
            "point",
            "occurred",
            "on",
            "February",
            "28",
            ",",
            "2019",
            ",",
            "after",
            "the",
            "occurrence",
            "of",
            "235",
            "deaths",
            ".",
            "On",
            "March",
            "7",
            ",",
            "2019",
            ",",
            "the",
            "independent",
            "data",
            "and",
            "safety",
            "monitoring",
            "com-mittee",
            "recommended",
            "that",
            "the",
            "unblinded",
            "results",
            "be",
            "provided",
            "to",
            "the",
            "trial",
            "executive",
            "committee",
            "so",
            "that",
            "plans",
            "for",
            "definitive",
            "analyses",
            "could",
            "be",
            "imple-mented",
            ".",
            "The",
            "observed",
            "P",
            "value",
            "of",
            "0.0016",
            "met",
            "the",
            "rejection",
            "boundary",
            "of",
            "0.0031",
            "for",
            "the",
            "null",
            "hypoth-esis",
            "that",
            "was",
            "specified",
            "for",
            "this",
            "interim",
            "analysis",
            ".",
            "The",
            "results",
            "that",
            "are",
            "reported",
            "here",
            "include",
            "10",
            "additional",
            "deaths",
            "(",
            "for",
            "a",
            "total",
            "of",
            "245",
            ")",
            "after",
            "a",
            "re-view",
            "to",
            "ascertain",
            "the",
            "survival",
            "status",
            "of",
            "all",
            "the",
            "patients",
            "as",
            "of",
            "February",
            "28",
            ",",
            "2019",
            ",",
            "after",
            "a",
            "median",
            "follow-up",
            "of",
            "34",
            "months.At",
            "the",
            "time",
            "of",
            "this",
            "analysis",
            ",",
            "there",
            "were",
            "102",
            "deaths",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "143",
            "deaths",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "hazard",
            "ratio",
            "for",
            "death",
            ",",
            "0.67",
            ";",
            "95",
            "%",
            "confidence",
            "interval",
            "[",
            "CI",
            "]",
            ",",
            "0.52",
            "to",
            "0.86",
            ";",
            "P",
            "=",
            "0.002",
            ")",
            "(",
            "Fig",
            ".",
            "1A",
            ")",
            ".",
            "The",
            "results",
            "were",
            "unaf-fected",
            "by",
            "adjustments",
            "for",
            "geographical",
            "region",
            ",",
            "volume",
            "of",
            "disease",
            ",",
            "use",
            "of",
            "early",
            "docetaxel",
            "treat-ment",
            ",",
            "bone",
            "antiresorptive",
            "therapy",
            ",",
            "and",
            "coexisting",
            "conditions",
            ".",
            "The",
            "median",
            "survival",
            "time",
            "was",
            "not",
            "yet",
            "estimable",
            "in",
            "either",
            "trial",
            "group",
            ".",
            "The",
            "Kaplan\u0152Meier",
            "estimates",
            "of",
            "overall",
            "survival",
            "at",
            "3",
            "years",
            "were",
            "80",
            "%",
            "(",
            "based",
            "on",
            "94",
            "events",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "72",
            "%",
            "(",
            "based",
            "on",
            "130",
            "events",
            ")",
            "in",
            "the",
            "standard-care",
            "group.Progression-free",
            "SurvivalThe",
            "effects",
            "of",
            "enzalutamide",
            "on",
            "PSA",
            "progression-free",
            "survival",
            "and",
            "clinical",
            "progression-free",
            "survival",
            "were",
            "larger",
            "than",
            "its",
            "effect",
            "on",
            "overall",
            "survival",
            ".",
            "For",
            "PSA",
            "progression-free",
            "survival",
            ",",
            "there",
            "were",
            "174",
            "events",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "333",
            "events",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "rate",
            "of",
            "event-free",
            "survival",
            "at",
            "3",
            "years",
            ",",
            "67",
            "%",
            "and",
            "37",
            "%",
            "respectively",
            ";",
            "hazard",
            "ratio",
            ",",
            "0.39",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.33",
            "to",
            "0.47",
            ";",
            "P",
            "<",
            "0.001",
            ")",
            "(",
            "Fig",
            ".",
            "1B",
            ")",
            ".",
            "For",
            "clinical",
            "progression-free",
            "survival",
            ",",
            "there",
            "were",
            "167",
            "events",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "320",
            "events",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "rate",
            "of",
            "event-free",
            "survival",
            "at",
            "3",
            "years",
            ",",
            "68",
            "%",
            "and",
            "41",
            "%",
            ",",
            "respectively",
            ";",
            "hazard",
            "ratio",
            ",",
            "0.40",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.33",
            "to",
            "0.49",
            ";",
            "P",
            "<",
            "0.001",
            ")",
            "(",
            "Fig",
            ".",
            "1C",
            ")",
            ".",
            "P",
            "values",
            "for",
            "analyses",
            "of",
            "the",
            "between-group",
            "difference",
            "in",
            "PSA",
            "progres-sion-free",
            "survival",
            "and",
            "clinical",
            "progression-free",
            "survival",
            "remained",
            "highly",
            "significant",
            "after",
            "adjust-ment",
            "for",
            "multiple",
            "comparisons.Subgroup",
            "AnalysesThe",
            "effects",
            "of",
            "enzalutamide",
            "on",
            "overall",
            "survival",
            "were",
            "smaller",
            "among",
            "the",
            "patients",
            "in",
            "the",
            "stratified",
            "subgroups",
            "with",
            "respect",
            "to",
            "bone",
            "antiresorptive",
            "therapy",
            ",",
            "planned",
            "early",
            "docetaxel",
            "treatment",
            ",",
            "and",
            "high-volume",
            "disease",
            "(",
            "Fig",
            ".",
            "2",
            ",",
            "and",
            "Table",
            "S3",
            "in",
            "the",
            "Supplementary",
            "Appendix",
            ")",
            ".",
            "After",
            "adjustment",
            "for",
            "multiple",
            "comparisons",
            ",",
            "P",
            "values",
            "for",
            "heterogeneity",
            "of",
            "the",
            "treatment",
            "effect",
            "of",
            "enzalutamide",
            "were",
            "0.14",
            "for",
            "volume",
            "of",
            "disease",
            ",",
            "0.14",
            "for",
            "early",
            "docetax-el",
            "treatment",
            ",",
            "and",
            "0.06",
            "for",
            "the",
            "use",
            "of",
            "bone",
            "anti-resorptive",
            "therapy.We",
            "anticipated",
            "that",
            "the",
            "smaller",
            "number",
            "of",
            "deaths",
            "would",
            "limit",
            "the",
            "reliability",
            "of",
            "subgroup",
            "analyses",
            "of",
            "overall",
            "survival",
            ".",
            "Thus",
            ",",
            "we",
            "specified",
            "in",
            "the",
            "analysis",
            "plan",
            "that",
            "subgroup",
            "analyses",
            "of",
            "progression-free",
            "survival",
            "would",
            "also",
            "be",
            "per-formed",
            "to",
            "take",
            "advantage",
            "of",
            "the",
            "larger",
            "number",
            "of",
            "events",
            "for",
            "this",
            "secondary",
            "end",
            "point",
            ".",
            "The",
            "ef-fects",
            "of",
            "enzalutamide",
            "on",
            "clinical",
            "progression-free",
            "survival",
            "were",
            "noted",
            "in",
            "all",
            "predefined",
            "sub-groups",
            ",",
            "including",
            "those",
            "with",
            "early",
            "docetaxel",
            "treatment",
            "(",
            "Fig",
            ".",
            "3",
            ",",
            "and",
            "Fig",
            ".",
            "S2",
            "in",
            "the",
            "Supplemen-tary",
            "Appendix",
            ")",
            ".",
            "The",
            "analyses",
            "of",
            "treatment",
            "effects",
            "on",
            "clinical",
            "progression-free",
            "survival",
            "according",
            "to",
            "the",
            "volume",
            "of",
            "disease",
            "and",
            "planned",
            "early",
            "docetax-el",
            "treatment",
            "showed",
            "consistently",
            "smaller",
            "effects",
            "of",
            "enzalutamide",
            "in",
            "patients",
            "with",
            "high-volume",
            "disease",
            "and",
            "in",
            "those",
            "with",
            "early",
            "docetaxel",
            "treat-ment",
            ".",
            "However",
            ",",
            "P",
            "values",
            "for",
            "heterogeneity",
            "of",
            "the",
            "treatment",
            "effect",
            "of",
            "enzalutamide",
            "were",
            "no",
            "longer",
            "significant",
            "after",
            "adjustment",
            "for",
            "multiple",
            "com-parisons",
            "(",
            "Figs",
            ".",
            "S2",
            ",",
            "S3",
            ",",
            "and",
            "S4",
            "in",
            "the",
            "Supplemen-tary",
            "Appendix",
            ")",
            ".Subsequent",
            "Anticancer",
            "TherapiesTreatment",
            "after",
            "progression",
            "was",
            "initiated",
            "at",
            "the",
            "discretion",
            "of",
            "the",
            "patients",
            "and",
            "their",
            "physicians",
            ".",
            "The",
            "number",
            "of",
            "patients",
            "who",
            "received",
            "anticancer",
            "n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019126The",
            "new",
            "england",
            "journal",
            "of",
            "medicinetherapies",
            "after",
            "the",
            "trial",
            "regimen",
            "was",
            "113",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "275",
            "in",
            "the",
            "standard-care",
            "group",
            ",",
            "a",
            "finding",
            "that",
            "was",
            "commensurate",
            "with",
            "the",
            "higher",
            "incidence",
            "of",
            "clinical",
            "progression",
            "in",
            "the",
            "standard-care",
            "group",
            ".",
            "Among",
            "the",
            "patients",
            "who",
            "had",
            "clinical",
            "progression",
            ",",
            "112",
            "of",
            "167",
            "(",
            "67",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "271",
            "of",
            "320",
            "(",
            "85",
            "%",
            ")",
            "in",
            "the",
            "standard-care",
            "group",
            "received",
            "one",
            "or",
            "more",
            "subsequent",
            "life-prolonging",
            "therapies",
            "(",
            "Table",
            "S4",
            "in",
            "the",
            "Supplementary",
            "Appendix",
            ")",
            ".Treatment",
            "DurationAt",
            "3",
            "years",
            ",",
            "the",
            "percentage",
            "of",
            "patients",
            "who",
            "were",
            "still",
            "receiving",
            "a",
            "trial",
            "regimen",
            "was",
            "62",
            "%",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "34",
            "%",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "Table",
            "S5",
            "in",
            "the",
            "Supplementary",
            "Appen-dix",
            ")",
            ".",
            "Disease",
            "progression",
            "or",
            "death",
            "was",
            "the",
            "rea-son",
            "for",
            "discontinuation",
            "in",
            "133",
            "of",
            "201",
            "patients",
            "(",
            "66",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "in",
            "251",
            "of",
            "356",
            "(",
            "71",
            "%",
            ")",
            "in",
            "the",
            "standard-care",
            "group",
            "who",
            "discon-tinued",
            "treatment",
            ".",
            "Discontinuation",
            "for",
            "reasons",
            "other",
            "than",
            "disease",
            "progression",
            "occurred",
            "in",
            "68",
            "of",
            "563",
            "patients",
            "(",
            "12",
            "%",
            ")",
            "and",
            "105",
            "of",
            "558",
            "patients",
            "(",
            "19",
            "%",
            ")",
            "in",
            "the",
            "respective",
            "groups",
            ".",
            "Early",
            "docetaxel",
            "treat-ment",
            "was",
            "administered",
            "in",
            "227",
            "of",
            "487",
            "patients",
            "(",
            "47",
            "%",
            ")",
            "who",
            "subsequently",
            "had",
            "clinical",
            "progression",
            "and",
            "in",
            "91",
            "of",
            "203",
            "(",
            "45",
            "%",
            ")",
            "who",
            "died",
            "from",
            "prostate",
            "cancer",
            ".",
            "Of",
            "the",
            "patients",
            "who",
            "died",
            "from",
            "prostate",
            "cancer",
            "without",
            "receiving",
            "subsequent",
            "therapy",
            ",",
            "ear-ly",
            "docetaxel",
            "treatment",
            "was",
            "administered",
            "in",
            "13",
            "of",
            "28",
            "(",
            "46",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "in",
            "3",
            "of",
            "13",
            "(",
            "23",
            "%",
            ")",
            "in",
            "the",
            "standard-care",
            "group.Adverse",
            "EventsAdverse",
            "events",
            "during",
            "the",
            "follow-up",
            "period",
            "were",
            "consistent",
            "with",
            "the",
            "stage",
            "of",
            "disease",
            ",",
            "the",
            "age",
            "of",
            "the",
            "patients",
            ",",
            "and",
            "known",
            "safety",
            "profiles",
            "of",
            "the",
            "trial",
            "regimen",
            "(",
            "Table",
            "2",
            ";",
            "and",
            "Tables",
            "S6",
            ",",
            "S7",
            ",",
            "and",
            "S8",
            "in",
            "the",
            "Supplementary",
            "Appendix",
            ")",
            ".",
            "During",
            "the",
            "first",
            "6",
            "months",
            ",",
            "adverse",
            "events",
            "of",
            "grades",
            "1",
            "to",
            "3",
            "were",
            "reported",
            "by",
            "more",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "than",
            "in",
            "the",
            "standard-care",
            "group",
            "(",
            "Table",
            "S8",
            "in",
            "the",
            "Supplementary",
            "Appendix",
            ")",
            ".The",
            "number",
            "of",
            "patients",
            "with",
            "febrile",
            "neutro-penia",
            "was",
            "similar",
            "in",
            "the",
            "two",
            "treatment",
            "groups",
            "(",
            "37",
            "with",
            "enzalutamide",
            "and",
            "32",
            "with",
            "standard",
            "care",
            ")",
            ",",
            "and",
            "all",
            "but",
            "2",
            "of",
            "these",
            "events",
            "(",
            "67",
            "of",
            "69",
            ")",
            "occurred",
            "during",
            "early",
            "docetaxel",
            "treatment",
            ".",
            "Seizures",
            "oc-curred",
            "more",
            "frequently",
            "in",
            "patients",
            "in",
            "the",
            "enzalu-tamide",
            "group",
            "(",
            "7",
            "vs.",
            "0",
            ")",
            ".",
            "Six",
            "patients",
            "discontinued",
            "enzalutamide",
            "because",
            "of",
            "seizure",
            ";",
            "1",
            "discontinued",
            "enzalutamide",
            "because",
            "of",
            "clinical",
            "progression",
            "be-fore",
            "the",
            "seizure",
            "event",
            ".",
            "Fatigue",
            "of",
            "any",
            "grade",
            "was",
            "Figure\u02dc1.\u02dcOverall\u02dcSurvival",
            ",",
            "\u02dcPSA\u02dcProgression-free\u02dcSurvival",
            ",",
            "\u02dcand\u02dcClinical\u02dc\u02dcProgression-free\u02dcSurvival.Among",
            "the",
            "patients",
            "who",
            "received",
            "enzalutamide",
            "and",
            "those",
            "who",
            "received",
            "standard",
            "nonsteroidal",
            "antiandrogen",
            "therapy",
            "(",
            "standard-care",
            "group",
            ")",
            ",",
            "shown",
            "are",
            "Kaplan\u0152Meier",
            "curves",
            "for",
            "overall",
            "survival",
            "(",
            "Panel",
            "A",
            ")",
            ",",
            "progression-free",
            "survival",
            "as",
            "determined",
            "by",
            "the",
            "prostate-specific",
            "antigen",
            "(",
            "PSA",
            ")",
            "level",
            "(",
            "Panel",
            "B",
            ")",
            ",",
            "and",
            "clinical",
            "progression-free",
            "survival",
            "as",
            "determined",
            "by",
            "results",
            "on",
            "imaging",
            ",",
            "symptoms",
            ",",
            "signs",
            ",",
            "or",
            "changes",
            "in",
            "therapy",
            "(",
            "Panel",
            "C",
            ")",
            ".\u02dc\u02da\u02da\u02db\u02dd\u02d9\u02dd\u02dd\u02da\u02da\u02da\u02c6\u02dc\u02d9\u02dc\u02c7\u02d9\u02d8\u02d8\u02c7\u02d8\u02dd\u02c6\u02d9\u02dd\u02dd\u02c7\u02dd\u02dd\u02dc\u02dd\u02d8\u02dc\u02dd\u02d9\u02db\u02dd\u02da\u02dc\u02d8\u02c7\u02da\u02d8\u02dd\u02d9\u02dc\u02db\u02d8\u02d8\u02dd\u02d8\u02d9\u02dc\u02da\u02c6\u02c7\u02c6\u02dc\u02da\u02da\u02db\u02dd\u02d9\u02dd\u02dd\u02da\u02da\u02da\u02c6\u02dc\u02d9\u02dc\u02c7\u02d9\u02d8\u02d8\u02c7\u02dd\u02c6\u02d9\u02d8\u02c7\u02c6\u02dd\u02da\u02da\u02d8\u02dd\u02dd\u02d8\u02dc\u02dc\u02dc\u02d8\u02c6\u02db\u02c7\u02dc\u02c6\u02dc\u02dc\u02db\u02d8\u02d9\u02db\u02db\u02d8\u02d8\u02dc\u02da\u02da\u02db\u02dd\u02d9\u02dd\u02dd\u02da\u02da\u02da\u02c6\u02dc\u02d9\u02dc\u02c7\u02d9\u02d8\u02d8\u02c7\u02dd\u02c6\u02d9\u02dd\u02d8\u02db\u02dd\u02dc\u02d9\u02dd\u02da\u02db\u02d8\u02dc\u02c7\u02d8\u02c6\u02c7\u02d8\u02d9\u02d8\u02d9\u02db\u02d9\u02dc\u02dd\u02c6\u02d9\u02c7\u02d8\u02dc\u02c7\u02d9\u02dc\u02db\u02d8\u02d9\u02c7\u02d8\u02dd\u02dan",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019127Enzalutamide",
            "with",
            "Standard",
            "Therapy",
            "in",
            "Prostate",
            "Cancermore",
            "common",
            "with",
            "enzalutamide",
            "than",
            "with",
            "stan-dard",
            "care",
            "(",
            "465",
            "patients",
            "and",
            "363",
            "patients",
            ",",
            "respec-tively",
            ")",
            ".",
            "Grade",
            "2",
            "(",
            "clinically",
            "significant",
            ")",
            "fatigue",
            "was",
            "reported",
            "in",
            "142",
            "patients",
            "(",
            "25",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "in",
            "80",
            "(",
            "14",
            "%",
            ")",
            "in",
            "the",
            "standard-care",
            "group.Adverse",
            "events",
            "that",
            "occurred",
            "during",
            "the",
            "first",
            "6",
            "months",
            "among",
            "the",
            "patients",
            "who",
            "received",
            "early",
            "docetaxel",
            "treatment",
            "are",
            "shown",
            "in",
            "Table",
            "S8",
            "in",
            "the",
            "Supplementary",
            "Appendix",
            ".",
            "Among",
            "those",
            "who",
            "re-ceived",
            "early",
            "docetaxel",
            "treatment",
            ",",
            "grade",
            "2",
            "periph-eral",
            "sensory",
            "neuropathy",
            "was",
            "reported",
            "in",
            "24",
            "of",
            "254",
            "patients",
            "(",
            "9",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "in",
            "7",
            "of",
            "246",
            "(",
            "3",
            "%",
            ")",
            "in",
            "the",
            "standard-care",
            "group",
            ".",
            "Among",
            "those",
            "who",
            "did",
            "not",
            "receive",
            "early",
            "docetax-el",
            "treatment",
            ",",
            "grade",
            "2",
            "peripheral",
            "neuropathy",
            "was",
            "reported",
            "in",
            "none",
            "of",
            "309",
            "patients",
            "in",
            "the",
            "enzalu-tamide",
            "group",
            "and",
            "in",
            "2",
            "of",
            "312",
            "(",
            "1",
            "%",
            ")",
            "in",
            "the",
            "stan-dard-care",
            "group",
            ";",
            "grade",
            "3",
            "peripheral",
            "sensory",
            "neu-ropathy",
            "with",
            "docetaxel",
            "occurred",
            "in",
            "3",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "in",
            "1",
            "in",
            "the",
            "stan-dard-care",
            "group.There",
            "were",
            "385",
            "serious",
            "adverse",
            "events",
            "reported",
            "in",
            "235",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "297",
            "in",
            "189",
            "patients",
            "in",
            "the",
            "standard-care",
            "group",
            ".",
            "Figure\u02dc2.\u02dcSubgroup\u02dcAnalysis\u02dcof\u02dcOverall\u02dcSurvival.Shown",
            "are",
            "the",
            "results",
            "of",
            "subgroup",
            "analysis",
            "of",
            "overall",
            "survival",
            "in",
            "10",
            "key",
            "subgroups",
            "of",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "the",
            "standard-care",
            "group",
            ".",
            "Hazard",
            "ratios",
            "and",
            "95",
            "%",
            "confidence",
            "intervals",
            "are",
            "provided",
            ".",
            "The",
            "size",
            "of",
            "the",
            "gray",
            "shaded",
            "boxes",
            "is",
            "proportional",
            "to",
            "the",
            "number",
            "of",
            "events",
            "in",
            "the",
            "subgroup",
            ".",
            "The",
            "dashed",
            "vertical",
            "line",
            "indicates",
            "the",
            "overall",
            "hazard",
            "ratio",
            "in",
            "all",
            "the",
            "patients",
            ".",
            "Scores",
            "on",
            "the",
            "Eastern",
            "Coopera-tive",
            "Oncology",
            "Group",
            "(",
            "ECOG",
            ")",
            "performance-status",
            "scale",
            "range",
            "from",
            "0",
            "(",
            "no",
            "disability",
            ")",
            "to",
            "5",
            "(",
            "death",
            ")",
            ".",
            "Scores",
            "on",
            "the",
            "Adult",
            "Comorbidity",
            "Evalu-ation",
            "27",
            "(",
            "ACE-27",
            ")",
            "are",
            "0",
            "(",
            "none",
            ")",
            "or",
            "1",
            "(",
            "mild",
            ")",
            "vs.",
            "2",
            "(",
            "moderate",
            ")",
            "or",
            "3",
            "(",
            "severe",
            ")",
            ".\u02dc\u02da\u02db\u02dd\u02da\u02dc\u02d9\u02da\u02dc\u0192",
            "\u2019",
            "\u02dc\u02dc\u02da\u02db",
            "\u2019",
            "\u02d8",
            "\u201e",
            "\u02dc\u02da",
            "\u201d",
            "\u02d9\u201a\u02dc\u02da\u2044\u02db\u2122\u02dc\u02da",
            "\u2019",
            "\u02d9\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01",
            "\u2019",
            "\u201a\u02dd\u02da\u02dc\ufb02\u2122\u02dc\u02da\u02db",
            "\u201d",
            "\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01",
            "\u2019",
            "\u201a\u02dc\u02da\u2044\ufb02\u2122\u02dc\u02da\u02db\u02d9\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01",
            "\u2019",
            "\u201a\u02dc\u02da\u2044\u02d9\u2122\u02dd\u02da\u02dc",
            "\u201d",
            "\u02d8",
            "\u201e",
            "\u02dc\u02da",
            "\u201d",
            "\ufb01\u201a\u02d9\u02da\u02dc\u02d9\u2122\u02dc\u02da\u02db\u02db\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01",
            "\u2019",
            "\u201a\u02dc\u02da\ufb02\u02d9\u2122\u02dc\u02da",
            "\u201d",
            "\u02db\u02d8",
            "\u201e",
            "\u02dc\u02da\u0161\ufb02\u201a\u02dc\u02da\u2044\u02dd\u2122\u02dc\u02da\u2044\u02dd\u02d8",
            "\u201e",
            "\u02dc\u02da",
            "\u201d",
            "\u02db\u201a\u02dd\u02da\u02dd",
            "\u201d",
            "\u2122\u02dc\u02da",
            "\u2019",
            "\u02dc\u02d8",
            "\u201e",
            "\u02dc\u02da",
            "\u201d",
            "\u02dc\u201a\u02dc\u02da\ufb02\u02db\u2122\u02dc\u02da",
            "\u201d",
            "\ufb02\u02d8",
            "\u201e",
            "\u02dc\u02da\u0161\u02dc\u201a\u02dd\u02da\u02dd\u02db\u2122\u02dc\u02da\u02db\u02db\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01",
            "\u201d",
            "\u201a\u02dc\u02da\ufb02\u2044\u2122\u02dc\u02da",
            "\u2019",
            "\u02d9\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01\u02dd\u201a\u02dd\u02da\u02d9",
            "\u201d",
            "\u2122\u02dd\u02da\u02dc\ufb01\u02d8",
            "\u201e",
            "\u02dc\u02da",
            "\u201d",
            "\u2019",
            "\u201a\u02dd\u02da\u2044\u2044\u2122\u02dc\u02da",
            "\u201d",
            "\ufb02\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01",
            "\u201d",
            "\u201a\u02dc\u02da",
            "\u2019",
            "\u2019",
            "\u2122\u02dc\u02da",
            "\u201d",
            "\u2044\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01\u02d9\u201a\u02dc\u02da\u2044\u02dd\u2122\u02dd\u02da",
            "\u2019",
            "\u2019",
            "\u02d8",
            "\u201e",
            "\u02dc\u02da\u2044\u0161\u201a\u0161\u02da",
            "\u2019",
            "\u2019",
            "\u2122\u02dc\u02da",
            "\u2019",
            "\u0161\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01\u02db\u201a\u02dd\u02da\u02dd\u02db\u2122\u02dc\u02da\u02db",
            "\u201d",
            "\u02d8",
            "\u201e",
            "\u02dc\u02da\ufb01\u2044\u201a\u02dc\u02da\u2044\u2044\u2122\u02dc\u02da",
            "\u201d",
            "\u0161\u02d8",
            "\u201e",
            "\u02dc\u02da\u0161",
            "\u2019",
            "\u201a\u02dc\u02da",
            "\u2019",
            "\u201d",
            "\u2122\u02dc\u02da\ufb02\u02dc\u02d8",
            "\u201e",
            "\u02dc\u02da\u02db\u02d9\u201a\u02dd\u02da\u0161\u02dd\u2122\u02dc\u02da\ufb01\u0161\u02d8",
            "\u201e",
            "\u02dc\u02da\u02d9\u02db\u201a\u02dc\u02da",
            "\u2019",
            "\u02d9\u2122\u02dc\u02da\u02d9\u02dc\u02da\u2044\u02dc\u02d8",
            "\u201e",
            "\u02dc\u02da",
            "\u201d",
            "\ufb02\u201a\u02dd\u02da\u02dc",
            "\u2019",
            "\u2122\u02dd\ufb01\u0161\u0141",
            "\u201d",
            "\u02db\u02d9\u02d8\u02d8\u02d8\u02d8\ufb01\u02db\u0141\u02d9\u02db",
            "\u201d",
            "\u02d8\u02d8\ufb02",
            "\u2019",
            "\u0141\u02d9\ufb02",
            "\u2019",
            "\u02d8\u02d8",
            "\u201d",
            "\u201d",
            "\u0141\u02d9\ufb01\ufb02\u02d8\u02d8\u2044\u2044\u0141\u0161\u02dd\u0161\u02d8\u02d8\ufb01\u02d9\u0141\u02dd\ufb01\u0161\u02dd\u02dc\u02dd\u0141\ufb01\u02dd\ufb02\u02dd\u02dd\u0141",
            "\u201d",
            "\u2044\u02dd\u0161\u02d9\u0141",
            "\u201d",
            "\u02dc\ufb01\u02d9\u02d9\u0141\ufb02\u0161\u02d8\u02d8\u0161\u02dd\u0141\u02dd\u02d9\ufb02\u02d8\u02d8\ufb02\u02dc\u0141\u0161\ufb01\u02dc\u02d8\u02d8\u02d9\u0161\u0141\u02dd\u02db\u0161\u02d8\u02d8\u2044\ufb01\u0141\u0161\u02d9\u02dd\u02d8\u02d8",
            "\u201d",
            "\ufb02\u0141\u02dd",
            "\u201d",
            "\u2019",
            "\u02d8\u02d8\u2044\ufb01\u0141\ufb01\u02dc",
            "\u201d",
            "\u02d8\u02d8",
            "\u2019",
            "\ufb02\u0141\u02d9",
            "\u201d",
            "\u2019",
            "\u02d8\u02d8\u02db\ufb01\u0141\u0161\u02dc",
            "\u201d",
            "\u02dd\u2044\u0141\u02db",
            "\u2019",
            "\u02dd\u02d9",
            "\u201d",
            "\u0141\ufb01\ufb02",
            "\u201d",
            "\u02d8\u02d8\ufb01\ufb02\u0141\u02d9\u0161",
            "\u201d",
            "\u02d8\u02d8\ufb02\ufb01\u0141\u0161\u02d9",
            "\u2019",
            "\u02dd\u02dc\u02d9\u0141",
            "\u201d",
            "\u02db\u0161\u02d8\u02d8\u02d9\u02d9\u0141\u02d9",
            "\u2019",
            "\u02d9\u02d8\u02d8\u2044\u02dc\u0141\u02d9\ufb02\u02dd\u02d8\u02d8",
            "\u201d",
            "\u02d9\u0141\u02d9",
            "\u201d",
            "\ufb01\u02d8\u02d8",
            "\u201d",
            "\u02dc\u0141\u0161\u02dc\ufb02\u02d8\u02d8\u0161\u02dd\u0141\u02dd\ufb01\u02dd\u02d8\u02d8",
            "\u2019",
            "\u02dd\u0141\ufb01\u02d9\u02d9\u02dd",
            "\u2019",
            "\u0141",
            "\u201d",
            "\u201d",
            "\u02d8\u02d8\u2044",
            "\u201d",
            "\u0141",
            "\u201d",
            "\u02dc\u2044\u02d8\u02d8\u02d9\u02d9\u0141\u02dd\u02dc\u02d9\u02d8\u02d8\u02d9\u02dd\u0141\u02dd\u02dd",
            "\u2019",
            "\u02d8\u02d8",
            "\u201d",
            "\ufb02\u0141\u0161\ufb01\ufb01\u02d8\u02d8\u02dd\u0161\u0141\u02dd",
            "\u201d",
            "\u02d9\u02d8\u02d8\u02db\u02db\u0141\u0161\u0161",
            "\u201d",
            "\u02d8\u02d8\ufb01\ufb01\u0141\u02dd",
            "\u201d",
            "\u2044\u02d8\u02d8",
            "\u201d",
            "\u2044\u0141\ufb01\u02dc",
            "\u201d",
            "\u02d8\u02d8\ufb01",
            "\u2019",
            "\u0141\u02d9",
            "\u201d",
            "\u2019",
            "\u02d8\u02d8",
            "\u201d",
            "\u201d",
            "\u0141\u0161\u02dc\u02db\u02dd\u2044\u0141\u02db\u02d9\u02d8\u02d8\u2044\ufb01\u0141",
            "\u201d",
            "\u02dc\u02dd\u02d8\u02d8\u0161\ufb02\u0141\u02d9\u0161\u2044\u02d8\u02d8\u02db\u0161\u0141\u0161\u02d9",
            "\u201d",
            "\u02dc\u02da\u02dc\ufb01\u02dc\u02da\u02dc\ufb01\u02dc\u02da",
            "\u2019",
            "\u0161\u02dc\u02da\u02dc\u02dc\u02db\u02dc\u02da\u02d9",
            "\u201d",
            "\u02dc\u02da\u02db\u02db\u02dc\u02da\ufb02\u02db\u02dc\u02da\u02dd\u02db\u02dc\u02da\u02dd\u02db\u02dc\u02da",
            "\u2019",
            "\u02d9\u02dc\u02da\u02dd\ufb01\u02dc\u02da\u02dd\ufb01\u02dc\u02da\u2044\u02dd\u02dc\u02da\u02dc\u02db\u02dc\u02da\ufb01\u02d9\u02dc\u02da\u2044\u02dd\u02dc\u02da\ufb02\u02db\u02dc\u02da\u0161\u0161\u02dc\u02da\u0161\u0161\u02dc\u02da\u2044\u02ddn",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019128The",
            "new",
            "england",
            "journal",
            "of",
            "medicineThe",
            "larger",
            "number",
            "of",
            "serious",
            "adverse",
            "events",
            "as-sociated",
            "with",
            "enzalutamide",
            "was",
            "commensurate",
            "with",
            "the",
            "longer",
            "duration",
            "of",
            "trial",
            "treatment",
            ".",
            "The",
            "frequency",
            "of",
            "serious",
            "adverse",
            "events",
            "per",
            "person-year",
            "of",
            "exposure",
            "to",
            "a",
            "trial",
            "regimen",
            "was",
            "similar",
            "in",
            "the",
            "two",
            "groups",
            "(",
            "Table",
            "2",
            ")",
            ".DiscussionEnzalutamide",
            "was",
            "associated",
            "with",
            "longer",
            "overall",
            "survival",
            "and",
            "progression-free",
            "survival",
            "than",
            "stan-dard",
            "care",
            "with",
            "nonsteroidal",
            "antiandrogen",
            "therapy",
            "in",
            "men",
            "with",
            "metastatic",
            ",",
            "hormone-sensitive",
            "pros-tate",
            "cancer",
            ".",
            "All",
            "the",
            "patients",
            "received",
            "testosterone",
            "suppression",
            ",",
            "plus",
            "the",
            "addition",
            "of",
            "docetaxel",
            "when",
            "appropriate",
            ".",
            "The",
            "control",
            "group",
            "in",
            "this",
            "trial",
            "was",
            "treated",
            "with",
            "standard",
            "antiandrogen",
            "therapy",
            "to",
            "provide",
            "a",
            "stringent",
            "comparator",
            ".",
            "All",
            "the",
            "patients",
            "had",
            "access",
            "to",
            "further",
            "effective",
            "therapies",
            "if",
            "the",
            "cancer",
            "progressed",
            ",",
            "and",
            "a",
            "high",
            "proportion",
            "of",
            "the",
            "patients",
            "in",
            "the",
            "standard-care",
            "group",
            "received",
            "enzalutamide",
            "or",
            "abiraterone",
            "after",
            "disease",
            "pro-gression",
            ".",
            "The",
            "frequency",
            "of",
            "early",
            "docetaxel",
            "treat-ment",
            "was",
            "similar",
            "in",
            "the",
            "two",
            "groups",
            ".",
            "Thus",
            ",",
            "the",
            "Figure\u02dc3.\u02dcSubgroup\u02dcAnalysis\u02dcof\u02dcClinical\u02dcProgression-free\u02dcSurvival.Shown",
            "are",
            "the",
            "results",
            "of",
            "subgroup",
            "analysis",
            "of",
            "clinical",
            "progression-free",
            "survival",
            "in",
            "10",
            "key",
            "subgroups",
            "of",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "standard-care",
            "group",
            ".",
            "Clinical",
            "progression-free",
            "survival",
            "was",
            "determined",
            "by",
            "results",
            "on",
            "imaging",
            ",",
            "symptoms",
            ",",
            "signs",
            ",",
            "or",
            "changes",
            "in",
            "therapy.\u02dc\u02da\u02db\u02dd\u02da\u02dc\u02d9\u02da\u02dc\u0192",
            "\u2019",
            "\u02dc\u02dc\u02da\u02d9\u02dd\u02dd\u2044",
            "\u201e",
            "\u02d9\u02db",
            "\u201d",
            "\u02dd",
            "\u2019",
            "\u201a",
            "\u201e",
            "\u0161\u02dd\u0161\u02dd",
            "\u201d",
            "\u2122",
            "\u201e",
            "\u02d9",
            "\u201d",
            "\u2019",
            "\u02d8\u02d8\u02db",
            "\u2019",
            "\u201e",
            "\u02dd\u02db\u0161\u02dd\u2122",
            "\u2019",
            "\u201e",
            "\u0161\u201a\u02dc\u02dd\u02db\u02dd",
            "\u201e",
            "\u0161\u02dc",
            "\u201d",
            "\u02d9\u02dd\u201a",
            "\u201e",
            "\u201a\u02dc",
            "\u201d",
            "\u02dd\u02dc\u02db",
            "\u201e",
            "\u02dd",
            "\u201d",
            "\u2019",
            "\u02dd\u201a\u02db",
            "\u201e",
            "\u02d9\u201a\u2122\u02d9\u0161\u02d9",
            "\u201e",
            "\u201a\u02dd\u2122\u0161",
            "\u201d",
            "\u201e",
            "\u201d",
            "\u2044\u02d9\u2044",
            "\u201d",
            "\u201e",
            "\u201d",
            "\u02dc\u201a\u201a\u2044",
            "\u201e",
            "\u2122\u0161\u02dd\u2122\u02dc",
            "\u201e",
            "\u0161\u02d9\u02dd\u201a\u02dd",
            "\u201e",
            "\u02db",
            "\u2019",
            "\u02d9",
            "\u2019",
            "\u2122",
            "\u201e",
            "\u201a\u2122",
            "\u201d",
            "\u0161\u02d9\u02dc",
            "\u201e",
            "\u201d",
            "\u02db\u02d9\u02dd\u02d9\u02dc",
            "\u201e",
            "\u02d9\u0161",
            "\u201d",
            "\u02d8\u02d8",
            "\u2019",
            "\u201d",
            "\u201e",
            "\u02dd\u02d9\u2122\u02d9\u02dc\u02d9",
            "\u201e",
            "\u02d9\u2122",
            "\u2019",
            "\u02d8\u02d8\u2044\u2044",
            "\u201e",
            "\u02dd\u201a\u0161\u02d8\u02d8\u201a\u02db",
            "\u201e",
            "\u02d9",
            "\u2019",
            "\u02d9\u02d8\u02d8",
            "\u2019",
            "\u02db",
            "\u201e",
            "\u0161\u02dc\u2122",
            "\u2019",
            "\u02dd",
            "\u201e",
            "\u02d9",
            "\u201d",
            "\u2019",
            "\u02d8\u02d8\u02d9\u201a",
            "\u201e",
            "\u02dd",
            "\u201d",
            "\u02d9\u02d8\u02d8\u2122\u2044",
            "\u201e",
            "\u0161\u201a\u201a\u02d8\u02d8\u2122\u02db",
            "\u201e",
            "\u0161\u02dc\u02db\u02dd\u02dc\u0161",
            "\u201e",
            "\u201a\u02dc",
            "\u201d",
            "\u02d8\u02d8\u02db\u201a",
            "\u201e",
            "\u02dd",
            "\u201d",
            "\u2044\u02d8\u02d8\u2122\u02dd",
            "\u201e",
            "\u02d9",
            "\u201d",
            "\u201a\u02dd\u02d9\u0161",
            "\u201e",
            "\u201a\u02d9\u02d9\u02d9\u02d9",
            "\u201e",
            "\u201d",
            "\u201d",
            "\u02dd\u201a",
            "\u201d",
            "\u201e",
            "\u201d",
            "\u02dc\u2044\u02d8\u02d8\u0161\u02db",
            "\u201e",
            "\u02dd\u02dc\u02d9\u02dd\u02dd\u02dc",
            "\u201e",
            "\u0161\u0161",
            "\u201d",
            "\u02d9\u02db",
            "\u201e",
            "\u02db\u02d9\u02dd\u201a\u02dd",
            "\u201e",
            "\u201d",
            "\u02dc\u02dd\u02dd\u02db",
            "\u2019",
            "\u201e",
            "\u201d",
            "\u02db\u0161\u02d8\u02d8\u02db\u201a",
            "\u201e",
            "\u02d9\u0161\u2044\u02d8\u02d8\u0161\u0161",
            "\u201e",
            "\u02dd\u02dd",
            "\u2019",
            "\u02dd\u02d9\u02dd",
            "\u201e",
            "\u02d9\u2122\u02dd\u02d8\u02d8\u201a\u201a",
            "\u201e",
            "\u02dd\u201a\u02dd\u02dc\u02da\u0161\u0161\u02d8\ufb01\u02dc\u02da\u02d9",
            "\u201d",
            "\ufb02\u02dc\u02da\u201a\u201a\u0141\u02dc\u02da\u0161\u2044\u02d8\ufb01\u02dc\u02da\u0161\u02dc\ufb02\u02dc\u02da\u201a\u2044\u0141\u02dc\u02da\u201a\u02dd\u02d8\ufb01\u02dc\u02da\u0161\u0161\ufb02\u02dc\u02da",
            "\u201d",
            "\u02dd\u0141\u02dc\u02da",
            "\u201d",
            "\u2019",
            "\u02d8\ufb01\u02dc\u02da\u0161\u201a\ufb02\u02dc\u02da\u2122\u2044\u0141\u02dc\u02da",
            "\u201d",
            "\u2122\u02d8\ufb01\u02dc\u02da\u0161\u2044\ufb02\u02dc\u02da\u2122\u02dd\u0141\u02dc\u02da",
            "\u201d",
            "\u2044\u02d8\ufb01\u02dc\u02da\u0161",
            "\u201d",
            "\ufb02\u02dc\u02da\u2122",
            "\u201d",
            "\u0141\u02dc\u02da\u201a\u02d9\u02d8\ufb01\u02dc\u02da\u0161\u02dd\ufb02\u02dc\u02da",
            "\u201d",
            "\u2019",
            "\u0141\u02dc\u02da\u0161\u02db\u02d8\ufb01\u02dc\u02da\u02d9\u201a\ufb02\u02dc\u02da",
            "\u201d",
            "\u201d",
            "\u0141\u02dc\u02da\u201a\u02dc\u02d8\ufb01\u02dc\u02da\u02d9\u2044\ufb02\u02dc\u02da",
            "\u201d",
            "\u2019",
            "\u0141\u02dc\u02da\u02dc",
            "\u201d",
            "\u02dc\u02da\u02dd\u2044\u02dc\u02da\u02dc\u02db\u02dc\u02da",
            "\u201d",
            "\u02db\u02dc\u02da\u2044\u2044\u02dc\u02da\u02dd\u2122\u02dc\u02da\u0161\u02db\u02dc\u02da\u02dd\u0161\u02dc\u02da\u02dc",
            "\u2019",
            "\u02dc\u02da\u0161\u02dc\u02d8\ufb01\u02dc\u02da\u02d9\u02d9\ufb02\u02dc\u02da\u201a\u0161\u0141\u02dc\u02da\u0161\u201a\u02d8\ufb01\u02dc\u02da\u02d9\u02db\ufb02\u02dc\u02da\u201a\u201a\u0141\u02dc\u02da\u0161\u0161\u02d8\ufb01\u02dc\u02da\u02d9\u02dd\ufb02\u02dc\u02da",
            "\u201d",
            "\u0161\u0141\u02dc\u02da\u0161",
            "\u2019",
            "\u02d8\ufb01\u02dc\u02da\u02d9\u2122\ufb02\u02dc\u02da\u201a\u2044\u0141\u02dc\u02da\u201a",
            "\u2019",
            "\u02d8\ufb01\u02dc\u02da\u0161",
            "\u2019",
            "\ufb02\u02dc\u02da\u02db\u02dd\u0141\u02dc\u02da\u201a\u201a\u02d8\ufb01\u02dc\u02da\u0161\u02d9\ufb02\u02dc\u02da\u02db\u02dc\u0141\u02dc\u02da\u201a\u2044\u02d8\ufb01\u02dc\u02da\u0161",
            "\u2019",
            "\ufb02\u02dc\u02da\u02db\u02d9\u0141\u02dc\u02da\u0161\u2122\u02d8\ufb01\u02dc\u02da\u0161\u02d9\ufb02\u02dc\u02da\u201a",
            "\u2019",
            "\u0141\u02dc\u02da\u201a\u02d9\u02d8\ufb01\u02dc\u02da\u0161\u0161\ufb02\u02dc\u02da",
            "\u201d",
            "\u0161\u0141\u02dc\u02da\u0161\u2044\u02d8\ufb01\u02dc\u02da\u0161\u02dd\ufb02\u02dc\u02da\u201a",
            "\u2019",
            "\u0141\u02dc\u02da\u201a\u02dc\u02d8\ufb01\u02dc\u02da\u0161\u0161\ufb02\u02dc\u02da\u201a\u2122\u0141\u02dc\u02da\u201a",
            "\u201d",
            "\u02d8\ufb01\u02dc\u02da\u0161\u02db\ufb02\u02dc\u02da",
            "\u201d",
            "\u2019",
            "\u0141\u02d9\u02dc\u02dc",
            "\u201e",
            "\u0161\u02d9",
            "\u2019",
            "\u02dd\u02dc\u0161",
            "\u201e",
            "\u0161\u02d9",
            "\u201d",
            "\u02dc\u02da",
            "\u2019",
            "\u2019",
            "\u02dc\u02da\u02d9\u0161\u02dc\u02da\u0161\u02dd\u02dc\u02da\u02d9\u0161\u02dc\u02da",
            "\u2019",
            "\u02dd\u02dc\u02da\u2044\u2044\u02dc\u02da\u0161\u02dd\u02dc\u02da",
            "\u201d",
            "\u02dd\u02dc\u02da\u0161\u02dd\u02dc\u02da\u02d9\u0161\u02dc\u02da\u2044\u02db\u02dc\u02da\u0161\u2122\u02d8\ufb01\u02dc\u02da\u0161\u02dd\ufb02\u02dc\u02da",
            "\u201d",
            "\u02dc\u0141n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019129Enzalutamide",
            "with",
            "Standard",
            "Therapy",
            "in",
            "Prostate",
            "Cancerobserved",
            "benefits",
            "of",
            "early",
            "enzalutamide",
            "therapy",
            "are",
            "not",
            "explained",
            "by",
            "differences",
            "in",
            "access",
            "to",
            "or",
            "use",
            "of",
            "subsequent",
            "therapies.We",
            "found",
            "that",
            "adding",
            "early",
            "enzalutamide",
            "to",
            "testosterone",
            "suppression",
            "was",
            "associated",
            "with",
            "a",
            "higher",
            "frequency",
            "of",
            "toxic",
            "effects",
            ",",
            "especially",
            "periph-eral",
            "neuropathy",
            "associated",
            "with",
            "the",
            "concomitant",
            "use",
            "of",
            "docetaxel",
            ".",
            "Patients",
            "who",
            "were",
            "treated",
            "with",
            "enzalutamide",
            "reported",
            "more",
            "fatigue",
            "and",
            "more",
            "often",
            "discontinued",
            "therapy",
            "before",
            "disease",
            "progres-sion",
            ".",
            "Seven",
            "patients",
            "(",
            "1",
            "%",
            ")",
            "in",
            "this",
            "group",
            "had",
            "seizures",
            ",",
            "a",
            "known",
            "potential",
            "side",
            "effect",
            "of",
            "enzalutamide.Adverse\u02dcEventEnzalutamide\u02dc",
            "(",
            "N\u02dc=\u02dc563",
            ")",
            "Standard\u02dcCare\u02dc",
            "(",
            "N\u02dc=\u02dc558",
            ")",
            "Any",
            "adverse",
            "event",
            "\u0160",
            "no",
            ".",
            "of",
            "patients",
            "(",
            "%",
            ")",
            "*",
            "Grade",
            "140",
            "(",
            "7",
            ")",
            "77",
            "(",
            "14",
            ")",
            "Grade",
            "2202",
            "(",
            "36",
            ")",
            "230",
            "(",
            "41",
            ")",
            "Grade",
            "3277",
            "(",
            "49",
            ")",
            "194",
            "(",
            "35",
            ")",
            "Grade",
            "438",
            "(",
            "7",
            ")",
            "40",
            "(",
            "7",
            ")",
            "Grade",
            "56",
            "(",
            "1",
            ")",
            "7",
            "(",
            "1",
            ")",
            "Serious",
            "adverse",
            "eventNo",
            ".",
            "of",
            "patients",
            "(",
            "%",
            ")",
            "235",
            "(",
            "42",
            ")",
            "189",
            "(",
            "34",
            ")",
            "No",
            ".",
            "of",
            "events385297Rate",
            "during",
            "treatment",
            "exposure",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "\u0160",
            "no./yr\u01920.34",
            "(",
            "0.29\u01520.40",
            ")",
            "0.33",
            "(",
            "0.28\u01520.39",
            ")",
            "Adverse",
            "event",
            "leading",
            "to",
            "treatment",
            "discontinuation",
            "at",
            "any",
            "time",
            "\u0160",
            "no",
            ".",
            "of",
            "patients3314Grade",
            "3",
            "to",
            "5",
            "adverse",
            "event",
            "\u0160",
            "no",
            ".",
            "of",
            "patients",
            "(",
            "%",
            ")",
            "\u2044Febrile",
            "neutropenia37",
            "(",
            "7",
            ")",
            "32",
            "(",
            "6",
            ")",
            "Hypertension43",
            "(",
            "8",
            ")",
            "25",
            "(",
            "4",
            ")",
            "Neutrophil",
            "count",
            "decreased31",
            "(",
            "6",
            ")",
            "16",
            "(",
            "3",
            ")",
            "Fatigue31",
            "(",
            "6",
            ")",
            "4",
            "(",
            "1",
            ")",
            "Syncope20",
            "(",
            "4",
            ")",
            "6",
            "(",
            "1",
            ")",
            "Surgical",
            "or",
            "medical",
            "procedure13",
            "(",
            "2",
            ")",
            "10",
            "(",
            "2",
            ")",
            "Anemia4",
            "(",
            "1",
            ")",
            "5",
            "(",
            "1",
            ")",
            "Fall6",
            "(",
            "1",
            ")",
            "2",
            "(",
            "<",
            "1",
            ")",
            "Thromboembolic",
            "event4",
            "(",
            "1",
            ")",
            "4",
            "(",
            "1",
            ")",
            "Acute",
            "coronary",
            "syndrome3",
            "(",
            "1",
            ")",
            "4",
            "(",
            "1",
            ")",
            "Myocardial",
            "infarction5",
            "(",
            "1",
            ")",
            "2",
            "(",
            "<",
            "1",
            ")",
            "Chest",
            "pain",
            "from",
            "cardiac",
            "cause3",
            "(",
            "1",
            ")",
            "2",
            "(",
            "<",
            "1",
            ")",
            "Stroke1",
            "(",
            "<",
            "1",
            ")",
            "2",
            "(",
            "<",
            "1",
            ")",
            "Seizure\u00a72",
            "(",
            "<",
            "1",
            ")",
            "0Delirium01",
            "(",
            "<",
            "1",
            ")",
            "*",
            "When",
            "a",
            "patient",
            "had",
            "multiple",
            "events",
            "identified",
            "by",
            "a",
            "particular",
            "term",
            ",",
            "the",
            "worst",
            "grade",
            "is",
            "shown.\u0192",
            "The",
            "rate",
            "of",
            "serious",
            "adverse",
            "events",
            "per",
            "year",
            "of",
            "treatment",
            "exposure",
            "was",
            "estimated",
            "with",
            "the",
            "use",
            "of",
            "a",
            "negative",
            "binomial",
            "regression",
            "model.\u2044",
            "These",
            "adverse",
            "events",
            "occurred",
            "in",
            "at",
            "least",
            "2",
            "%",
            "of",
            "the",
            "patients",
            "in",
            "either",
            "group",
            "or",
            "were",
            "selected",
            "as",
            "being",
            "events",
            "of",
            "special",
            "interest",
            ".",
            "In",
            "the",
            "enzalutamide",
            "group",
            ",",
            "6",
            "grade",
            "5",
            "adverse",
            "events",
            "were",
            "reported",
            ":",
            "death",
            "from",
            "an",
            "unknown",
            "cause",
            "in",
            "2",
            "patients",
            "and",
            "1",
            "patient",
            "each",
            "with",
            "stroke",
            ",",
            "myocardial",
            "infarction",
            ",",
            "aspiration",
            "pneumonia",
            ",",
            "and",
            "acidosis",
            ".",
            "In",
            "the",
            "standard-care",
            "group",
            ",",
            "7",
            "grade",
            "5",
            "adverse",
            "events",
            "were",
            "reported",
            ":",
            "sepsis",
            "in",
            "2",
            "patients",
            "and",
            "1",
            "patient",
            "each",
            "with",
            "cardiac",
            "arrest",
            ",",
            "sudden",
            "death",
            "from",
            "an",
            "unknown",
            "cause",
            ",",
            "gastric",
            "hemorrhage",
            ",",
            "urinary",
            "tract",
            "infection",
            ",",
            "and",
            "symptomatic",
            "progression",
            "of",
            "prostate",
            "cancer.\u00a7",
            "Seizure",
            "of",
            "any",
            "grade",
            "occurred",
            "in",
            "7",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "in",
            "no",
            "patients",
            "in",
            "the",
            "standard-care",
            "group.Table\u02dc2.\u02dcAdverse\u02dcEvents.n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019130The",
            "new",
            "england",
            "journal",
            "of",
            "medicineThe",
            "effect",
            "of",
            "enzalutamide",
            "on",
            "overall",
            "survival",
            "appeared",
            "to",
            "be",
            "smaller",
            "in",
            "the",
            "subgroup",
            "with",
            "early",
            "docetaxel",
            "treatment",
            ".",
            "However",
            ",",
            "this",
            "trial",
            "was",
            "neither",
            "designed",
            "nor",
            "powered",
            "to",
            "reliably",
            "analyze",
            "the",
            "results",
            "in",
            "this",
            "subgroup",
            ".",
            "The",
            "effects",
            "of",
            "enzalu-tamide",
            "on",
            "clinical",
            "progression-free",
            "survival",
            ",",
            "an",
            "earlier",
            "end",
            "point",
            "with",
            "considerably",
            "more",
            "events",
            "and",
            "consequently",
            "greater",
            "statistical",
            "reliability",
            ",",
            "remained",
            "substantial",
            "regardless",
            "of",
            "early",
            "docetax-el",
            "treatment",
            ".",
            "This",
            "finding",
            "indicates",
            "that",
            "longer",
            "follow-up",
            "is",
            "needed",
            "to",
            "determine",
            "the",
            "effects",
            "of",
            "enzalutamide",
            "on",
            "overall",
            "survival",
            "beyond",
            "3",
            "years",
            "in",
            "those",
            "with",
            "early",
            "docetaxel",
            "treatment",
            ".",
            "Our",
            "cur-rent",
            "data",
            "support",
            "the",
            "claim",
            "that",
            "early",
            "enzalu-tamide",
            "prolongs",
            "survival",
            "within",
            "3",
            "years",
            "in",
            "the",
            "entire",
            "trial",
            "population",
            "but",
            "provide",
            "limited",
            "sup-port",
            "that",
            "it",
            "prolongs",
            "overall",
            "survival",
            "within",
            "3",
            "years",
            "in",
            "patients",
            "who",
            "received",
            "early",
            "docetaxel",
            "treatment.The",
            "main",
            "limitations",
            "of",
            "this",
            "trial",
            "are",
            "conse-quences",
            "of",
            "the",
            "detection",
            "of",
            "evidence",
            "of",
            "benefit",
            "at",
            "the",
            "first",
            "planned",
            "interim",
            "analysis",
            ".",
            "This",
            "early",
            "analy-sis",
            "may",
            "have",
            "overestimated",
            "the",
            "eventual",
            "treatment",
            "benefit.20",
            "There",
            "was",
            "no",
            "central",
            "review",
            "of",
            "actual",
            "imaging",
            ",",
            "but",
            "this",
            "factor",
            "would",
            "have",
            "no",
            "effect",
            "on",
            "the",
            "rate",
            "of",
            "death",
            ",",
            "the",
            "primary",
            "end",
            "point",
            ".",
            "The",
            "me-dian",
            "follow-up",
            "of",
            "34",
            "months",
            "is",
            "sufficient",
            "to",
            "pro-vide",
            "evidence",
            "about",
            "the",
            "effects",
            "within",
            "this",
            "interval",
            "but",
            "not",
            "beyond",
            "it",
            ".",
            "The",
            "sample",
            "size",
            "and",
            "number",
            "of",
            "events",
            "allow",
            "for",
            "strong",
            "conclusions",
            "about",
            "the",
            "effects",
            "of",
            "enzalutamide",
            "on",
            "survival",
            "in",
            "the",
            "entire",
            "trial",
            "population",
            "and",
            "the",
            "effects",
            "on",
            "progression-free",
            "survival",
            "in",
            "some",
            "subgroups",
            ";",
            "however",
            ",",
            "we",
            "can",
            "not",
            "determine",
            "the",
            "effects",
            "on",
            "overall",
            "survival",
            "in",
            "any",
            "of",
            "the",
            "prespecified",
            "subgroups.In",
            "conclusion",
            ",",
            "in",
            "men",
            "with",
            "metastatic",
            "hor-mone-sensitive",
            "prostate",
            "cancer",
            "receiving",
            "testos-terone",
            "suppression",
            ",",
            "the",
            "addition",
            "of",
            "enzalutamide",
            "resulted",
            "in",
            "longer",
            "overall",
            "survival",
            ",",
            "PSA",
            "progres-sion-free",
            "survival",
            ",",
            "and",
            "clinical",
            "progression-free",
            "survival",
            "within",
            "3",
            "years",
            "than",
            "the",
            "use",
            "of",
            "standard",
            "nonsteroidal",
            "antiandrogen",
            "therapy",
            ".",
            "However",
            ",",
            "enzalutamide",
            "was",
            "associated",
            "with",
            "some",
            "additional",
            "toxic",
            "effects",
            ",",
            "including",
            "fatigue",
            "and",
            "a",
            "small",
            "risk",
            "of",
            "seizures",
            ".",
            "Among",
            "the",
            "patients",
            "who",
            "also",
            "received",
            "early",
            "docetaxel",
            "treatment",
            ",",
            "the",
            "addition",
            "of",
            "enzalu-tamide",
            "was",
            "associated",
            "with",
            "additional",
            "toxic",
            "ef-fects",
            "and",
            "longer",
            "progression-free",
            "survival",
            "but",
            "not",
            "longer",
            "overall",
            "survival.Supported",
            "by",
            "Astellas",
            "Scientific",
            "and",
            "Medical",
            "Affairs",
            ",",
            "a",
            "grant",
            "(",
            "704970",
            ")",
            "from",
            "the",
            "Canadian",
            "Cancer",
            "Society",
            ",",
            "the",
            "Support",
            "for",
            "Cancer",
            "Clinical",
            "Trials",
            "Program",
            "of",
            "Cancer",
            "Australia",
            ",",
            "and",
            "a",
            "prac-titioner",
            "fellowship",
            "(",
            "APP1102604",
            ")",
            "and",
            "program",
            "grants",
            "(",
            "1037786",
            "and",
            "1150467",
            ")",
            "from",
            "the",
            "National",
            "Health",
            "and",
            "Medical",
            "Research",
            "Council",
            "of",
            "the",
            "Australian",
            "Government",
            "Department",
            "of",
            "Health.Disclosure",
            "forms",
            "provided",
            "by",
            "the",
            "authors",
            "are",
            "available",
            "with",
            "the",
            "full",
            "text",
            "of",
            "this",
            "article",
            "at",
            "NEJM.org.A",
            "data",
            "sharing",
            "statement",
            "provided",
            "by",
            "the",
            "authors",
            "is",
            "available",
            "with",
            "the",
            "full",
            "text",
            "of",
            "this",
            "article",
            "at",
            "NEJM.org.AppendixThe",
            "authors\u2122",
            "full",
            "names",
            "and",
            "academic",
            "degrees",
            "are",
            "as",
            "follows",
            ":",
            "Ian",
            "D.",
            "Davis",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Ph.D.",
            ",",
            "Andrew",
            "J.",
            "Martin",
            ",",
            "Ph.D.",
            ",",
            "Martin",
            "R.",
            "Stockler",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Stephen",
            "Begbie",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Kim",
            "N.",
            "Chi",
            ",",
            "M.D.",
            ",",
            "Simon",
            "Chowdhury",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Ph.D.",
            ",",
            "Xanthi",
            "Coskinas",
            ",",
            "M.Med.Sc.",
            ",",
            "Mark",
            "Frydenberg",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Wendy",
            "E.",
            "Hague",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Ph.D.",
            ",",
            "Lisa",
            "G.",
            "Horvath",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Ph.D.",
            ",",
            "Anthony",
            "M.",
            "Joshua",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Ph.D.",
            ",",
            "Nicola",
            "J.",
            "Lawrence",
            ",",
            "M.B.",
            ",",
            "Ch.B.",
            ",",
            "Gavin",
            "Marx",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "John",
            "McCaffrey",
            ",",
            "M.B.",
            ",",
            "B.Ch.",
            ",",
            "Ray",
            "McDermott",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Margaret",
            "McJannett",
            ",",
            "R.N.",
            ",",
            "Scott",
            "A",
            ".",
            "North",
            ",",
            "M.D.",
            ",",
            "Francis",
            "Parnis",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Wendy",
            "Parulekar",
            ",",
            "M.D.",
            ",",
            "David",
            "W.",
            "Pook",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "M.D.",
            ",",
            "M.",
            "Neil",
            "Reaume",
            ",",
            "M.D.",
            ",",
            "Shahneen",
            "K.",
            "Sandhu",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Alvin",
            "Tan",
            ",",
            "M.B.",
            ",",
            "Ch.B.",
            ",",
            "T.",
            "Hsiang",
            "Tan",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Alastair",
            "Thomson",
            ",",
            "B.M.",
            ",",
            "Emily",
            "Tu",
            ",",
            "Ph.D.",
            ",",
            "Francisco",
            "Vera-Badillo",
            ",",
            "M.D.",
            ",",
            "Scott",
            "G.",
            "Williams",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "M.D.",
            ",",
            "Sonia",
            "Yip",
            ",",
            "Ph.D.",
            ",",
            "Alison",
            "Y.",
            "Zhang",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "Robert",
            "R.",
            "Zielinski",
            ",",
            "M.B.",
            ",",
            "B.S.",
            ",",
            "and",
            "Christopher",
            "J.",
            "Sweeney",
            ",",
            "M.B.",
            ",",
            "B.S.The",
            "authors\u2122",
            "affiliations",
            "are",
            "as",
            "follows",
            ":",
            "Monash",
            "University",
            "(",
            "I.D.D.",
            ",",
            "M.F.",
            ",",
            "D.W.P",
            ".",
            ")",
            ",",
            "Eastern",
            "Health",
            "(",
            "I.D.D",
            ".",
            ")",
            ",",
            "Australian",
            "Urology",
            "As-sociates",
            "(",
            "M.F",
            ".",
            ")",
            ",",
            "Monash",
            "Health",
            "(",
            "D.W.P",
            ".",
            ")",
            ",",
            "and",
            "the",
            "Peter",
            "MacCallum",
            "Cancer",
            "Centre",
            "and",
            "the",
            "University",
            "of",
            "Melbourne",
            "(",
            "S.K.S.",
            ",",
            "S.G.W",
            ".",
            ")",
            ",",
            "Melbourne",
            ",",
            "VIC",
            ",",
            "the",
            "National",
            "Health",
            "and",
            "Medical",
            "Research",
            "Council",
            "Clinical",
            "Trials",
            "Centre",
            ",",
            "University",
            "of",
            "Sydney",
            "(",
            "A.J.M.",
            ",",
            "M.R.S.",
            ",",
            "X.C.",
            ",",
            "W.E.H.",
            ",",
            "E.T.",
            ",",
            "S.Y.",
            ",",
            "A.Y.Z",
            ".",
            ")",
            ",",
            "the",
            "Chris",
            "O\u2122Brien",
            "Lifehouse",
            "(",
            "M.R.S.",
            ",",
            "L.G.H.",
            ",",
            "A.Y.Z",
            ".",
            ")",
            ",",
            "the",
            "University",
            "of",
            "Sydney",
            "(",
            "L.G.H.",
            ",",
            "G.M",
            ".",
            ")",
            ",",
            "Royal",
            "Prince",
            "Alfred",
            "Hospital",
            "(",
            "L.G.H",
            ".",
            ")",
            ",",
            "Kinghorn",
            "Cancer",
            "Centre",
            ",",
            "St.",
            "Vincent\u2122s",
            "Hospital",
            ",",
            "and",
            "Garvan",
            "Institute",
            "of",
            "Medical",
            "Research",
            "(",
            "A.M.J",
            ".",
            ")",
            ",",
            "Macquarie",
            "University",
            "(",
            "A.Y.Z",
            ".",
            ")",
            ",",
            "and",
            "Western",
            "Sydney",
            "University",
            "(",
            "R.R.Z",
            ".",
            ")",
            ",",
            "Sydney",
            ",",
            "Concord",
            "Cancer",
            "Centre",
            ",",
            "Concord",
            "Repatriation",
            "General",
            "Hospital",
            ",",
            "Concord",
            ",",
            "NSW",
            "(",
            "M.R.S",
            ".",
            ")",
            ",",
            "Port",
            "Macquarie",
            "Base",
            "Hospital",
            "and",
            "Mid",
            "North",
            "Coast",
            "Cancer",
            "Institute",
            "Port",
            "Macquarie",
            ",",
            "Port",
            "Macquarie",
            ",",
            "NSW",
            "(",
            "S.B",
            ".",
            ")",
            ",",
            "Sydney",
            "Adventist",
            "Hospital",
            ",",
            "Wahroonga",
            ",",
            "NSW",
            "(",
            "G.M",
            ".",
            ")",
            ",",
            "the",
            "ANZUP",
            "Cancer",
            "Trials",
            "Group",
            ",",
            "Camperdown",
            ",",
            "NSW",
            "(",
            "M.M",
            ".",
            ")",
            ",",
            "the",
            "Adelaide",
            "Cancer",
            "Centre",
            "and",
            "the",
            "University",
            "of",
            "Adelaide",
            "(",
            "F.P",
            ".",
            ")",
            "and",
            "the",
            "Royal",
            "Adelaide",
            "Hospital",
            "(",
            "T.H.T",
            ".",
            ")",
            ",",
            "Adelaide",
            ",",
            "SA",
            ",",
            "and",
            "Orange",
            "Health",
            "Service",
            ",",
            "Central",
            "West",
            "Cancer",
            "Care",
            "Centre",
            ",",
            "Orange",
            ",",
            "NSW",
            "(",
            "R.R.Z",
            ".",
            ")",
            "\u0160",
            "all",
            "in",
            "Australia",
            ";",
            "BC",
            "Cancer",
            "and",
            "the",
            "University",
            "of",
            "British",
            "Columbia",
            ",",
            "Vancou-ver",
            "(",
            "K.N.C",
            ".",
            ")",
            ",",
            "the",
            "Cross",
            "Cancer",
            "Institute",
            "and",
            "the",
            "University",
            "of",
            "Alberta",
            ",",
            "Edmonton",
            "(",
            "S.A.N",
            ".",
            ")",
            ",",
            "Canadian",
            "Cancer",
            "Trials",
            "Group",
            ",",
            "Queen\u2122s",
            "University",
            "(",
            "W.P.",
            ",",
            "F.V.-B",
            ".",
            ")",
            ",",
            "and",
            "the",
            "Kingston",
            "Health",
            "Sciences",
            "Center",
            "(",
            "F.V.-B",
            ".",
            ")",
            ",",
            "Kingston",
            ",",
            "ON",
            ",",
            "and",
            "the",
            "University",
            "of",
            "Ottawa",
            "and",
            "the",
            "Ot-tawa",
            "Hospital",
            "Research",
            "Institute",
            ",",
            "Ottawa",
            "(",
            "M.N.R",
            ".",
            ")",
            "\u0160",
            "all",
            "in",
            "Canada",
            ";",
            "Guy\u2122s",
            "and",
            "St.",
            "Thomas\u2122",
            "NHS",
            "Foundation",
            "Trust",
            "Biomedical",
            "Research",
            "Centre",
            ",",
            "Cancer",
            "Research",
            "UK",
            "and",
            "King\u2122s",
            "College",
            "London",
            ",",
            "and",
            "Sarah",
            "Cannon",
            "Research",
            "UK",
            ",",
            "London",
            "(",
            "S.C.",
            ")",
            ",",
            "and",
            "the",
            "Royal",
            "Cornwall",
            "Hospital",
            ",",
            "Truro",
            "(",
            "A.",
            "Thomson",
            ")",
            "\u0160",
            "all",
            "in",
            "the",
            "United",
            "Kingdom",
            ";",
            "Auckland",
            "City",
            "Hospital",
            ",",
            "Auckland",
            "(",
            "N.J.L",
            ".",
            ")",
            ",",
            "and",
            "the",
            "Waikato",
            "District",
            "Health",
            "Board",
            ",",
            "Hamilton",
            "(",
            "A.",
            "Tan",
            ")",
            "\u0160",
            "both",
            "in",
            "New",
            "Zealand",
            ";",
            "Cancer",
            "Trials",
            "Ireland",
            "(",
            "J.M.",
            ",",
            "R.M",
            ".",
            ")",
            ",",
            "Mater",
            "Misericordiae",
            "University",
            "Hospital",
            "(",
            "J.M",
            ".",
            ")",
            ",",
            "and",
            "St.",
            "Vincent\u2122s",
            "University",
            "Hospital",
            "and",
            "University",
            "College",
            "Dublin",
            "(",
            "R.M.D",
            ".",
            ")",
            "\u0160",
            "all",
            "in",
            "Dublin",
            ";",
            "and",
            "Dana\u0152Farber",
            "Cancer",
            "Institute",
            "and",
            "Harvard",
            "Medical",
            "School",
            "(",
            "C.J.S",
            ".",
            ")",
            "\u0160",
            "both",
            "in",
            "Boston.n",
            "engl",
            "j",
            "med",
            "381",
            ";",
            "2",
            "nejm.org",
            "July",
            "11",
            ",",
            "2019131Enzalutamide",
            "with",
            "Standard",
            "Therapy",
            "in",
            "Prostate",
            "CancerReferences1",
            ".",
            "Sweeney",
            "CJ",
            ",",
            "Chen",
            "Y-H",
            ",",
            "Carducci",
            "M",
            ",",
            "et",
            "al",
            ".",
            "Chemohormonal",
            "therapy",
            "in",
            "metastatic",
            "hormone-sensitive",
            "prostate",
            "cancer",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2015",
            ";",
            "373",
            ":",
            "737-46.2",
            ".",
            "Kyriakopoulos",
            "CE",
            ",",
            "Chen",
            "YH",
            ",",
            "Carducci",
            "MA",
            ",",
            "et",
            "al",
            ".",
            "Chemohormonal",
            "therapy",
            "in",
            "metastatic",
            "hormone-sensitive",
            "prostate",
            "can-cer",
            ":",
            "long-term",
            "survival",
            "analysis",
            "of",
            "the",
            "randomized",
            "phase",
            "III",
            "E3805",
            "CHAARTED",
            "trial",
            ".",
            "J",
            "Clin",
            "Oncol",
            "2018",
            ";",
            "36",
            ":",
            "1080-7.3",
            ".",
            "James",
            "ND",
            ",",
            "Sydes",
            "MR",
            ",",
            "Clarke",
            "NW",
            ",",
            "et",
            "al",
            ".",
            "Addition",
            "of",
            "docetaxel",
            ",",
            "zoledronic",
            "acid",
            ",",
            "or",
            "both",
            "to",
            "first-line",
            "long-term",
            "hormone",
            "therapy",
            "in",
            "prostate",
            "cancer",
            "(",
            "STAMPEDE",
            ")",
            ":",
            "survival",
            "results",
            "from",
            "an",
            "adaptive",
            ",",
            "multi-arm",
            ",",
            "multistage",
            ",",
            "platform",
            "randomised",
            "con-trolled",
            "trial",
            ".",
            "Lancet",
            "2016",
            ";",
            "387",
            ":",
            "1163-77.4",
            ".",
            "Gravis",
            "G",
            ",",
            "Fizazi",
            "K",
            ",",
            "Joly",
            "F",
            ",",
            "et",
            "al",
            ".",
            "Andro-gen-deprivation",
            "therapy",
            "alone",
            "or",
            "with",
            "docetaxel",
            "in",
            "non-castrate",
            "metastatic",
            "pros-tate",
            "cancer",
            "(",
            "GETUG-AFU",
            "15",
            ")",
            ":",
            "a",
            "random-ised",
            ",",
            "open-label",
            ",",
            "phase",
            "3",
            "trial",
            ".",
            "Lancet",
            "Oncol",
            "2013",
            ";",
            "14",
            ":",
            "149-58.5",
            ".",
            "Gravis",
            "G",
            ",",
            "Boher",
            "JM",
            ",",
            "Joly",
            "F",
            ",",
            "et",
            "al",
            ".",
            "Andro-gen-deprivation",
            "therapy",
            "(",
            "ADT",
            ")",
            "plus",
            "docetaxel",
            "versus",
            "ADT",
            "alone",
            "in",
            "metastat-ic",
            "non",
            "castrate",
            "prostate",
            "cancer",
            ":",
            "impact",
            "of",
            "metastatic",
            "burden",
            "and",
            "long-term",
            "sur-vival",
            "analysis",
            "of",
            "the",
            "randomized",
            "phase",
            "3",
            "GETUG-AFU15",
            "trial",
            ".",
            "Eur",
            "Urol",
            "2016",
            ";",
            "70",
            ":",
            "256-62.6",
            ".",
            "Vale",
            "CL",
            ",",
            "Burdett",
            "S",
            ",",
            "Rydzewska",
            "LHM",
            ",",
            "et",
            "al",
            ".",
            "Addition",
            "of",
            "docetaxel",
            "or",
            "bisphos-phonates",
            "to",
            "standard",
            "of",
            "care",
            "in",
            "men",
            "with",
            "localised",
            "or",
            "metastatic",
            ",",
            "hormone-sensi-tive",
            "prostate",
            "cancer",
            ":",
            "a",
            "systematic",
            "review",
            "and",
            "meta-analyses",
            "of",
            "aggregate",
            "data",
            ".",
            "Lancet",
            "Oncol",
            "2016",
            ";",
            "17",
            ":",
            "243-56.7",
            ".",
            "Gravis",
            "G",
            ",",
            "Boher",
            "J-M",
            ",",
            "Chen",
            "Y-H",
            ",",
            "et",
            "al",
            ".",
            "Burden",
            "of",
            "metastatic",
            "castrate",
            "naive",
            "pros-tate",
            "cancer",
            "patients",
            ",",
            "to",
            "identify",
            "men",
            "more",
            "likely",
            "to",
            "benefit",
            "from",
            "early",
            "docetax-el",
            ":",
            "further",
            "analyses",
            "of",
            "CHAARTED",
            "and",
            "GETUG-AFU15",
            "studies",
            ".",
            "Eur",
            "Urol",
            "2018",
            ";",
            "73",
            ":",
            "847-55.8",
            ".",
            "Fizazi",
            "K",
            ",",
            "Tran",
            "N",
            ",",
            "Fein",
            "L",
            ",",
            "et",
            "al",
            ".",
            "Abi-raterone",
            "plus",
            "prednisone",
            "in",
            "metastatic",
            ",",
            "castration-sensitive",
            "prostate",
            "cancer",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2017",
            ";",
            "377",
            ":",
            "352-60.9",
            ".",
            "James",
            "ND",
            ",",
            "de",
            "Bono",
            "JS",
            ",",
            "Spears",
            "MR",
            ",",
            "et",
            "al",
            ".",
            "Abiraterone",
            "for",
            "prostate",
            "cancer",
            "not",
            "previously",
            "treated",
            "with",
            "hormone",
            "therapy",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2017",
            ";",
            "377",
            ":",
            "338-51.10",
            ".",
            "Hoyle",
            "AP",
            ",",
            "Ali",
            "SA",
            ",",
            "James",
            "ND",
            ",",
            "et",
            "al",
            ".",
            "Ef-fects",
            "of",
            "abiraterone",
            "acetate",
            "plus",
            "predni-sone/prednisolone",
            "in",
            "high",
            "and",
            "low",
            "risk",
            "metastatic",
            "hormone",
            "sensitive",
            "prostate",
            "cancer",
            ".",
            "Ann",
            "Oncol",
            "2018",
            ";",
            "29",
            ":",
            "Suppl",
            "8",
            ":",
            "LBA4",
            ".",
            "abstract.11",
            ".",
            "Tannock",
            "IF",
            ",",
            "de",
            "Wit",
            "R",
            ",",
            "Berry",
            "WR",
            ",",
            "et",
            "al",
            ".",
            "Docetaxel",
            "plus",
            "prednisone",
            "or",
            "mitoxan-trone",
            "plus",
            "prednisone",
            "for",
            "advanced",
            "pros-tate",
            "cancer",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2004",
            ";",
            "351",
            ":",
            "1502-12.12",
            ".",
            "Berthold",
            "DR",
            ",",
            "Pond",
            "GR",
            ",",
            "de",
            "Wit",
            "R",
            ",",
            "Eisenberger",
            "M",
            ",",
            "Tannock",
            "IF",
            ".",
            "Survival",
            "and",
            "PSA",
            "response",
            "of",
            "patients",
            "in",
            "the",
            "TAX",
            "327",
            "study",
            "who",
            "crossed",
            "over",
            "to",
            "receive",
            "docetax-el",
            "after",
            "mitoxantrone",
            "or",
            "vice",
            "versa",
            ".",
            "Ann",
            "Oncol",
            "2008",
            ";",
            "19",
            ":",
            "1749-53.13",
            ".",
            "Prostate",
            "Cancer",
            "Trialists",
            "Collabora-tive",
            "Group",
            ".",
            "Maximum",
            "androgen",
            "blockade",
            "in",
            "advanced",
            "prostate",
            "cancer",
            ":",
            "an",
            "overview",
            "of",
            "the",
            "randomised",
            "trials",
            ".",
            "Lancet",
            "2000",
            ";",
            "355",
            ":",
            "1491-8.14",
            ".",
            "Sydes",
            "MR",
            ",",
            "Spears",
            "MR",
            ",",
            "Mason",
            "MD",
            ",",
            "et",
            "al",
            ".",
            "Adding",
            "abiraterone",
            "or",
            "docetaxel",
            "to",
            "long-term",
            "hormone",
            "therapy",
            "for",
            "prostate",
            "cancer",
            ":",
            "directly",
            "randomised",
            "data",
            "from",
            "the",
            "STAMPEDE",
            "multi-arm",
            ",",
            "multi-stage",
            "plat-form",
            "protocol",
            ".",
            "Ann",
            "Oncol",
            "2018",
            ";",
            "29",
            ":",
            "1235-48.15",
            ".",
            "Scher",
            "HI",
            ",",
            "Fizazi",
            "K",
            ",",
            "Saad",
            "F",
            ",",
            "et",
            "al",
            ".",
            "In-creased",
            "survival",
            "with",
            "enzalutamide",
            "in",
            "pros-tate",
            "cancer",
            "after",
            "chemotherapy",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2012",
            ";",
            "367",
            ":",
            "1187-97.16",
            ".",
            "Beer",
            "TM",
            ",",
            "Armstrong",
            "AJ",
            ",",
            "Rathkopf",
            "DE",
            ",",
            "et",
            "al",
            ".",
            "Enzalutamide",
            "in",
            "metastatic",
            "prostate",
            "cancer",
            "before",
            "chemotherapy",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2014",
            ";",
            "371",
            ":",
            "424-33.17",
            ".",
            "Piccirillo",
            "JF",
            ",",
            "Tierney",
            "RM",
            ",",
            "Costas",
            "I",
            ",",
            "Grove",
            "L",
            ",",
            "Spitznagel",
            "EL",
            "Jr.",
            "Prognostic",
            "impor-tance",
            "of",
            "comorbidity",
            "in",
            "a",
            "hospital-based",
            "cancer",
            "registry",
            ".",
            "JAMA",
            "2004",
            ";",
            "291",
            ":",
            "2441-7.18",
            ".",
            "Scher",
            "HI",
            ",",
            "Halabi",
            "S",
            ",",
            "Tannock",
            "I",
            ",",
            "et",
            "al",
            ".",
            "Design",
            "and",
            "end",
            "points",
            "of",
            "clinical",
            "trials",
            "for",
            "patients",
            "with",
            "progressive",
            "prostate",
            "cancer",
            "and",
            "castrate",
            "levels",
            "of",
            "testosterone",
            ":",
            "recommendations",
            "of",
            "the",
            "Prostate",
            "Cancer",
            "Clinical",
            "Trials",
            "Working",
            "Group",
            ".",
            "J",
            "Clin",
            "On-col",
            "2008",
            ";",
            "26",
            ":",
            "1148-59.19",
            ".",
            "Eisenhauer",
            "EA",
            ",",
            "Therasse",
            "P",
            ",",
            "Bogaerts",
            "J",
            ",",
            "et",
            "al",
            ".",
            "New",
            "response",
            "evaluation",
            "criteria",
            "in",
            "solid",
            "tumours",
            ":",
            "revised",
            "RECIST",
            "guideline",
            "(",
            "version",
            "1.1",
            ")",
            ".",
            "Eur",
            "J",
            "Cancer",
            "2009",
            ";",
            "45",
            ":",
            "228-47.20",
            ".",
            "Pocock",
            "SJ",
            ",",
            "Hughes",
            "MD",
            ".",
            "Practical",
            "prob-lems",
            "in",
            "interim",
            "analyses",
            ",",
            "with",
            "particular",
            "regard",
            "to",
            "estimation",
            ".",
            "Control",
            "Clin",
            "Trials",
            "1989",
            ";",
            "10",
            ":",
            "Suppl",
            ":",
            "209S-221S.Copyright",
            "\u00a9",
            "2019",
            "Massachusetts",
            "Medical",
            "Society.RECEIVE",
            "IMMEDIATE",
            "NOTIFICATION",
            "WHEN",
            "AN",
            "ARTICLE",
            "IS",
            "PUBLISHED",
            "ONLINE",
            "FIRSTTo",
            "be",
            "notified",
            "by",
            "email",
            "when",
            "Journal",
            "articles",
            "are",
            "published",
            "online",
            "first",
            ",",
            "sign",
            "up",
            "at",
            "NEJM.org",
            "."
        ]
    },
    {
        "name": "Sternberg",
        "sentences": [
            "n engl j med   nejm.org 1From the Englander Institute for Preci-sion Medicine, Weill Cornell Medicine, New York (C.N.S.",
            "); the University of Paris Saclay, Villejuif, France (K.F.",
            "); the Univer-sity of Montreal Hospital Center, Mon-treal (F.S.",
            "), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.)",
            "\u0160 both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.",
            "); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.",
            "); Vanderbilt University, Nashville (D.F.P.",
            "); the State University of Campinas (Unicamp), Campinas (U.F.",
            "), and the ABC Founda-tion School of Medicine, Santo Andr\u00e9 (D.I.G.C.)",
            "\u0160 both in Brazil; M.D.",
            "Ander-son Cancer Center, Houston (E.E.",
            "); Wro-claw Medical University, Wroclaw, Po-land (K. Madziarska); Sygehus Lilleb\u00e6lt, Vejle, Denmark (B.N.",
            "); Pfizer, La Jolla (F.Z., X.L.",
            "), and Pfizer, San Francisco  (K. Modelska) \u0160 both in California; and Astellas Pharma, Northbrook (J. Sugg,  J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, North-western University, Chicago (M.H.)",
            "\u0160 both in Illinois.",
            "Address reprint requests to Dr. Sternberg at Weill Cornell Medi-cine, Belfer Research Bldg., 413 E. 69th St., Rm.",
            "1412, New York, NY 10021-5608, or at  cns9006@  med .",
            "cornell .",
            "edu.",
            "*A list of the PROSPER investigators is provided in the Supplementary Appen-dix, available at NEJM.org.This article was published on May 29, 2020, and updated on May 29, 2020, at NEJM.org.DOI:\u02dc10.1056/NEJMoa2003892Copyright \u00a9 2020 Massachusetts Medical Society.BACKGROUNDPreliminary trial results showed that enzalutamide significantly improved metas-tasis-free survival among men who had nonmetastatic, castration-resistant pros-tate cancer and rapidly increasing prostate-specific antigen (PSA) levels while taking androgen-deprivation therapy.",
            "Results from the final analysis of overall survival have not yet been reported.METHODSIn this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of \u02dc10 months) who were continuing to receive androgen-deprivation therapy were randomly assigned (in a 2:1 ratio) to receive enzalutamide at a dose of 160 mg or placebo once daily.",
            "Overall survival was assessed with a group sequential test-ing procedure and an O\u2122Brien\u0152Fleming\u0152type alpha-spending function.RESULTSAs of October 15, 2019, a total of 288 of 933 patients (31%) in the enzalutamide group and 178 of 468 (38%) in the placebo group had died.",
            "Median overall sur-vival was 67.0 months (95% confidence interval [CI], 64.0 to not reached) in the enzalutamide group and 56.3 months (95% CI, 54.4 to 63.0) in the placebo group (hazard ratio for death, 0.73; 95% CI, 0.61 to 0.89; P = 0.001).",
            "The exposure-adjust-ed rate of adverse events of grade 3 or higher was 17 per 100 patient-years in the enzalutamide group and 20 per 100 patient-years in the placebo group.",
            "Adverse events in the enzalutamide group were consistent with those previously reported for enzalutamide; the most frequently reported events were fatigue and musculo-skeletal events.CONCLUSIONSEnzalutamide plus androgen-deprivation therapy resulted in longer median overall survival than placebo plus androgen-deprivation therapy among men with non-metastatic, castration-resistant prostate cancer and a rapidly rising PSA level.",
            "The risk of death associated with enzalutamide was 27% lower than with placebo.",
            "Adverse events were consistent with the established safety profile of enzalutamide.",
            "(Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924.",
            ")ABSTRACTEnzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N. Sternberg, M.D., Karim Fizazi, M.D., Ph.D., Fred Saad, M.D., Neal D. Shore, M.D., Ugo De Giorgi, M.D., Ph.D., David F. Penson, M.D., M.P.H., Ubirajara Ferreira, M.D., Ph.D., Eleni Efstathiou, M.D., Ph.D., Katarzyna Madziarska, M.D., Ph.D., Michael P. Kolinsky, M.D., Daniel I. G. Cubero, M.D., Ph.D., Bettina Noerby, M.D., Fabian Zohren, M.D., Ph.D., Xun Lin, Ph.D., Katharina Modelska, M.D., Ph.D., Jennifer Sugg, M.S., Joyce Steinberg, M.D., and Maha Hussain, M.D., for the PROSPER Investigators*  Original Articlen engl j med   nejm.org 2The new england journal of medicineEnzalutamide, an oral androgen-receptor inhibitor, in combination with androgen-deprivation therapy was approved by the Food and Drug Administration to treat nonmetastatic, castration-resistant prostate can-cer in 2018 on the basis of a significantly lower risk of metastasis or death without radiographic progression than with androgen-deprivation ther-apy alone (hazard ratio, 0.29; 95% confidence interval [CI], 0.24 to 0.35; P<0.001) in the phase 3 PROSPER trial.1,2 Enzalutamide had a safety pro-file consistent with that shown in multiple previ-ous phase 3 trials.1,3-5 Enzalutamide was associ-ated with a better health-related quality of life and with a significantly lower risk of prostate-specific antigen (PSA) progression (hazard ratio, 0.07; 95% CI, 0.05 to 0.08; P<0.001), as well as with a longer time to use of subsequent antineo-plastic therapy (hazard ratio, 0.21; 95% CI, 0.17 to 0.26; P<0.001),1 than androgen-deprivation therapy alone.6It is estimated that bone metastases develop in one third of patients with nonmetastatic, castration-resistant prostate cancer within 2 years after diagnosis.7 Because metastatic, castration-resistant prostate cancer is associated with de-creased overall survival,5,8 worsening quality of life,9 and increased health care-related costs,10 delaying the time to metastasis is a clinically relevant goal.11,12Although delaying metastasis and maintain-ing quality of life are meaningful outcomes, overall survival has long been considered an important end point and the standard for regu-latory approval.",
            "At the primary analysis in the PROSPER trial, after 23 months of follow-up, the data on overall survival were immature, with 165 deaths during the trial (28% of 596 prespecified events for the final analysis).",
            "Median overall survival was not reached in either treatment group (hazard ratio, 0.80; 95% CI, 0.58 to 1.09; P = 0.15).1 Here, we report results from the pre-specified third interim analysis of overall sur-vival.MethodsTrial Design and OversightWe conducted this multinational, double-blind, randomized, placebo-controlled phase 3 trial, which was approved by the independent review boards at more than 300 sites in 32 countries, in accordance with the provisions of the Declara-tion of Helsinki and Good Clinical Practice guide-lines of the International Conference on Harmoni-sation.",
            "All patients provided written informed consent before participating.",
            "An independent data and safety monitoring committee reviewed safety data in an unblinded fashion at regular intervals.The trial was designed and written in collabo-ration with the principal investigators and em-ployees of the sponsors \u0160 Medivation (a Pfizer company) and Astellas Pharma, the codevelopers of enzalutamide.",
            "Local site investigators treated patients, conducted follow-up, and collected data, which were first analyzed by the sponsors.",
            "Data analyses were conducted by the sponsors and were provided to the authors, who wrote the manuscript.",
            "The authors vouch for the accuracy and completeness of the data and its analysis and for the adherence of the trial to the proto-col, available with the full text of this article at NEJM.org.",
            "A medical writer and medical editor were paid by the sponsors and assisted in the preparation of the manuscript that was submitted.The trial design has been described previous-ly.1 To be eligible for participation, men had to have pathologically confirmed prostate adeno-carcinoma with an increasing PSA despite cas-trate levels of testosterone (serum testosterone level, \u02dc1.73 nmol per liter [0.50 ng per millili-ter]), a baseline PSA level of 2 ng or greater per milliliter, and a PSA doubling time of 10 months or less.",
            "Patients had no previous or current evi-dence of metastatic disease, as assessed with computed tomography or magnetic resonance imaging for soft-tissue disease and with whole-body radionuclide bone scan, with results con-firmed by independent central reviewers.",
            "Pa-tients were stratified according to PSA doubling time (<6 months or \u02da6 months) and previous or current use of a bone-targeting agent at baseline (yes or no) and were randomly assigned in a 2:1 ratio to continue receiving androgen-deprivation therapy (either with a gonadotropin-releasing hor-mone agonist or antagonist or with previous bilateral orchiectomy) plus either enzalutamide at a dose of 160 mg or placebo once daily until radiographic progression, unacceptable toxic ef-fects, or death.",
            "Patients and investigators were unaware of the PSA levels during the trial.",
            "Dis-n engl j med   nejm.org 3Enzalutamide in Castration-Resistant Prostate Cancercontinuation of the trial regimen solely because of an increase in PSA level was discouraged.",
            "After the trial was unblinded, patients in the placebo group were given the option to enroll in an open-label extension in which they would receive enzalutamide.",
            "All enrolled patients were followed for survival and for the use of subse-quent therapies after discontinuation of the trial regimen.Trial End PointsThe primary end point was metastasis-free sur-vival, defined as time from randomization to imaging-based progression, as determined by central review at any time, or as the time to death from any cause without evidence of imaging-based progression during the period from ran-domization to 112 days after discontinuation of the trial regimen, whichever occurred first.",
            "Secondary end points included overall survival, defined as the time from randomization to death from any cause, time to PSA progression, PSA response rate, time to first use of a subse-quent antineoplastic therapy, time to first use of cytotoxic chemotherapy, chemotherapy-free sur-vival, time to pain progression, health-related quality of life, and the frequency and severity of adverse events.",
            "Definitions of the end points are provided in Table S1 in the Supplementary Ap-pendix, available at NEJM.org.At the primary analysis (data cutoff date, June 28, 2017), the results with respect to metastasis-free survival, time to PSA progression, and time to first use of a new subsequent antineoplastic therapy met the criteria for significance; there-fore, in accordance with the protocol, the analy-sis of these end points was considered final.1 Patients were then followed for safety and over-all survival; two additional interim analyses of overall survival (after approximately 285 deaths and 440 deaths) and a final analysis (after ap-proximately 596 deaths) were planned.",
            "Updated analyses of time to first use of subsequent ther-apy, time to first use of cytotoxic chemotherapy, and chemotherapy-free survival were also per-formed.Statistical AnalysisEfficacy end points were analyzed in the inten-tion-to-treat population, defined as all patients who underwent randomization.",
            "Patients who had been randomly assigned to receive placebo who crossed over to receive enzalutamide during the open-label extension (the crossover group) were included in the placebo group for all effi-cacy analyses.",
            "Safety was analyzed in all patients who received at least one dose of enzalutamide or placebo.",
            "The analysis of safety included events that occurred from the time of the first dose of enzalutamide or placebo to 30 days after the last dose or to the day before initiation of a new antineoplastic therapy, whichever occurred first.For the final analysis of overall survival, we calculated that 590 deaths were required to pro-vide 85% power to detect a hazard ratio of 0.77 at a two-sided significance level of 0.05.",
            "Overall survival was assessed with the use of a group sequential testing procedure based on an O\u2122Brien\u0152Fleming\u0152type alpha-spending function with three preplanned interim analyses.",
            "If an interim analy-sis of overall survival crossed the significance boundary, it would be reported as the final analysis and no subsequent analyses would be performed.",
            "The results of the first and second (data not shown) interim analyses of overall survival did not cross the significance bound-ary.1 This was the third preplanned interim analysis, performed after approximately 440 deaths had occurred.",
            "After adjustment for multiplicity, a P value of 0.021 or less was required to indicate statistical significance.The trial groups were compared with the use of a log-rank test with stratification according to the same factors that were used in randomiza-tion.",
            "The Kaplan\u0152Meier method was used to estimate medians.",
            "A stratified Cox regression model was used to estimate hazard ratios and 95% confidence intervals, which were not ad-justed for multiplicity.ResultsPatientsFrom November 26, 2013, to June 28, 2017, a total of 1401 eligible patients were enrolled and underwent randomization; 933 were assigned to the enzalutamide group and 468 were assigned to the placebo group (Fig.",
            "S1).",
            "Demographic and baseline characteristics were well balanced be-tween the groups.1 The median age was 74 years in the enzalutamide group and 73 years in the n engl j med   nejm.org 4The new england journal of medicine\u02dc\u02da\u02db\u02dd\u02d9\u02c6\u02c7\u02d8\u02c7\u02c6\u02c6\u02c6\u02c6\u02c7\u02c6\u02c7\u02c6\u02dc\u02da\ufb01\u02c7\u02da\u2030\u02dd\ufb02\u02c7\u02da\u2030\u02dd\u0160\u0161\u2026\u2212\u02dc\u02c7\u02c6\u02c7\u02c7\u02c6\u02dc\u02c6\u02c6\u02dc\u02c6n engl j med   nejm.org 5Enzalutamide in Castration-Resistant Prostate Cancerplacebo group (Table S2).",
            "The median PSA dou-bling time was 3.8 months in the enzalutamide group and 3.6 months in the placebo group.After the primary analysis was completed, the trial data were unblinded, and patients in the placebo group were given the opportunity to receive enzalutamide (crossover began on Febru-ary 12, 2018).",
            "Of the 114 patients in the placebo group who were still receiving treatment when crossover began, 87 received enzalutamide in the open-label extension.",
            "At the data cutoff (Oc-tober 15, 2019), 552 of 933 patients (59%) from the enzalutamide group and 17 of 87 patients (20%) from the crossover group had discontin-ued enzalutamide.",
            "The most common reason for discontinuation was disease progression in the enzalutamide group (288 of 552 patients; 31% of total patients assigned to enzalutamide and 52% of patients assigned to enzalutamide who dis-continued) and in the placebo group (247 of 465; 53%), and adverse events were the most common reason in the crossover group (10 of 17; 59%).",
            "Median follow-up for the trial was 48 months.Overall SurvivalAt the data cutoff, 288 patients (31%) in the enzalutamide group and 178 patients (38%) in the placebo group had died.",
            "In the enzalutamide group, 178 deaths (19%) were prostate cancer\u0152related, and 110 (12%) were not prostate cancer\u0152related, as compared with 136 deaths (29%) and 42 deaths (9%), respectively, in the placebo group.",
            "Median overall survival was 67.0 months (95% CI, 64.0 to not reached) in the enzalutamide group and 56.3 months (95% CI, 54.4 to 63.0) in the placebo group (Fig.",
            "1A).",
            "Enzalutamide plus androgen-deprivation therapy was associated with a significant 27% lower risk of death than placebo plus androgen-deprivation therapy (hazard ratio, 0.73; 95% CI, 0.61 to 0.89; P = 0.001).",
            "Because the O\u2122Brien\u0152Fleming significance boundary was crossed, this became the final analysis.",
            "The treat-ment effect of enzalutamide was generally consis-tent across prespecified subgroups, with the pos-sible exception of patients receiving bone-sparing agents, although the number of such patients was small (Fig.",
            "1B).",
            "In an unplanned analysis, the percentage of patients alive at 3 years was 80% (95% CI, 77 to 83) in the enzalutamide group and 73% (95% CI, 69 to 77) in the placebo group.Subsequent TherapyEnzalutamide was associated with a delay in the use of a new subsequent antineoplastic therapy (hazard ratio for the use of any subsequent anti-neoplastic therapy, 0.29; 95% CI, 0.25 to 0.35) (Fig.",
            "S2A).",
            "The median time to first use of new antineoplastic therapy was 66.7 months in the enzalutamide group and 19.1 months in the pla-cebo group.",
            "A total of 310 patients in the enzalu-tamide group (33% of all patients assigned to enzalutamide and 56% of those who discontin-ued treatment) and 303 patients in the placebo group (65%) received at least one subsequent antineoplastic therapy after discontinuation of the trial regimen (Table 1).",
            "The median time from discontinuation to the start of a subse-quent antineoplastic therapy was 30 days in the enzalutamide group and 22 days in the placebo group.",
            "The most common subsequent antineo-plastic therapy was docetaxel (185 patients, 60%) in the enzalutamide group and abiraterone (178 patients, 59%) in the placebo group.SafetyThe median treatment duration was 33.9 months (95% CI, 0.2 to 68.8) in the enzalutamide group Figure\u02dc1\u02dc(facing\u02dcpage).\u02dcKaplan\u0152Meier\u02dcEstimates\u02dc\u02dcand\u02dcSubgroup\u02dcAnalysis\u02dcof\u02dcOverall\u02dcSurvival.Panel A shows the data for the final Kaplan\u0152Meier analy-sis of overall survival.",
            "The hazard ratio was based on a Cox regression model stratified according to prostate-specific antigen (PSA) doubling time (<6 months or  \u02dc6 months) and previous or current use of a bone-tar-geting agent (yes or no), with trial group as the only  covariate and a value of less than 1.00 favoring enzalu-tamide treatment.",
            "The dashed line indicates the median, and symbols indicate censored data in the Kaplan\u0152Meier curve.",
            "NR denotes not reached.",
            "Panel B shows the sub-group analysis of overall survival.",
            "The analyses of all subgroups were unstratified, and 95% confidence inter-vals were not adjusted for multiplicity.",
            "The size of each circle reflects the number of patients in the subgroup.",
            "At baseline, the median age of the patients was 74 years, the median PSA level was 10.75 ng per milliliter, the median lactate dehydrogenase (LDH) level was 1.78 U per liter, and the median hemoglobin level was 134 g per liter.",
            "Eastern Cooperative Oncology Group (ECOG) per-formance-status scores range from 0 to 5, with higher scores indicating greater disability.",
            "Gleason scores range from 6 to 10, with higher scores indicating more aggres-sive cancer.n engl j med   nejm.org 6The new england journal of medicineand 14.2 months (95% CI, 0.1 to 51.3) in the placebo group.",
            "The incidences of adverse events within the first 3 months and 6 months were higher in the enzalutamide group than in the placebo group.",
            "However, after adjustment for exposure, the rates of adverse events per 100 patient-years were similar in the two groups (Table 2).",
            "Cumulative incidence plots showed a similar onset of grade 3 or 4 adverse events and serious adverse events in the enzalutamide and placebo groups, whereas adverse events of spe-cial interest (Table 3) had a steeper rate of initial onset in the enzalutamide group (Fig.",
            "S3).",
            "The most frequently reported adverse events were consistent with those reported in the primary analysis1 (Tables S3 and S4), primarily fatigue and musculoskeletal events.The adverse events of special interest with exposure-adjusted rates that were 3 or more events per 100 patient-years higher in the enzalu-tamide group than in the placebo group were falls (9 vs. 4 events per 100 patient-years) and fractures (9 vs. 5 events per 100 patient-years) (Table S5).",
            "The most frequently reported adverse Table\u02dc2.\u02dcSummary\u02dcof\u02dcAdverse\u02dcEvents,\u02dcIrrespective\u02dcof\u02dcRelationship\u02dcto\u02dcEnzalutamide\u02dcor\u02dcPlacebo.*Adverse\u02dcEventEnzalutamide\u02dcGroup\u02dc(N\u02dc=\u02dc930)Placebo\u02dcGroup\u02dc(N\u02dc=\u02dc465)PatientsEventsPatientsEventsno.",
            "(%)no.",
            "(no./100 patient-yr)no.",
            "(%)no.",
            "(no/100 patient-yr)Any adverse event876 (94)876 (34)380 (82)380 (60)Within the first 3 mo609 (65)\u0160241 (52)\u0160Within the first 6 mo703 (76)\u0160298 (64)\u0160Any grade \u02dc3 adverse event446 (48)446 (17)126 (27)126 (20)Within the first 3 mo89 (10)\u016022 (5)\u0160Within the first 6 mo140 (15)\u016056 (12)\u0160Any serious adverse event\u0192372 (40)372 (14)100 (22)100 (16)Any adverse event leading to discontinuation of trial regimen158 (17)158 (6)41 (9)41 (6)Any adverse event leading to death51 (5)51 (2)3 (1)3 (<1)*  Total patient-years of exposure were 2613.41 for the enzalutamide group and 634.45 for the placebo group.",
            "The event rate was calculated as 100 \u00d7 number of events/total patient-years of exposure for the treatment group.\u0192  Serious adverse events were events that resulted in death, were life-threatening, resulted in or prolonged hospitalization, resulted in the inability to conduct normal life functions, or led to a congenital anomaly or birth defect.",
            "A full definition is provided in the protocol.Table\u02dc1.\u02dcAntineoplastic\u02dcTherapy\u02dcReceived\u02dcafter\u02dcDiscontinuation\u02dcof\u02dcEnzalutamide\u02dcor\u02dcPlacebo.Subsequent\u02dcTherapyEnzalutamide\u02dcGroup\u02dc(N\u02dc=\u02dc930)Placebo\u02dc\u02dcGroup\u02dc(N\u02dc=\u02dc465)no.",
            "of patients (%)At least one antineoplastic agent310 (33)303 (65)Agents used by \u02dc5% of patients in either treatment group*Abiraterone acetate152 (49)178 (59)Docetaxel185 (60)141 (47)Enzalutamide44 (14)109 (36)\u0192Cabazitaxel46 (15)49 (16)Bicalutamide28 (9)41 (14)*  Percentages are based on the number of patients who received at least one antineoplastic agent after discontinuation of the trial regimen (310 in the enzalutamide group and 303 in the placebo group).\u0192  A total of 87 patients who received enzalutamide in the crossover group after the trial was unblinded were not included in this analysis, since they received enzalutamide as open-label treatment.",
            "After inclusion of these 87 patients, the total number of patients randomly assigned to placebo who received at least one subsequent antineoplastic agent increased to 390 (84%), and the to-tal number of patients who received subsequent treatment with enzalutamide was 196.n engl j med   nejm.org 7Enzalutamide in Castration-Resistant Prostate Cancerevents leading to death during the entire trial period were cardiovascular events (14 [2%] in the enzalutamide group and 2 [<1%] in the pla-cebo group) (the full list is provided in Table 4).",
            "In the enzalutamide group, 10 of 14 patients with a cardiovascular event leading to death had clinically significant previous or ongoing cardio-vascular disease.",
            "Seventeen adverse events lead-ing to death occurred after the primary analysis; the group of men who were affected had a me-dian age of 80 years (range, 63 to 93).",
            "None of the cardiovascular events that led to death in the trial were considered by the investigators to be related to treatment with enzalutamide.Crossover GroupA total of 87 patients received enzalutamide in the crossover group.",
            "The median treatment du-ration with enzalutamide after crossover treat-ment began was 14.5 months (95% CI, 0.4 to 18.8), a shorter period than among patients who had been randomly assigned to enzalutamide from the outset.",
            "Four patients (5%) received subsequent therapy after discontinuation of en-zalutamide (docetaxel, abiraterone, enzaluta-mide, and sipuleucel-T were received by 1 patient each).",
            "The exposure-adjusted rates of adverse events and adverse events of special interest were consistent with those in the enzalutamide group (Table S6).",
            "The most frequently reported adverse events (occurring in \u02da10% of the patients) were fatigue (15%) and asthenia (11%) (Table S7).",
            "Four patients (5%) had adverse events leading to death after crossover began; none of these events were considered by the investigators to be related to enzalutamide (Table S8).DiscussionIn this final analysis of overall survival in the PROSPER trial, treatment with enzalutamide was associated with a significant 27% lower risk of death than placebo in men with nonmeta-static, castration-resistant prostate cancer and a rapidly increasing PSA levels who were receiving androgen-deprivation therapy, despite the use of subsequent life-prolonging antineoplastic thera-pies (including enzalutamide) by patients in the placebo group.",
            "The time to subsequent antineo-plastic therapy, time to cytotoxic chemotherapy, Table\u02dc3.\u02dcAdverse\u02dcEvents\u02dcof\u02dcSpecial\u02dcInterest,\u02dcIrrespective\u02dcof\u02dcRelationship\u02dc\u02dcto\u02dcEnzalutamide\u02dcor\u02dcPlacebo.Adverse\u02dcEventEnzalutamide\u02dcGroup\u02dc(N\u02dc=\u02dc930)Placebo\u02dcGroup\u02dc(N\u02dc=\u02dc465)no.",
            "of patients (%)Fatigue*424 (46)103 (22)Musculoskeletal event\u0192315 (34)107 (23)Fracture\u2044168 (18)29 (6)Hypertension\u00a7167 (18)28 (6)Fall164 (18)25 (5)Cognitive and memory impairment\u00b673 (8)10 (2)Cardiovascular events\u02da60 (6)11 (2)Ischemic heart disease**60 (6)8 (2)Second primary cancer48 (5)7 (2)Rash\u0192\u019238 (4)13 (3)Loss of consciousness\u2044\u204434 (4)4 (1)Angioedema\u00a7\u00a720 (2)4 (1)Hepatic disorder\u00b6\u00b616 (2)15 (3)Renal disorder14 (2)8 (2)Thrombocytopenia\u02da\u02da12 (1)4 (1)Neutropenia12 (1)1 (<1)Severe cutaneous adverse reaction1 (<1)0Seizure3 (<1)0Posterior reversible encephalopathy syndrome00*  Fatigue events included asthenia.\u0192  Musculoskeletal events included back pain, arthralgia, myalgia, musculo-skeletal pain, pain in extremity, musculoskeletal stiffness, muscular weak-ness, and muscle spasms.\u2044  Fracture events included bone and joint injuries.\u00a7  Hypertension events included hypertensive retinopathy, increased blood pressure, systolic hypertension, and hypertensive crisis.\u00b6  Events of cognitive and memory impairment included disturbance in atten-tion, cognitive disorders, amnesia, Alzheimer\u2122s disease, dementia, senile dementia, mental impairment, and vascular dementia.\u02da  Cardiovascular events included hemorrhagic central nervous system vascu-lar conditions, ischemic central nervous system vascular conditions, and cardiac failure.",
            "**  Events of ischemic heart disease included myocardial infarction and other ischemic heart disease.\u0192\u0192  Rash events included maculopapular rash, generalized rash, macular rash, papular rash, and pruritic rash.\u2044\u2044  Loss-of-consciousness events included syncope and presyncope.\u00a7\u00a7  Angioedema events included urticaria, eyelid edema, periorbital edema, swollen tongue, swollen lip, face edema, laryngeal edema, pharyngeal  edema.\u00b6\u00b6  Hepatic disorders included hepatic failure; fibrosis, cirrhosis, and other liver damage\u0152related conditions; and hepatitis and liver-related investigations, signs, and symptoms.\u02da\u02da  Thrombocytopenia events included decreases in platelet count.n engl j med   nejm.org 8The new england journal of medicineTable\u02dc4.\u02dcAdverse\u02dcEvents\u02dcLeading\u02dcto\u02dcDeath,\u02dcIrrespective\u02dcof\u02dcRelationship\u02dcto\u02dcEnzalutamide\u02dcor\u02dcPlacebo.Adverse\u02dcEventEnzalutamide\u02dcGroup\u02dc(N\u02dc=\u02dc930)Placebo\u02dcGroup\u02dc(N\u02dc=\u02dc465)At least one adverse event leading to death \u0160 no.",
            "of patients (%)*51 (5)3 (1)Adverse events leading to death \u0160 no.",
            "(events/100 patient-yr)\u019257 (2)3 (<1)Specific events leading to death \u0160 no.",
            "(%)Cardiovascular event\u204414 (2)2 (<1)Second primary cancer\u00a77 (1)1 (<1)Stroke\u00b64 (<1)0Sudden death\u02da4 (<1)0Disease progression3 (<1)0Pneumonia**3 (<1)0Septic shock\u0192\u01923 (<1)0Hemorrhage\u2044\u20442 (<1)0General deterioration of physical health\u00a7\u00a72 (<1)0Intestinal congestion1 (<1)0Mesenteric-vein thrombosis1 (<1)0Malaise1 (<1)0Hepatic failure1 (<1)0Lung infection1 (<1)0Gangrene in small intestine1 (<1)0Pelvic fracture1 (<1)0Renal impairment1 (<1)0Urinary retention1 (<1)0Interstitial lung disease1 (<1)0Pleurisy1 (<1)0Anemia1 (<1)0Type 2 diabetes mellitus1 (<1)0*  Patients with multiple events resulting in death for a given adverse-event term were counted only once per term.\u0192  The total patient-years of exposure were 2613.41 for the enzalutamide group and 634.45 for the placebo group.",
            "The event rate was calculated as 100 \u00d7 number of events/total patient-years of exposure for the treatment group.\u2044  Cardiovascular events included acute myocardial infarction, myocardial infarction, cardiac failure, cardiac arrest, car-diorespiratory arrest, cardiogenic shock, cardiovascular insufficiency, coronary artery disease, ventricular arrhythmia, and left ventricular failure.",
            "Ten patients in the enzalutamide group had a history of cardiovascular disease.\u00a7  Second primary cancers included acute myeloid leukemia, brain neoplasm, malignant neoplasm of unknown primary site, mesothelioma, metastasis to liver, metastasis to peritoneum, neoplasm progression, metastatic pancreatic car-cinoma, prostate cancer, and small-cell lung cancer.\u00b6  Stroke events included cerebrovascular accident, cerebral infarction, hemorrhagic stroke, and ischemic stroke.\u02da  Sudden deaths included death, sudden death, and sudden cardiac death.",
            "One death was considered by the investiga-tors to be related to enzalutamide.",
            "**  Pneumonia events included pneumonia and aspiration pneumonia.\u0192\u0192  Septic shock events included septic shock and sepsis.\u2044\u2044  Hemorrhage events included hemorrhage and duodenal ulcer hemorrhage.",
            "The duodenal ulcer hemorrhage was con-sidered by the investigators to be related to enzalutamide.\u00a7\u00a7  This event was considered by the investigators to be related to enzalutamide in 1 patient.n engl j med   nejm.org 9Enzalutamide in Castration-Resistant Prostate Cancerand chemotherapy-free survival were also longer in the enzalutamide group than in the placebo group.In line with recent studies,13,14 these results add to the growing body of evidence that andro-gen-receptor inhibitors not only delay the time to metastasis but also improve overall survival among men with nonmetastatic, castration-resis-tant prostate cancer.",
            "Enzalutamide prolongs survival in both nonmetastatic and metastatic castration-resistant prostate cancer.3,5The treatment effect of enzalutamide was consistent across all prespecified subgroups, except in patients who had received bone-target-ing agents at baseline; however, the number of patients in this subgroup was low, which makes interpretation of this result difficult.",
            "Further research is necessary.As treatments are evaluated at earlier stages of disease and more life-prolonging therapies are available, it is increasingly difficult to show improvements in overall survival in clinical tri-als.",
            "Metastasis-free survival has been shown to be a surrogate for overall survival among pa-tients with intermediate-risk, high-risk, clinically localized prostate cancer.15 These results provide clinical validation for the use of metastasis-free survival as a meaningful end point and as a po-tential surrogate for overall survival among patients with nonmetastatic, castration-resistant prostate cancer.Our trial had several limitations.",
            "Conventional imaging has been used in our trial as well as in the SPARTAN (Selective Prostate Androgen Re-ceptor Targeting with ARN-509) and ARAMIS (Androgen Receptor Antagonizing Agent for Metastasis-free Survival) phase 3 clinical trials in nonmetastatic, castration-resistant prostate cancer to obtain diagnoses and monitor patients\u2122 conditions.1,16,17 More sensitive techniques are be-coming available, allowing for earlier detection of metastasis, which may affect the classification of patients as having nonmetastatic disease.18 Data on the time to progression while receiving the next subsequent therapy were not collected, so we cannot evaluate whether treatment with enzalutamide also translated into differences in treatment effects of subsequent therapies.After a median of 15 additional months of treatment, the safety profile of enzalutamide with androgen-deprivation therapy was similar to that reported at the time of the primary analysis,1 which includes an increase in falls, fatigue, hypertension, and deaths from cardio-vascular causes.",
            "The exposure-adjusted rates of cardiovascular events were slightly higher in the enzalutamide group than in the placebo group (3 vs. 2 per 100 patient-years).",
            "Three events of seizures were reported at the time of the pri-mary analysis, but no subsequent events were reported.",
            "Men, especially those who are asymp-tomatic, should consider whether the increased risk of adverse events is acceptable before initiat-ing treatment.Although adverse events leading to death were more common in the enzalutamide group than in the placebo group, it is important to consider the significantly longer median treat-ment duration in the enzalutamide group (33.9 months vs. 14.2 months).",
            "The most frequently reported adverse events leading to death in the enzalutamide group were cardiovascular events.",
            "Most men who died from a cardiovascular event had a clinically significant history of cardiovas-cular disease.",
            "The World Health Organization reports that the leading cause of death among men older than 70 years of age in 2016 was ische-mic heart disease.19 The longer follow-up inter-val, history of cardiovascular risk factors, and advanced age in patients treated with enzalu-tamide may explain this finding in our trial.",
            "Although none of the cardiovascular deaths were attributed to enzalutamide by the investigators, physicians should be aware of the increased risk when determining whether a patient with pre-existing cardiovascular disease should receive enzalutamide, and patients receiving this treat-ment should be followed closely.In our trial, enzalutamide treatment in men with nonmetastatic, castration-resistant prostate cancer and rapidly increasing PSA levels resulted in a significantly longer overall survival than placebo.",
            "The adverse event profile was similar to the established safety profile of enzalu-tamide.3,5,20,21Supported by Pfizer and Astellas Pharma.Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.We thank Petro Ivashchenko, M.D.",
            "(Kiev City Clinical Hos-pital 3), for his contribution to the trial and previous presenta-tions, and Stephanie Vadasz, Ph.D., and Dena McWain (Ashfield Healthcare Communications) for medical writing and editorial assistance with an earlier version of the manuscript (funded by both sponsor companies).n engl j med   nejm.org 10The new england journal of medicineReferences1.Hussain M, Fizazi K, Saad F, et al.Enzalutamide in men with nonmetastat-ic, castration-resistant prostate cancer.N Engl J Med 2018; 378: 2465-74.2.Xtandi (enzalutamide) prescribinginformation.",
            "Northbrook, IL:  AstellasPharma US, 2018 (https://www .astellas .us/docs/ 12A005 - ENZ - WPI .PDF).3.Scher HI, Fizazi K, Saad F, et al.",
            "In-creased survival with enzalutamide inprostate cancer after chemotherapy.",
            "N Engl J Med 2012; 367: 1187-97.4.",
            "Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al.",
            "ARCHES: a randomized, phase III study of androgen deprivation therapy withenzalutamide or placebo in men with meta-static hormone-sensitive prostate cancer.J Clin Oncol 2019; 37: 2974-86.5.",
            "Beer TM, Armstrong AJ, Rathkopf DE,et al.",
            "Enzalutamide in metastatic prostate cancer before chemotherapy.",
            "N Engl J Med 2014; 371: 424-33.6.Tombal B, Saad F, Penson D, et al.Patient-reported outcomes following en-zalutamide or placebo in men with non-metastatic, castration-resistant prostatecancer (PROSPER): a multicentre, random-ised, double-blind, phase 3 trial.",
            "LancetOncol 2019; 20: 556-69.7.",
            "Smith MR, Kabbinavar F, Saad F, et al.",
            "Natural history of rising serum prostate-specific antigen in men with castrate non-metastatic prostate cancer.",
            "J Clin Oncol2005; 23: 2918-25.8.",
            "Afshar M, Evison F, James ND, Patel P. Shifting paradigms in the estimation ofsurvival for castration-resistant prostate cancer: a tertiary academic center experi-ence.",
            "Urol Oncol 2015; 33(8): 338.e1-338.e7.9.Jenkins V, Solis-Trapala I, Payne H,et al.",
            "Treatment experiences, informationneeds, pain and quality of life in menwith metastatic castrate-resistant pros-tate cancer: results from the EXTREQOLstudy.",
            "Clin Oncol (R Coll Radiol) 2019; 31: 99-107.10.",
            "Appukkuttan S, Tangirala K, Babajan-yan S, Wen L, Simmons S, Shore N. A ret-rospective claims analysis of advancedprostate cancer costs and resource use.Pharmacoecon Open 2019 October 22(Epub ahead of print).11.Gillessen S, Attard G, Beer TM, et al.Management of patients with advancedprostate cancer: report of the AdvancedProstate Cancer Consensus Conference2019.",
            "Eur Urol 2020; 77: 508-47.12.Mateo J, Fizazi K, Gillessen S, et al.Managing nonmetastatic castration-resis-tant prostate cancer.",
            "Eur Urol 2019; 75:285-93.13.Small EJ, Saad F, Chowdhury S, et al.Apalutamide and overall survival in non-metastatic castration-resistant prostatecancer.",
            "Ann Oncol 2019; 30: 1813-20.14.Darolutamide plus androgen depriva-tion therapy significantly increased over-all survival in men with non-metastaticcastration-resistant prostate cancer.",
            "Lever-kusen, Germany:  Bayer, 2020 (https://www .investor .bayer .de/ en/ nc/ news/ investor - news/ investor - news/ darolutamide - plus - androgen - deprivation - therapy - significantly - increased - overall - survival - in - men - with/ ).15.Xie W, Regan MM, Buyse M, et al.Metastasis-free survival is a strong surro-gate of overall survival in localized pros-tate cancer.",
            "J Clin Oncol 2017; 35: 3097-104.16.",
            "Smith MR, Saad F, Chowdhury S, et al.",
            "Apalutamide treatment and metastasis-free survival in prostate cancer.",
            "N Engl JMed 2018; 378: 1408-18.17.Fizazi K, Shore N, Tammela TL, et al.Darolutamide in nonmetastatic, castration-resistant prostate cancer.",
            "N Engl J Med2019; 380: 1235-46.18.",
            "Fendler WP, Weber M, Iravani A, et al.",
            "Prostate-specific membrane antigen ligandpositron emission tomography in menwith nonmetastatic castration-resistantprostate cancer.",
            "Clin Cancer Res 2019; 25:7448-54.19.World Health Organization.",
            "Top 10causes of death.",
            "2020 (https://www .who.int/ gho/ mortality_burden_disease/ causes_death/ top_10/ en/ ).20.Penson DF, Armstrong AJ, Concep-cion R, et al.",
            "Enzalutamide versus bicalu-tamide in castration-resistant prostate can-cer: the STRIVE trial.",
            "J Clin Oncol 2016;34: 2098-106.21.Shore ND, Chowdhury S, Villers A,et al.",
            "Efficacy and safety of enzalutamideversus bicalutamide for patients withmetastatic prostate cancer (TERRAIN):a randomised, double-blind, phase 2 study.",
            "Lancet Oncol 2016; 17: 153-63.Copyright \u00a9 2020 Massachusetts Medical Society."
        ],
        "words": [
            "n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "1From",
            "the",
            "Englander",
            "Institute",
            "for",
            "Preci-sion",
            "Medicine",
            ",",
            "Weill",
            "Cornell",
            "Medicine",
            ",",
            "New",
            "York",
            "(",
            "C.N.S",
            ".",
            ")",
            ";",
            "the",
            "University",
            "of",
            "Paris",
            "Saclay",
            ",",
            "Villejuif",
            ",",
            "France",
            "(",
            "K.F",
            ".",
            ")",
            ";",
            "the",
            "Univer-sity",
            "of",
            "Montreal",
            "Hospital",
            "Center",
            ",",
            "Mon-treal",
            "(",
            "F.S",
            ".",
            ")",
            ",",
            "and",
            "Cross",
            "Cancer",
            "Institute",
            ",",
            "University",
            "of",
            "Alberta",
            ",",
            "Edmonton",
            "(",
            "M.P.K",
            ".",
            ")",
            "\u0160",
            "both",
            "in",
            "Canada",
            ";",
            "the",
            "Carolina",
            "Urologic",
            "Research",
            "Center",
            ",",
            "Myrtle",
            "Beach",
            ",",
            "SC",
            "(",
            "N.D.S",
            ".",
            ")",
            ";",
            "Istituto",
            "Scientifico",
            "Romagnolo",
            "per",
            "lo",
            "Studio",
            "e",
            "la",
            "Cura",
            "dei",
            "Tumori",
            "(",
            "IRST",
            ")",
            "IRCCS",
            ",",
            "Meldola",
            ",",
            "Italy",
            "(",
            "U.D",
            ".",
            ")",
            ";",
            "Vanderbilt",
            "University",
            ",",
            "Nashville",
            "(",
            "D.F.P",
            ".",
            ")",
            ";",
            "the",
            "State",
            "University",
            "of",
            "Campinas",
            "(",
            "Unicamp",
            ")",
            ",",
            "Campinas",
            "(",
            "U.F",
            ".",
            ")",
            ",",
            "and",
            "the",
            "ABC",
            "Founda-tion",
            "School",
            "of",
            "Medicine",
            ",",
            "Santo",
            "Andr\u00e9",
            "(",
            "D.I.G.C",
            ".",
            ")",
            "\u0160",
            "both",
            "in",
            "Brazil",
            ";",
            "M.D",
            ".",
            "Ander-son",
            "Cancer",
            "Center",
            ",",
            "Houston",
            "(",
            "E.E",
            ".",
            ")",
            ";",
            "Wro-claw",
            "Medical",
            "University",
            ",",
            "Wroclaw",
            ",",
            "Po-land",
            "(",
            "K.",
            "Madziarska",
            ")",
            ";",
            "Sygehus",
            "Lilleb\u00e6lt",
            ",",
            "Vejle",
            ",",
            "Denmark",
            "(",
            "B.N",
            ".",
            ")",
            ";",
            "Pfizer",
            ",",
            "La",
            "Jolla",
            "(",
            "F.Z.",
            ",",
            "X.L",
            ".",
            ")",
            ",",
            "and",
            "Pfizer",
            ",",
            "San",
            "Francisco",
            "(",
            "K.",
            "Modelska",
            ")",
            "\u0160",
            "both",
            "in",
            "California",
            ";",
            "and",
            "Astellas",
            "Pharma",
            ",",
            "Northbrook",
            "(",
            "J.",
            "Sugg",
            ",",
            "J.",
            "Steinberg",
            ")",
            ",",
            "and",
            "the",
            "Robert",
            "H.",
            "Lurie",
            "Comprehensive",
            "Cancer",
            "Center",
            ",",
            "North-western",
            "University",
            ",",
            "Chicago",
            "(",
            "M.H",
            ".",
            ")",
            "\u0160",
            "both",
            "in",
            "Illinois",
            ".",
            "Address",
            "reprint",
            "requests",
            "to",
            "Dr.",
            "Sternberg",
            "at",
            "Weill",
            "Cornell",
            "Medi-cine",
            ",",
            "Belfer",
            "Research",
            "Bldg.",
            ",",
            "413",
            "E.",
            "69th",
            "St.",
            ",",
            "Rm",
            ".",
            "1412",
            ",",
            "New",
            "York",
            ",",
            "NY",
            "10021-5608",
            ",",
            "or",
            "at",
            "cns9006",
            "@",
            "med",
            ".",
            "cornell",
            ".",
            "edu",
            ".",
            "*",
            "A",
            "list",
            "of",
            "the",
            "PROSPER",
            "investigators",
            "is",
            "provided",
            "in",
            "the",
            "Supplementary",
            "Appen-dix",
            ",",
            "available",
            "at",
            "NEJM.org.This",
            "article",
            "was",
            "published",
            "on",
            "May",
            "29",
            ",",
            "2020",
            ",",
            "and",
            "updated",
            "on",
            "May",
            "29",
            ",",
            "2020",
            ",",
            "at",
            "NEJM.org.DOI",
            ":",
            "\u02dc10.1056/NEJMoa2003892Copyright",
            "\u00a9",
            "2020",
            "Massachusetts",
            "Medical",
            "Society.BACKGROUNDPreliminary",
            "trial",
            "results",
            "showed",
            "that",
            "enzalutamide",
            "significantly",
            "improved",
            "metas-tasis-free",
            "survival",
            "among",
            "men",
            "who",
            "had",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "pros-tate",
            "cancer",
            "and",
            "rapidly",
            "increasing",
            "prostate-specific",
            "antigen",
            "(",
            "PSA",
            ")",
            "levels",
            "while",
            "taking",
            "androgen-deprivation",
            "therapy",
            ".",
            "Results",
            "from",
            "the",
            "final",
            "analysis",
            "of",
            "overall",
            "survival",
            "have",
            "not",
            "yet",
            "been",
            "reported.METHODSIn",
            "this",
            "double-blind",
            ",",
            "phase",
            "3",
            "trial",
            ",",
            "men",
            "with",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            "(",
            "defined",
            "on",
            "the",
            "basis",
            "of",
            "conventional",
            "imaging",
            "and",
            "a",
            "PSA",
            "doubling",
            "time",
            "of",
            "\u02dc10",
            "months",
            ")",
            "who",
            "were",
            "continuing",
            "to",
            "receive",
            "androgen-deprivation",
            "therapy",
            "were",
            "randomly",
            "assigned",
            "(",
            "in",
            "a",
            "2:1",
            "ratio",
            ")",
            "to",
            "receive",
            "enzalutamide",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "or",
            "placebo",
            "once",
            "daily",
            ".",
            "Overall",
            "survival",
            "was",
            "assessed",
            "with",
            "a",
            "group",
            "sequential",
            "test-ing",
            "procedure",
            "and",
            "an",
            "O\u2122Brien\u0152Fleming\u0152type",
            "alpha-spending",
            "function.RESULTSAs",
            "of",
            "October",
            "15",
            ",",
            "2019",
            ",",
            "a",
            "total",
            "of",
            "288",
            "of",
            "933",
            "patients",
            "(",
            "31",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "178",
            "of",
            "468",
            "(",
            "38",
            "%",
            ")",
            "in",
            "the",
            "placebo",
            "group",
            "had",
            "died",
            ".",
            "Median",
            "overall",
            "sur-vival",
            "was",
            "67.0",
            "months",
            "(",
            "95",
            "%",
            "confidence",
            "interval",
            "[",
            "CI",
            "]",
            ",",
            "64.0",
            "to",
            "not",
            "reached",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "56.3",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "54.4",
            "to",
            "63.0",
            ")",
            "in",
            "the",
            "placebo",
            "group",
            "(",
            "hazard",
            "ratio",
            "for",
            "death",
            ",",
            "0.73",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.61",
            "to",
            "0.89",
            ";",
            "P",
            "=",
            "0.001",
            ")",
            ".",
            "The",
            "exposure-adjust-ed",
            "rate",
            "of",
            "adverse",
            "events",
            "of",
            "grade",
            "3",
            "or",
            "higher",
            "was",
            "17",
            "per",
            "100",
            "patient-years",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "20",
            "per",
            "100",
            "patient-years",
            "in",
            "the",
            "placebo",
            "group",
            ".",
            "Adverse",
            "events",
            "in",
            "the",
            "enzalutamide",
            "group",
            "were",
            "consistent",
            "with",
            "those",
            "previously",
            "reported",
            "for",
            "enzalutamide",
            ";",
            "the",
            "most",
            "frequently",
            "reported",
            "events",
            "were",
            "fatigue",
            "and",
            "musculo-skeletal",
            "events.CONCLUSIONSEnzalutamide",
            "plus",
            "androgen-deprivation",
            "therapy",
            "resulted",
            "in",
            "longer",
            "median",
            "overall",
            "survival",
            "than",
            "placebo",
            "plus",
            "androgen-deprivation",
            "therapy",
            "among",
            "men",
            "with",
            "non-metastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            "and",
            "a",
            "rapidly",
            "rising",
            "PSA",
            "level",
            ".",
            "The",
            "risk",
            "of",
            "death",
            "associated",
            "with",
            "enzalutamide",
            "was",
            "27",
            "%",
            "lower",
            "than",
            "with",
            "placebo",
            ".",
            "Adverse",
            "events",
            "were",
            "consistent",
            "with",
            "the",
            "established",
            "safety",
            "profile",
            "of",
            "enzalutamide",
            ".",
            "(",
            "Funded",
            "by",
            "Pfizer",
            "and",
            "Astellas",
            "Pharma",
            ";",
            "PROSPER",
            "ClinicalTrials.gov",
            "number",
            ",",
            "NCT02003924",
            ".",
            ")",
            "ABSTRACTEnzalutamide",
            "and",
            "Survival",
            "in",
            "Nonmetastatic",
            ",",
            "Castration-Resistant",
            "Prostate",
            "CancerCora",
            "N.",
            "Sternberg",
            ",",
            "M.D.",
            ",",
            "Karim",
            "Fizazi",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Fred",
            "Saad",
            ",",
            "M.D.",
            ",",
            "Neal",
            "D.",
            "Shore",
            ",",
            "M.D.",
            ",",
            "Ugo",
            "De",
            "Giorgi",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "David",
            "F.",
            "Penson",
            ",",
            "M.D.",
            ",",
            "M.P.H.",
            ",",
            "Ubirajara",
            "Ferreira",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Eleni",
            "Efstathiou",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Katarzyna",
            "Madziarska",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Michael",
            "P.",
            "Kolinsky",
            ",",
            "M.D.",
            ",",
            "Daniel",
            "I.",
            "G.",
            "Cubero",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Bettina",
            "Noerby",
            ",",
            "M.D.",
            ",",
            "Fabian",
            "Zohren",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Xun",
            "Lin",
            ",",
            "Ph.D.",
            ",",
            "Katharina",
            "Modelska",
            ",",
            "M.D.",
            ",",
            "Ph.D.",
            ",",
            "Jennifer",
            "Sugg",
            ",",
            "M.S.",
            ",",
            "Joyce",
            "Steinberg",
            ",",
            "M.D.",
            ",",
            "and",
            "Maha",
            "Hussain",
            ",",
            "M.D.",
            ",",
            "for",
            "the",
            "PROSPER",
            "Investigators",
            "*",
            "Original",
            "Articlen",
            "engl",
            "j",
            "med",
            "nejm.org",
            "2The",
            "new",
            "england",
            "journal",
            "of",
            "medicineEnzalutamide",
            ",",
            "an",
            "oral",
            "androgen-receptor",
            "inhibitor",
            ",",
            "in",
            "combination",
            "with",
            "androgen-deprivation",
            "therapy",
            "was",
            "approved",
            "by",
            "the",
            "Food",
            "and",
            "Drug",
            "Administration",
            "to",
            "treat",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "prostate",
            "can-cer",
            "in",
            "2018",
            "on",
            "the",
            "basis",
            "of",
            "a",
            "significantly",
            "lower",
            "risk",
            "of",
            "metastasis",
            "or",
            "death",
            "without",
            "radiographic",
            "progression",
            "than",
            "with",
            "androgen-deprivation",
            "ther-apy",
            "alone",
            "(",
            "hazard",
            "ratio",
            ",",
            "0.29",
            ";",
            "95",
            "%",
            "confidence",
            "interval",
            "[",
            "CI",
            "]",
            ",",
            "0.24",
            "to",
            "0.35",
            ";",
            "P",
            "<",
            "0.001",
            ")",
            "in",
            "the",
            "phase",
            "3",
            "PROSPER",
            "trial.1,2",
            "Enzalutamide",
            "had",
            "a",
            "safety",
            "pro-file",
            "consistent",
            "with",
            "that",
            "shown",
            "in",
            "multiple",
            "previ-ous",
            "phase",
            "3",
            "trials.1,3-5",
            "Enzalutamide",
            "was",
            "associ-ated",
            "with",
            "a",
            "better",
            "health-related",
            "quality",
            "of",
            "life",
            "and",
            "with",
            "a",
            "significantly",
            "lower",
            "risk",
            "of",
            "prostate-specific",
            "antigen",
            "(",
            "PSA",
            ")",
            "progression",
            "(",
            "hazard",
            "ratio",
            ",",
            "0.07",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.05",
            "to",
            "0.08",
            ";",
            "P",
            "<",
            "0.001",
            ")",
            ",",
            "as",
            "well",
            "as",
            "with",
            "a",
            "longer",
            "time",
            "to",
            "use",
            "of",
            "subsequent",
            "antineo-plastic",
            "therapy",
            "(",
            "hazard",
            "ratio",
            ",",
            "0.21",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.17",
            "to",
            "0.26",
            ";",
            "P",
            "<",
            "0.001",
            ")",
            ",1",
            "than",
            "androgen-deprivation",
            "therapy",
            "alone.6It",
            "is",
            "estimated",
            "that",
            "bone",
            "metastases",
            "develop",
            "in",
            "one",
            "third",
            "of",
            "patients",
            "with",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            "within",
            "2",
            "years",
            "after",
            "diagnosis.7",
            "Because",
            "metastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            "is",
            "associated",
            "with",
            "de-creased",
            "overall",
            "survival,5,8",
            "worsening",
            "quality",
            "of",
            "life,9",
            "and",
            "increased",
            "health",
            "care-related",
            "costs,10",
            "delaying",
            "the",
            "time",
            "to",
            "metastasis",
            "is",
            "a",
            "clinically",
            "relevant",
            "goal.11,12Although",
            "delaying",
            "metastasis",
            "and",
            "maintain-ing",
            "quality",
            "of",
            "life",
            "are",
            "meaningful",
            "outcomes",
            ",",
            "overall",
            "survival",
            "has",
            "long",
            "been",
            "considered",
            "an",
            "important",
            "end",
            "point",
            "and",
            "the",
            "standard",
            "for",
            "regu-latory",
            "approval",
            ".",
            "At",
            "the",
            "primary",
            "analysis",
            "in",
            "the",
            "PROSPER",
            "trial",
            ",",
            "after",
            "23",
            "months",
            "of",
            "follow-up",
            ",",
            "the",
            "data",
            "on",
            "overall",
            "survival",
            "were",
            "immature",
            ",",
            "with",
            "165",
            "deaths",
            "during",
            "the",
            "trial",
            "(",
            "28",
            "%",
            "of",
            "596",
            "prespecified",
            "events",
            "for",
            "the",
            "final",
            "analysis",
            ")",
            ".",
            "Median",
            "overall",
            "survival",
            "was",
            "not",
            "reached",
            "in",
            "either",
            "treatment",
            "group",
            "(",
            "hazard",
            "ratio",
            ",",
            "0.80",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.58",
            "to",
            "1.09",
            ";",
            "P",
            "=",
            "0.15",
            ")",
            ".1",
            "Here",
            ",",
            "we",
            "report",
            "results",
            "from",
            "the",
            "pre-specified",
            "third",
            "interim",
            "analysis",
            "of",
            "overall",
            "sur-vival.MethodsTrial",
            "Design",
            "and",
            "OversightWe",
            "conducted",
            "this",
            "multinational",
            ",",
            "double-blind",
            ",",
            "randomized",
            ",",
            "placebo-controlled",
            "phase",
            "3",
            "trial",
            ",",
            "which",
            "was",
            "approved",
            "by",
            "the",
            "independent",
            "review",
            "boards",
            "at",
            "more",
            "than",
            "300",
            "sites",
            "in",
            "32",
            "countries",
            ",",
            "in",
            "accordance",
            "with",
            "the",
            "provisions",
            "of",
            "the",
            "Declara-tion",
            "of",
            "Helsinki",
            "and",
            "Good",
            "Clinical",
            "Practice",
            "guide-lines",
            "of",
            "the",
            "International",
            "Conference",
            "on",
            "Harmoni-sation",
            ".",
            "All",
            "patients",
            "provided",
            "written",
            "informed",
            "consent",
            "before",
            "participating",
            ".",
            "An",
            "independent",
            "data",
            "and",
            "safety",
            "monitoring",
            "committee",
            "reviewed",
            "safety",
            "data",
            "in",
            "an",
            "unblinded",
            "fashion",
            "at",
            "regular",
            "intervals.The",
            "trial",
            "was",
            "designed",
            "and",
            "written",
            "in",
            "collabo-ration",
            "with",
            "the",
            "principal",
            "investigators",
            "and",
            "em-ployees",
            "of",
            "the",
            "sponsors",
            "\u0160",
            "Medivation",
            "(",
            "a",
            "Pfizer",
            "company",
            ")",
            "and",
            "Astellas",
            "Pharma",
            ",",
            "the",
            "codevelopers",
            "of",
            "enzalutamide",
            ".",
            "Local",
            "site",
            "investigators",
            "treated",
            "patients",
            ",",
            "conducted",
            "follow-up",
            ",",
            "and",
            "collected",
            "data",
            ",",
            "which",
            "were",
            "first",
            "analyzed",
            "by",
            "the",
            "sponsors",
            ".",
            "Data",
            "analyses",
            "were",
            "conducted",
            "by",
            "the",
            "sponsors",
            "and",
            "were",
            "provided",
            "to",
            "the",
            "authors",
            ",",
            "who",
            "wrote",
            "the",
            "manuscript",
            ".",
            "The",
            "authors",
            "vouch",
            "for",
            "the",
            "accuracy",
            "and",
            "completeness",
            "of",
            "the",
            "data",
            "and",
            "its",
            "analysis",
            "and",
            "for",
            "the",
            "adherence",
            "of",
            "the",
            "trial",
            "to",
            "the",
            "proto-col",
            ",",
            "available",
            "with",
            "the",
            "full",
            "text",
            "of",
            "this",
            "article",
            "at",
            "NEJM.org",
            ".",
            "A",
            "medical",
            "writer",
            "and",
            "medical",
            "editor",
            "were",
            "paid",
            "by",
            "the",
            "sponsors",
            "and",
            "assisted",
            "in",
            "the",
            "preparation",
            "of",
            "the",
            "manuscript",
            "that",
            "was",
            "submitted.The",
            "trial",
            "design",
            "has",
            "been",
            "described",
            "previous-ly.1",
            "To",
            "be",
            "eligible",
            "for",
            "participation",
            ",",
            "men",
            "had",
            "to",
            "have",
            "pathologically",
            "confirmed",
            "prostate",
            "adeno-carcinoma",
            "with",
            "an",
            "increasing",
            "PSA",
            "despite",
            "cas-trate",
            "levels",
            "of",
            "testosterone",
            "(",
            "serum",
            "testosterone",
            "level",
            ",",
            "\u02dc1.73",
            "nmol",
            "per",
            "liter",
            "[",
            "0.50",
            "ng",
            "per",
            "millili-ter",
            "]",
            ")",
            ",",
            "a",
            "baseline",
            "PSA",
            "level",
            "of",
            "2",
            "ng",
            "or",
            "greater",
            "per",
            "milliliter",
            ",",
            "and",
            "a",
            "PSA",
            "doubling",
            "time",
            "of",
            "10",
            "months",
            "or",
            "less",
            ".",
            "Patients",
            "had",
            "no",
            "previous",
            "or",
            "current",
            "evi-dence",
            "of",
            "metastatic",
            "disease",
            ",",
            "as",
            "assessed",
            "with",
            "computed",
            "tomography",
            "or",
            "magnetic",
            "resonance",
            "imaging",
            "for",
            "soft-tissue",
            "disease",
            "and",
            "with",
            "whole-body",
            "radionuclide",
            "bone",
            "scan",
            ",",
            "with",
            "results",
            "con-firmed",
            "by",
            "independent",
            "central",
            "reviewers",
            ".",
            "Pa-tients",
            "were",
            "stratified",
            "according",
            "to",
            "PSA",
            "doubling",
            "time",
            "(",
            "<",
            "6",
            "months",
            "or",
            "\u02da6",
            "months",
            ")",
            "and",
            "previous",
            "or",
            "current",
            "use",
            "of",
            "a",
            "bone-targeting",
            "agent",
            "at",
            "baseline",
            "(",
            "yes",
            "or",
            "no",
            ")",
            "and",
            "were",
            "randomly",
            "assigned",
            "in",
            "a",
            "2:1",
            "ratio",
            "to",
            "continue",
            "receiving",
            "androgen-deprivation",
            "therapy",
            "(",
            "either",
            "with",
            "a",
            "gonadotropin-releasing",
            "hor-mone",
            "agonist",
            "or",
            "antagonist",
            "or",
            "with",
            "previous",
            "bilateral",
            "orchiectomy",
            ")",
            "plus",
            "either",
            "enzalutamide",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "or",
            "placebo",
            "once",
            "daily",
            "until",
            "radiographic",
            "progression",
            ",",
            "unacceptable",
            "toxic",
            "ef-fects",
            ",",
            "or",
            "death",
            ".",
            "Patients",
            "and",
            "investigators",
            "were",
            "unaware",
            "of",
            "the",
            "PSA",
            "levels",
            "during",
            "the",
            "trial",
            ".",
            "Dis-n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "3Enzalutamide",
            "in",
            "Castration-Resistant",
            "Prostate",
            "Cancercontinuation",
            "of",
            "the",
            "trial",
            "regimen",
            "solely",
            "because",
            "of",
            "an",
            "increase",
            "in",
            "PSA",
            "level",
            "was",
            "discouraged",
            ".",
            "After",
            "the",
            "trial",
            "was",
            "unblinded",
            ",",
            "patients",
            "in",
            "the",
            "placebo",
            "group",
            "were",
            "given",
            "the",
            "option",
            "to",
            "enroll",
            "in",
            "an",
            "open-label",
            "extension",
            "in",
            "which",
            "they",
            "would",
            "receive",
            "enzalutamide",
            ".",
            "All",
            "enrolled",
            "patients",
            "were",
            "followed",
            "for",
            "survival",
            "and",
            "for",
            "the",
            "use",
            "of",
            "subse-quent",
            "therapies",
            "after",
            "discontinuation",
            "of",
            "the",
            "trial",
            "regimen.Trial",
            "End",
            "PointsThe",
            "primary",
            "end",
            "point",
            "was",
            "metastasis-free",
            "sur-vival",
            ",",
            "defined",
            "as",
            "time",
            "from",
            "randomization",
            "to",
            "imaging-based",
            "progression",
            ",",
            "as",
            "determined",
            "by",
            "central",
            "review",
            "at",
            "any",
            "time",
            ",",
            "or",
            "as",
            "the",
            "time",
            "to",
            "death",
            "from",
            "any",
            "cause",
            "without",
            "evidence",
            "of",
            "imaging-based",
            "progression",
            "during",
            "the",
            "period",
            "from",
            "ran-domization",
            "to",
            "112",
            "days",
            "after",
            "discontinuation",
            "of",
            "the",
            "trial",
            "regimen",
            ",",
            "whichever",
            "occurred",
            "first",
            ".",
            "Secondary",
            "end",
            "points",
            "included",
            "overall",
            "survival",
            ",",
            "defined",
            "as",
            "the",
            "time",
            "from",
            "randomization",
            "to",
            "death",
            "from",
            "any",
            "cause",
            ",",
            "time",
            "to",
            "PSA",
            "progression",
            ",",
            "PSA",
            "response",
            "rate",
            ",",
            "time",
            "to",
            "first",
            "use",
            "of",
            "a",
            "subse-quent",
            "antineoplastic",
            "therapy",
            ",",
            "time",
            "to",
            "first",
            "use",
            "of",
            "cytotoxic",
            "chemotherapy",
            ",",
            "chemotherapy-free",
            "sur-vival",
            ",",
            "time",
            "to",
            "pain",
            "progression",
            ",",
            "health-related",
            "quality",
            "of",
            "life",
            ",",
            "and",
            "the",
            "frequency",
            "and",
            "severity",
            "of",
            "adverse",
            "events",
            ".",
            "Definitions",
            "of",
            "the",
            "end",
            "points",
            "are",
            "provided",
            "in",
            "Table",
            "S1",
            "in",
            "the",
            "Supplementary",
            "Ap-pendix",
            ",",
            "available",
            "at",
            "NEJM.org.At",
            "the",
            "primary",
            "analysis",
            "(",
            "data",
            "cutoff",
            "date",
            ",",
            "June",
            "28",
            ",",
            "2017",
            ")",
            ",",
            "the",
            "results",
            "with",
            "respect",
            "to",
            "metastasis-free",
            "survival",
            ",",
            "time",
            "to",
            "PSA",
            "progression",
            ",",
            "and",
            "time",
            "to",
            "first",
            "use",
            "of",
            "a",
            "new",
            "subsequent",
            "antineoplastic",
            "therapy",
            "met",
            "the",
            "criteria",
            "for",
            "significance",
            ";",
            "there-fore",
            ",",
            "in",
            "accordance",
            "with",
            "the",
            "protocol",
            ",",
            "the",
            "analy-sis",
            "of",
            "these",
            "end",
            "points",
            "was",
            "considered",
            "final.1",
            "Patients",
            "were",
            "then",
            "followed",
            "for",
            "safety",
            "and",
            "over-all",
            "survival",
            ";",
            "two",
            "additional",
            "interim",
            "analyses",
            "of",
            "overall",
            "survival",
            "(",
            "after",
            "approximately",
            "285",
            "deaths",
            "and",
            "440",
            "deaths",
            ")",
            "and",
            "a",
            "final",
            "analysis",
            "(",
            "after",
            "ap-proximately",
            "596",
            "deaths",
            ")",
            "were",
            "planned",
            ".",
            "Updated",
            "analyses",
            "of",
            "time",
            "to",
            "first",
            "use",
            "of",
            "subsequent",
            "ther-apy",
            ",",
            "time",
            "to",
            "first",
            "use",
            "of",
            "cytotoxic",
            "chemotherapy",
            ",",
            "and",
            "chemotherapy-free",
            "survival",
            "were",
            "also",
            "per-formed.Statistical",
            "AnalysisEfficacy",
            "end",
            "points",
            "were",
            "analyzed",
            "in",
            "the",
            "inten-tion-to-treat",
            "population",
            ",",
            "defined",
            "as",
            "all",
            "patients",
            "who",
            "underwent",
            "randomization",
            ".",
            "Patients",
            "who",
            "had",
            "been",
            "randomly",
            "assigned",
            "to",
            "receive",
            "placebo",
            "who",
            "crossed",
            "over",
            "to",
            "receive",
            "enzalutamide",
            "during",
            "the",
            "open-label",
            "extension",
            "(",
            "the",
            "crossover",
            "group",
            ")",
            "were",
            "included",
            "in",
            "the",
            "placebo",
            "group",
            "for",
            "all",
            "effi-cacy",
            "analyses",
            ".",
            "Safety",
            "was",
            "analyzed",
            "in",
            "all",
            "patients",
            "who",
            "received",
            "at",
            "least",
            "one",
            "dose",
            "of",
            "enzalutamide",
            "or",
            "placebo",
            ".",
            "The",
            "analysis",
            "of",
            "safety",
            "included",
            "events",
            "that",
            "occurred",
            "from",
            "the",
            "time",
            "of",
            "the",
            "first",
            "dose",
            "of",
            "enzalutamide",
            "or",
            "placebo",
            "to",
            "30",
            "days",
            "after",
            "the",
            "last",
            "dose",
            "or",
            "to",
            "the",
            "day",
            "before",
            "initiation",
            "of",
            "a",
            "new",
            "antineoplastic",
            "therapy",
            ",",
            "whichever",
            "occurred",
            "first.For",
            "the",
            "final",
            "analysis",
            "of",
            "overall",
            "survival",
            ",",
            "we",
            "calculated",
            "that",
            "590",
            "deaths",
            "were",
            "required",
            "to",
            "pro-vide",
            "85",
            "%",
            "power",
            "to",
            "detect",
            "a",
            "hazard",
            "ratio",
            "of",
            "0.77",
            "at",
            "a",
            "two-sided",
            "significance",
            "level",
            "of",
            "0.05",
            ".",
            "Overall",
            "survival",
            "was",
            "assessed",
            "with",
            "the",
            "use",
            "of",
            "a",
            "group",
            "sequential",
            "testing",
            "procedure",
            "based",
            "on",
            "an",
            "O\u2122Brien\u0152Fleming\u0152type",
            "alpha-spending",
            "function",
            "with",
            "three",
            "preplanned",
            "interim",
            "analyses",
            ".",
            "If",
            "an",
            "interim",
            "analy-sis",
            "of",
            "overall",
            "survival",
            "crossed",
            "the",
            "significance",
            "boundary",
            ",",
            "it",
            "would",
            "be",
            "reported",
            "as",
            "the",
            "final",
            "analysis",
            "and",
            "no",
            "subsequent",
            "analyses",
            "would",
            "be",
            "performed",
            ".",
            "The",
            "results",
            "of",
            "the",
            "first",
            "and",
            "second",
            "(",
            "data",
            "not",
            "shown",
            ")",
            "interim",
            "analyses",
            "of",
            "overall",
            "survival",
            "did",
            "not",
            "cross",
            "the",
            "significance",
            "bound-ary.1",
            "This",
            "was",
            "the",
            "third",
            "preplanned",
            "interim",
            "analysis",
            ",",
            "performed",
            "after",
            "approximately",
            "440",
            "deaths",
            "had",
            "occurred",
            ".",
            "After",
            "adjustment",
            "for",
            "multiplicity",
            ",",
            "a",
            "P",
            "value",
            "of",
            "0.021",
            "or",
            "less",
            "was",
            "required",
            "to",
            "indicate",
            "statistical",
            "significance.The",
            "trial",
            "groups",
            "were",
            "compared",
            "with",
            "the",
            "use",
            "of",
            "a",
            "log-rank",
            "test",
            "with",
            "stratification",
            "according",
            "to",
            "the",
            "same",
            "factors",
            "that",
            "were",
            "used",
            "in",
            "randomiza-tion",
            ".",
            "The",
            "Kaplan\u0152Meier",
            "method",
            "was",
            "used",
            "to",
            "estimate",
            "medians",
            ".",
            "A",
            "stratified",
            "Cox",
            "regression",
            "model",
            "was",
            "used",
            "to",
            "estimate",
            "hazard",
            "ratios",
            "and",
            "95",
            "%",
            "confidence",
            "intervals",
            ",",
            "which",
            "were",
            "not",
            "ad-justed",
            "for",
            "multiplicity.ResultsPatientsFrom",
            "November",
            "26",
            ",",
            "2013",
            ",",
            "to",
            "June",
            "28",
            ",",
            "2017",
            ",",
            "a",
            "total",
            "of",
            "1401",
            "eligible",
            "patients",
            "were",
            "enrolled",
            "and",
            "underwent",
            "randomization",
            ";",
            "933",
            "were",
            "assigned",
            "to",
            "the",
            "enzalutamide",
            "group",
            "and",
            "468",
            "were",
            "assigned",
            "to",
            "the",
            "placebo",
            "group",
            "(",
            "Fig",
            ".",
            "S1",
            ")",
            ".",
            "Demographic",
            "and",
            "baseline",
            "characteristics",
            "were",
            "well",
            "balanced",
            "be-tween",
            "the",
            "groups.1",
            "The",
            "median",
            "age",
            "was",
            "74",
            "years",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "73",
            "years",
            "in",
            "the",
            "n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "4The",
            "new",
            "england",
            "journal",
            "of",
            "medicine\u02dc\u02da\u02db\u02dd\u02d9\u02c6\u02c7\u02d8\u02c7\u02c6\u02c6\u02c6\u02c6\u02c7\u02c6\u02c7\u02c6\u02dc\u02da\ufb01\u02c7\u02da\u2030\u02dd\ufb02\u02c7\u02da\u2030\u02dd\u0160\u0161\u2026\u2212\u02dc\u02c7\u02c6\u02c7\u02c7\u02c6\u02dc\u02c6\u02c6\u02dc\u02c6n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "5Enzalutamide",
            "in",
            "Castration-Resistant",
            "Prostate",
            "Cancerplacebo",
            "group",
            "(",
            "Table",
            "S2",
            ")",
            ".",
            "The",
            "median",
            "PSA",
            "dou-bling",
            "time",
            "was",
            "3.8",
            "months",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "3.6",
            "months",
            "in",
            "the",
            "placebo",
            "group.After",
            "the",
            "primary",
            "analysis",
            "was",
            "completed",
            ",",
            "the",
            "trial",
            "data",
            "were",
            "unblinded",
            ",",
            "and",
            "patients",
            "in",
            "the",
            "placebo",
            "group",
            "were",
            "given",
            "the",
            "opportunity",
            "to",
            "receive",
            "enzalutamide",
            "(",
            "crossover",
            "began",
            "on",
            "Febru-ary",
            "12",
            ",",
            "2018",
            ")",
            ".",
            "Of",
            "the",
            "114",
            "patients",
            "in",
            "the",
            "placebo",
            "group",
            "who",
            "were",
            "still",
            "receiving",
            "treatment",
            "when",
            "crossover",
            "began",
            ",",
            "87",
            "received",
            "enzalutamide",
            "in",
            "the",
            "open-label",
            "extension",
            ".",
            "At",
            "the",
            "data",
            "cutoff",
            "(",
            "Oc-tober",
            "15",
            ",",
            "2019",
            ")",
            ",",
            "552",
            "of",
            "933",
            "patients",
            "(",
            "59",
            "%",
            ")",
            "from",
            "the",
            "enzalutamide",
            "group",
            "and",
            "17",
            "of",
            "87",
            "patients",
            "(",
            "20",
            "%",
            ")",
            "from",
            "the",
            "crossover",
            "group",
            "had",
            "discontin-ued",
            "enzalutamide",
            ".",
            "The",
            "most",
            "common",
            "reason",
            "for",
            "discontinuation",
            "was",
            "disease",
            "progression",
            "in",
            "the",
            "enzalutamide",
            "group",
            "(",
            "288",
            "of",
            "552",
            "patients",
            ";",
            "31",
            "%",
            "of",
            "total",
            "patients",
            "assigned",
            "to",
            "enzalutamide",
            "and",
            "52",
            "%",
            "of",
            "patients",
            "assigned",
            "to",
            "enzalutamide",
            "who",
            "dis-continued",
            ")",
            "and",
            "in",
            "the",
            "placebo",
            "group",
            "(",
            "247",
            "of",
            "465",
            ";",
            "53",
            "%",
            ")",
            ",",
            "and",
            "adverse",
            "events",
            "were",
            "the",
            "most",
            "common",
            "reason",
            "in",
            "the",
            "crossover",
            "group",
            "(",
            "10",
            "of",
            "17",
            ";",
            "59",
            "%",
            ")",
            ".",
            "Median",
            "follow-up",
            "for",
            "the",
            "trial",
            "was",
            "48",
            "months.Overall",
            "SurvivalAt",
            "the",
            "data",
            "cutoff",
            ",",
            "288",
            "patients",
            "(",
            "31",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "178",
            "patients",
            "(",
            "38",
            "%",
            ")",
            "in",
            "the",
            "placebo",
            "group",
            "had",
            "died",
            ".",
            "In",
            "the",
            "enzalutamide",
            "group",
            ",",
            "178",
            "deaths",
            "(",
            "19",
            "%",
            ")",
            "were",
            "prostate",
            "cancer\u0152related",
            ",",
            "and",
            "110",
            "(",
            "12",
            "%",
            ")",
            "were",
            "not",
            "prostate",
            "cancer\u0152related",
            ",",
            "as",
            "compared",
            "with",
            "136",
            "deaths",
            "(",
            "29",
            "%",
            ")",
            "and",
            "42",
            "deaths",
            "(",
            "9",
            "%",
            ")",
            ",",
            "respectively",
            ",",
            "in",
            "the",
            "placebo",
            "group",
            ".",
            "Median",
            "overall",
            "survival",
            "was",
            "67.0",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "64.0",
            "to",
            "not",
            "reached",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "56.3",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "54.4",
            "to",
            "63.0",
            ")",
            "in",
            "the",
            "placebo",
            "group",
            "(",
            "Fig",
            ".",
            "1A",
            ")",
            ".",
            "Enzalutamide",
            "plus",
            "androgen-deprivation",
            "therapy",
            "was",
            "associated",
            "with",
            "a",
            "significant",
            "27",
            "%",
            "lower",
            "risk",
            "of",
            "death",
            "than",
            "placebo",
            "plus",
            "androgen-deprivation",
            "therapy",
            "(",
            "hazard",
            "ratio",
            ",",
            "0.73",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.61",
            "to",
            "0.89",
            ";",
            "P",
            "=",
            "0.001",
            ")",
            ".",
            "Because",
            "the",
            "O\u2122Brien\u0152Fleming",
            "significance",
            "boundary",
            "was",
            "crossed",
            ",",
            "this",
            "became",
            "the",
            "final",
            "analysis",
            ".",
            "The",
            "treat-ment",
            "effect",
            "of",
            "enzalutamide",
            "was",
            "generally",
            "consis-tent",
            "across",
            "prespecified",
            "subgroups",
            ",",
            "with",
            "the",
            "pos-sible",
            "exception",
            "of",
            "patients",
            "receiving",
            "bone-sparing",
            "agents",
            ",",
            "although",
            "the",
            "number",
            "of",
            "such",
            "patients",
            "was",
            "small",
            "(",
            "Fig",
            ".",
            "1B",
            ")",
            ".",
            "In",
            "an",
            "unplanned",
            "analysis",
            ",",
            "the",
            "percentage",
            "of",
            "patients",
            "alive",
            "at",
            "3",
            "years",
            "was",
            "80",
            "%",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "77",
            "to",
            "83",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "73",
            "%",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "69",
            "to",
            "77",
            ")",
            "in",
            "the",
            "placebo",
            "group.Subsequent",
            "TherapyEnzalutamide",
            "was",
            "associated",
            "with",
            "a",
            "delay",
            "in",
            "the",
            "use",
            "of",
            "a",
            "new",
            "subsequent",
            "antineoplastic",
            "therapy",
            "(",
            "hazard",
            "ratio",
            "for",
            "the",
            "use",
            "of",
            "any",
            "subsequent",
            "anti-neoplastic",
            "therapy",
            ",",
            "0.29",
            ";",
            "95",
            "%",
            "CI",
            ",",
            "0.25",
            "to",
            "0.35",
            ")",
            "(",
            "Fig",
            ".",
            "S2A",
            ")",
            ".",
            "The",
            "median",
            "time",
            "to",
            "first",
            "use",
            "of",
            "new",
            "antineoplastic",
            "therapy",
            "was",
            "66.7",
            "months",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "19.1",
            "months",
            "in",
            "the",
            "pla-cebo",
            "group",
            ".",
            "A",
            "total",
            "of",
            "310",
            "patients",
            "in",
            "the",
            "enzalu-tamide",
            "group",
            "(",
            "33",
            "%",
            "of",
            "all",
            "patients",
            "assigned",
            "to",
            "enzalutamide",
            "and",
            "56",
            "%",
            "of",
            "those",
            "who",
            "discontin-ued",
            "treatment",
            ")",
            "and",
            "303",
            "patients",
            "in",
            "the",
            "placebo",
            "group",
            "(",
            "65",
            "%",
            ")",
            "received",
            "at",
            "least",
            "one",
            "subsequent",
            "antineoplastic",
            "therapy",
            "after",
            "discontinuation",
            "of",
            "the",
            "trial",
            "regimen",
            "(",
            "Table",
            "1",
            ")",
            ".",
            "The",
            "median",
            "time",
            "from",
            "discontinuation",
            "to",
            "the",
            "start",
            "of",
            "a",
            "subse-quent",
            "antineoplastic",
            "therapy",
            "was",
            "30",
            "days",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "22",
            "days",
            "in",
            "the",
            "placebo",
            "group",
            ".",
            "The",
            "most",
            "common",
            "subsequent",
            "antineo-plastic",
            "therapy",
            "was",
            "docetaxel",
            "(",
            "185",
            "patients",
            ",",
            "60",
            "%",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "abiraterone",
            "(",
            "178",
            "patients",
            ",",
            "59",
            "%",
            ")",
            "in",
            "the",
            "placebo",
            "group.SafetyThe",
            "median",
            "treatment",
            "duration",
            "was",
            "33.9",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "0.2",
            "to",
            "68.8",
            ")",
            "in",
            "the",
            "enzalutamide",
            "group",
            "Figure\u02dc1\u02dc",
            "(",
            "facing\u02dcpage",
            ")",
            ".\u02dcKaplan\u0152Meier\u02dcEstimates\u02dc\u02dcand\u02dcSubgroup\u02dcAnalysis\u02dcof\u02dcOverall\u02dcSurvival.Panel",
            "A",
            "shows",
            "the",
            "data",
            "for",
            "the",
            "final",
            "Kaplan\u0152Meier",
            "analy-sis",
            "of",
            "overall",
            "survival",
            ".",
            "The",
            "hazard",
            "ratio",
            "was",
            "based",
            "on",
            "a",
            "Cox",
            "regression",
            "model",
            "stratified",
            "according",
            "to",
            "prostate-specific",
            "antigen",
            "(",
            "PSA",
            ")",
            "doubling",
            "time",
            "(",
            "<",
            "6",
            "months",
            "or",
            "\u02dc6",
            "months",
            ")",
            "and",
            "previous",
            "or",
            "current",
            "use",
            "of",
            "a",
            "bone-tar-geting",
            "agent",
            "(",
            "yes",
            "or",
            "no",
            ")",
            ",",
            "with",
            "trial",
            "group",
            "as",
            "the",
            "only",
            "covariate",
            "and",
            "a",
            "value",
            "of",
            "less",
            "than",
            "1.00",
            "favoring",
            "enzalu-tamide",
            "treatment",
            ".",
            "The",
            "dashed",
            "line",
            "indicates",
            "the",
            "median",
            ",",
            "and",
            "symbols",
            "indicate",
            "censored",
            "data",
            "in",
            "the",
            "Kaplan\u0152Meier",
            "curve",
            ".",
            "NR",
            "denotes",
            "not",
            "reached",
            ".",
            "Panel",
            "B",
            "shows",
            "the",
            "sub-group",
            "analysis",
            "of",
            "overall",
            "survival",
            ".",
            "The",
            "analyses",
            "of",
            "all",
            "subgroups",
            "were",
            "unstratified",
            ",",
            "and",
            "95",
            "%",
            "confidence",
            "inter-vals",
            "were",
            "not",
            "adjusted",
            "for",
            "multiplicity",
            ".",
            "The",
            "size",
            "of",
            "each",
            "circle",
            "reflects",
            "the",
            "number",
            "of",
            "patients",
            "in",
            "the",
            "subgroup",
            ".",
            "At",
            "baseline",
            ",",
            "the",
            "median",
            "age",
            "of",
            "the",
            "patients",
            "was",
            "74",
            "years",
            ",",
            "the",
            "median",
            "PSA",
            "level",
            "was",
            "10.75",
            "ng",
            "per",
            "milliliter",
            ",",
            "the",
            "median",
            "lactate",
            "dehydrogenase",
            "(",
            "LDH",
            ")",
            "level",
            "was",
            "1.78",
            "U",
            "per",
            "liter",
            ",",
            "and",
            "the",
            "median",
            "hemoglobin",
            "level",
            "was",
            "134",
            "g",
            "per",
            "liter",
            ".",
            "Eastern",
            "Cooperative",
            "Oncology",
            "Group",
            "(",
            "ECOG",
            ")",
            "per-formance-status",
            "scores",
            "range",
            "from",
            "0",
            "to",
            "5",
            ",",
            "with",
            "higher",
            "scores",
            "indicating",
            "greater",
            "disability",
            ".",
            "Gleason",
            "scores",
            "range",
            "from",
            "6",
            "to",
            "10",
            ",",
            "with",
            "higher",
            "scores",
            "indicating",
            "more",
            "aggres-sive",
            "cancer.n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "6The",
            "new",
            "england",
            "journal",
            "of",
            "medicineand",
            "14.2",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "0.1",
            "to",
            "51.3",
            ")",
            "in",
            "the",
            "placebo",
            "group",
            ".",
            "The",
            "incidences",
            "of",
            "adverse",
            "events",
            "within",
            "the",
            "first",
            "3",
            "months",
            "and",
            "6",
            "months",
            "were",
            "higher",
            "in",
            "the",
            "enzalutamide",
            "group",
            "than",
            "in",
            "the",
            "placebo",
            "group",
            ".",
            "However",
            ",",
            "after",
            "adjustment",
            "for",
            "exposure",
            ",",
            "the",
            "rates",
            "of",
            "adverse",
            "events",
            "per",
            "100",
            "patient-years",
            "were",
            "similar",
            "in",
            "the",
            "two",
            "groups",
            "(",
            "Table",
            "2",
            ")",
            ".",
            "Cumulative",
            "incidence",
            "plots",
            "showed",
            "a",
            "similar",
            "onset",
            "of",
            "grade",
            "3",
            "or",
            "4",
            "adverse",
            "events",
            "and",
            "serious",
            "adverse",
            "events",
            "in",
            "the",
            "enzalutamide",
            "and",
            "placebo",
            "groups",
            ",",
            "whereas",
            "adverse",
            "events",
            "of",
            "spe-cial",
            "interest",
            "(",
            "Table",
            "3",
            ")",
            "had",
            "a",
            "steeper",
            "rate",
            "of",
            "initial",
            "onset",
            "in",
            "the",
            "enzalutamide",
            "group",
            "(",
            "Fig",
            ".",
            "S3",
            ")",
            ".",
            "The",
            "most",
            "frequently",
            "reported",
            "adverse",
            "events",
            "were",
            "consistent",
            "with",
            "those",
            "reported",
            "in",
            "the",
            "primary",
            "analysis1",
            "(",
            "Tables",
            "S3",
            "and",
            "S4",
            ")",
            ",",
            "primarily",
            "fatigue",
            "and",
            "musculoskeletal",
            "events.The",
            "adverse",
            "events",
            "of",
            "special",
            "interest",
            "with",
            "exposure-adjusted",
            "rates",
            "that",
            "were",
            "3",
            "or",
            "more",
            "events",
            "per",
            "100",
            "patient-years",
            "higher",
            "in",
            "the",
            "enzalu-tamide",
            "group",
            "than",
            "in",
            "the",
            "placebo",
            "group",
            "were",
            "falls",
            "(",
            "9",
            "vs.",
            "4",
            "events",
            "per",
            "100",
            "patient-years",
            ")",
            "and",
            "fractures",
            "(",
            "9",
            "vs.",
            "5",
            "events",
            "per",
            "100",
            "patient-years",
            ")",
            "(",
            "Table",
            "S5",
            ")",
            ".",
            "The",
            "most",
            "frequently",
            "reported",
            "adverse",
            "Table\u02dc2.\u02dcSummary\u02dcof\u02dcAdverse\u02dcEvents",
            ",",
            "\u02dcIrrespective\u02dcof\u02dcRelationship\u02dcto\u02dcEnzalutamide\u02dcor\u02dcPlacebo.",
            "*",
            "Adverse\u02dcEventEnzalutamide\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc930",
            ")",
            "Placebo\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc465",
            ")",
            "PatientsEventsPatientsEventsno",
            ".",
            "(",
            "%",
            ")",
            "no",
            ".",
            "(",
            "no./100",
            "patient-yr",
            ")",
            "no",
            ".",
            "(",
            "%",
            ")",
            "no",
            ".",
            "(",
            "no/100",
            "patient-yr",
            ")",
            "Any",
            "adverse",
            "event876",
            "(",
            "94",
            ")",
            "876",
            "(",
            "34",
            ")",
            "380",
            "(",
            "82",
            ")",
            "380",
            "(",
            "60",
            ")",
            "Within",
            "the",
            "first",
            "3",
            "mo609",
            "(",
            "65",
            ")",
            "\u0160241",
            "(",
            "52",
            ")",
            "\u0160Within",
            "the",
            "first",
            "6",
            "mo703",
            "(",
            "76",
            ")",
            "\u0160298",
            "(",
            "64",
            ")",
            "\u0160Any",
            "grade",
            "\u02dc3",
            "adverse",
            "event446",
            "(",
            "48",
            ")",
            "446",
            "(",
            "17",
            ")",
            "126",
            "(",
            "27",
            ")",
            "126",
            "(",
            "20",
            ")",
            "Within",
            "the",
            "first",
            "3",
            "mo89",
            "(",
            "10",
            ")",
            "\u016022",
            "(",
            "5",
            ")",
            "\u0160Within",
            "the",
            "first",
            "6",
            "mo140",
            "(",
            "15",
            ")",
            "\u016056",
            "(",
            "12",
            ")",
            "\u0160Any",
            "serious",
            "adverse",
            "event\u0192372",
            "(",
            "40",
            ")",
            "372",
            "(",
            "14",
            ")",
            "100",
            "(",
            "22",
            ")",
            "100",
            "(",
            "16",
            ")",
            "Any",
            "adverse",
            "event",
            "leading",
            "to",
            "discontinuation",
            "of",
            "trial",
            "regimen158",
            "(",
            "17",
            ")",
            "158",
            "(",
            "6",
            ")",
            "41",
            "(",
            "9",
            ")",
            "41",
            "(",
            "6",
            ")",
            "Any",
            "adverse",
            "event",
            "leading",
            "to",
            "death51",
            "(",
            "5",
            ")",
            "51",
            "(",
            "2",
            ")",
            "3",
            "(",
            "1",
            ")",
            "3",
            "(",
            "<",
            "1",
            ")",
            "*",
            "Total",
            "patient-years",
            "of",
            "exposure",
            "were",
            "2613.41",
            "for",
            "the",
            "enzalutamide",
            "group",
            "and",
            "634.45",
            "for",
            "the",
            "placebo",
            "group",
            ".",
            "The",
            "event",
            "rate",
            "was",
            "calculated",
            "as",
            "100",
            "\u00d7",
            "number",
            "of",
            "events/total",
            "patient-years",
            "of",
            "exposure",
            "for",
            "the",
            "treatment",
            "group.\u0192",
            "Serious",
            "adverse",
            "events",
            "were",
            "events",
            "that",
            "resulted",
            "in",
            "death",
            ",",
            "were",
            "life-threatening",
            ",",
            "resulted",
            "in",
            "or",
            "prolonged",
            "hospitalization",
            ",",
            "resulted",
            "in",
            "the",
            "inability",
            "to",
            "conduct",
            "normal",
            "life",
            "functions",
            ",",
            "or",
            "led",
            "to",
            "a",
            "congenital",
            "anomaly",
            "or",
            "birth",
            "defect",
            ".",
            "A",
            "full",
            "definition",
            "is",
            "provided",
            "in",
            "the",
            "protocol.Table\u02dc1.\u02dcAntineoplastic\u02dcTherapy\u02dcReceived\u02dcafter\u02dcDiscontinuation\u02dcof\u02dcEnzalutamide\u02dcor\u02dcPlacebo.Subsequent\u02dcTherapyEnzalutamide\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc930",
            ")",
            "Placebo\u02dc\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc465",
            ")",
            "no",
            ".",
            "of",
            "patients",
            "(",
            "%",
            ")",
            "At",
            "least",
            "one",
            "antineoplastic",
            "agent310",
            "(",
            "33",
            ")",
            "303",
            "(",
            "65",
            ")",
            "Agents",
            "used",
            "by",
            "\u02dc5",
            "%",
            "of",
            "patients",
            "in",
            "either",
            "treatment",
            "group",
            "*",
            "Abiraterone",
            "acetate152",
            "(",
            "49",
            ")",
            "178",
            "(",
            "59",
            ")",
            "Docetaxel185",
            "(",
            "60",
            ")",
            "141",
            "(",
            "47",
            ")",
            "Enzalutamide44",
            "(",
            "14",
            ")",
            "109",
            "(",
            "36",
            ")",
            "\u0192Cabazitaxel46",
            "(",
            "15",
            ")",
            "49",
            "(",
            "16",
            ")",
            "Bicalutamide28",
            "(",
            "9",
            ")",
            "41",
            "(",
            "14",
            ")",
            "*",
            "Percentages",
            "are",
            "based",
            "on",
            "the",
            "number",
            "of",
            "patients",
            "who",
            "received",
            "at",
            "least",
            "one",
            "antineoplastic",
            "agent",
            "after",
            "discontinuation",
            "of",
            "the",
            "trial",
            "regimen",
            "(",
            "310",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "303",
            "in",
            "the",
            "placebo",
            "group",
            ")",
            ".\u0192",
            "A",
            "total",
            "of",
            "87",
            "patients",
            "who",
            "received",
            "enzalutamide",
            "in",
            "the",
            "crossover",
            "group",
            "after",
            "the",
            "trial",
            "was",
            "unblinded",
            "were",
            "not",
            "included",
            "in",
            "this",
            "analysis",
            ",",
            "since",
            "they",
            "received",
            "enzalutamide",
            "as",
            "open-label",
            "treatment",
            ".",
            "After",
            "inclusion",
            "of",
            "these",
            "87",
            "patients",
            ",",
            "the",
            "total",
            "number",
            "of",
            "patients",
            "randomly",
            "assigned",
            "to",
            "placebo",
            "who",
            "received",
            "at",
            "least",
            "one",
            "subsequent",
            "antineoplastic",
            "agent",
            "increased",
            "to",
            "390",
            "(",
            "84",
            "%",
            ")",
            ",",
            "and",
            "the",
            "to-tal",
            "number",
            "of",
            "patients",
            "who",
            "received",
            "subsequent",
            "treatment",
            "with",
            "enzalutamide",
            "was",
            "196.n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "7Enzalutamide",
            "in",
            "Castration-Resistant",
            "Prostate",
            "Cancerevents",
            "leading",
            "to",
            "death",
            "during",
            "the",
            "entire",
            "trial",
            "period",
            "were",
            "cardiovascular",
            "events",
            "(",
            "14",
            "[",
            "2",
            "%",
            "]",
            "in",
            "the",
            "enzalutamide",
            "group",
            "and",
            "2",
            "[",
            "<",
            "1",
            "%",
            "]",
            "in",
            "the",
            "pla-cebo",
            "group",
            ")",
            "(",
            "the",
            "full",
            "list",
            "is",
            "provided",
            "in",
            "Table",
            "4",
            ")",
            ".",
            "In",
            "the",
            "enzalutamide",
            "group",
            ",",
            "10",
            "of",
            "14",
            "patients",
            "with",
            "a",
            "cardiovascular",
            "event",
            "leading",
            "to",
            "death",
            "had",
            "clinically",
            "significant",
            "previous",
            "or",
            "ongoing",
            "cardio-vascular",
            "disease",
            ".",
            "Seventeen",
            "adverse",
            "events",
            "lead-ing",
            "to",
            "death",
            "occurred",
            "after",
            "the",
            "primary",
            "analysis",
            ";",
            "the",
            "group",
            "of",
            "men",
            "who",
            "were",
            "affected",
            "had",
            "a",
            "me-dian",
            "age",
            "of",
            "80",
            "years",
            "(",
            "range",
            ",",
            "63",
            "to",
            "93",
            ")",
            ".",
            "None",
            "of",
            "the",
            "cardiovascular",
            "events",
            "that",
            "led",
            "to",
            "death",
            "in",
            "the",
            "trial",
            "were",
            "considered",
            "by",
            "the",
            "investigators",
            "to",
            "be",
            "related",
            "to",
            "treatment",
            "with",
            "enzalutamide.Crossover",
            "GroupA",
            "total",
            "of",
            "87",
            "patients",
            "received",
            "enzalutamide",
            "in",
            "the",
            "crossover",
            "group",
            ".",
            "The",
            "median",
            "treatment",
            "du-ration",
            "with",
            "enzalutamide",
            "after",
            "crossover",
            "treat-ment",
            "began",
            "was",
            "14.5",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ",",
            "0.4",
            "to",
            "18.8",
            ")",
            ",",
            "a",
            "shorter",
            "period",
            "than",
            "among",
            "patients",
            "who",
            "had",
            "been",
            "randomly",
            "assigned",
            "to",
            "enzalutamide",
            "from",
            "the",
            "outset",
            ".",
            "Four",
            "patients",
            "(",
            "5",
            "%",
            ")",
            "received",
            "subsequent",
            "therapy",
            "after",
            "discontinuation",
            "of",
            "en-zalutamide",
            "(",
            "docetaxel",
            ",",
            "abiraterone",
            ",",
            "enzaluta-mide",
            ",",
            "and",
            "sipuleucel-T",
            "were",
            "received",
            "by",
            "1",
            "patient",
            "each",
            ")",
            ".",
            "The",
            "exposure-adjusted",
            "rates",
            "of",
            "adverse",
            "events",
            "and",
            "adverse",
            "events",
            "of",
            "special",
            "interest",
            "were",
            "consistent",
            "with",
            "those",
            "in",
            "the",
            "enzalutamide",
            "group",
            "(",
            "Table",
            "S6",
            ")",
            ".",
            "The",
            "most",
            "frequently",
            "reported",
            "adverse",
            "events",
            "(",
            "occurring",
            "in",
            "\u02da10",
            "%",
            "of",
            "the",
            "patients",
            ")",
            "were",
            "fatigue",
            "(",
            "15",
            "%",
            ")",
            "and",
            "asthenia",
            "(",
            "11",
            "%",
            ")",
            "(",
            "Table",
            "S7",
            ")",
            ".",
            "Four",
            "patients",
            "(",
            "5",
            "%",
            ")",
            "had",
            "adverse",
            "events",
            "leading",
            "to",
            "death",
            "after",
            "crossover",
            "began",
            ";",
            "none",
            "of",
            "these",
            "events",
            "were",
            "considered",
            "by",
            "the",
            "investigators",
            "to",
            "be",
            "related",
            "to",
            "enzalutamide",
            "(",
            "Table",
            "S8",
            ")",
            ".DiscussionIn",
            "this",
            "final",
            "analysis",
            "of",
            "overall",
            "survival",
            "in",
            "the",
            "PROSPER",
            "trial",
            ",",
            "treatment",
            "with",
            "enzalutamide",
            "was",
            "associated",
            "with",
            "a",
            "significant",
            "27",
            "%",
            "lower",
            "risk",
            "of",
            "death",
            "than",
            "placebo",
            "in",
            "men",
            "with",
            "nonmeta-static",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            "and",
            "a",
            "rapidly",
            "increasing",
            "PSA",
            "levels",
            "who",
            "were",
            "receiving",
            "androgen-deprivation",
            "therapy",
            ",",
            "despite",
            "the",
            "use",
            "of",
            "subsequent",
            "life-prolonging",
            "antineoplastic",
            "thera-pies",
            "(",
            "including",
            "enzalutamide",
            ")",
            "by",
            "patients",
            "in",
            "the",
            "placebo",
            "group",
            ".",
            "The",
            "time",
            "to",
            "subsequent",
            "antineo-plastic",
            "therapy",
            ",",
            "time",
            "to",
            "cytotoxic",
            "chemotherapy",
            ",",
            "Table\u02dc3.\u02dcAdverse\u02dcEvents\u02dcof\u02dcSpecial\u02dcInterest",
            ",",
            "\u02dcIrrespective\u02dcof\u02dcRelationship\u02dc\u02dcto\u02dcEnzalutamide\u02dcor\u02dcPlacebo.Adverse\u02dcEventEnzalutamide\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc930",
            ")",
            "Placebo\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc465",
            ")",
            "no",
            ".",
            "of",
            "patients",
            "(",
            "%",
            ")",
            "Fatigue",
            "*",
            "424",
            "(",
            "46",
            ")",
            "103",
            "(",
            "22",
            ")",
            "Musculoskeletal",
            "event\u0192315",
            "(",
            "34",
            ")",
            "107",
            "(",
            "23",
            ")",
            "Fracture\u2044168",
            "(",
            "18",
            ")",
            "29",
            "(",
            "6",
            ")",
            "Hypertension\u00a7167",
            "(",
            "18",
            ")",
            "28",
            "(",
            "6",
            ")",
            "Fall164",
            "(",
            "18",
            ")",
            "25",
            "(",
            "5",
            ")",
            "Cognitive",
            "and",
            "memory",
            "impairment\u00b673",
            "(",
            "8",
            ")",
            "10",
            "(",
            "2",
            ")",
            "Cardiovascular",
            "events\u02da60",
            "(",
            "6",
            ")",
            "11",
            "(",
            "2",
            ")",
            "Ischemic",
            "heart",
            "disease",
            "*",
            "*",
            "60",
            "(",
            "6",
            ")",
            "8",
            "(",
            "2",
            ")",
            "Second",
            "primary",
            "cancer48",
            "(",
            "5",
            ")",
            "7",
            "(",
            "2",
            ")",
            "Rash\u0192\u019238",
            "(",
            "4",
            ")",
            "13",
            "(",
            "3",
            ")",
            "Loss",
            "of",
            "consciousness\u2044\u204434",
            "(",
            "4",
            ")",
            "4",
            "(",
            "1",
            ")",
            "Angioedema\u00a7\u00a720",
            "(",
            "2",
            ")",
            "4",
            "(",
            "1",
            ")",
            "Hepatic",
            "disorder\u00b6\u00b616",
            "(",
            "2",
            ")",
            "15",
            "(",
            "3",
            ")",
            "Renal",
            "disorder14",
            "(",
            "2",
            ")",
            "8",
            "(",
            "2",
            ")",
            "Thrombocytopenia\u02da\u02da12",
            "(",
            "1",
            ")",
            "4",
            "(",
            "1",
            ")",
            "Neutropenia12",
            "(",
            "1",
            ")",
            "1",
            "(",
            "<",
            "1",
            ")",
            "Severe",
            "cutaneous",
            "adverse",
            "reaction1",
            "(",
            "<",
            "1",
            ")",
            "0Seizure3",
            "(",
            "<",
            "1",
            ")",
            "0Posterior",
            "reversible",
            "encephalopathy",
            "syndrome00",
            "*",
            "Fatigue",
            "events",
            "included",
            "asthenia.\u0192",
            "Musculoskeletal",
            "events",
            "included",
            "back",
            "pain",
            ",",
            "arthralgia",
            ",",
            "myalgia",
            ",",
            "musculo-skeletal",
            "pain",
            ",",
            "pain",
            "in",
            "extremity",
            ",",
            "musculoskeletal",
            "stiffness",
            ",",
            "muscular",
            "weak-ness",
            ",",
            "and",
            "muscle",
            "spasms.\u2044",
            "Fracture",
            "events",
            "included",
            "bone",
            "and",
            "joint",
            "injuries.\u00a7",
            "Hypertension",
            "events",
            "included",
            "hypertensive",
            "retinopathy",
            ",",
            "increased",
            "blood",
            "pressure",
            ",",
            "systolic",
            "hypertension",
            ",",
            "and",
            "hypertensive",
            "crisis.\u00b6",
            "Events",
            "of",
            "cognitive",
            "and",
            "memory",
            "impairment",
            "included",
            "disturbance",
            "in",
            "atten-tion",
            ",",
            "cognitive",
            "disorders",
            ",",
            "amnesia",
            ",",
            "Alzheimer\u2122s",
            "disease",
            ",",
            "dementia",
            ",",
            "senile",
            "dementia",
            ",",
            "mental",
            "impairment",
            ",",
            "and",
            "vascular",
            "dementia.\u02da",
            "Cardiovascular",
            "events",
            "included",
            "hemorrhagic",
            "central",
            "nervous",
            "system",
            "vascu-lar",
            "conditions",
            ",",
            "ischemic",
            "central",
            "nervous",
            "system",
            "vascular",
            "conditions",
            ",",
            "and",
            "cardiac",
            "failure",
            ".",
            "*",
            "*",
            "Events",
            "of",
            "ischemic",
            "heart",
            "disease",
            "included",
            "myocardial",
            "infarction",
            "and",
            "other",
            "ischemic",
            "heart",
            "disease.\u0192\u0192",
            "Rash",
            "events",
            "included",
            "maculopapular",
            "rash",
            ",",
            "generalized",
            "rash",
            ",",
            "macular",
            "rash",
            ",",
            "papular",
            "rash",
            ",",
            "and",
            "pruritic",
            "rash.\u2044\u2044",
            "Loss-of-consciousness",
            "events",
            "included",
            "syncope",
            "and",
            "presyncope.\u00a7\u00a7",
            "Angioedema",
            "events",
            "included",
            "urticaria",
            ",",
            "eyelid",
            "edema",
            ",",
            "periorbital",
            "edema",
            ",",
            "swollen",
            "tongue",
            ",",
            "swollen",
            "lip",
            ",",
            "face",
            "edema",
            ",",
            "laryngeal",
            "edema",
            ",",
            "pharyngeal",
            "edema.\u00b6\u00b6",
            "Hepatic",
            "disorders",
            "included",
            "hepatic",
            "failure",
            ";",
            "fibrosis",
            ",",
            "cirrhosis",
            ",",
            "and",
            "other",
            "liver",
            "damage\u0152related",
            "conditions",
            ";",
            "and",
            "hepatitis",
            "and",
            "liver-related",
            "investigations",
            ",",
            "signs",
            ",",
            "and",
            "symptoms.\u02da\u02da",
            "Thrombocytopenia",
            "events",
            "included",
            "decreases",
            "in",
            "platelet",
            "count.n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "8The",
            "new",
            "england",
            "journal",
            "of",
            "medicineTable\u02dc4.\u02dcAdverse\u02dcEvents\u02dcLeading\u02dcto\u02dcDeath",
            ",",
            "\u02dcIrrespective\u02dcof\u02dcRelationship\u02dcto\u02dcEnzalutamide\u02dcor\u02dcPlacebo.Adverse\u02dcEventEnzalutamide\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc930",
            ")",
            "Placebo\u02dcGroup\u02dc",
            "(",
            "N\u02dc=\u02dc465",
            ")",
            "At",
            "least",
            "one",
            "adverse",
            "event",
            "leading",
            "to",
            "death",
            "\u0160",
            "no",
            ".",
            "of",
            "patients",
            "(",
            "%",
            ")",
            "*",
            "51",
            "(",
            "5",
            ")",
            "3",
            "(",
            "1",
            ")",
            "Adverse",
            "events",
            "leading",
            "to",
            "death",
            "\u0160",
            "no",
            ".",
            "(",
            "events/100",
            "patient-yr",
            ")",
            "\u019257",
            "(",
            "2",
            ")",
            "3",
            "(",
            "<",
            "1",
            ")",
            "Specific",
            "events",
            "leading",
            "to",
            "death",
            "\u0160",
            "no",
            ".",
            "(",
            "%",
            ")",
            "Cardiovascular",
            "event\u204414",
            "(",
            "2",
            ")",
            "2",
            "(",
            "<",
            "1",
            ")",
            "Second",
            "primary",
            "cancer\u00a77",
            "(",
            "1",
            ")",
            "1",
            "(",
            "<",
            "1",
            ")",
            "Stroke\u00b64",
            "(",
            "<",
            "1",
            ")",
            "0Sudden",
            "death\u02da4",
            "(",
            "<",
            "1",
            ")",
            "0Disease",
            "progression3",
            "(",
            "<",
            "1",
            ")",
            "0Pneumonia",
            "*",
            "*",
            "3",
            "(",
            "<",
            "1",
            ")",
            "0Septic",
            "shock\u0192\u01923",
            "(",
            "<",
            "1",
            ")",
            "0Hemorrhage\u2044\u20442",
            "(",
            "<",
            "1",
            ")",
            "0General",
            "deterioration",
            "of",
            "physical",
            "health\u00a7\u00a72",
            "(",
            "<",
            "1",
            ")",
            "0Intestinal",
            "congestion1",
            "(",
            "<",
            "1",
            ")",
            "0Mesenteric-vein",
            "thrombosis1",
            "(",
            "<",
            "1",
            ")",
            "0Malaise1",
            "(",
            "<",
            "1",
            ")",
            "0Hepatic",
            "failure1",
            "(",
            "<",
            "1",
            ")",
            "0Lung",
            "infection1",
            "(",
            "<",
            "1",
            ")",
            "0Gangrene",
            "in",
            "small",
            "intestine1",
            "(",
            "<",
            "1",
            ")",
            "0Pelvic",
            "fracture1",
            "(",
            "<",
            "1",
            ")",
            "0Renal",
            "impairment1",
            "(",
            "<",
            "1",
            ")",
            "0Urinary",
            "retention1",
            "(",
            "<",
            "1",
            ")",
            "0Interstitial",
            "lung",
            "disease1",
            "(",
            "<",
            "1",
            ")",
            "0Pleurisy1",
            "(",
            "<",
            "1",
            ")",
            "0Anemia1",
            "(",
            "<",
            "1",
            ")",
            "0Type",
            "2",
            "diabetes",
            "mellitus1",
            "(",
            "<",
            "1",
            ")",
            "0",
            "*",
            "Patients",
            "with",
            "multiple",
            "events",
            "resulting",
            "in",
            "death",
            "for",
            "a",
            "given",
            "adverse-event",
            "term",
            "were",
            "counted",
            "only",
            "once",
            "per",
            "term.\u0192",
            "The",
            "total",
            "patient-years",
            "of",
            "exposure",
            "were",
            "2613.41",
            "for",
            "the",
            "enzalutamide",
            "group",
            "and",
            "634.45",
            "for",
            "the",
            "placebo",
            "group",
            ".",
            "The",
            "event",
            "rate",
            "was",
            "calculated",
            "as",
            "100",
            "\u00d7",
            "number",
            "of",
            "events/total",
            "patient-years",
            "of",
            "exposure",
            "for",
            "the",
            "treatment",
            "group.\u2044",
            "Cardiovascular",
            "events",
            "included",
            "acute",
            "myocardial",
            "infarction",
            ",",
            "myocardial",
            "infarction",
            ",",
            "cardiac",
            "failure",
            ",",
            "cardiac",
            "arrest",
            ",",
            "car-diorespiratory",
            "arrest",
            ",",
            "cardiogenic",
            "shock",
            ",",
            "cardiovascular",
            "insufficiency",
            ",",
            "coronary",
            "artery",
            "disease",
            ",",
            "ventricular",
            "arrhythmia",
            ",",
            "and",
            "left",
            "ventricular",
            "failure",
            ".",
            "Ten",
            "patients",
            "in",
            "the",
            "enzalutamide",
            "group",
            "had",
            "a",
            "history",
            "of",
            "cardiovascular",
            "disease.\u00a7",
            "Second",
            "primary",
            "cancers",
            "included",
            "acute",
            "myeloid",
            "leukemia",
            ",",
            "brain",
            "neoplasm",
            ",",
            "malignant",
            "neoplasm",
            "of",
            "unknown",
            "primary",
            "site",
            ",",
            "mesothelioma",
            ",",
            "metastasis",
            "to",
            "liver",
            ",",
            "metastasis",
            "to",
            "peritoneum",
            ",",
            "neoplasm",
            "progression",
            ",",
            "metastatic",
            "pancreatic",
            "car-cinoma",
            ",",
            "prostate",
            "cancer",
            ",",
            "and",
            "small-cell",
            "lung",
            "cancer.\u00b6",
            "Stroke",
            "events",
            "included",
            "cerebrovascular",
            "accident",
            ",",
            "cerebral",
            "infarction",
            ",",
            "hemorrhagic",
            "stroke",
            ",",
            "and",
            "ischemic",
            "stroke.\u02da",
            "Sudden",
            "deaths",
            "included",
            "death",
            ",",
            "sudden",
            "death",
            ",",
            "and",
            "sudden",
            "cardiac",
            "death",
            ".",
            "One",
            "death",
            "was",
            "considered",
            "by",
            "the",
            "investiga-tors",
            "to",
            "be",
            "related",
            "to",
            "enzalutamide",
            ".",
            "*",
            "*",
            "Pneumonia",
            "events",
            "included",
            "pneumonia",
            "and",
            "aspiration",
            "pneumonia.\u0192\u0192",
            "Septic",
            "shock",
            "events",
            "included",
            "septic",
            "shock",
            "and",
            "sepsis.\u2044\u2044",
            "Hemorrhage",
            "events",
            "included",
            "hemorrhage",
            "and",
            "duodenal",
            "ulcer",
            "hemorrhage",
            ".",
            "The",
            "duodenal",
            "ulcer",
            "hemorrhage",
            "was",
            "con-sidered",
            "by",
            "the",
            "investigators",
            "to",
            "be",
            "related",
            "to",
            "enzalutamide.\u00a7\u00a7",
            "This",
            "event",
            "was",
            "considered",
            "by",
            "the",
            "investigators",
            "to",
            "be",
            "related",
            "to",
            "enzalutamide",
            "in",
            "1",
            "patient.n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "9Enzalutamide",
            "in",
            "Castration-Resistant",
            "Prostate",
            "Cancerand",
            "chemotherapy-free",
            "survival",
            "were",
            "also",
            "longer",
            "in",
            "the",
            "enzalutamide",
            "group",
            "than",
            "in",
            "the",
            "placebo",
            "group.In",
            "line",
            "with",
            "recent",
            "studies,13,14",
            "these",
            "results",
            "add",
            "to",
            "the",
            "growing",
            "body",
            "of",
            "evidence",
            "that",
            "andro-gen-receptor",
            "inhibitors",
            "not",
            "only",
            "delay",
            "the",
            "time",
            "to",
            "metastasis",
            "but",
            "also",
            "improve",
            "overall",
            "survival",
            "among",
            "men",
            "with",
            "nonmetastatic",
            ",",
            "castration-resis-tant",
            "prostate",
            "cancer",
            ".",
            "Enzalutamide",
            "prolongs",
            "survival",
            "in",
            "both",
            "nonmetastatic",
            "and",
            "metastatic",
            "castration-resistant",
            "prostate",
            "cancer.3,5The",
            "treatment",
            "effect",
            "of",
            "enzalutamide",
            "was",
            "consistent",
            "across",
            "all",
            "prespecified",
            "subgroups",
            ",",
            "except",
            "in",
            "patients",
            "who",
            "had",
            "received",
            "bone-target-ing",
            "agents",
            "at",
            "baseline",
            ";",
            "however",
            ",",
            "the",
            "number",
            "of",
            "patients",
            "in",
            "this",
            "subgroup",
            "was",
            "low",
            ",",
            "which",
            "makes",
            "interpretation",
            "of",
            "this",
            "result",
            "difficult",
            ".",
            "Further",
            "research",
            "is",
            "necessary.As",
            "treatments",
            "are",
            "evaluated",
            "at",
            "earlier",
            "stages",
            "of",
            "disease",
            "and",
            "more",
            "life-prolonging",
            "therapies",
            "are",
            "available",
            ",",
            "it",
            "is",
            "increasingly",
            "difficult",
            "to",
            "show",
            "improvements",
            "in",
            "overall",
            "survival",
            "in",
            "clinical",
            "tri-als",
            ".",
            "Metastasis-free",
            "survival",
            "has",
            "been",
            "shown",
            "to",
            "be",
            "a",
            "surrogate",
            "for",
            "overall",
            "survival",
            "among",
            "pa-tients",
            "with",
            "intermediate-risk",
            ",",
            "high-risk",
            ",",
            "clinically",
            "localized",
            "prostate",
            "cancer.15",
            "These",
            "results",
            "provide",
            "clinical",
            "validation",
            "for",
            "the",
            "use",
            "of",
            "metastasis-free",
            "survival",
            "as",
            "a",
            "meaningful",
            "end",
            "point",
            "and",
            "as",
            "a",
            "po-tential",
            "surrogate",
            "for",
            "overall",
            "survival",
            "among",
            "patients",
            "with",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer.Our",
            "trial",
            "had",
            "several",
            "limitations",
            ".",
            "Conventional",
            "imaging",
            "has",
            "been",
            "used",
            "in",
            "our",
            "trial",
            "as",
            "well",
            "as",
            "in",
            "the",
            "SPARTAN",
            "(",
            "Selective",
            "Prostate",
            "Androgen",
            "Re-ceptor",
            "Targeting",
            "with",
            "ARN-509",
            ")",
            "and",
            "ARAMIS",
            "(",
            "Androgen",
            "Receptor",
            "Antagonizing",
            "Agent",
            "for",
            "Metastasis-free",
            "Survival",
            ")",
            "phase",
            "3",
            "clinical",
            "trials",
            "in",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            "to",
            "obtain",
            "diagnoses",
            "and",
            "monitor",
            "patients\u2122",
            "conditions.1,16,17",
            "More",
            "sensitive",
            "techniques",
            "are",
            "be-coming",
            "available",
            ",",
            "allowing",
            "for",
            "earlier",
            "detection",
            "of",
            "metastasis",
            ",",
            "which",
            "may",
            "affect",
            "the",
            "classification",
            "of",
            "patients",
            "as",
            "having",
            "nonmetastatic",
            "disease.18",
            "Data",
            "on",
            "the",
            "time",
            "to",
            "progression",
            "while",
            "receiving",
            "the",
            "next",
            "subsequent",
            "therapy",
            "were",
            "not",
            "collected",
            ",",
            "so",
            "we",
            "can",
            "not",
            "evaluate",
            "whether",
            "treatment",
            "with",
            "enzalutamide",
            "also",
            "translated",
            "into",
            "differences",
            "in",
            "treatment",
            "effects",
            "of",
            "subsequent",
            "therapies.After",
            "a",
            "median",
            "of",
            "15",
            "additional",
            "months",
            "of",
            "treatment",
            ",",
            "the",
            "safety",
            "profile",
            "of",
            "enzalutamide",
            "with",
            "androgen-deprivation",
            "therapy",
            "was",
            "similar",
            "to",
            "that",
            "reported",
            "at",
            "the",
            "time",
            "of",
            "the",
            "primary",
            "analysis,1",
            "which",
            "includes",
            "an",
            "increase",
            "in",
            "falls",
            ",",
            "fatigue",
            ",",
            "hypertension",
            ",",
            "and",
            "deaths",
            "from",
            "cardio-vascular",
            "causes",
            ".",
            "The",
            "exposure-adjusted",
            "rates",
            "of",
            "cardiovascular",
            "events",
            "were",
            "slightly",
            "higher",
            "in",
            "the",
            "enzalutamide",
            "group",
            "than",
            "in",
            "the",
            "placebo",
            "group",
            "(",
            "3",
            "vs.",
            "2",
            "per",
            "100",
            "patient-years",
            ")",
            ".",
            "Three",
            "events",
            "of",
            "seizures",
            "were",
            "reported",
            "at",
            "the",
            "time",
            "of",
            "the",
            "pri-mary",
            "analysis",
            ",",
            "but",
            "no",
            "subsequent",
            "events",
            "were",
            "reported",
            ".",
            "Men",
            ",",
            "especially",
            "those",
            "who",
            "are",
            "asymp-tomatic",
            ",",
            "should",
            "consider",
            "whether",
            "the",
            "increased",
            "risk",
            "of",
            "adverse",
            "events",
            "is",
            "acceptable",
            "before",
            "initiat-ing",
            "treatment.Although",
            "adverse",
            "events",
            "leading",
            "to",
            "death",
            "were",
            "more",
            "common",
            "in",
            "the",
            "enzalutamide",
            "group",
            "than",
            "in",
            "the",
            "placebo",
            "group",
            ",",
            "it",
            "is",
            "important",
            "to",
            "consider",
            "the",
            "significantly",
            "longer",
            "median",
            "treat-ment",
            "duration",
            "in",
            "the",
            "enzalutamide",
            "group",
            "(",
            "33.9",
            "months",
            "vs.",
            "14.2",
            "months",
            ")",
            ".",
            "The",
            "most",
            "frequently",
            "reported",
            "adverse",
            "events",
            "leading",
            "to",
            "death",
            "in",
            "the",
            "enzalutamide",
            "group",
            "were",
            "cardiovascular",
            "events",
            ".",
            "Most",
            "men",
            "who",
            "died",
            "from",
            "a",
            "cardiovascular",
            "event",
            "had",
            "a",
            "clinically",
            "significant",
            "history",
            "of",
            "cardiovas-cular",
            "disease",
            ".",
            "The",
            "World",
            "Health",
            "Organization",
            "reports",
            "that",
            "the",
            "leading",
            "cause",
            "of",
            "death",
            "among",
            "men",
            "older",
            "than",
            "70",
            "years",
            "of",
            "age",
            "in",
            "2016",
            "was",
            "ische-mic",
            "heart",
            "disease.19",
            "The",
            "longer",
            "follow-up",
            "inter-val",
            ",",
            "history",
            "of",
            "cardiovascular",
            "risk",
            "factors",
            ",",
            "and",
            "advanced",
            "age",
            "in",
            "patients",
            "treated",
            "with",
            "enzalu-tamide",
            "may",
            "explain",
            "this",
            "finding",
            "in",
            "our",
            "trial",
            ".",
            "Although",
            "none",
            "of",
            "the",
            "cardiovascular",
            "deaths",
            "were",
            "attributed",
            "to",
            "enzalutamide",
            "by",
            "the",
            "investigators",
            ",",
            "physicians",
            "should",
            "be",
            "aware",
            "of",
            "the",
            "increased",
            "risk",
            "when",
            "determining",
            "whether",
            "a",
            "patient",
            "with",
            "pre-existing",
            "cardiovascular",
            "disease",
            "should",
            "receive",
            "enzalutamide",
            ",",
            "and",
            "patients",
            "receiving",
            "this",
            "treat-ment",
            "should",
            "be",
            "followed",
            "closely.In",
            "our",
            "trial",
            ",",
            "enzalutamide",
            "treatment",
            "in",
            "men",
            "with",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            "and",
            "rapidly",
            "increasing",
            "PSA",
            "levels",
            "resulted",
            "in",
            "a",
            "significantly",
            "longer",
            "overall",
            "survival",
            "than",
            "placebo",
            ".",
            "The",
            "adverse",
            "event",
            "profile",
            "was",
            "similar",
            "to",
            "the",
            "established",
            "safety",
            "profile",
            "of",
            "enzalu-tamide.3,5,20,21Supported",
            "by",
            "Pfizer",
            "and",
            "Astellas",
            "Pharma.Disclosure",
            "forms",
            "provided",
            "by",
            "the",
            "authors",
            "are",
            "available",
            "with",
            "the",
            "full",
            "text",
            "of",
            "this",
            "article",
            "at",
            "NEJM.org.A",
            "data",
            "sharing",
            "statement",
            "provided",
            "by",
            "the",
            "authors",
            "is",
            "available",
            "with",
            "the",
            "full",
            "text",
            "of",
            "this",
            "article",
            "at",
            "NEJM.org.We",
            "thank",
            "Petro",
            "Ivashchenko",
            ",",
            "M.D",
            ".",
            "(",
            "Kiev",
            "City",
            "Clinical",
            "Hos-pital",
            "3",
            ")",
            ",",
            "for",
            "his",
            "contribution",
            "to",
            "the",
            "trial",
            "and",
            "previous",
            "presenta-tions",
            ",",
            "and",
            "Stephanie",
            "Vadasz",
            ",",
            "Ph.D.",
            ",",
            "and",
            "Dena",
            "McWain",
            "(",
            "Ashfield",
            "Healthcare",
            "Communications",
            ")",
            "for",
            "medical",
            "writing",
            "and",
            "editorial",
            "assistance",
            "with",
            "an",
            "earlier",
            "version",
            "of",
            "the",
            "manuscript",
            "(",
            "funded",
            "by",
            "both",
            "sponsor",
            "companies",
            ")",
            ".n",
            "engl",
            "j",
            "med",
            "nejm.org",
            "10The",
            "new",
            "england",
            "journal",
            "of",
            "medicineReferences1.Hussain",
            "M",
            ",",
            "Fizazi",
            "K",
            ",",
            "Saad",
            "F",
            ",",
            "et",
            "al.Enzalutamide",
            "in",
            "men",
            "with",
            "nonmetastat-ic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer.N",
            "Engl",
            "J",
            "Med",
            "2018",
            ";",
            "378",
            ":",
            "2465-74.2.Xtandi",
            "(",
            "enzalutamide",
            ")",
            "prescribinginformation",
            ".",
            "Northbrook",
            ",",
            "IL",
            ":",
            "AstellasPharma",
            "US",
            ",",
            "2018",
            "(",
            "https",
            ":",
            "//www",
            ".astellas",
            ".us/docs/",
            "12A005",
            "-",
            "ENZ",
            "-",
            "WPI",
            ".PDF",
            ")",
            ".3.Scher",
            "HI",
            ",",
            "Fizazi",
            "K",
            ",",
            "Saad",
            "F",
            ",",
            "et",
            "al",
            ".",
            "In-creased",
            "survival",
            "with",
            "enzalutamide",
            "inprostate",
            "cancer",
            "after",
            "chemotherapy",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2012",
            ";",
            "367",
            ":",
            "1187-97.4",
            ".",
            "Armstrong",
            "AJ",
            ",",
            "Szmulewitz",
            "RZ",
            ",",
            "Petrylak",
            "DP",
            ",",
            "et",
            "al",
            ".",
            "ARCHES",
            ":",
            "a",
            "randomized",
            ",",
            "phase",
            "III",
            "study",
            "of",
            "androgen",
            "deprivation",
            "therapy",
            "withenzalutamide",
            "or",
            "placebo",
            "in",
            "men",
            "with",
            "meta-static",
            "hormone-sensitive",
            "prostate",
            "cancer.J",
            "Clin",
            "Oncol",
            "2019",
            ";",
            "37",
            ":",
            "2974-86.5",
            ".",
            "Beer",
            "TM",
            ",",
            "Armstrong",
            "AJ",
            ",",
            "Rathkopf",
            "DE",
            ",",
            "et",
            "al",
            ".",
            "Enzalutamide",
            "in",
            "metastatic",
            "prostate",
            "cancer",
            "before",
            "chemotherapy",
            ".",
            "N",
            "Engl",
            "J",
            "Med",
            "2014",
            ";",
            "371",
            ":",
            "424-33.6.Tombal",
            "B",
            ",",
            "Saad",
            "F",
            ",",
            "Penson",
            "D",
            ",",
            "et",
            "al.Patient-reported",
            "outcomes",
            "following",
            "en-zalutamide",
            "or",
            "placebo",
            "in",
            "men",
            "with",
            "non-metastatic",
            ",",
            "castration-resistant",
            "prostatecancer",
            "(",
            "PROSPER",
            ")",
            ":",
            "a",
            "multicentre",
            ",",
            "random-ised",
            ",",
            "double-blind",
            ",",
            "phase",
            "3",
            "trial",
            ".",
            "LancetOncol",
            "2019",
            ";",
            "20",
            ":",
            "556-69.7",
            ".",
            "Smith",
            "MR",
            ",",
            "Kabbinavar",
            "F",
            ",",
            "Saad",
            "F",
            ",",
            "et",
            "al",
            ".",
            "Natural",
            "history",
            "of",
            "rising",
            "serum",
            "prostate-specific",
            "antigen",
            "in",
            "men",
            "with",
            "castrate",
            "non-metastatic",
            "prostate",
            "cancer",
            ".",
            "J",
            "Clin",
            "Oncol2005",
            ";",
            "23",
            ":",
            "2918-25.8",
            ".",
            "Afshar",
            "M",
            ",",
            "Evison",
            "F",
            ",",
            "James",
            "ND",
            ",",
            "Patel",
            "P.",
            "Shifting",
            "paradigms",
            "in",
            "the",
            "estimation",
            "ofsurvival",
            "for",
            "castration-resistant",
            "prostate",
            "cancer",
            ":",
            "a",
            "tertiary",
            "academic",
            "center",
            "experi-ence",
            ".",
            "Urol",
            "Oncol",
            "2015",
            ";",
            "33",
            "(",
            "8",
            ")",
            ":",
            "338.e1-338.e7.9.Jenkins",
            "V",
            ",",
            "Solis-Trapala",
            "I",
            ",",
            "Payne",
            "H",
            ",",
            "et",
            "al",
            ".",
            "Treatment",
            "experiences",
            ",",
            "informationneeds",
            ",",
            "pain",
            "and",
            "quality",
            "of",
            "life",
            "in",
            "menwith",
            "metastatic",
            "castrate-resistant",
            "pros-tate",
            "cancer",
            ":",
            "results",
            "from",
            "the",
            "EXTREQOLstudy",
            ".",
            "Clin",
            "Oncol",
            "(",
            "R",
            "Coll",
            "Radiol",
            ")",
            "2019",
            ";",
            "31",
            ":",
            "99-107.10",
            ".",
            "Appukkuttan",
            "S",
            ",",
            "Tangirala",
            "K",
            ",",
            "Babajan-yan",
            "S",
            ",",
            "Wen",
            "L",
            ",",
            "Simmons",
            "S",
            ",",
            "Shore",
            "N.",
            "A",
            "ret-rospective",
            "claims",
            "analysis",
            "of",
            "advancedprostate",
            "cancer",
            "costs",
            "and",
            "resource",
            "use.Pharmacoecon",
            "Open",
            "2019",
            "October",
            "22",
            "(",
            "Epub",
            "ahead",
            "of",
            "print",
            ")",
            ".11.Gillessen",
            "S",
            ",",
            "Attard",
            "G",
            ",",
            "Beer",
            "TM",
            ",",
            "et",
            "al.Management",
            "of",
            "patients",
            "with",
            "advancedprostate",
            "cancer",
            ":",
            "report",
            "of",
            "the",
            "AdvancedProstate",
            "Cancer",
            "Consensus",
            "Conference2019",
            ".",
            "Eur",
            "Urol",
            "2020",
            ";",
            "77",
            ":",
            "508-47.12.Mateo",
            "J",
            ",",
            "Fizazi",
            "K",
            ",",
            "Gillessen",
            "S",
            ",",
            "et",
            "al.Managing",
            "nonmetastatic",
            "castration-resis-tant",
            "prostate",
            "cancer",
            ".",
            "Eur",
            "Urol",
            "2019",
            ";",
            "75:285-93.13.Small",
            "EJ",
            ",",
            "Saad",
            "F",
            ",",
            "Chowdhury",
            "S",
            ",",
            "et",
            "al.Apalutamide",
            "and",
            "overall",
            "survival",
            "in",
            "non-metastatic",
            "castration-resistant",
            "prostatecancer",
            ".",
            "Ann",
            "Oncol",
            "2019",
            ";",
            "30",
            ":",
            "1813-20.14.Darolutamide",
            "plus",
            "androgen",
            "depriva-tion",
            "therapy",
            "significantly",
            "increased",
            "over-all",
            "survival",
            "in",
            "men",
            "with",
            "non-metastaticcastration-resistant",
            "prostate",
            "cancer",
            ".",
            "Lever-kusen",
            ",",
            "Germany",
            ":",
            "Bayer",
            ",",
            "2020",
            "(",
            "https",
            ":",
            "//www",
            ".investor",
            ".bayer",
            ".de/",
            "en/",
            "nc/",
            "news/",
            "investor",
            "-",
            "news/",
            "investor",
            "-",
            "news/",
            "darolutamide",
            "-",
            "plus",
            "-",
            "androgen",
            "-",
            "deprivation",
            "-",
            "therapy",
            "-",
            "significantly",
            "-",
            "increased",
            "-",
            "overall",
            "-",
            "survival",
            "-",
            "in",
            "-",
            "men",
            "-",
            "with/",
            ")",
            ".15.Xie",
            "W",
            ",",
            "Regan",
            "MM",
            ",",
            "Buyse",
            "M",
            ",",
            "et",
            "al.Metastasis-free",
            "survival",
            "is",
            "a",
            "strong",
            "surro-gate",
            "of",
            "overall",
            "survival",
            "in",
            "localized",
            "pros-tate",
            "cancer",
            ".",
            "J",
            "Clin",
            "Oncol",
            "2017",
            ";",
            "35",
            ":",
            "3097-104.16",
            ".",
            "Smith",
            "MR",
            ",",
            "Saad",
            "F",
            ",",
            "Chowdhury",
            "S",
            ",",
            "et",
            "al",
            ".",
            "Apalutamide",
            "treatment",
            "and",
            "metastasis-free",
            "survival",
            "in",
            "prostate",
            "cancer",
            ".",
            "N",
            "Engl",
            "JMed",
            "2018",
            ";",
            "378",
            ":",
            "1408-18.17.Fizazi",
            "K",
            ",",
            "Shore",
            "N",
            ",",
            "Tammela",
            "TL",
            ",",
            "et",
            "al.Darolutamide",
            "in",
            "nonmetastatic",
            ",",
            "castration-resistant",
            "prostate",
            "cancer",
            ".",
            "N",
            "Engl",
            "J",
            "Med2019",
            ";",
            "380",
            ":",
            "1235-46.18",
            ".",
            "Fendler",
            "WP",
            ",",
            "Weber",
            "M",
            ",",
            "Iravani",
            "A",
            ",",
            "et",
            "al",
            ".",
            "Prostate-specific",
            "membrane",
            "antigen",
            "ligandpositron",
            "emission",
            "tomography",
            "in",
            "menwith",
            "nonmetastatic",
            "castration-resistantprostate",
            "cancer",
            ".",
            "Clin",
            "Cancer",
            "Res",
            "2019",
            ";",
            "25:7448-54.19.World",
            "Health",
            "Organization",
            ".",
            "Top",
            "10causes",
            "of",
            "death",
            ".",
            "2020",
            "(",
            "https",
            ":",
            "//www",
            ".who.int/",
            "gho/",
            "mortality_burden_disease/",
            "causes_death/",
            "top_10/",
            "en/",
            ")",
            ".20.Penson",
            "DF",
            ",",
            "Armstrong",
            "AJ",
            ",",
            "Concep-cion",
            "R",
            ",",
            "et",
            "al",
            ".",
            "Enzalutamide",
            "versus",
            "bicalu-tamide",
            "in",
            "castration-resistant",
            "prostate",
            "can-cer",
            ":",
            "the",
            "STRIVE",
            "trial",
            ".",
            "J",
            "Clin",
            "Oncol",
            "2016",
            ";",
            "34",
            ":",
            "2098-106.21.Shore",
            "ND",
            ",",
            "Chowdhury",
            "S",
            ",",
            "Villers",
            "A",
            ",",
            "et",
            "al",
            ".",
            "Efficacy",
            "and",
            "safety",
            "of",
            "enzalutamideversus",
            "bicalutamide",
            "for",
            "patients",
            "withmetastatic",
            "prostate",
            "cancer",
            "(",
            "TERRAIN",
            ")",
            ":",
            "a",
            "randomised",
            ",",
            "double-blind",
            ",",
            "phase",
            "2",
            "study",
            ".",
            "Lancet",
            "Oncol",
            "2016",
            ";",
            "17",
            ":",
            "153-63.Copyright",
            "\u00a9",
            "2020",
            "Massachusetts",
            "Medical",
            "Society",
            "."
        ]
    },
    {
        "name": "example1",
        "sentences": [
            "REFINING SELF-SUPERVISED LEARNING IN IMAGING: BEYOND LINEAR METRICBo Jiang(cid:63)Hamid Krim(cid:63)Tianfu Wu(cid:63)Derya Cansever\u2020(cid:63) North Carolina State University\u2020US Army Research Of\ufb01ce2202 beF 52  ]VC.sc[  1v12921.2022:viXraABSTRACTWe introduce in this paper a new statistical perspective, exploit-ing the Jaccard similarity metric, as a measure-based metricto effectively invoke non-linear features in the loss of self-supervised contrastive learning.",
            "Speci\ufb01cally, our proposedmetric may be interpreted as a dependence measure betweentwo adapted projections learned from the so-called latent repre-sentations.",
            "This is in contrast to the cosine similarity measurein the conventional contrastive learning model, which accountsfor correlation information.",
            "To the best of our knowledge, thiseffectively non-linearly fused information embedded in theJaccard similarity, is novel to self-supervision learning withpromising results.",
            "The proposed approach is compared to twostate-of-the-art self-supervised contrastive learning methodson three image datasets.",
            "We not only demonstrate its amenableapplicability in current ML problems, but also its improvedperformance and training ef\ufb01ciency.Index Terms\u2014 Self-Supervised learning, ContrastiveLearning, Jaccard Index, Non-linearity1.",
            "INTRODUCTIONThe notion of latent representation of data has, over the lastfew years, emerged as a signi\ufb01cant catalyst, particularly incomputer vision, where a visual representation in the latentspace provides a powerful grounding for supervised learn-ing and inference.",
            "Scaling learning-based inference to largedatasets (e.g., ImageNet), however, is labor-intensive and time-consuming, and calls for a more viable alternative.",
            "The increas-ing popularity of Self-Supervised Learning (SSL) particularlyin Computer Vision (CV) in conjunction with learned visualrepresentations [1, 2] and pretext tasks [3, 4, 5] seeks labellingfrom a diverse view or a fraction of a given data sample.",
            "Akey feature of SSL is the adopted contrastive loss, which isaimed at discriminating positive keys (i.e., different views ofthe sample) from negative ones in the latent space of images.To de\ufb01ne some notion of semantic space, a contrastivelearning model was proposed in [6].",
            "In so doing, they pro-posed a L2-norm distance to estimate similarity among twoimages[7].",
            "This procedure entailed minimizing a semantic dis-tance between images from the same class while maximizingthat from different classes.",
            "The recent focus in research hasgradually shifted to only minimizing the distance between thepositive pairs without simultaneously maximizing the distancebetween negative pairs [8, 9, 10].",
            "Given different views ofthe original images, the encoder is trained by minimizing thedistance between different views in the hidden space.",
            "Thepaper[10] also highlights the impact of a potential asymmetrywith the larger number of negative keys than the number ofpositive keys skewing the learning.",
            "Empirically choosing thetransformation and augmentation methods[11] and handlingnegative samples[12] may also induce biases and hence signi\ufb01-cantly affect the learning encoders\u2019 performance.",
            "As a result ofthese augmentation procedures, a selection of a correct metricis in order as it will clearly impact any training procedure.",
            "Theadoption of a cosine similarity implies a linear measurabilityof the similarity in the latent space.",
            "The features are, however,the result of non-linear processing across the learning layersand are hence elements lying on some manifold rather thanon a linear space.",
            "To that end, we propose to account for theintrinsic non-linearity by proposing the Jaccard similarity coef-\ufb01cient, developed in the early 1900\u2019s[13], to capture non-linearcharacteristics in the similarity between \ufb01nite sets of prevailingfeatures.",
            "Upon interpreting SSL as an inference problem, andusing a hypothesis test for a quantitative decision in contrastivelearning, we propose a bi-projector Jaccard-based loss whicheffectively re\ufb02ects the non-linearities in the hidden spaces.Our proposed adaptive approach effectively aims at ad-dressing the inherent modal structure of the latent/pseudo-invariant characteristics of the data (using Jaccard-metric) witha comparative validation using two well-known self-supervisedlearning models SimCLR[1] and MoCo[2], based on both thek-nearest neighbors (k-NN) classi\ufb01cation and the standard lin-ear classi\ufb01cation methods.",
            "The selected datasets are CIFAR-10, CIFAR-100, and Tiny-ImageNet-200 to capture the classvariability bandwidth used in evaluating the performance ofSSL.",
            "Our contributions in this paper include (1) Our providinga theoretically sound and tractable hypothesis testing formula-tion of the contrastive loss, and of the ensuing projection forprocedure stabilization; (2) Our introduction of a bi-projectormodel along with a novel Jaccard-similarity-based contrastiveloss evaluation; (3) Our derivation of similarity maximiza-tion/minimization of positive/negative pairs in each of the hid-den spaces separately accounting for the non-linear featuresby a Jaccard metric-based fusion.",
            "2.",
            "SSL: BACKGROUND AND DEVELOPMENT2.1.",
            "NotationThroughout the paper, we will adopt a notationally caligraphicupper case letter to denote a space, and an upper case letter todenote a data representation in different spaces, speci\ufb01cally,X represents the original data, X K the transformation andaugmentation of the original image data in the pixel space,with Q and K respectively denoting the features in the latentrepresentation spaces of the original and augmented images.We use the subscripted lower case letter to distinguish differentelements in different spaces, i.e., xi indicates the ith object el-ement of X.",
            "We consider f\u03b8(\u00b7) to be a function parameterizedby \u03b8.2.2.",
            "Contrastive Loss= g\u03b8p \u25e6 f\u03b8(x\u2212Given an unlabeled dataset X = {x1, x2, .",
            ". . , xN }, a similar-ity calculation method s(\u00b7, \u00b7), an embedding function f\u03b8(\u00b7),and a projector g\u03b8p (\u00b7), which collaboratively projects thedata from the original space X into a \ufb02at hidden space H.De\ufb01ne x a data sample in X, x+ as a positive key, and x\u2212jdenotes the jth of negative keys of x, hq = g\u03b8p \u25e6 f\u03b8(x),hk+ = g\u03b8p \u25e6 f\u03b8(x+), and hk\u2212j ).",
            "To carryjthrough the original idea of contrasting positive with nega-tive keys, a triplet loss, was \ufb01rst proposed in [14, 15], andis aimed at learning an invariant mapping to project highdimensional features onto a low dimensional space, suchthat intra-class features are close to each other while keep-ing inter-class features far apart, Ltriplet(x, x+, x\u2212|\u03b8, \u03b8p) =max(0, d(hq, hk+) \u2212 d(hq, hk\u2212 ) + m), with d(\u00b7, \u00b7) denotinga metric, and m is some margin that restricts the largestmeaningful distance difference between intra-class andinter-class latent representations.",
            "A probabilistic interpre-tation has recently emerged \"softmax\" expression to high-light the frequential aspect of sampling, Lco(x, x+, x\u2212j ) =(cid:18)\u2212logexp (s(hq,hk+ )/\u03c4)exp (s(hq,hk+ )/\u03c4)+(cid:80)j exp (s(hq,h)/\u03c4)k\u2212j(cid:19), where \u03c4 isreferred to as the temperature scalar in the contrastive lossto modulate the in\ufb02uence of the exponent term.",
            "Note thatthe cosine similarity expression Cos-Sim(x, y) = (cid:104)x,y(cid:105)(cid:107)x(cid:107)(cid:107)y(cid:107)is a common similarity measure choice between latent repre-sentations.",
            "While seemingly distinct, these two losses bear arelation as shown next,Theorem 1.",
            "The mean zero-margin triplet loss is upperbounded and smoothly approximated by the contrastive loss.Proof: The LogSumExp term in the denominator can be inter-preted as the smooth approximation to the maximum function.Consider a \ufb01nite set Y = {y1, ..., yn}, log(cid:18)(cid:19)(cid:19)(cid:18)log(cid:80)i eyi\u2264 lognemax(Y ).",
            "While the so-called soft-(cid:18)(cid:19)emax(Y ))\u2264max is often applied in ML to avoid non-smoothness whencalculating the gradient, it often is implicit in other settings.The contrastive loss equation thus yields the mean triplet losswith the zero margin.",
            "By de\ufb01ning s+ = Cos-Sim(hq, hk+ )/\u03c4and s\u2212)/\u03c4 , we can rewrite,j = Cos-Sim(hq, hk\u2212jLco = \u2212log(cid:18)es+es+ + (cid:80)(cid:18)\u2265 max0, s\u2212ji es\u22121 \u2212 s+, .",
            ". . , s\u2212(cid:19)n \u2212 s+\u2265(cid:19)(cid:18)= loge0 +(cid:88)j \u2212s+(cid:19)es\u2212i1n(cid:88)jLjtriplet.",
            "(1)The minimization of the contrastive loss function implies asmooth enhancement of proximity of positive pairs and ofseparation of negative pairs.2.3.",
            "A Variation on a Theme: A Jaccard-index Assess-ment2.3.1.",
            "Jaccard SimilarityThe Jaccard index[13], commonly called the Jaccard simi-larity coef\ufb01cient, is a set-theoretic measure to genericallyevaluate similarity between two \ufb01nite sample sets.",
            "In gen-eral, the Jaccard similarity coef\ufb01cient is evaluated as a ra-tio of the intersection of two \ufb01nite sets A and B and theirunion, J(A, B) = |A\u2229B||A\\B|+|B\\A|+|A\u2229B| .",
            "Analternative measure-inspired interpretation of the Jaccard in-dex may also be attained.",
            "Speci\ufb01cally, an information theo-retic/probabilistic interpretation unveils a measure-theoretichence deeper comparison using a probability measure \u00b5 on themeasurable sample space S, yielding a similar coef\ufb01cient as,J\u00b5(A, B) = \u00b5(A\u2229B)\u00b5(A\u222aB) .|A\u222aB| =|A\u2229B|The use of measures (i.e., a probabilistic model capturingall moments), particularly points to the signi\ufb01cance of theinformation scoped out and beyond the linear (i.e., second-order moment) typically invoked by a Cosine similarity.",
            "Thisis hence consistent with our goal of gleaning additional sec-ondary information beyond that normally sought in the latentspace of the classes.",
            "The \ufb02exibility of the proposed Jaccardsimilarity measure accounts for the inherent nonlinear infor-mation moments, thus affording a more accurate assessmentof non-linear features in the latent space.2.3.2.",
            "Proposed Contrastive Learning ModelA hypothesis is a proposed explanation of an observedphenomenon[16].",
            "Self-supervised contrastive learning, viewedas a guessing exercise, is the assessment result of randomlysampled data and its subsequent assignment to either a positiveor negative class, each with an underlying distribution.",
            "As aresult, a null hypothesis H0 stating that two observations (i.e.,images) are from the same class, with a corresponding distri-butional score f\u03b8+(\u00b7, \u00b7).",
            "Similarly, an alternative hypothesis\ftion sets extracted by the \ufb01rst projector g\u03b81(\u00b7) for measuringthe intersection, (cid:104)g\u03b81(q1), g\u03b81(q2)(cid:105), while the second projectoris for measuring the dissimilarity, (cid:107)g\u03b82(q1) \u2212 g\u03b82(q2)(cid:107)22, whenultimately computing the Jaccard similarity.Claim 1.",
            "The Jaccard index, acting on two hidden spaces tomeasure their similarity is equivalent to respectively maximiz-ing and minimizing the Jaccard similarity between positiveand negative pairs.LJ\u2212T ri(a) = \u2212\u00b5(x \u2229 x+)\u00b5(x \u222a x+)=s+s+ + ds+ \u2212(cid:12)(cid:12)(cid:12)(cid:12)\u03b8,\u03b81,\u03b82(2)+\u00b5(x \u2229 x\u2212i )\u00b5(x \u222a x\u2212i )s\u2212ii + ds\u2212s\u2212.i = (cid:104)g\u03b81 \u25e6 f\u03b8(x), g\u03b81 \u25e6 f\u03b8(x\u2212ii , \u03b8, \u03b81, \u03b82), s+ = (cid:104)g\u03b81 \u25e6 f\u03b8(x), g\u03b81 \u25e6i )(cid:105), ds+ = (cid:107)g\u03b82 \u25e6i = (cid:107)g\u03b82 \u25e6 f\u03b8(x) \u2212 g\u03b82 \u25e62, and ds\u2212where a = (x, x+, x\u2212f\u03b8(x+)(cid:105), s\u2212f\u03b8(x) \u2212 g\u03b82 \u25e6 f\u03b8(x+)(cid:107)2f\u03b8(x\u2212i )(cid:107)22.In Eq.",
            "(1), we prove that the contrastive loss is a smoothapproximation to the triplet loss.",
            "Therefore, we can also applythe smoothness property of LogSumExp function to Jaccard-based triplet loss.",
            "Then, the smooth version of Jaccard-basedcontrastive loss is shown below,LJ\u2212T ri(a) = \u22121N(cid:18)(cid:88)s+s+ + ds+ \u2212(cid:19)s\u2212ii + ds\u2212s\u2212ii(cid:18)\u2248 \u2212logs+s++ds+e(3)(cid:19).s+s++ds+ + (cid:80)es\u2212ii es\u2212i+ds\u2212iTo better achieve the intra/inter-class clustering in the hid-den spaces, we follow the conventional self-supervised learn-ing and calculate the contrastive loss among positive and neg-ative keys in each hidden space, respectively.",
            "Subsequentlyapplying the Jaccard similarity to achieve the feature fusionbetween two hidden spaces (as noted with sensitivity to similar-ity and dissimilarity, respectively) yields the proposed modeldetailed next.",
            "As a result we postulate the following,Proposed self-supervision loss:(cid:18)e(cid:104)h(1)q ,h(1)k+ (cid:105)/\u03c4(cid:19)q ,h(1)k+ (cid:105)/\u03c4 + (cid:80)i e(cid:104)h(1)q ,h(1)\u2212ik(cid:105)/\u03c4e(cid:104)h(1)e(cid:104)h(2)q ,h(2)k+ (cid:105)/\u03c4(cid:19)q ,h(2)e(cid:104)h(2)k+ (cid:105)/\u03c4 + (cid:80)i e(cid:104)h(2)q ,h(1)\u2212ik(cid:105)/\u03c4LJ (a) = \u2212\u03b11log(cid:18)\u2212 \u03b12log\u2212 (1 \u2212 \u03b11 \u2212 \u03b12)\u00d7\uf8eblog\uf8ed(cid:104)h(1)q ,h(cid:105)(1)k+(2)q \u2212h(cid:104)h(1)q ,h(1)k+e(cid:105)+(cid:107)h/\u03c4(2)k+(cid:107)22(cid:104)h(1)q ,h(cid:105)(1)k+(2)q \u2212h(cid:104)h(1)q ,h(1)k+e(cid:105)+(cid:107)h/\u03c4(2)k+(cid:107)22+(cid:80)i e(cid:104)h(1)q ,h(1)\u2212ik(cid:105)+(cid:107)h(cid:104)h(1)q ,h(cid:105)(1)\u2212ki(2)q \u2212h/\u03c4(cid:107)22(2)\u2212ik\uf8f6\uf8f8,(4)Fig.",
            "1.",
            "An intuitive explanation of our model.H1 is de\ufb01ned for two observations from different classes, witha corresponding score f\u03b8\u2212 (\u00b7, \u00b7).With the inferential perspective in mind and the Jaccardsimilarity measure in hand, we propose to seek hidden repre-sentations as \ufb01nite information sets/distributions of originalobjects.",
            "As is typically interpreted with measures in proba-bilistic settings, intersections will account for similarity, whileset differences re\ufb02ect dissimilarities (disparities) among thedata samples.",
            "To that end, we introduce a bi-projector sys-tem model g\u03b8i(\u00b7), i = 1, 2, with the \ufb01rst following H0 (i.e.,that two objects are from the same class by measuring theintersection of extracted features), while the other follow-ing H1.",
            "We can hence de\ufb01ne two hypotheses scoring func-:= f\u03b8+(\u00b7, \u00b7) = s \u25e6 g\u03b81 \u25e6 f\u03b8, andtions, f (x1, x2|H0, \u03b8)f (x1, x2|H1, \u03b8) := f\u03b8\u2212 (\u00b7, \u00b7) = ds \u25e6 g\u03b82 \u25e6 f\u03b8, respectively,where s(\u00b7, \u00b7),ds(\u00b7, \u00b7) is each respectively, a similarity and dis-similarity measure.",
            "Fig.",
            "1 provides a high-level and intuitivedescription of the proposed rationale.",
            "The latent representa-tions of the original data lying on an unknown curved man-ifold, make it unreasonable and possibly detrimental to thetraining/learning, to be using Euclidean-based similarity met-rics.",
            "The key idea is to then learn a homeomorphism g\u03b8(\u00b7) thatprojects the latent space information onto a set of Euclideanspaces, where a similarity can be measured by L2-norm, andconsistently integrate the extracted information.",
            "In our case,we hence seek two distinct projectors which directly contributeto the computation of the Jaccard similarity which is in turn,used to optimize the encoder.",
            "A carefully designed combi-nation of the information extracted by the two projectors asdescribed next, will yield a Jaccard similarity.2.3.3.",
            "Proposed Algorithmic SolutionThis Jaccard-based similarity/loss provides a non-linear combi-nation (fusion) of features thereby avoiding asymmetry in thetraining.",
            "Different measurement focus also prevent the two pro-jectors from collapsing into one single point.",
            "To proceed withthe detailed development of the Jaccard index-based model, we\ufb01rst note that the similarity/dissimilarity are Euclidean-based(i.e., ds(x, y) =(cid:107) x \u2212 y (cid:107)2), where x, y are normalized in thehidden space.",
            "Speci\ufb01cally, for given latent representations oftwo images q1 and q2, we only consider the two \ufb01nite informa-\fwhere h(j)qh(j)k\u2212i= g\u03b8j \u25e6 f\u03b8(x), h(j)i ), j = 1, 2.= g\u03b8j \u25e6 f\u03b8(x\u2212k+ = g\u03b8j \u25e6 f\u03b8(x+), and3.",
            "EXPERIMENTAL RESULTSIn this section, we demonstrate the compatibility, ef\ufb01ciency,and accuracy of the Jaccard-similarity-based model.",
            "We con-sider SimCLR[1] and MoCo[2] as the benchmarks and testthe models\u2019 performance on CIFAR-10/100[17] and Tiny-imagenet-200[18].",
            "Due to our limited GPU resources, wecan not run full-scale experiments on the ImageNet-1k.In the SSL training stage, we use ResNet-50[19] as thebackbone network for all models.",
            "All neural networks aretrained with a batch size of 512 for 500 epochs on both CIFAR-10 and CIFAR-100 datasets and a batch size of 256 on theTiny-Imagenet dataset.",
            "All models apply the same set of aug-mentation methods as SimCLR, and a constant learning rate10\u22123.",
            "We \ufb01x the encoder after each training epoch and applythe k-NN classi\ufb01cation method to verify the encoder\u2019s perfor-mance during the training.",
            "Different temperature parameters(\u03c4 ) are chosen for training, and we choose the best encoder\u2019sperformance as the model\u2019s \ufb01nal result.",
            "We have reproducedthe results of the two benchmarks.We show in Table 1 the complexity, i.e., the running time,of our model compared with SimCLR.",
            "The training time ofone epoch is recorded on one NVIDIA Tesla V100 GPU forall models.",
            "Only one additional projector, a 2-layer fullyconnected neural network, is added to our model, and the lossis computed in matrix format.",
            "The recording time shows ourmodel takes 1.1 times of SimCLR running time in CIFARdatasets and 1.01 times of it in the Tiny-Imagenet-200 dataset.Fig.2 shows the encoders\u2019 performance curves of SimCLR andour model based on the k-NN method w.r.t the training epoch.We can observe that our model\u2019s encoder demonstrates quitea convincing learning speed compared with the conventionalmodel with the same learning rate setup.DatasetSimCLROur modelCIFAR1m36s/epoch1m47s/epochTiny-Imagenet-20013m51s/epoch14m01s/epochTable 1.",
            "Running time.Table 2 shows the linear evaluation results\u2019 comparison ondifferent datasets between conventional self-supervised learn-ing models and our modi\ufb01ed models.",
            "Note that compared withthe conventional contrastive learning model, the complexity ofthe whole system is rarely increased, and the main differenceis based on the similarity metric.",
            "The results show that ourproposal of considering a non-linear metric helps improve theaccuracy in most comparable experiments.",
            "The more complexthe data is, the more improvement is achieved, con\ufb01rming thatthe non-linear impart is more pronounced.",
            "These observationsre\ufb02ect the fact that latent representations of a complex datasetFig.",
            "2. k-NN accuracylie on non-linear manifold, where the linear metric may lead toimprecise estimation.",
            "Overall, the encoder based on SimCLRsetup with our proposed model obtains the best performancein all datasets.Top-1 Accuracy (%)DatasetModelMethodCIFAR CIFARSimCLRSimCLR +our modelMoCoMoCo +our modelk-NNlineark-NNlineark-NNlineark-NNlinear1088.691.588.691.885.590.585.190.2TinyImageNet35.950.739.553.833.549.635.451.210062.168.663.969.556.866.859.267.5Table 2.",
            "Linear evaluation results.4.",
            "CONCLUSIONSThis paper explains the contrastive loss from a hypothesis-testing point of view by distinguishing whether a pair of im-ages is from the same category.",
            "We subsequently introducea bi-projector model and a Jaccard-similarity-based loss tofuse the information extracted by the two projectors.",
            "In the ex-periments, we demonstrate the compatibility of our model byapplying it as a plug-in unit to the state-of-art approaches.",
            "Wealso show that our model outperforms state-of-art contrastiveSSL methods.",
            "The accuracy improvement is more pronouncedfor more complex datasets proving that the similarity measureshould account for non-linearity on the latent space.",
            "Futureresearch can consider model transport between the samples, toprovide better insight on their behavior on the manifold.",
            "[11] Ting Chen, Simon Kornblith, Kevin Swersky, Moham-mad Norouzi, and Geoffrey Hinton.",
            "Big self-supervisedarXivmodels are strong semi-supervised learners.preprint arXiv:2006.10029, 2020.",
            "[12] Ching-Yao Chuang, Joshua Robinson, Lin Yen-Chen,Antonio Torralba, and Stefanie Jegelka.",
            "Debiased con-trastive learning.",
            "arXiv preprint arXiv:2007.00224, 2020.",
            "[13] Paul Jaccard.",
            "The distribution of the \ufb02ora in the alpinezone.",
            "1.",
            "New phytologist, 11(2):37\u201350, 1912.",
            "[14] Florian Schroff, Dmitry Kalenichenko, and JamesPhilbin.",
            "Facenet: A uni\ufb01ed embedding for face recogni-tion and clustering.",
            "In Proceedings of the IEEE confer-ence on computer vision and pattern recognition, pages815\u2013823, 2015.",
            "[15] Raia Hadsell, Sumit Chopra, and Yann LeCun.",
            "Dimen-sionality reduction by learning an invariant mapping.",
            "In2006 IEEE Computer Society Conference on ComputerVision and Pattern Recognition (CVPR\u201906), volume 2,pages 1735\u20131742.",
            "IEEE, 2006.",
            "[16] Erich L Lehmann and Joseph P Romano.",
            "Testing statis-tical hypotheses.",
            "Springer Science & Business Media,2006.",
            "[17] Alex Krizhevsky, Geoffrey Hinton, et al.",
            "Learning multi-ple layers of features from tiny images.",
            "2009.",
            "[18] Ya Le and Xuan Yang.",
            "Tiny imagenet visual recognitionchallenge.",
            "CS 231N, 7:7, 2015.",
            "[19] Kaiming He, Xiangyu Zhang, Shaoqing Ren, and JianSun.",
            "Deep residual learning for image recognition.",
            "InProceedings of the IEEE conference on computer visionand pattern recognition, pages 770\u2013778, 2016.5.",
            "REFERENCES[1] Ting Chen, Simon Kornblith, Mohammad Norouzi, andGeoffrey Hinton.",
            "A simple framework for contrastivelearning of visual representations.",
            "In International con-ference on machine learning, pages 1597\u20131607.",
            "PMLR,2020.",
            "[2] Kaiming He, Haoqi Fan, Yuxin Wu, Saining Xie, andRoss Girshick.",
            "Momentum contrast for unsupervisedIn Proceedings of thevisual representation learning.IEEE/CVF Conference on Computer Vision and PatternRecognition, pages 9729\u20139738, 2020.",
            "[3] Carl Doersch, Abhinav Gupta, and Alexei A Efros.",
            "Unsu-pervised visual representation learning by context predic-tion.",
            "In Proceedings of the IEEE international conferenceon computer vision, pages 1422\u20131430, 2015.",
            "[4] Simon Jenni and Paolo Favaro.",
            "Self-supervised featurelearning by learning to spot artifacts.",
            "In Proceedings ofthe IEEE Conference on Computer Vision and PatternRecognition, pages 2733\u20132742, 2018.",
            "[5] Dahun Kim, Donghyeon Cho, Donggeun Yoo, and In SoKweon.",
            "Learning image representations by completingdamaged jigsaw puzzles.",
            "In 2018 IEEE Winter Confer-ence on Applications of Computer Vision (WACV), pages793\u2013802.",
            "IEEE, 2018.",
            "[6] Sumit Chopra, Raia Hadsell, and Yann LeCun.",
            "Learn-ing a similarity metric discriminatively, with applicationIn 2005 IEEE Computer Societyto face veri\ufb01cation.Conference on Computer Vision and Pattern Recognition(CVPR\u201905), volume 1, pages 539\u2013546.",
            "IEEE, 2005.",
            "[7] A Ben Hamza.",
            "Jensen-rhyi divergence measure: Theoret-ical and computational perspectives.",
            "In IEEE Int.",
            "Symp.Inf.",
            "Theory, 2003.",
            "[8] Xinlei Chen and Kaiming He.",
            "Exploring simple siameserepresentation learning.",
            "In Proceedings of the IEEE/CVFConference on Computer Vision and Pattern Recognition,pages 15750\u201315758, 2021.",
            "[9] Jean-Bastien Grill, Florian Strub, Florent Altch\u00e9,Corentin Tallec,Pierre H Richemond, ElenaBuchatskaya, Carl Doersch, Bernardo Avila Pires,Zhaohan Daniel Guo, Mohammad Gheshlaghi Azar,et al.",
            "Bootstrap your own latent: A new approach to self-supervised learning.",
            "arXiv preprint arXiv:2006.07733,2020.",
            "[10] Yuandong Tian, Xinlei Chen, and Surya Ganguli.",
            "Under-standing self-supervised learning dynamics without con-trastive pairs.",
            "arXiv preprint arXiv:2102.06810, 2021."
        ],
        "words": [
            "REFINING",
            "SELF-SUPERVISED",
            "LEARNING",
            "IN",
            "IMAGING",
            ":",
            "BEYOND",
            "LINEAR",
            "METRIC",
            "Bo",
            "Jiang",
            "(",
            "cid:63",
            ")",
            "Hamid",
            "Krim",
            "(",
            "cid:63",
            ")",
            "Tianfu",
            "Wu",
            "(",
            "cid:63",
            ")",
            "Derya",
            "Cansever\u2020",
            "(",
            "cid:63",
            ")",
            "North",
            "Carolina",
            "State",
            "University",
            "\u2020US",
            "Army",
            "Research",
            "Of\ufb01ce",
            "2",
            "2",
            "0",
            "2",
            "b",
            "e",
            "F",
            "5",
            "2",
            "]",
            "V",
            "C",
            ".",
            "s",
            "c",
            "[",
            "1",
            "v",
            "1",
            "2",
            "9",
            "2",
            "1",
            ".",
            "2",
            "0",
            "2",
            "2",
            ":",
            "v",
            "i",
            "X",
            "r",
            "a",
            "ABSTRACT",
            "We",
            "introduce",
            "in",
            "this",
            "paper",
            "a",
            "new",
            "statistical",
            "perspective",
            ",",
            "exploit-",
            "ing",
            "the",
            "Jaccard",
            "similarity",
            "metric",
            ",",
            "as",
            "a",
            "measure-based",
            "metric",
            "to",
            "effectively",
            "invoke",
            "non-linear",
            "features",
            "in",
            "the",
            "loss",
            "of",
            "self-",
            "supervised",
            "contrastive",
            "learning",
            ".",
            "Speci\ufb01cally",
            ",",
            "our",
            "proposed",
            "metric",
            "may",
            "be",
            "interpreted",
            "as",
            "a",
            "dependence",
            "measure",
            "between",
            "two",
            "adapted",
            "projections",
            "learned",
            "from",
            "the",
            "so-called",
            "latent",
            "repre-",
            "sentations",
            ".",
            "This",
            "is",
            "in",
            "contrast",
            "to",
            "the",
            "cosine",
            "similarity",
            "measure",
            "in",
            "the",
            "conventional",
            "contrastive",
            "learning",
            "model",
            ",",
            "which",
            "accounts",
            "for",
            "correlation",
            "information",
            ".",
            "To",
            "the",
            "best",
            "of",
            "our",
            "knowledge",
            ",",
            "this",
            "effectively",
            "non-linearly",
            "fused",
            "information",
            "embedded",
            "in",
            "the",
            "Jaccard",
            "similarity",
            ",",
            "is",
            "novel",
            "to",
            "self-supervision",
            "learning",
            "with",
            "promising",
            "results",
            ".",
            "The",
            "proposed",
            "approach",
            "is",
            "compared",
            "to",
            "two",
            "state-of-the-art",
            "self-supervised",
            "contrastive",
            "learning",
            "methods",
            "on",
            "three",
            "image",
            "datasets",
            ".",
            "We",
            "not",
            "only",
            "demonstrate",
            "its",
            "amenable",
            "applicability",
            "in",
            "current",
            "ML",
            "problems",
            ",",
            "but",
            "also",
            "its",
            "improved",
            "performance",
            "and",
            "training",
            "ef\ufb01ciency",
            ".",
            "Index",
            "Terms\u2014",
            "Self-Supervised",
            "learning",
            ",",
            "Contrastive",
            "Learning",
            ",",
            "Jaccard",
            "Index",
            ",",
            "Non-linearity",
            "1",
            ".",
            "INTRODUCTION",
            "The",
            "notion",
            "of",
            "latent",
            "representation",
            "of",
            "data",
            "has",
            ",",
            "over",
            "the",
            "last",
            "few",
            "years",
            ",",
            "emerged",
            "as",
            "a",
            "signi\ufb01cant",
            "catalyst",
            ",",
            "particularly",
            "in",
            "computer",
            "vision",
            ",",
            "where",
            "a",
            "visual",
            "representation",
            "in",
            "the",
            "latent",
            "space",
            "provides",
            "a",
            "powerful",
            "grounding",
            "for",
            "supervised",
            "learn-",
            "ing",
            "and",
            "inference",
            ".",
            "Scaling",
            "learning-based",
            "inference",
            "to",
            "large",
            "datasets",
            "(",
            "e.g.",
            ",",
            "ImageNet",
            ")",
            ",",
            "however",
            ",",
            "is",
            "labor-intensive",
            "and",
            "time-",
            "consuming",
            ",",
            "and",
            "calls",
            "for",
            "a",
            "more",
            "viable",
            "alternative",
            ".",
            "The",
            "increas-",
            "ing",
            "popularity",
            "of",
            "Self-Supervised",
            "Learning",
            "(",
            "SSL",
            ")",
            "particularly",
            "in",
            "Computer",
            "Vision",
            "(",
            "CV",
            ")",
            "in",
            "conjunction",
            "with",
            "learned",
            "visual",
            "representations",
            "[",
            "1",
            ",",
            "2",
            "]",
            "and",
            "pretext",
            "tasks",
            "[",
            "3",
            ",",
            "4",
            ",",
            "5",
            "]",
            "seeks",
            "labelling",
            "from",
            "a",
            "diverse",
            "view",
            "or",
            "a",
            "fraction",
            "of",
            "a",
            "given",
            "data",
            "sample",
            ".",
            "A",
            "key",
            "feature",
            "of",
            "SSL",
            "is",
            "the",
            "adopted",
            "contrastive",
            "loss",
            ",",
            "which",
            "is",
            "aimed",
            "at",
            "discriminating",
            "positive",
            "keys",
            "(",
            "i.e.",
            ",",
            "different",
            "views",
            "of",
            "the",
            "sample",
            ")",
            "from",
            "negative",
            "ones",
            "in",
            "the",
            "latent",
            "space",
            "of",
            "images",
            ".",
            "To",
            "de\ufb01ne",
            "some",
            "notion",
            "of",
            "semantic",
            "space",
            ",",
            "a",
            "contrastive",
            "learning",
            "model",
            "was",
            "proposed",
            "in",
            "[",
            "6",
            "]",
            ".",
            "In",
            "so",
            "doing",
            ",",
            "they",
            "pro-",
            "posed",
            "a",
            "L2-norm",
            "distance",
            "to",
            "estimate",
            "similarity",
            "among",
            "two",
            "images",
            "[",
            "7",
            "]",
            ".",
            "This",
            "procedure",
            "entailed",
            "minimizing",
            "a",
            "semantic",
            "dis-",
            "tance",
            "between",
            "images",
            "from",
            "the",
            "same",
            "class",
            "while",
            "maximizing",
            "that",
            "from",
            "different",
            "classes",
            ".",
            "The",
            "recent",
            "focus",
            "in",
            "research",
            "has",
            "gradually",
            "shifted",
            "to",
            "only",
            "minimizing",
            "the",
            "distance",
            "between",
            "the",
            "positive",
            "pairs",
            "without",
            "simultaneously",
            "maximizing",
            "the",
            "distance",
            "between",
            "negative",
            "pairs",
            "[",
            "8",
            ",",
            "9",
            ",",
            "10",
            "]",
            ".",
            "Given",
            "different",
            "views",
            "of",
            "the",
            "original",
            "images",
            ",",
            "the",
            "encoder",
            "is",
            "trained",
            "by",
            "minimizing",
            "the",
            "distance",
            "between",
            "different",
            "views",
            "in",
            "the",
            "hidden",
            "space",
            ".",
            "The",
            "paper",
            "[",
            "10",
            "]",
            "also",
            "highlights",
            "the",
            "impact",
            "of",
            "a",
            "potential",
            "asymmetry",
            "with",
            "the",
            "larger",
            "number",
            "of",
            "negative",
            "keys",
            "than",
            "the",
            "number",
            "of",
            "positive",
            "keys",
            "skewing",
            "the",
            "learning",
            ".",
            "Empirically",
            "choosing",
            "the",
            "transformation",
            "and",
            "augmentation",
            "methods",
            "[",
            "11",
            "]",
            "and",
            "handling",
            "negative",
            "samples",
            "[",
            "12",
            "]",
            "may",
            "also",
            "induce",
            "biases",
            "and",
            "hence",
            "signi\ufb01-",
            "cantly",
            "affect",
            "the",
            "learning",
            "encoders",
            "\u2019",
            "performance",
            ".",
            "As",
            "a",
            "result",
            "of",
            "these",
            "augmentation",
            "procedures",
            ",",
            "a",
            "selection",
            "of",
            "a",
            "correct",
            "metric",
            "is",
            "in",
            "order",
            "as",
            "it",
            "will",
            "clearly",
            "impact",
            "any",
            "training",
            "procedure",
            ".",
            "The",
            "adoption",
            "of",
            "a",
            "cosine",
            "similarity",
            "implies",
            "a",
            "linear",
            "measurability",
            "of",
            "the",
            "similarity",
            "in",
            "the",
            "latent",
            "space",
            ".",
            "The",
            "features",
            "are",
            ",",
            "however",
            ",",
            "the",
            "result",
            "of",
            "non-linear",
            "processing",
            "across",
            "the",
            "learning",
            "layers",
            "and",
            "are",
            "hence",
            "elements",
            "lying",
            "on",
            "some",
            "manifold",
            "rather",
            "than",
            "on",
            "a",
            "linear",
            "space",
            ".",
            "To",
            "that",
            "end",
            ",",
            "we",
            "propose",
            "to",
            "account",
            "for",
            "the",
            "intrinsic",
            "non-linearity",
            "by",
            "proposing",
            "the",
            "Jaccard",
            "similarity",
            "coef-",
            "\ufb01cient",
            ",",
            "developed",
            "in",
            "the",
            "early",
            "1900",
            "\u2019",
            "s",
            "[",
            "13",
            "]",
            ",",
            "to",
            "capture",
            "non-linear",
            "characteristics",
            "in",
            "the",
            "similarity",
            "between",
            "\ufb01nite",
            "sets",
            "of",
            "prevailing",
            "features",
            ".",
            "Upon",
            "interpreting",
            "SSL",
            "as",
            "an",
            "inference",
            "problem",
            ",",
            "and",
            "using",
            "a",
            "hypothesis",
            "test",
            "for",
            "a",
            "quantitative",
            "decision",
            "in",
            "contrastive",
            "learning",
            ",",
            "we",
            "propose",
            "a",
            "bi-projector",
            "Jaccard-based",
            "loss",
            "which",
            "effectively",
            "re\ufb02ects",
            "the",
            "non-linearities",
            "in",
            "the",
            "hidden",
            "spaces",
            ".",
            "Our",
            "proposed",
            "adaptive",
            "approach",
            "effectively",
            "aims",
            "at",
            "ad-",
            "dressing",
            "the",
            "inherent",
            "modal",
            "structure",
            "of",
            "the",
            "latent/pseudo-",
            "invariant",
            "characteristics",
            "of",
            "the",
            "data",
            "(",
            "using",
            "Jaccard-metric",
            ")",
            "with",
            "a",
            "comparative",
            "validation",
            "using",
            "two",
            "well-known",
            "self-supervised",
            "learning",
            "models",
            "SimCLR",
            "[",
            "1",
            "]",
            "and",
            "MoCo",
            "[",
            "2",
            "]",
            ",",
            "based",
            "on",
            "both",
            "the",
            "k-nearest",
            "neighbors",
            "(",
            "k-NN",
            ")",
            "classi\ufb01cation",
            "and",
            "the",
            "standard",
            "lin-",
            "ear",
            "classi\ufb01cation",
            "methods",
            ".",
            "The",
            "selected",
            "datasets",
            "are",
            "CIFAR-",
            "10",
            ",",
            "CIFAR-100",
            ",",
            "and",
            "Tiny-ImageNet-200",
            "to",
            "capture",
            "the",
            "class",
            "variability",
            "bandwidth",
            "used",
            "in",
            "evaluating",
            "the",
            "performance",
            "of",
            "SSL",
            ".",
            "Our",
            "contributions",
            "in",
            "this",
            "paper",
            "include",
            "(",
            "1",
            ")",
            "Our",
            "providing",
            "a",
            "theoretically",
            "sound",
            "and",
            "tractable",
            "hypothesis",
            "testing",
            "formula-",
            "tion",
            "of",
            "the",
            "contrastive",
            "loss",
            ",",
            "and",
            "of",
            "the",
            "ensuing",
            "projection",
            "for",
            "procedure",
            "stabilization",
            ";",
            "(",
            "2",
            ")",
            "Our",
            "introduction",
            "of",
            "a",
            "bi-projector",
            "model",
            "along",
            "with",
            "a",
            "novel",
            "Jaccard-similarity-based",
            "contrastive",
            "loss",
            "evaluation",
            ";",
            "(",
            "3",
            ")",
            "Our",
            "derivation",
            "of",
            "similarity",
            "maximiza-",
            "tion/minimization",
            "of",
            "positive/negative",
            "pairs",
            "in",
            "each",
            "of",
            "the",
            "hid-",
            "den",
            "spaces",
            "separately",
            "accounting",
            "for",
            "the",
            "non-linear",
            "features",
            "by",
            "a",
            "Jaccard",
            "metric-based",
            "fusion",
            ".",
            "2",
            ".",
            "SSL",
            ":",
            "BACKGROUND",
            "AND",
            "DEVELOPMENT",
            "2.1",
            ".",
            "Notation",
            "Throughout",
            "the",
            "paper",
            ",",
            "we",
            "will",
            "adopt",
            "a",
            "notationally",
            "caligraphic",
            "upper",
            "case",
            "letter",
            "to",
            "denote",
            "a",
            "space",
            ",",
            "and",
            "an",
            "upper",
            "case",
            "letter",
            "to",
            "denote",
            "a",
            "data",
            "representation",
            "in",
            "different",
            "spaces",
            ",",
            "speci\ufb01cally",
            ",",
            "X",
            "represents",
            "the",
            "original",
            "data",
            ",",
            "X",
            "K",
            "the",
            "transformation",
            "and",
            "augmentation",
            "of",
            "the",
            "original",
            "image",
            "data",
            "in",
            "the",
            "pixel",
            "space",
            ",",
            "with",
            "Q",
            "and",
            "K",
            "respectively",
            "denoting",
            "the",
            "features",
            "in",
            "the",
            "latent",
            "representation",
            "spaces",
            "of",
            "the",
            "original",
            "and",
            "augmented",
            "images",
            ".",
            "We",
            "use",
            "the",
            "subscripted",
            "lower",
            "case",
            "letter",
            "to",
            "distinguish",
            "different",
            "elements",
            "in",
            "different",
            "spaces",
            ",",
            "i.e.",
            ",",
            "xi",
            "indicates",
            "the",
            "ith",
            "object",
            "el-",
            "ement",
            "of",
            "X",
            ".",
            "We",
            "consider",
            "f\u03b8",
            "(",
            "\u00b7",
            ")",
            "to",
            "be",
            "a",
            "function",
            "parameterized",
            "by",
            "\u03b8",
            ".",
            "2.2",
            ".",
            "Contrastive",
            "Loss",
            "=",
            "g\u03b8p",
            "\u25e6",
            "f\u03b8",
            "(",
            "x\u2212",
            "Given",
            "an",
            "unlabeled",
            "dataset",
            "X",
            "=",
            "{",
            "x1",
            ",",
            "x2",
            ",",
            ".",
            ".",
            ".",
            ",",
            "xN",
            "}",
            ",",
            "a",
            "similar-",
            "ity",
            "calculation",
            "method",
            "s",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            ",",
            "an",
            "embedding",
            "function",
            "f\u03b8",
            "(",
            "\u00b7",
            ")",
            ",",
            "and",
            "a",
            "projector",
            "g\u03b8p",
            "(",
            "\u00b7",
            ")",
            ",",
            "which",
            "collaboratively",
            "projects",
            "the",
            "data",
            "from",
            "the",
            "original",
            "space",
            "X",
            "into",
            "a",
            "\ufb02at",
            "hidden",
            "space",
            "H.",
            "De\ufb01ne",
            "x",
            "a",
            "data",
            "sample",
            "in",
            "X",
            ",",
            "x+",
            "as",
            "a",
            "positive",
            "key",
            ",",
            "and",
            "x\u2212",
            "j",
            "denotes",
            "the",
            "jth",
            "of",
            "negative",
            "keys",
            "of",
            "x",
            ",",
            "hq",
            "=",
            "g\u03b8p",
            "\u25e6",
            "f\u03b8",
            "(",
            "x",
            ")",
            ",",
            "hk+",
            "=",
            "g\u03b8p",
            "\u25e6",
            "f\u03b8",
            "(",
            "x+",
            ")",
            ",",
            "and",
            "hk\u2212",
            "j",
            ")",
            ".",
            "To",
            "carry",
            "j",
            "through",
            "the",
            "original",
            "idea",
            "of",
            "contrasting",
            "positive",
            "with",
            "nega-",
            "tive",
            "keys",
            ",",
            "a",
            "triplet",
            "loss",
            ",",
            "was",
            "\ufb01rst",
            "proposed",
            "in",
            "[",
            "14",
            ",",
            "15",
            "]",
            ",",
            "and",
            "is",
            "aimed",
            "at",
            "learning",
            "an",
            "invariant",
            "mapping",
            "to",
            "project",
            "high",
            "dimensional",
            "features",
            "onto",
            "a",
            "low",
            "dimensional",
            "space",
            ",",
            "such",
            "that",
            "intra-class",
            "features",
            "are",
            "close",
            "to",
            "each",
            "other",
            "while",
            "keep-",
            "ing",
            "inter-class",
            "features",
            "far",
            "apart",
            ",",
            "Ltriplet",
            "(",
            "x",
            ",",
            "x+",
            ",",
            "x\u2212|\u03b8",
            ",",
            "\u03b8p",
            ")",
            "=",
            "max",
            "(",
            "0",
            ",",
            "d",
            "(",
            "hq",
            ",",
            "hk+",
            ")",
            "\u2212",
            "d",
            "(",
            "hq",
            ",",
            "hk\u2212",
            ")",
            "+",
            "m",
            ")",
            ",",
            "with",
            "d",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            "denoting",
            "a",
            "metric",
            ",",
            "and",
            "m",
            "is",
            "some",
            "margin",
            "that",
            "restricts",
            "the",
            "largest",
            "meaningful",
            "distance",
            "difference",
            "between",
            "intra-class",
            "and",
            "inter-class",
            "latent",
            "representations",
            ".",
            "A",
            "probabilistic",
            "interpre-",
            "tation",
            "has",
            "recently",
            "emerged",
            "``",
            "softmax",
            "''",
            "expression",
            "to",
            "high-",
            "light",
            "the",
            "frequential",
            "aspect",
            "of",
            "sampling",
            ",",
            "Lco",
            "(",
            "x",
            ",",
            "x+",
            ",",
            "x\u2212",
            "j",
            ")",
            "=",
            "(",
            "cid:18",
            ")",
            "\u2212log",
            "exp",
            "(",
            "s",
            "(",
            "hq",
            ",",
            "hk+",
            ")",
            "/\u03c4",
            ")",
            "exp",
            "(",
            "s",
            "(",
            "hq",
            ",",
            "hk+",
            ")",
            "/\u03c4",
            ")",
            "+",
            "(",
            "cid:80",
            ")",
            "j",
            "exp",
            "(",
            "s",
            "(",
            "hq",
            ",",
            "h",
            ")",
            "/\u03c4",
            ")",
            "k",
            "\u2212",
            "j",
            "(",
            "cid:19",
            ")",
            ",",
            "where",
            "\u03c4",
            "is",
            "referred",
            "to",
            "as",
            "the",
            "temperature",
            "scalar",
            "in",
            "the",
            "contrastive",
            "loss",
            "to",
            "modulate",
            "the",
            "in\ufb02uence",
            "of",
            "the",
            "exponent",
            "term",
            ".",
            "Note",
            "that",
            "the",
            "cosine",
            "similarity",
            "expression",
            "Cos-Sim",
            "(",
            "x",
            ",",
            "y",
            ")",
            "=",
            "(",
            "cid:104",
            ")",
            "x",
            ",",
            "y",
            "(",
            "cid:105",
            ")",
            "(",
            "cid:107",
            ")",
            "x",
            "(",
            "cid:107",
            ")",
            "(",
            "cid:107",
            ")",
            "y",
            "(",
            "cid:107",
            ")",
            "is",
            "a",
            "common",
            "similarity",
            "measure",
            "choice",
            "between",
            "latent",
            "repre-",
            "sentations",
            ".",
            "While",
            "seemingly",
            "distinct",
            ",",
            "these",
            "two",
            "losses",
            "bear",
            "a",
            "relation",
            "as",
            "shown",
            "next",
            ",",
            "Theorem",
            "1",
            ".",
            "The",
            "mean",
            "zero-margin",
            "triplet",
            "loss",
            "is",
            "upper",
            "bounded",
            "and",
            "smoothly",
            "approximated",
            "by",
            "the",
            "contrastive",
            "loss",
            ".",
            "Proof",
            ":",
            "The",
            "LogSumExp",
            "term",
            "in",
            "the",
            "denominator",
            "can",
            "be",
            "inter-",
            "preted",
            "as",
            "the",
            "smooth",
            "approximation",
            "to",
            "the",
            "maximum",
            "function",
            ".",
            "Consider",
            "a",
            "\ufb01nite",
            "set",
            "Y",
            "=",
            "{",
            "y1",
            ",",
            "...",
            ",",
            "yn",
            "}",
            ",",
            "log",
            "(",
            "cid:18",
            ")",
            "(",
            "cid:19",
            ")",
            "(",
            "cid:19",
            ")",
            "(",
            "cid:18",
            ")",
            "log",
            "(",
            "cid:80",
            ")",
            "i",
            "eyi",
            "\u2264",
            "log",
            "nemax",
            "(",
            "Y",
            ")",
            ".",
            "While",
            "the",
            "so-called",
            "soft-",
            "(",
            "cid:18",
            ")",
            "(",
            "cid:19",
            ")",
            "emax",
            "(",
            "Y",
            ")",
            ")",
            "\u2264",
            "max",
            "is",
            "often",
            "applied",
            "in",
            "ML",
            "to",
            "avoid",
            "non-smoothness",
            "when",
            "calculating",
            "the",
            "gradient",
            ",",
            "it",
            "often",
            "is",
            "implicit",
            "in",
            "other",
            "settings",
            ".",
            "The",
            "contrastive",
            "loss",
            "equation",
            "thus",
            "yields",
            "the",
            "mean",
            "triplet",
            "loss",
            "with",
            "the",
            "zero",
            "margin",
            ".",
            "By",
            "de\ufb01ning",
            "s+",
            "=",
            "Cos-Sim",
            "(",
            "hq",
            ",",
            "hk+",
            ")",
            "/\u03c4",
            "and",
            "s\u2212",
            ")",
            "/\u03c4",
            ",",
            "we",
            "can",
            "rewrite",
            ",",
            "j",
            "=",
            "Cos-Sim",
            "(",
            "hq",
            ",",
            "hk\u2212",
            "j",
            "Lco",
            "=",
            "\u2212log",
            "(",
            "cid:18",
            ")",
            "es+",
            "es+",
            "+",
            "(",
            "cid:80",
            ")",
            "(",
            "cid:18",
            ")",
            "\u2265",
            "max",
            "0",
            ",",
            "s\u2212",
            "j",
            "i",
            "es\u2212",
            "1",
            "\u2212",
            "s+",
            ",",
            ".",
            ".",
            ".",
            ",",
            "s\u2212",
            "(",
            "cid:19",
            ")",
            "n",
            "\u2212",
            "s+",
            "\u2265",
            "(",
            "cid:19",
            ")",
            "(",
            "cid:18",
            ")",
            "=",
            "log",
            "e0",
            "+",
            "(",
            "cid:88",
            ")",
            "j",
            "\u2212s+",
            "(",
            "cid:19",
            ")",
            "es\u2212",
            "i",
            "1",
            "n",
            "(",
            "cid:88",
            ")",
            "j",
            "Lj",
            "triplet",
            ".",
            "(",
            "1",
            ")",
            "The",
            "minimization",
            "of",
            "the",
            "contrastive",
            "loss",
            "function",
            "implies",
            "a",
            "smooth",
            "enhancement",
            "of",
            "proximity",
            "of",
            "positive",
            "pairs",
            "and",
            "of",
            "separation",
            "of",
            "negative",
            "pairs",
            ".",
            "2.3",
            ".",
            "A",
            "Variation",
            "on",
            "a",
            "Theme",
            ":",
            "A",
            "Jaccard-index",
            "Assess-",
            "ment",
            "2.3.1",
            ".",
            "Jaccard",
            "Similarity",
            "The",
            "Jaccard",
            "index",
            "[",
            "13",
            "]",
            ",",
            "commonly",
            "called",
            "the",
            "Jaccard",
            "simi-",
            "larity",
            "coef\ufb01cient",
            ",",
            "is",
            "a",
            "set-theoretic",
            "measure",
            "to",
            "generically",
            "evaluate",
            "similarity",
            "between",
            "two",
            "\ufb01nite",
            "sample",
            "sets",
            ".",
            "In",
            "gen-",
            "eral",
            ",",
            "the",
            "Jaccard",
            "similarity",
            "coef\ufb01cient",
            "is",
            "evaluated",
            "as",
            "a",
            "ra-",
            "tio",
            "of",
            "the",
            "intersection",
            "of",
            "two",
            "\ufb01nite",
            "sets",
            "A",
            "and",
            "B",
            "and",
            "their",
            "union",
            ",",
            "J",
            "(",
            "A",
            ",",
            "B",
            ")",
            "=",
            "|A\u2229B|",
            "|A\\B|+|B\\A|+|A\u2229B|",
            ".",
            "An",
            "alternative",
            "measure-inspired",
            "interpretation",
            "of",
            "the",
            "Jaccard",
            "in-",
            "dex",
            "may",
            "also",
            "be",
            "attained",
            ".",
            "Speci\ufb01cally",
            ",",
            "an",
            "information",
            "theo-",
            "retic/probabilistic",
            "interpretation",
            "unveils",
            "a",
            "measure-theoretic",
            "hence",
            "deeper",
            "comparison",
            "using",
            "a",
            "probability",
            "measure",
            "\u00b5",
            "on",
            "the",
            "measurable",
            "sample",
            "space",
            "S",
            ",",
            "yielding",
            "a",
            "similar",
            "coef\ufb01cient",
            "as",
            ",",
            "J\u00b5",
            "(",
            "A",
            ",",
            "B",
            ")",
            "=",
            "\u00b5",
            "(",
            "A\u2229B",
            ")",
            "\u00b5",
            "(",
            "A\u222aB",
            ")",
            ".",
            "|A\u222aB|",
            "=",
            "|A\u2229B|",
            "The",
            "use",
            "of",
            "measures",
            "(",
            "i.e.",
            ",",
            "a",
            "probabilistic",
            "model",
            "capturing",
            "all",
            "moments",
            ")",
            ",",
            "particularly",
            "points",
            "to",
            "the",
            "signi\ufb01cance",
            "of",
            "the",
            "information",
            "scoped",
            "out",
            "and",
            "beyond",
            "the",
            "linear",
            "(",
            "i.e.",
            ",",
            "second-",
            "order",
            "moment",
            ")",
            "typically",
            "invoked",
            "by",
            "a",
            "Cosine",
            "similarity",
            ".",
            "This",
            "is",
            "hence",
            "consistent",
            "with",
            "our",
            "goal",
            "of",
            "gleaning",
            "additional",
            "sec-",
            "ondary",
            "information",
            "beyond",
            "that",
            "normally",
            "sought",
            "in",
            "the",
            "latent",
            "space",
            "of",
            "the",
            "classes",
            ".",
            "The",
            "\ufb02exibility",
            "of",
            "the",
            "proposed",
            "Jaccard",
            "similarity",
            "measure",
            "accounts",
            "for",
            "the",
            "inherent",
            "nonlinear",
            "infor-",
            "mation",
            "moments",
            ",",
            "thus",
            "affording",
            "a",
            "more",
            "accurate",
            "assessment",
            "of",
            "non-linear",
            "features",
            "in",
            "the",
            "latent",
            "space",
            ".",
            "2.3.2",
            ".",
            "Proposed",
            "Contrastive",
            "Learning",
            "Model",
            "A",
            "hypothesis",
            "is",
            "a",
            "proposed",
            "explanation",
            "of",
            "an",
            "observed",
            "phenomenon",
            "[",
            "16",
            "]",
            ".",
            "Self-supervised",
            "contrastive",
            "learning",
            ",",
            "viewed",
            "as",
            "a",
            "guessing",
            "exercise",
            ",",
            "is",
            "the",
            "assessment",
            "result",
            "of",
            "randomly",
            "sampled",
            "data",
            "and",
            "its",
            "subsequent",
            "assignment",
            "to",
            "either",
            "a",
            "positive",
            "or",
            "negative",
            "class",
            ",",
            "each",
            "with",
            "an",
            "underlying",
            "distribution",
            ".",
            "As",
            "a",
            "result",
            ",",
            "a",
            "null",
            "hypothesis",
            "H0",
            "stating",
            "that",
            "two",
            "observations",
            "(",
            "i.e.",
            ",",
            "images",
            ")",
            "are",
            "from",
            "the",
            "same",
            "class",
            ",",
            "with",
            "a",
            "corresponding",
            "distri-",
            "butional",
            "score",
            "f\u03b8+",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            ".",
            "Similarly",
            ",",
            "an",
            "alternative",
            "hypothesis",
            "tion",
            "sets",
            "extracted",
            "by",
            "the",
            "\ufb01rst",
            "projector",
            "g\u03b81",
            "(",
            "\u00b7",
            ")",
            "for",
            "measuring",
            "the",
            "intersection",
            ",",
            "(",
            "cid:104",
            ")",
            "g\u03b81",
            "(",
            "q1",
            ")",
            ",",
            "g\u03b81",
            "(",
            "q2",
            ")",
            "(",
            "cid:105",
            ")",
            ",",
            "while",
            "the",
            "second",
            "projector",
            "is",
            "for",
            "measuring",
            "the",
            "dissimilarity",
            ",",
            "(",
            "cid:107",
            ")",
            "g\u03b82",
            "(",
            "q1",
            ")",
            "\u2212",
            "g\u03b82",
            "(",
            "q2",
            ")",
            "(",
            "cid:107",
            ")",
            "2",
            "2",
            ",",
            "when",
            "ultimately",
            "computing",
            "the",
            "Jaccard",
            "similarity",
            ".",
            "Claim",
            "1",
            ".",
            "The",
            "Jaccard",
            "index",
            ",",
            "acting",
            "on",
            "two",
            "hidden",
            "spaces",
            "to",
            "measure",
            "their",
            "similarity",
            "is",
            "equivalent",
            "to",
            "respectively",
            "maximiz-",
            "ing",
            "and",
            "minimizing",
            "the",
            "Jaccard",
            "similarity",
            "between",
            "positive",
            "and",
            "negative",
            "pairs",
            ".",
            "LJ\u2212T",
            "ri",
            "(",
            "a",
            ")",
            "=",
            "\u2212",
            "\u00b5",
            "(",
            "x",
            "\u2229",
            "x+",
            ")",
            "\u00b5",
            "(",
            "x",
            "\u222a",
            "x+",
            ")",
            "=",
            "s+",
            "s+",
            "+",
            "ds+",
            "\u2212",
            "(",
            "cid:12",
            ")",
            "(",
            "cid:12",
            ")",
            "(",
            "cid:12",
            ")",
            "(",
            "cid:12",
            ")",
            "\u03b8",
            ",",
            "\u03b81",
            ",",
            "\u03b82",
            "(",
            "2",
            ")",
            "+",
            "\u00b5",
            "(",
            "x",
            "\u2229",
            "x\u2212",
            "i",
            ")",
            "\u00b5",
            "(",
            "x",
            "\u222a",
            "x\u2212",
            "i",
            ")",
            "s\u2212",
            "i",
            "i",
            "+",
            "ds\u2212",
            "s\u2212",
            ".",
            "i",
            "=",
            "(",
            "cid:104",
            ")",
            "g\u03b81",
            "\u25e6",
            "f\u03b8",
            "(",
            "x",
            ")",
            ",",
            "g\u03b81",
            "\u25e6",
            "f\u03b8",
            "(",
            "x\u2212",
            "i",
            "i",
            ",",
            "\u03b8",
            ",",
            "\u03b81",
            ",",
            "\u03b82",
            ")",
            ",",
            "s+",
            "=",
            "(",
            "cid:104",
            ")",
            "g\u03b81",
            "\u25e6",
            "f\u03b8",
            "(",
            "x",
            ")",
            ",",
            "g\u03b81",
            "\u25e6",
            "i",
            ")",
            "(",
            "cid:105",
            ")",
            ",",
            "ds+",
            "=",
            "(",
            "cid:107",
            ")",
            "g\u03b82",
            "\u25e6",
            "i",
            "=",
            "(",
            "cid:107",
            ")",
            "g\u03b82",
            "\u25e6",
            "f\u03b8",
            "(",
            "x",
            ")",
            "\u2212",
            "g\u03b82",
            "\u25e6",
            "2",
            ",",
            "and",
            "ds\u2212",
            "where",
            "a",
            "=",
            "(",
            "x",
            ",",
            "x+",
            ",",
            "x\u2212",
            "f\u03b8",
            "(",
            "x+",
            ")",
            "(",
            "cid:105",
            ")",
            ",",
            "s\u2212",
            "f\u03b8",
            "(",
            "x",
            ")",
            "\u2212",
            "g\u03b82",
            "\u25e6",
            "f\u03b8",
            "(",
            "x+",
            ")",
            "(",
            "cid:107",
            ")",
            "2",
            "f\u03b8",
            "(",
            "x\u2212",
            "i",
            ")",
            "(",
            "cid:107",
            ")",
            "2",
            "2",
            ".",
            "In",
            "Eq",
            ".",
            "(",
            "1",
            ")",
            ",",
            "we",
            "prove",
            "that",
            "the",
            "contrastive",
            "loss",
            "is",
            "a",
            "smooth",
            "approximation",
            "to",
            "the",
            "triplet",
            "loss",
            ".",
            "Therefore",
            ",",
            "we",
            "can",
            "also",
            "apply",
            "the",
            "smoothness",
            "property",
            "of",
            "LogSumExp",
            "function",
            "to",
            "Jaccard-",
            "based",
            "triplet",
            "loss",
            ".",
            "Then",
            ",",
            "the",
            "smooth",
            "version",
            "of",
            "Jaccard-based",
            "contrastive",
            "loss",
            "is",
            "shown",
            "below",
            ",",
            "LJ\u2212T",
            "ri",
            "(",
            "a",
            ")",
            "=",
            "\u2212",
            "1",
            "N",
            "(",
            "cid:18",
            ")",
            "(",
            "cid:88",
            ")",
            "s+",
            "s+",
            "+",
            "ds+",
            "\u2212",
            "(",
            "cid:19",
            ")",
            "s\u2212",
            "i",
            "i",
            "+",
            "ds\u2212",
            "s\u2212",
            "i",
            "i",
            "(",
            "cid:18",
            ")",
            "\u2248",
            "\u2212log",
            "s+",
            "s++ds+",
            "e",
            "(",
            "3",
            ")",
            "(",
            "cid:19",
            ")",
            ".",
            "s+",
            "s++ds+",
            "+",
            "(",
            "cid:80",
            ")",
            "e",
            "s",
            "\u2212",
            "i",
            "i",
            "e",
            "s",
            "\u2212",
            "i",
            "+ds",
            "\u2212",
            "i",
            "To",
            "better",
            "achieve",
            "the",
            "intra/inter-class",
            "clustering",
            "in",
            "the",
            "hid-",
            "den",
            "spaces",
            ",",
            "we",
            "follow",
            "the",
            "conventional",
            "self-supervised",
            "learn-",
            "ing",
            "and",
            "calculate",
            "the",
            "contrastive",
            "loss",
            "among",
            "positive",
            "and",
            "neg-",
            "ative",
            "keys",
            "in",
            "each",
            "hidden",
            "space",
            ",",
            "respectively",
            ".",
            "Subsequently",
            "applying",
            "the",
            "Jaccard",
            "similarity",
            "to",
            "achieve",
            "the",
            "feature",
            "fusion",
            "between",
            "two",
            "hidden",
            "spaces",
            "(",
            "as",
            "noted",
            "with",
            "sensitivity",
            "to",
            "similar-",
            "ity",
            "and",
            "dissimilarity",
            ",",
            "respectively",
            ")",
            "yields",
            "the",
            "proposed",
            "model",
            "detailed",
            "next",
            ".",
            "As",
            "a",
            "result",
            "we",
            "postulate",
            "the",
            "following",
            ",",
            "Proposed",
            "self-supervision",
            "loss",
            ":",
            "(",
            "cid:18",
            ")",
            "e",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "1",
            ")",
            "k+",
            "(",
            "cid:105",
            ")",
            "/\u03c4",
            "(",
            "cid:19",
            ")",
            "q",
            ",",
            "h",
            "(",
            "1",
            ")",
            "k+",
            "(",
            "cid:105",
            ")",
            "/\u03c4",
            "+",
            "(",
            "cid:80",
            ")",
            "i",
            "e",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "1",
            ")",
            "\u2212",
            "i",
            "k",
            "(",
            "cid:105",
            ")",
            "/\u03c4",
            "e",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "e",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "2",
            ")",
            "q",
            ",",
            "h",
            "(",
            "2",
            ")",
            "k+",
            "(",
            "cid:105",
            ")",
            "/\u03c4",
            "(",
            "cid:19",
            ")",
            "q",
            ",",
            "h",
            "(",
            "2",
            ")",
            "e",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "2",
            ")",
            "k+",
            "(",
            "cid:105",
            ")",
            "/\u03c4",
            "+",
            "(",
            "cid:80",
            ")",
            "i",
            "e",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "2",
            ")",
            "q",
            ",",
            "h",
            "(",
            "1",
            ")",
            "\u2212",
            "i",
            "k",
            "(",
            "cid:105",
            ")",
            "/\u03c4",
            "LJ",
            "(",
            "a",
            ")",
            "=",
            "\u2212\u03b11log",
            "(",
            "cid:18",
            ")",
            "\u2212",
            "\u03b12log",
            "\u2212",
            "(",
            "1",
            "\u2212",
            "\u03b11",
            "\u2212",
            "\u03b12",
            ")",
            "\u00d7",
            "\uf8eb",
            "log",
            "\uf8ed",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "cid:105",
            ")",
            "(",
            "1",
            ")",
            "k+",
            "(",
            "2",
            ")",
            "q",
            "\u2212h",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "1",
            ")",
            "k+",
            "e",
            "(",
            "cid:105",
            ")",
            "+",
            "(",
            "cid:107",
            ")",
            "h",
            "/\u03c4",
            "(",
            "2",
            ")",
            "k+",
            "(",
            "cid:107",
            ")",
            "2",
            "2",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "cid:105",
            ")",
            "(",
            "1",
            ")",
            "k+",
            "(",
            "2",
            ")",
            "q",
            "\u2212h",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "1",
            ")",
            "k+",
            "e",
            "(",
            "cid:105",
            ")",
            "+",
            "(",
            "cid:107",
            ")",
            "h",
            "/\u03c4",
            "(",
            "2",
            ")",
            "k+",
            "(",
            "cid:107",
            ")",
            "2",
            "2",
            "+",
            "(",
            "cid:80",
            ")",
            "i",
            "e",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "1",
            ")",
            "\u2212",
            "i",
            "k",
            "(",
            "cid:105",
            ")",
            "+",
            "(",
            "cid:107",
            ")",
            "h",
            "(",
            "cid:104",
            ")",
            "h",
            "(",
            "1",
            ")",
            "q",
            ",",
            "h",
            "(",
            "cid:105",
            ")",
            "(",
            "1",
            ")",
            "\u2212",
            "k",
            "i",
            "(",
            "2",
            ")",
            "q",
            "\u2212h",
            "/\u03c4",
            "(",
            "cid:107",
            ")",
            "2",
            "2",
            "(",
            "2",
            ")",
            "\u2212",
            "i",
            "k",
            "\uf8f6",
            "\uf8f8",
            ",",
            "(",
            "4",
            ")",
            "Fig",
            ".",
            "1",
            ".",
            "An",
            "intuitive",
            "explanation",
            "of",
            "our",
            "model",
            ".",
            "H1",
            "is",
            "de\ufb01ned",
            "for",
            "two",
            "observations",
            "from",
            "different",
            "classes",
            ",",
            "with",
            "a",
            "corresponding",
            "score",
            "f\u03b8\u2212",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            ".",
            "With",
            "the",
            "inferential",
            "perspective",
            "in",
            "mind",
            "and",
            "the",
            "Jaccard",
            "similarity",
            "measure",
            "in",
            "hand",
            ",",
            "we",
            "propose",
            "to",
            "seek",
            "hidden",
            "repre-",
            "sentations",
            "as",
            "\ufb01nite",
            "information",
            "sets/distributions",
            "of",
            "original",
            "objects",
            ".",
            "As",
            "is",
            "typically",
            "interpreted",
            "with",
            "measures",
            "in",
            "proba-",
            "bilistic",
            "settings",
            ",",
            "intersections",
            "will",
            "account",
            "for",
            "similarity",
            ",",
            "while",
            "set",
            "differences",
            "re\ufb02ect",
            "dissimilarities",
            "(",
            "disparities",
            ")",
            "among",
            "the",
            "data",
            "samples",
            ".",
            "To",
            "that",
            "end",
            ",",
            "we",
            "introduce",
            "a",
            "bi-projector",
            "sys-",
            "tem",
            "model",
            "g\u03b8i",
            "(",
            "\u00b7",
            ")",
            ",",
            "i",
            "=",
            "1",
            ",",
            "2",
            ",",
            "with",
            "the",
            "\ufb01rst",
            "following",
            "H0",
            "(",
            "i.e.",
            ",",
            "that",
            "two",
            "objects",
            "are",
            "from",
            "the",
            "same",
            "class",
            "by",
            "measuring",
            "the",
            "intersection",
            "of",
            "extracted",
            "features",
            ")",
            ",",
            "while",
            "the",
            "other",
            "follow-",
            "ing",
            "H1",
            ".",
            "We",
            "can",
            "hence",
            "de\ufb01ne",
            "two",
            "hypotheses",
            "scoring",
            "func-",
            ":",
            "=",
            "f\u03b8+",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            "=",
            "s",
            "\u25e6",
            "g\u03b81",
            "\u25e6",
            "f\u03b8",
            ",",
            "and",
            "tions",
            ",",
            "f",
            "(",
            "x1",
            ",",
            "x2|H0",
            ",",
            "\u03b8",
            ")",
            "f",
            "(",
            "x1",
            ",",
            "x2|H1",
            ",",
            "\u03b8",
            ")",
            ":",
            "=",
            "f\u03b8\u2212",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            "=",
            "ds",
            "\u25e6",
            "g\u03b82",
            "\u25e6",
            "f\u03b8",
            ",",
            "respectively",
            ",",
            "where",
            "s",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            ",",
            "ds",
            "(",
            "\u00b7",
            ",",
            "\u00b7",
            ")",
            "is",
            "each",
            "respectively",
            ",",
            "a",
            "similarity",
            "and",
            "dis-",
            "similarity",
            "measure",
            ".",
            "Fig",
            ".",
            "1",
            "provides",
            "a",
            "high-level",
            "and",
            "intuitive",
            "description",
            "of",
            "the",
            "proposed",
            "rationale",
            ".",
            "The",
            "latent",
            "representa-",
            "tions",
            "of",
            "the",
            "original",
            "data",
            "lying",
            "on",
            "an",
            "unknown",
            "curved",
            "man-",
            "ifold",
            ",",
            "make",
            "it",
            "unreasonable",
            "and",
            "possibly",
            "detrimental",
            "to",
            "the",
            "training/learning",
            ",",
            "to",
            "be",
            "using",
            "Euclidean-based",
            "similarity",
            "met-",
            "rics",
            ".",
            "The",
            "key",
            "idea",
            "is",
            "to",
            "then",
            "learn",
            "a",
            "homeomorphism",
            "g\u03b8",
            "(",
            "\u00b7",
            ")",
            "that",
            "projects",
            "the",
            "latent",
            "space",
            "information",
            "onto",
            "a",
            "set",
            "of",
            "Euclidean",
            "spaces",
            ",",
            "where",
            "a",
            "similarity",
            "can",
            "be",
            "measured",
            "by",
            "L2-norm",
            ",",
            "and",
            "consistently",
            "integrate",
            "the",
            "extracted",
            "information",
            ".",
            "In",
            "our",
            "case",
            ",",
            "we",
            "hence",
            "seek",
            "two",
            "distinct",
            "projectors",
            "which",
            "directly",
            "contribute",
            "to",
            "the",
            "computation",
            "of",
            "the",
            "Jaccard",
            "similarity",
            "which",
            "is",
            "in",
            "turn",
            ",",
            "used",
            "to",
            "optimize",
            "the",
            "encoder",
            ".",
            "A",
            "carefully",
            "designed",
            "combi-",
            "nation",
            "of",
            "the",
            "information",
            "extracted",
            "by",
            "the",
            "two",
            "projectors",
            "as",
            "described",
            "next",
            ",",
            "will",
            "yield",
            "a",
            "Jaccard",
            "similarity",
            ".",
            "2.3.3",
            ".",
            "Proposed",
            "Algorithmic",
            "Solution",
            "This",
            "Jaccard-based",
            "similarity/loss",
            "provides",
            "a",
            "non-linear",
            "combi-",
            "nation",
            "(",
            "fusion",
            ")",
            "of",
            "features",
            "thereby",
            "avoiding",
            "asymmetry",
            "in",
            "the",
            "training",
            ".",
            "Different",
            "measurement",
            "focus",
            "also",
            "prevent",
            "the",
            "two",
            "pro-",
            "jectors",
            "from",
            "collapsing",
            "into",
            "one",
            "single",
            "point",
            ".",
            "To",
            "proceed",
            "with",
            "the",
            "detailed",
            "development",
            "of",
            "the",
            "Jaccard",
            "index-based",
            "model",
            ",",
            "we",
            "\ufb01rst",
            "note",
            "that",
            "the",
            "similarity/dissimilarity",
            "are",
            "Euclidean-based",
            "(",
            "i.e.",
            ",",
            "ds",
            "(",
            "x",
            ",",
            "y",
            ")",
            "=",
            "(",
            "cid:107",
            ")",
            "x",
            "\u2212",
            "y",
            "(",
            "cid:107",
            ")",
            "2",
            ")",
            ",",
            "where",
            "x",
            ",",
            "y",
            "are",
            "normalized",
            "in",
            "the",
            "hidden",
            "space",
            ".",
            "Speci\ufb01cally",
            ",",
            "for",
            "given",
            "latent",
            "representations",
            "of",
            "two",
            "images",
            "q1",
            "and",
            "q2",
            ",",
            "we",
            "only",
            "consider",
            "the",
            "two",
            "\ufb01nite",
            "informa-",
            "where",
            "h",
            "(",
            "j",
            ")",
            "q",
            "h",
            "(",
            "j",
            ")",
            "k\u2212",
            "i",
            "=",
            "g\u03b8j",
            "\u25e6",
            "f\u03b8",
            "(",
            "x",
            ")",
            ",",
            "h",
            "(",
            "j",
            ")",
            "i",
            ")",
            ",",
            "j",
            "=",
            "1",
            ",",
            "2",
            ".",
            "=",
            "g\u03b8j",
            "\u25e6",
            "f\u03b8",
            "(",
            "x\u2212",
            "k+",
            "=",
            "g\u03b8j",
            "\u25e6",
            "f\u03b8",
            "(",
            "x+",
            ")",
            ",",
            "and",
            "3",
            ".",
            "EXPERIMENTAL",
            "RESULTS",
            "In",
            "this",
            "section",
            ",",
            "we",
            "demonstrate",
            "the",
            "compatibility",
            ",",
            "ef\ufb01ciency",
            ",",
            "and",
            "accuracy",
            "of",
            "the",
            "Jaccard-similarity-based",
            "model",
            ".",
            "We",
            "con-",
            "sider",
            "SimCLR",
            "[",
            "1",
            "]",
            "and",
            "MoCo",
            "[",
            "2",
            "]",
            "as",
            "the",
            "benchmarks",
            "and",
            "test",
            "the",
            "models",
            "\u2019",
            "performance",
            "on",
            "CIFAR-10/100",
            "[",
            "17",
            "]",
            "and",
            "Tiny-",
            "imagenet-200",
            "[",
            "18",
            "]",
            ".",
            "Due",
            "to",
            "our",
            "limited",
            "GPU",
            "resources",
            ",",
            "we",
            "can",
            "not",
            "run",
            "full-scale",
            "experiments",
            "on",
            "the",
            "ImageNet-1k",
            ".",
            "In",
            "the",
            "SSL",
            "training",
            "stage",
            ",",
            "we",
            "use",
            "ResNet-50",
            "[",
            "19",
            "]",
            "as",
            "the",
            "backbone",
            "network",
            "for",
            "all",
            "models",
            ".",
            "All",
            "neural",
            "networks",
            "are",
            "trained",
            "with",
            "a",
            "batch",
            "size",
            "of",
            "512",
            "for",
            "500",
            "epochs",
            "on",
            "both",
            "CIFAR-",
            "10",
            "and",
            "CIFAR-100",
            "datasets",
            "and",
            "a",
            "batch",
            "size",
            "of",
            "256",
            "on",
            "the",
            "Tiny-Imagenet",
            "dataset",
            ".",
            "All",
            "models",
            "apply",
            "the",
            "same",
            "set",
            "of",
            "aug-",
            "mentation",
            "methods",
            "as",
            "SimCLR",
            ",",
            "and",
            "a",
            "constant",
            "learning",
            "rate",
            "10\u22123",
            ".",
            "We",
            "\ufb01x",
            "the",
            "encoder",
            "after",
            "each",
            "training",
            "epoch",
            "and",
            "apply",
            "the",
            "k-NN",
            "classi\ufb01cation",
            "method",
            "to",
            "verify",
            "the",
            "encoder",
            "\u2019",
            "s",
            "perfor-",
            "mance",
            "during",
            "the",
            "training",
            ".",
            "Different",
            "temperature",
            "parameters",
            "(",
            "\u03c4",
            ")",
            "are",
            "chosen",
            "for",
            "training",
            ",",
            "and",
            "we",
            "choose",
            "the",
            "best",
            "encoder",
            "\u2019",
            "s",
            "performance",
            "as",
            "the",
            "model",
            "\u2019",
            "s",
            "\ufb01nal",
            "result",
            ".",
            "We",
            "have",
            "reproduced",
            "the",
            "results",
            "of",
            "the",
            "two",
            "benchmarks",
            ".",
            "We",
            "show",
            "in",
            "Table",
            "1",
            "the",
            "complexity",
            ",",
            "i.e.",
            ",",
            "the",
            "running",
            "time",
            ",",
            "of",
            "our",
            "model",
            "compared",
            "with",
            "SimCLR",
            ".",
            "The",
            "training",
            "time",
            "of",
            "one",
            "epoch",
            "is",
            "recorded",
            "on",
            "one",
            "NVIDIA",
            "Tesla",
            "V100",
            "GPU",
            "for",
            "all",
            "models",
            ".",
            "Only",
            "one",
            "additional",
            "projector",
            ",",
            "a",
            "2-layer",
            "fully",
            "connected",
            "neural",
            "network",
            ",",
            "is",
            "added",
            "to",
            "our",
            "model",
            ",",
            "and",
            "the",
            "loss",
            "is",
            "computed",
            "in",
            "matrix",
            "format",
            ".",
            "The",
            "recording",
            "time",
            "shows",
            "our",
            "model",
            "takes",
            "1.1",
            "times",
            "of",
            "SimCLR",
            "running",
            "time",
            "in",
            "CIFAR",
            "datasets",
            "and",
            "1.01",
            "times",
            "of",
            "it",
            "in",
            "the",
            "Tiny-Imagenet-200",
            "dataset",
            ".",
            "Fig.2",
            "shows",
            "the",
            "encoders",
            "\u2019",
            "performance",
            "curves",
            "of",
            "SimCLR",
            "and",
            "our",
            "model",
            "based",
            "on",
            "the",
            "k-NN",
            "method",
            "w.r.t",
            "the",
            "training",
            "epoch",
            ".",
            "We",
            "can",
            "observe",
            "that",
            "our",
            "model",
            "\u2019",
            "s",
            "encoder",
            "demonstrates",
            "quite",
            "a",
            "convincing",
            "learning",
            "speed",
            "compared",
            "with",
            "the",
            "conventional",
            "model",
            "with",
            "the",
            "same",
            "learning",
            "rate",
            "setup",
            ".",
            "Dataset",
            "SimCLR",
            "Our",
            "model",
            "CIFAR",
            "1m36s/epoch",
            "1m47s/epoch",
            "Tiny-Imagenet-200",
            "13m51s/epoch",
            "14m01s/epoch",
            "Table",
            "1",
            ".",
            "Running",
            "time",
            ".",
            "Table",
            "2",
            "shows",
            "the",
            "linear",
            "evaluation",
            "results",
            "\u2019",
            "comparison",
            "on",
            "different",
            "datasets",
            "between",
            "conventional",
            "self-supervised",
            "learn-",
            "ing",
            "models",
            "and",
            "our",
            "modi\ufb01ed",
            "models",
            ".",
            "Note",
            "that",
            "compared",
            "with",
            "the",
            "conventional",
            "contrastive",
            "learning",
            "model",
            ",",
            "the",
            "complexity",
            "of",
            "the",
            "whole",
            "system",
            "is",
            "rarely",
            "increased",
            ",",
            "and",
            "the",
            "main",
            "difference",
            "is",
            "based",
            "on",
            "the",
            "similarity",
            "metric",
            ".",
            "The",
            "results",
            "show",
            "that",
            "our",
            "proposal",
            "of",
            "considering",
            "a",
            "non-linear",
            "metric",
            "helps",
            "improve",
            "the",
            "accuracy",
            "in",
            "most",
            "comparable",
            "experiments",
            ".",
            "The",
            "more",
            "complex",
            "the",
            "data",
            "is",
            ",",
            "the",
            "more",
            "improvement",
            "is",
            "achieved",
            ",",
            "con\ufb01rming",
            "that",
            "the",
            "non-linear",
            "impart",
            "is",
            "more",
            "pronounced",
            ".",
            "These",
            "observations",
            "re\ufb02ect",
            "the",
            "fact",
            "that",
            "latent",
            "representations",
            "of",
            "a",
            "complex",
            "dataset",
            "Fig",
            ".",
            "2.",
            "k-NN",
            "accuracy",
            "lie",
            "on",
            "non-linear",
            "manifold",
            ",",
            "where",
            "the",
            "linear",
            "metric",
            "may",
            "lead",
            "to",
            "imprecise",
            "estimation",
            ".",
            "Overall",
            ",",
            "the",
            "encoder",
            "based",
            "on",
            "SimCLR",
            "setup",
            "with",
            "our",
            "proposed",
            "model",
            "obtains",
            "the",
            "best",
            "performance",
            "in",
            "all",
            "datasets",
            ".",
            "Top-1",
            "Accuracy",
            "(",
            "%",
            ")",
            "Dataset",
            "Model",
            "Method",
            "CIFAR",
            "CIFAR",
            "SimCLR",
            "SimCLR",
            "+",
            "our",
            "model",
            "MoCo",
            "MoCo",
            "+",
            "our",
            "model",
            "k-NN",
            "linear",
            "k-NN",
            "linear",
            "k-NN",
            "linear",
            "k-NN",
            "linear",
            "10",
            "88.6",
            "91.5",
            "88.6",
            "91.8",
            "85.5",
            "90.5",
            "85.1",
            "90.2",
            "Tiny",
            "ImageNet",
            "35.9",
            "50.7",
            "39.5",
            "53.8",
            "33.5",
            "49.6",
            "35.4",
            "51.2",
            "100",
            "62.1",
            "68.6",
            "63.9",
            "69.5",
            "56.8",
            "66.8",
            "59.2",
            "67.5",
            "Table",
            "2",
            ".",
            "Linear",
            "evaluation",
            "results",
            ".",
            "4",
            ".",
            "CONCLUSIONS",
            "This",
            "paper",
            "explains",
            "the",
            "contrastive",
            "loss",
            "from",
            "a",
            "hypothesis-",
            "testing",
            "point",
            "of",
            "view",
            "by",
            "distinguishing",
            "whether",
            "a",
            "pair",
            "of",
            "im-",
            "ages",
            "is",
            "from",
            "the",
            "same",
            "category",
            ".",
            "We",
            "subsequently",
            "introduce",
            "a",
            "bi-projector",
            "model",
            "and",
            "a",
            "Jaccard-similarity-based",
            "loss",
            "to",
            "fuse",
            "the",
            "information",
            "extracted",
            "by",
            "the",
            "two",
            "projectors",
            ".",
            "In",
            "the",
            "ex-",
            "periments",
            ",",
            "we",
            "demonstrate",
            "the",
            "compatibility",
            "of",
            "our",
            "model",
            "by",
            "applying",
            "it",
            "as",
            "a",
            "plug-in",
            "unit",
            "to",
            "the",
            "state-of-art",
            "approaches",
            ".",
            "We",
            "also",
            "show",
            "that",
            "our",
            "model",
            "outperforms",
            "state-of-art",
            "contrastive",
            "SSL",
            "methods",
            ".",
            "The",
            "accuracy",
            "improvement",
            "is",
            "more",
            "pronounced",
            "for",
            "more",
            "complex",
            "datasets",
            "proving",
            "that",
            "the",
            "similarity",
            "measure",
            "should",
            "account",
            "for",
            "non-linearity",
            "on",
            "the",
            "latent",
            "space",
            ".",
            "Future",
            "research",
            "can",
            "consider",
            "model",
            "transport",
            "between",
            "the",
            "samples",
            ",",
            "to",
            "provide",
            "better",
            "insight",
            "on",
            "their",
            "behavior",
            "on",
            "the",
            "manifold",
            ".",
            "[",
            "11",
            "]",
            "Ting",
            "Chen",
            ",",
            "Simon",
            "Kornblith",
            ",",
            "Kevin",
            "Swersky",
            ",",
            "Moham-",
            "mad",
            "Norouzi",
            ",",
            "and",
            "Geoffrey",
            "Hinton",
            ".",
            "Big",
            "self-supervised",
            "arXiv",
            "models",
            "are",
            "strong",
            "semi-supervised",
            "learners",
            ".",
            "preprint",
            "arXiv:2006.10029",
            ",",
            "2020",
            ".",
            "[",
            "12",
            "]",
            "Ching-Yao",
            "Chuang",
            ",",
            "Joshua",
            "Robinson",
            ",",
            "Lin",
            "Yen-Chen",
            ",",
            "Antonio",
            "Torralba",
            ",",
            "and",
            "Stefanie",
            "Jegelka",
            ".",
            "Debiased",
            "con-",
            "trastive",
            "learning",
            ".",
            "arXiv",
            "preprint",
            "arXiv:2007.00224",
            ",",
            "2020",
            ".",
            "[",
            "13",
            "]",
            "Paul",
            "Jaccard",
            ".",
            "The",
            "distribution",
            "of",
            "the",
            "\ufb02ora",
            "in",
            "the",
            "alpine",
            "zone",
            ".",
            "1",
            ".",
            "New",
            "phytologist",
            ",",
            "11",
            "(",
            "2",
            ")",
            ":37\u201350",
            ",",
            "1912",
            ".",
            "[",
            "14",
            "]",
            "Florian",
            "Schroff",
            ",",
            "Dmitry",
            "Kalenichenko",
            ",",
            "and",
            "James",
            "Philbin",
            ".",
            "Facenet",
            ":",
            "A",
            "uni\ufb01ed",
            "embedding",
            "for",
            "face",
            "recogni-",
            "tion",
            "and",
            "clustering",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "IEEE",
            "confer-",
            "ence",
            "on",
            "computer",
            "vision",
            "and",
            "pattern",
            "recognition",
            ",",
            "pages",
            "815\u2013823",
            ",",
            "2015",
            ".",
            "[",
            "15",
            "]",
            "Raia",
            "Hadsell",
            ",",
            "Sumit",
            "Chopra",
            ",",
            "and",
            "Yann",
            "LeCun",
            ".",
            "Dimen-",
            "sionality",
            "reduction",
            "by",
            "learning",
            "an",
            "invariant",
            "mapping",
            ".",
            "In",
            "2006",
            "IEEE",
            "Computer",
            "Society",
            "Conference",
            "on",
            "Computer",
            "Vision",
            "and",
            "Pattern",
            "Recognition",
            "(",
            "CVPR",
            "\u2019",
            "06",
            ")",
            ",",
            "volume",
            "2",
            ",",
            "pages",
            "1735\u20131742",
            ".",
            "IEEE",
            ",",
            "2006",
            ".",
            "[",
            "16",
            "]",
            "Erich",
            "L",
            "Lehmann",
            "and",
            "Joseph",
            "P",
            "Romano",
            ".",
            "Testing",
            "statis-",
            "tical",
            "hypotheses",
            ".",
            "Springer",
            "Science",
            "&",
            "Business",
            "Media",
            ",",
            "2006",
            ".",
            "[",
            "17",
            "]",
            "Alex",
            "Krizhevsky",
            ",",
            "Geoffrey",
            "Hinton",
            ",",
            "et",
            "al",
            ".",
            "Learning",
            "multi-",
            "ple",
            "layers",
            "of",
            "features",
            "from",
            "tiny",
            "images",
            ".",
            "2009",
            ".",
            "[",
            "18",
            "]",
            "Ya",
            "Le",
            "and",
            "Xuan",
            "Yang",
            ".",
            "Tiny",
            "imagenet",
            "visual",
            "recognition",
            "challenge",
            ".",
            "CS",
            "231N",
            ",",
            "7:7",
            ",",
            "2015",
            ".",
            "[",
            "19",
            "]",
            "Kaiming",
            "He",
            ",",
            "Xiangyu",
            "Zhang",
            ",",
            "Shaoqing",
            "Ren",
            ",",
            "and",
            "Jian",
            "Sun",
            ".",
            "Deep",
            "residual",
            "learning",
            "for",
            "image",
            "recognition",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "IEEE",
            "conference",
            "on",
            "computer",
            "vision",
            "and",
            "pattern",
            "recognition",
            ",",
            "pages",
            "770\u2013778",
            ",",
            "2016",
            ".",
            "5",
            ".",
            "REFERENCES",
            "[",
            "1",
            "]",
            "Ting",
            "Chen",
            ",",
            "Simon",
            "Kornblith",
            ",",
            "Mohammad",
            "Norouzi",
            ",",
            "and",
            "Geoffrey",
            "Hinton",
            ".",
            "A",
            "simple",
            "framework",
            "for",
            "contrastive",
            "learning",
            "of",
            "visual",
            "representations",
            ".",
            "In",
            "International",
            "con-",
            "ference",
            "on",
            "machine",
            "learning",
            ",",
            "pages",
            "1597\u20131607",
            ".",
            "PMLR",
            ",",
            "2020",
            ".",
            "[",
            "2",
            "]",
            "Kaiming",
            "He",
            ",",
            "Haoqi",
            "Fan",
            ",",
            "Yuxin",
            "Wu",
            ",",
            "Saining",
            "Xie",
            ",",
            "and",
            "Ross",
            "Girshick",
            ".",
            "Momentum",
            "contrast",
            "for",
            "unsupervised",
            "In",
            "Proceedings",
            "of",
            "the",
            "visual",
            "representation",
            "learning",
            ".",
            "IEEE/CVF",
            "Conference",
            "on",
            "Computer",
            "Vision",
            "and",
            "Pattern",
            "Recognition",
            ",",
            "pages",
            "9729\u20139738",
            ",",
            "2020",
            ".",
            "[",
            "3",
            "]",
            "Carl",
            "Doersch",
            ",",
            "Abhinav",
            "Gupta",
            ",",
            "and",
            "Alexei",
            "A",
            "Efros",
            ".",
            "Unsu-",
            "pervised",
            "visual",
            "representation",
            "learning",
            "by",
            "context",
            "predic-",
            "tion",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "IEEE",
            "international",
            "conference",
            "on",
            "computer",
            "vision",
            ",",
            "pages",
            "1422\u20131430",
            ",",
            "2015",
            ".",
            "[",
            "4",
            "]",
            "Simon",
            "Jenni",
            "and",
            "Paolo",
            "Favaro",
            ".",
            "Self-supervised",
            "feature",
            "learning",
            "by",
            "learning",
            "to",
            "spot",
            "artifacts",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "IEEE",
            "Conference",
            "on",
            "Computer",
            "Vision",
            "and",
            "Pattern",
            "Recognition",
            ",",
            "pages",
            "2733\u20132742",
            ",",
            "2018",
            ".",
            "[",
            "5",
            "]",
            "Dahun",
            "Kim",
            ",",
            "Donghyeon",
            "Cho",
            ",",
            "Donggeun",
            "Yoo",
            ",",
            "and",
            "In",
            "So",
            "Kweon",
            ".",
            "Learning",
            "image",
            "representations",
            "by",
            "completing",
            "damaged",
            "jigsaw",
            "puzzles",
            ".",
            "In",
            "2018",
            "IEEE",
            "Winter",
            "Confer-",
            "ence",
            "on",
            "Applications",
            "of",
            "Computer",
            "Vision",
            "(",
            "WACV",
            ")",
            ",",
            "pages",
            "793\u2013802",
            ".",
            "IEEE",
            ",",
            "2018",
            ".",
            "[",
            "6",
            "]",
            "Sumit",
            "Chopra",
            ",",
            "Raia",
            "Hadsell",
            ",",
            "and",
            "Yann",
            "LeCun",
            ".",
            "Learn-",
            "ing",
            "a",
            "similarity",
            "metric",
            "discriminatively",
            ",",
            "with",
            "application",
            "In",
            "2005",
            "IEEE",
            "Computer",
            "Society",
            "to",
            "face",
            "veri\ufb01cation",
            ".",
            "Conference",
            "on",
            "Computer",
            "Vision",
            "and",
            "Pattern",
            "Recognition",
            "(",
            "CVPR",
            "\u2019",
            "05",
            ")",
            ",",
            "volume",
            "1",
            ",",
            "pages",
            "539\u2013546",
            ".",
            "IEEE",
            ",",
            "2005",
            ".",
            "[",
            "7",
            "]",
            "A",
            "Ben",
            "Hamza",
            ".",
            "Jensen-rhyi",
            "divergence",
            "measure",
            ":",
            "Theoret-",
            "ical",
            "and",
            "computational",
            "perspectives",
            ".",
            "In",
            "IEEE",
            "Int",
            ".",
            "Symp",
            ".",
            "Inf",
            ".",
            "Theory",
            ",",
            "2003",
            ".",
            "[",
            "8",
            "]",
            "Xinlei",
            "Chen",
            "and",
            "Kaiming",
            "He",
            ".",
            "Exploring",
            "simple",
            "siamese",
            "representation",
            "learning",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "IEEE/CVF",
            "Conference",
            "on",
            "Computer",
            "Vision",
            "and",
            "Pattern",
            "Recognition",
            ",",
            "pages",
            "15750\u201315758",
            ",",
            "2021",
            ".",
            "[",
            "9",
            "]",
            "Jean-Bastien",
            "Grill",
            ",",
            "Florian",
            "Strub",
            ",",
            "Florent",
            "Altch\u00e9",
            ",",
            "Corentin",
            "Tallec",
            ",",
            "Pierre",
            "H",
            "Richemond",
            ",",
            "Elena",
            "Buchatskaya",
            ",",
            "Carl",
            "Doersch",
            ",",
            "Bernardo",
            "Avila",
            "Pires",
            ",",
            "Zhaohan",
            "Daniel",
            "Guo",
            ",",
            "Mohammad",
            "Gheshlaghi",
            "Azar",
            ",",
            "et",
            "al",
            ".",
            "Bootstrap",
            "your",
            "own",
            "latent",
            ":",
            "A",
            "new",
            "approach",
            "to",
            "self-",
            "supervised",
            "learning",
            ".",
            "arXiv",
            "preprint",
            "arXiv:2006.07733",
            ",",
            "2020",
            ".",
            "[",
            "10",
            "]",
            "Yuandong",
            "Tian",
            ",",
            "Xinlei",
            "Chen",
            ",",
            "and",
            "Surya",
            "Ganguli",
            ".",
            "Under-",
            "standing",
            "self-supervised",
            "learning",
            "dynamics",
            "without",
            "con-",
            "trastive",
            "pairs",
            ".",
            "arXiv",
            "preprint",
            "arXiv:2102.06810",
            ",",
            "2021",
            "."
        ]
    },
    {
        "name": "example2",
        "sentences": [
            "Embarrassingly Simple Performance Prediction forAbductive Natural Language InferenceEm\u00af\u0131ls Kadik, is, Vaibhav Srivastav, and Roman KlingerInstitut f\u00fcr Maschinelle SprachverarbeitungUniversity of StuttgartPfaffenwaldring 5b, 70569 Stuttgart{emils.kadikis,vaibhav.srivastav,klinger@ims.uni-stuttgart.de}AbstractThe task of abductive natural language infer-ence (\u03b1NLI), to decide which hypothesis isthe more likely explanation for a set of obser-vations, is a particularly dif\ufb01cult type of NLI.Instead of just determining a causal relation-ship, it requires common sense to also eval-uate how reasonable an explanation is.",
            "Allrecent competitive systems build on top ofcontextualized representations and make useof transformer architectures for learning anNLI model.",
            "When somebody is faced witha particular NLI task,they need to selectthe best model that is available.",
            "This is atime-consuming and resource-intense endeav-our.",
            "To solve this practical problem, we pro-pose a simple method for predicting the perfor-mance without actually \ufb01ne-tuning the model.We do this by testing how well the pre-trainedmodels perform on the \u03b1NLI task when justcomparing sentence embeddings with cosineissimilarity to whatachieved when training a classi\ufb01er on top ofthese embeddings.",
            "We show that the accu-racy of the cosine similarity approach corre-lates strongly with the accuracy of the classi-\ufb01cation approach with a Pearson correlationcoef\ufb01cient of 0.65.",
            "Since the similarity com-putation is orders of magnitude faster to com-pute on a given dataset (less than a minute vs.hours), our method can lead to signi\ufb01cant timesavings in the process of model selection.the performance that1IntroductionAbduction is a type of reasoning that infers an ex-planation for some observations (Peirce, 1931).",
            "Itis a particularly challenging type of inference; asopposed to deduction and induction, which derivethe conclusion from only the information presentin the observations, abduction requires making as-sumptions about an implicit context beyond just thegiven observations.",
            "Abductive reasoning is there-fore at the core of the way humans understand theworld and how world knowledge is involved.Abductive reasoning in the natural language do-main has been introduced by Bhagavatula et al.",
            "(2020) who de\ufb01ned the abductive natural languageinference (\u03b1NLI) task.",
            "In it, we are given foursentences \u2013 two observations o1 and o2 and twohypotheses h1 and h2, where we know that the se-quence of events was o1 \u2192 (h1|h2) \u2192 o2.",
            "Thetask then is to decide which of the two hypothesesis the more plausible one.An example from Bhagavatula et al.",
            "(2020) isthe following:o1 : It was lunchtime and Kat was hungry.o2 : Kat and her coworkers enjoyed a nice lunchoutside.h1 : Kat went to get a salad.h2 : Kat decided to take a nap instead of eating.While it is not inconceivable that someone woulddecide to take a nap on their lunch break (h2), giveno2 the \ufb01rst hypothesis becomes more likely.Currently,architecturestransformer-based(Vaswani et al., 2017) are state of the art in a widevariety of natural language processing (NLP) tasks(Devlin et al., 2019; He et al., 2021; Li et al., 2021),including \u03b1NLI.",
            "However, with an ever-changinglandscape of transformer models and pre-trainingtechniques (with over 100001 different \ufb01ne-tunedmodels available on the HuggingFace hub (Wolfet al., 2020)), \ufb01nding the best model for a giventask has become a time-consuming process since,in order to compare multiple models, they eachneed to be separately \ufb01ne-tuned on the task.This model selection process might lead to aprohibitive runtime, which has led to research onperformance prediction, namely to predict the ex-pected performance out of parameters of the modelcon\ufb01guration, without actually training the model.This procedure has been evaluated for a set of NLPtasks, including span prediction (Papay et al., 2020)and language modelling (Chen, 2009).",
            "However,1https://huggingface.co/models2202 beF 12  ]LC.sc[  1v80401.2022:viXra\fwe are not aware of any previous work that per-formed performance prediction for \u03b1NLI.In this paper, we introduce a fast performanceprediction method for the \u03b1NLI task that allowsa more guided way of choosing which models to\ufb01ne-tune.",
            "We use various pre-trained transformermodels to embed the observations and hypothe-ses with the approach introduced in Reimers andGurevych (2019), then compare which hypothesisis closer to the observations with cosine similar-ity.",
            "We \ufb01nd that the performance of the similarity-based approach is correlated to results obtainedvia \ufb01ne-tuning.",
            "Therefore, the similarity-basedapproach can serve as a performance predictionmethod.2 Related workThere are three research topics that need to be men-tioned.",
            "Approaches to abductive reasoning, pre-trained language models, and performance predic-tion.",
            "In this section, we explore them in detail.language inference.",
            "NLIAbductive naturalhas been proposed as the task of recognizing textualentailment by MacCartney and Manning (2008)and now constitutes a major challenge in NLPwhich has found application for other downstreamtasks, including question answering or zero-shotclassi\ufb01cation (Yin et al., 2019; Mishra et al., 2020).Based on the initial goal of establishing inferencerelations between two short texts, a myriad of vari-ants have been proposed (Yin et al., 2021; Williamset al., 2018; Bowman et al., 2015).",
            "One such vari-ant is abductive NLI (\u03b1NLI, Bhagavatula et al.,2020).Transformer-based architectures dominate the\u03b1NLI leaderboard,2 including RoBERTa-basedmodels (Liu et al., 2020; Mitra et al., 2020) whichexplore how additional knowledge can improve per-formance on reasoning tasks, and Zhu et al.",
            "(2020)who approach \u03b1NLI as a ranking task.",
            "The taskauthors improved upon their result in Lourie et al.",
            "(2021) by using a T5 model (Raffel et al., 2020) andexperimenting with multi-task training and \ufb01ne-tuning over multiple reasoning tasks.",
            "Both themulti-task criteria and the Text-to-Text frameworkof T5 help the model generalize and understand thecontext better.The second-best model on the leaderboard is aDeBERTa model (He et al., 2021).",
            "The model re-2https://leaderboard.allenai.org/anli/submissions/publicplaces the masked language modelling task with areplaced-token detection task.",
            "It also uses a disen-tangled attention mechanism to encode the positionand content information.The current state of the art shows an accuracyof 91.18% using a new uni\ufb01ed-modal pre-trainingmethod to leverage multi-modal data for single-modal tasks (Li et al., 2021).",
            "This result approachesthe human baseline of 92.9%.Pre-trained language models.",
            "The \u03b1NLI taskrequires the model to successfully \u201cunderstand\u201d thecontext of both the observations and use that un-derstanding to identify the more likely hypothe-sis entailing it.",
            "Most semantic representations inpractical applications rely on distributional seman-tics.",
            "Such methods include the word-level embed-ding methods Word2Vec (Mikolov et al., 2013)and GloVe (Pennington et al., 2014) and languagemodel-based word representation like ELMo (Pe-ters et al., 2018), ULMFit (Howard and Ruder,2018), and GPT (Radford et al., 2018).The current state of the art are pre-trained trans-former architectures (Vaswani et al., 2017) likeBERT (Devlin et al., 2019), which use a maskedlanguage modelling and next sentence predictionobjective.",
            "This not only helps the model under-stand the context within a sentence but also in-between consecutive sentences.",
            "There is however atrade-off in terms of the time it takes to train trans-former models.",
            "For example, a from-scratch train-ing of BERT takes 6.4 days on an 8 GPU NvidiaV100 server3.",
            "Devlin et al.",
            "(2019) recommend \ufb01ne-tuning the language model between 2-4 epochs fora given task.",
            "However, in practice, multiple trialsare required to \ufb01nd the optimal hyperparameters.These long training times and multiple \ufb01ne-tuningruns make model selection a time-intensive process(Liu and Wang, 2021).Performance prediction.",
            "The task of perfor-mance prediction is to estimate the performance ofa speci\ufb01c system without explicitly running it.",
            "Ithelps in setting hyperparameters, \ufb01nding featuresets, or identifying candidate language models fora downstream NLP task.",
            "Chen (2009) develop,for instance, a generalized method for predictingthe performance of exponential language models.They analyze the backoff features in an exponen-tial n-gram model.",
            "Papay et al.",
            "(2020) leverage3https://aws.amazon.com/blogs/machine-learning/amazon-web-services-achieves-fastest-training-times-for-bert-and-mask-r-cnn/\fmeta-learning to identify candidate model perfor-mance on the task of span identi\ufb01cation.",
            "They traina linear regressor as a meta-model to predict spanID performance based on model features and taskmetrics for an unseen task.",
            "Ye et al.",
            "(2021) pro-pose performance prediction methods particularlysuited for \ufb01ne-grained evaluation metrics.",
            "Theyalso develop methods for estimating the reliabil-ity of these performance predictions.",
            "Contrary tothe previously mentioned papers, Xia et al.",
            "(2020)build regression models to predict the performanceacross a variety of NLP tasks, however, they do notconsider NLI as one of them.In contrast to our work, all these previous meth-ods build on top of the idea to train a surrogatemodel for performance prediction and depend onthe information about past runs of these models.Our approach focuses solely on the embeddingsprovided by the language model and leveragesthose as a predictor of performance.",
            "This particularsetup is also motivated by the \u03b1NLI task itself, inwhich a sentence needs to be chosen for a given setof other sentences.3 MethodsOur paper investigates how well a \ufb01ne-tuned trans-former model\u2019s performance on the \u03b1NLI task(Bhagavatula et al., 2020) is approximated by thecosine similarity of embeddings of the input sen-tences which we obtain from the pre-trained modelsbefore \ufb01ne-tuning them.Intuitively, if a model embeds the correct hypoth-esis close to the observations in some latent space(not necessarily a semantic similarity space), then aclassi\ufb01cation model built on top of that latent spaceshould have an easier time discerning which is thecorrect hypothesis, because apparently that latentspace captured some features that were salient forthe \u03b1NLI task.3.1 Sentence EmbeddingFor both the similarity baseline and the \ufb01ne-tunedclassi\ufb01cation model, the starting point is the pre-trained transformer model itself.",
            "We add a meanpooling layer to convert the token-by-token out-put of the model into a single sentence embed-ding (Reimers and Gurevych, 2019).",
            "Given sometokenized input x = [x1, x2, .",
            ". . , xn] and a pre-trained transformer model E which encodes eachtoken E(xi), we calculate the sentence embeddingemb(x) = 1ni=1 E(xi).",
            "(cid:80)nAl alternative to mean pooling would have beento use the embedding of the CLS token.",
            "We optedagainst that for three reasons.",
            "Firstly, Reimers andGurevych (2019) show that mean pooling slightlyoutperforms using the CLS token in their seman-tic similarity models.",
            "Secondly, for some mod-els, the CLS token does not have any particularsigni\ufb01cance before \ufb01ne-tuning on the downstreamtask due to the training objective they use (such asRoBERTa (Liu et al., 2020), which uses maskedlanguage modelling).",
            "Thirdly, pooling is a generalapproach that can be adopted for any model, evenif it does not output a CLS token.",
            "Since our goalwas to avoid any model-speci\ufb01c enhancements, auniversal blanket approach like this was preferable.3.2 Similarity-based \u03b1NLITo perform \u03b1NLI on a validation instance, we ob-tain three sentence embeddings \u2013 one for the com-bined observations o1 + o2 and one for each of thehypotheses h1, h2.",
            "To predict the more plausiblehypothesis, we calculate which of them is closer tothe observations with cosine similarity:\u02c6h = arg maxh(cid:48)\u2208{h1,h2}cos(emb(o1 + o2), emb(h(cid:48)))3.3 Classi\ufb01cation-based \u03b1NLIFor the classi\ufb01cation model, we add a classi\ufb01cationhead on top of the pre-trained model, which con-sists of a mean pooling layer to get sentence embed-dings, then a fully-connected layer and a softmaxoutput layer.",
            "For each instance of (o1, o2, h1, h2),the model takes two different inputs which consistof both observations with each of the hypotheses,namely emb(o1 + o2 + h1) and emb(o1 + o2 + h2).Both of these input representations are then usedin a fully connected layer f with a softmax outputlayer to get the probability score for each input.The hypothesis that is assigned the largest proba-bility constitutes the prediction:\u02c6h(cid:48) = arg maxh\u2208{h1,h2}softmax(f (emb(o1 + o2 + h)))In our experiments, we \ufb01ne-tune the classi\ufb01ca-tion head on the \u03b1NLI training set without updatingweights in the underlying language model.",
            "This ismostly due to time and resource constraints, how-ever, we believe that while \ufb01ne-tuning would im-prove classi\ufb01cation performance across the board,it would not affect the ranking as such.",
            "Since weare comparing models amongst themselves, theranking is more important.",
            "AccuracyRun timeModelalbert-base-v2albert-large-v2bert-base-uncasedbert-large-uncaseddistilbert-base-uncasedsqueezebert/squeezebert-uncasedgoogle/mobilebert-uncasedgoogle/canine-sgoogle/electra-small-discriminatorgoogle/electra-base-discriminatorgoogle/electra-large-discriminatormicrosoft/mpnet-baseroberta-baseroberta-largegoogle/bigbird-roberta-basekssteven/ibert-roberta-basedistilroberta-baseCitationLan (2020)Lan (2020)Devlin (2019)Devlin (2019)Sanh (2019)Iandola (2020)Sun (2020)Clark (2021)Clark (2020)Clark (2020)Clark (2020)Song (2020)Liu (2020)Liu (2020)Zaheer (2020)Kim (2021)Sanh (2019)Sim.50.78%50.13%51.69%52.67%51.63%50.52%48.75%49.21%51.17%52.28%52.74%51.50%51.50%51.63%51.50%51.50%51.43%Class.65.34%69.71%65.99%67.04%62.60%61.95%61.68%58.09%63.51%78.07%88.51%74.87%74.15%84.14%71.02%73.63%65.99%Sim.5.687.932.697.221.632.234.293.821.692.777.232.772.706.875.742.781.67Class.0:55:582:51:011:13:283:13:540:26:360:37:000:36:201:30:400:12:270:51:513:09:350:52:360:52:283:32:471:02:081:00:390:29:08Table 1: Accuracy on the \u03b1NLI validation set using similarity and a classi\ufb01cation model.",
            "The similarity runtime(how long it takes to evaluate the model since no training is required) is shown in seconds, the classi\ufb01cation runtime(how long it takes to \ufb01ne-tune and evaluate the model) in hours, minutes, and seconds.",
            "Note that the given trainingtime is for a single set of hyperparameters.",
            "Identifying the best hyperparameters involved training each modelmultiple times.4 ExperimentsWe compare the similarity-prediction-based \u03b1NLIapproach and the classi\ufb01cation-based \u03b1NLI ap-proach to evaluate if the \ufb01rst can act as an ap-proximation for the performance expected by thesecond.",
            "We use the pre-trained transformer mod-els which are available on the HuggingFace (Wolfet al., 2020) hub.",
            "The full list of models we use islisted in Table 1.",
            "The code for the experiments isavailable online.4.4.1 DatasetAll of our experiments were run on the train andvalidation split in the ART dataset provided forthe \u03b1NLI challenge (Bhagavatula et al., 2020).",
            "Itconsists of 169,654 training and 1,532 validationsamples, each consisting of two observations andtwo hypotheses obtained from a narrative shortstory corpus and augmented with wrong hypothe-ses written by crowd-sourced workers.The training data contains repetitions of the same(o1, o2) pairs with different sets of hypotheses,ranging from one plausible and one implausiblehypothesis to two plausible hypotheses where oneof them is more plausible.",
            "The validation set wasconstructed using adversarial \ufb01ltering, which se-lects one plausible and one implausible hypothesis4https://github.com/Vaibhavs10/anli-performance-predictionfor each set of observations that are hard to dis-tinguish.",
            "This increases the probability that theinstances are free of annotation artifacts, which theauthors de\ufb01ned as \u201cunintentional patterns in thedata that leak information about the target label\u201d(Bhagavatula et al., 2020).4.2 Experimental SetupAll of our classi\ufb01cation and similarity experimentswere run on an Nvidia RTX 2080 GPU.",
            "For trainingthe classi\ufb01er we used the maximum batch size that\ufb01t on the GPU (which is different for different sizedmodels, ranging between 12 and 128).",
            "For similar-ity experiments, we only infer the embeddings frompre-trained models.",
            "For hyperparameter selection,to keep the comparison fair, we tuned the batch sizeand learning rate and considered the same set ofpossible combinations across all the models.",
            "Thespeci\ufb01c values used for each model are availablein Table 2 in the appendix.",
            "We train for 3 epochswith learning rates ranging [10\u22125; 9 \u00b7 10\u22125] and aweight decay of 0.01.",
            "For each pre-trained model,we pick the one that achieved the highest accuracyon the validation set.4.3 Evaluation and ResultsTable 1 shows the results as accuracy scores, ob-tained with each pre-trained model when usingcosine similarity and when using a classi\ufb01er builton top of it.",
            "We also show the training runtimes.",
            "1008060.ccanoitac\ufb01ssacil4648505254similarity acc.Figure 1: Relation between similarity and classi\ufb01cationaccuracy scores.",
            "Note that the similarities are closer toeach other than the classi\ufb01cation values, therefore wechose a different scale.The primary observation is that the accuracyscores of classi\ufb01cation and similarity are corre-lated.",
            "This can be seen in Figure 1.",
            "The Pearsoncorrelation coef\ufb01cient is r = .65 (p = 0.005).The Spearman\u2019s correlation coef\ufb01cient is \u03c1 = .67(p = 0.003), indicating that the ranking obtainedwith the similarity-based prediction is a reliableindicator that is helpful for model selection.",
            "Ad-ditionally, model \ufb01ne-tuning takes on average 620times longer than the similarity-based estimate.Tuning the hyperparameters involved training eachmodel multiple times.5 Conclusions & Future WorkIn this paper, we have shown that similarity mea-sures based on the distributional semantic represen-tation in pre-trained transformer models serve asan effective proxy for \ufb01ne-tuned transformer-basedclassi\ufb01cation in \u03b1NLI.",
            "Since \ufb01ne-tuning a trans-former model takes notably more time than per-forming similarity comparisons, our approach sup-ports ef\ufb01cient model selection procedures.",
            "Futurework should investigate the suitability of similarity-based performance prediction for other similartasks, like next sentence prediction, question an-swering, summarization.ReferencesSamuel R. Bowman, Gabor Angeli, Christopher Potts,and Christopher D. Manning.",
            "2015.",
            "A large anno-tated corpus for learning natural language inference.In Proceedings of the 2015 Conference on Empiri-cal Methods in Natural Language Processing, pages632\u2013642, Lisbon, Portugal.",
            "Association for Compu-tational Linguistics.Stanley Chen.",
            "2009.",
            "Performance prediction for expo-nential language models.",
            "In Proceedings of HumanLanguage Technologies: The 2009 Annual Confer-ence of the North American Chapter of the Associa-tion for Computational Linguistics, pages 450\u2013458,Boulder, Colorado.",
            "Association for ComputationalLinguistics.Jonathan H. Clark, Dan Garrette, Iulia Turc, and JohnWieting.",
            "2021.",
            "CANINE: pre-training an ef\ufb01cienttokenization-free encoder for language representa-tion.",
            "CoRR, abs/2103.06874.Kevin Clark, Minh-Thang Luong, Quoc V. Le, andChristopher D. Manning.",
            "2020.Electra: Pre-training text encoders as discriminators rather thanIn International Conference on Learn-generators.ing Representations.Jacob Devlin, Ming-Wei Chang, Kenton Lee, andKristina Toutanova.",
            "2019.",
            "BERT: Pre-training ofdeep bidirectional transformers for language under-In Proceedings of the 2019 Conferencestanding.of the North American Chapter of the Associationfor Computational Linguistics: Human LanguageTechnologies, Volume 1 (Long and Short Papers),pages 4171\u20134186, Minneapolis, Minnesota.",
            "Associ-ation for Computational Linguistics.Pengcheng He, Xiaodong Liu, Jianfeng Gao, andWeizhu Chen.",
            "2021.",
            "Deberta: Decoding-enhancedIn Internationalbert with disentangled attention.Conference on Learning Representations.Jeremy Howard and Sebastian Ruder.",
            "2018.",
            "Universallanguage model \ufb01ne-tuning for text classi\ufb01cation.",
            "InProceedings of the 56th Annual Meeting of the As-sociation for Computational Linguistics (Volume 1:Long Papers), pages 328\u2013339, Melbourne, Australia.Association for Computational Linguistics.Forrest Iandola, Albert Shaw, Ravi Krishna, and KurtKeutzer.",
            "2020.",
            "SqueezeBERT: What can computervision teach NLP about ef\ufb01cient neural networks?In Proceedings of SustaiNLP: Workshop on Simpleand Ef\ufb01cient Natural Language Processing, pages124\u2013135, Online.",
            "Association for ComputationalLinguistics.Chandra Bhagavatula, Ronan Le Bras, ChaitanyaMalaviya, Keisuke Sakaguchi, Ari Holtzman, Han-nah Rashkin, Doug Downey, Wen tau Yih, and YejinChoi.",
            "2020.",
            "Abductive commonsense reasoning.",
            "InInternational Conference on Learning Representa-tions.Sehoon Kim, Amir Gholami, Zhewei Yao, Michael W.Mahoney, and Kurt Keutzer.",
            "2021.",
            "I-bert: Integer-only bert quantization.",
            "In Proceedings of the 38thInternational Conference on Machine Learning, vol-ume 139 of Proceedings of Machine Learning Re-search, pages 5506\u20135518.",
            "PMLR.",
            "Zhenzhong Lan, Mingda Chen, Sebastian Goodman,Kevin Gimpel, Piyush Sharma, and Radu Soricut.2020.",
            "ALBERT: A lite BERT for self-supervisedIn Proceed-learning of language representations.ings of the International Conference on LearningRepresentations.Wei Li, Can Gao, Guocheng Niu, Xinyan Xiao, HaoLiu, Jiachen Liu, Hua Wu, and Haifeng Wang.",
            "2021.UNIMO: Towards uni\ufb01ed-modal understanding andgeneration via cross-modal contrastive learning.",
            "InProceedings oftheAssociation for Computational Linguistics and the11th International Joint Conference on Natural Lan-guage Processing (Volume 1: Long Papers), pages2592\u20132607, Online.",
            "Association for ComputationalLinguistics.the 59th Annual Meeting ofXueqing Liu and Chi Wang.",
            "2021.",
            "An empirical studyon hyperparameter optimization for \ufb01ne-tuning pre-In Proceedings of thetrained language models.59th Annual Meeting of the Association for Compu-tational Linguistics and the 11th International JointConference on Natural Language Processing (Vol-ume 1: Long Papers), pages 2286\u20132300, Online.",
            "As-sociation for Computational Linguistics.Yinhan Liu, Myle Ott, Naman Goyal, Jingfei Du, Man-dar Joshi, Danqi Chen, Omer Levy, Mike Lewis,Luke Zettlemoyer, and Veselin Stoyanov.",
            "2020.RoBERTa: A robustly optimized BERT pretrainingapproach.Nicholas Lourie, Ronan Le Bras, Chandra Bhagavat-ula, and Yejin Choi.",
            "2021.",
            "Unicorn on rainbow: Auniversal commonsense reasoning model on a newIn Proceedings of the AAAImultitask benchmark.Conference on Arti\ufb01cial Intelligence, pages 13480\u201313488.Bill MacCartney and Christopher D. Manning.",
            "2008.Modeling semantic containment and exclusion inIn Proceedings of thenatural language inference.22nd International Conference on ComputationalLinguistics (Coling 2008), pages 521\u2013528, Manch-ester, UK.",
            "Coling 2008 Organizing Committee.Tom\u00e1s Mikolov, Kai Chen, Greg Corrado, and JeffreyDean.",
            "2013.",
            "Ef\ufb01cient estimation of word represen-In 1st International Con-tations in vector space.ference on Learning Representations, ICLR 2013,Scottsdale, Arizona, USA, May 2-4, 2013, WorkshopTrack Proceedings.Anshuman Mishra, Dhruvesh Patel, Aparna Vijayaku-mar, Xiang Li, Pavan Kapanipathi, and Kartik Tala-madupula.",
            "2020.",
            "Reading comprehension as naturallanguage inference:a semantic analysis.",
            "In Proceed-ings of the Ninth Joint Conference on Lexical andComputational Semantics, pages 12\u201319, Barcelona,Spain (Online).",
            "Association for Computational Lin-guistics.Arindam Mitra, Pratyay Banerjee, Kuntal Kumar Pal,Swaroop Mishra, and Chitta Baral.",
            "2020.",
            "How addi-tional knowledge can improve natural language com-monsense question answering?Sean Papay, Roman Klinger, and Sebastian Pad\u00f3.2020.",
            "Dissecting span identi\ufb01cation tasks with per-In Proceedings of the 2020formance prediction.Conference on Empirical Methods in Natural Lan-guage Processing (EMNLP), pages 4881\u20134895, On-line.",
            "Association for Computational Linguistics.Charles Sanders Peirce.",
            "1931.",
            "Collected papers ofCharles Sanders Peirce.",
            "Harvard University Press.Jeffrey Pennington, Richard Socher, and ChristopherManning.",
            "2014.",
            "GloVe: Global vectors for wordrepresentation.",
            "In Proceedings of the 2014 Confer-ence on Empirical Methods in Natural LanguageProcessing (EMNLP), pages 1532\u20131543, Doha,Qatar.",
            "Association for Computational Linguistics.Matthew E. Peters, Mark Neumann, Mohit Iyyer, MattGardner, Christopher Clark, Kenton Lee, and LukeZettlemoyer.",
            "2018.",
            "Deep contextualized word rep-In Proceedings of the 2018 Confer-resentations.ence of the North American Chapter of the Associ-ation for Computational Linguistics: Human Lan-guage Technologies, Volume 1 (Long Papers), pages2227\u20132237, New Orleans, Louisiana.",
            "Associationfor Computational Linguistics.Alec Radford, Karthik Narasimhan, Tim Salimans, andImproving language under-Ilya Sutskever.",
            "2018.standing by generative pre-training.",
            "Preprint.Colin Raffel, Noam Shazeer, Adam Roberts, Kather-ine Lee, Sharan Narang, Michael Matena, YanqiZhou, Wei Li, and Peter J. Liu.",
            "2020.",
            "Exploringthe limits of transfer learning with a uni\ufb01ed text-to-text transformer.",
            "Journal of Machine Learning Re-search, 21(140):1\u201367.Nils Reimers and Iryna Gurevych.",
            "2019.",
            "Sentence-BERT: Sentence embeddings using Siamese BERT-networks.",
            "In Proceedings of the 2019 Conference onEmpirical Methods in Natural Language Processingand the 9th International Joint Conference on Natu-ral Language Processing (EMNLP-IJCNLP), pages3982\u20133992, Hong Kong, China.",
            "Association forComputational Linguistics.Victor Sanh, Lysandre Debut, Julien Chaumond, andThomas Wolf.",
            "2019.",
            "Distilbert, a distilled version ofbert: smaller, faster, cheaper and lighter.",
            "In NeurIPSEMC \u02c62 Workshop.Kaitao Song, Xu Tan, Tao Qin, Jianfeng Lu, and Tie-Yan Liu.",
            "2020.",
            "Mpnet: Masked and permuted pre-training for language understanding.",
            "In Advances inNeural Information Processing Systems, volume 33,pages 16857\u201316867.",
            "Curran Associates, Inc.Zhiqing Sun, Hongkun Yu, Xiaodan Song, Renjie Liu,Yiming Yang, and Denny Zhou.",
            "2020.",
            "MobileBERT:a compact task-agnostic BERT for resource-limitedIn Proceedings of the 58th Annual Meet-devices.ing of the Association for Computational Linguistics,\fManzil Zaheer, Guru Guruganesh, Kumar AvinavaDubey, Joshua Ainslie, Chris Alberti, Santiago On-tanon, Philip Pham, Anirudh Ravula, Qifan Wang,Li Yang, et al.",
            "2020.",
            "Big bird: Transformers forlonger sequences.",
            "Advances in Neural InformationProcessing Systems, 33.Yunchang Zhu, Liang Pang, Yanyan Lan, and XueqiCheng.",
            "2020.",
            "L2r\u00b2: Leveraging ranking for abduc-tive reasoning.",
            "In Proceedings of the 43rd Interna-tional ACM SIGIR Conference on Research and De-velopment in Information Retrieval, SIGIR \u201920.A Model HyperparametersAll models were trained for 3 epochs with a weightdecay of 0.01.",
            "The batch size and learning rateused for each model can be seen in Table 2ModelLearning rate Batch sizealbert-base-v2albert-large-v2bert-base-uncasedbert-large-uncaseddistilbert-base-unc.squeezebert/squeezebert-unc.google/mobilebert-unc.google/canine-sgoogle/electra-small-discr.google/electra-base-discr.google/electra-large-discr.microsoft/mpnet-baseroberta-baseroberta-largegoogle/bigbird-roberta-basekssteven/ibert-roberta-basedistilroberta-base10\u2212510\u221255 \u00b7 10\u2212510\u221259 \u00b7 10\u221257 \u00b7 10\u221257 \u00b7 10\u2212510\u221257 \u00b7 10\u221253 \u00b7 10\u2212510\u221253 \u00b7 10\u221253 \u00b7 10\u2212510\u2212510\u221253 \u00b7 10\u221255 \u00b7 10\u221256020321612864100241286416646012406480Table 2: The learning rate and batch size that resultedin the best classi\ufb01cation accuracy for each model.pages 2158\u20132170, Online.",
            "Association for Computa-tional Linguistics.Ashish Vaswani, Noam Shazeer, Niki Parmar, JakobUszkoreit, Llion Jones, Aidan N Gomez, \u0141 ukaszKaiser, and Illia Polosukhin.",
            "2017.",
            "Attention is allyou need.",
            "In Advances in Neural Information Pro-cessing Systems, volume 30.",
            "Curran Associates, Inc.Adina Williams, Nikita Nangia, and Samuel Bowman.2018.",
            "A broad-coverage challenge corpus for sen-tence understanding through inference.",
            "In Proceed-ings of the 2018 Conference of the North AmericanChapter of the Association for Computational Lin-guistics: Human Language Technologies, Volume1 (Long Papers), pages 1112\u20131122, New Orleans,Louisiana.",
            "Association for Computational Linguis-tics.Thomas Wolf, Lysandre Debut, Victor Sanh, JulienChaumond, Clement Delangue, Anthony Moi, Pier-ric Cistac, Tim Rault, Remi Louf, Morgan Funtow-icz, Joe Davison, Sam Shleifer, Patrick von Platen,Clara Ma, Yacine Jernite, Julien Plu, Canwen Xu,Teven Le Scao, Sylvain Gugger, Mariama Drame,Quentin Lhoest, and Alexander Rush.",
            "2020.",
            "Hug-gingface\u2019s transformers: State-of-the-art natural lan-guage processing.",
            "In Proceedings of the 2020 Con-ference on Empirical Methods in Natural LanguageProcessing: System Demonstrations, pages 38\u201345,Online.",
            "Association for Computational Linguistics.Mengzhou Xia, Antonios Anastasopoulos, RuochenXu, Yiming Yang, and Graham Neubig.",
            "2020.",
            "Pre-dicting performance for natural language process-ing tasks.",
            "In Proceedings of the 58th Annual Meet-ing of the Association for Computational Linguistics,pages 8625\u20138646, Online.",
            "Association for Computa-tional Linguistics.Zihuiwen Ye, Pengfei Liu, Jinlan Fu, and Graham Neu-big.",
            "2021.",
            "Towards more \ufb01ne-grained and reliableNLP performance prediction.",
            "In Proceedings of the16th Conference of the European Chapter of theAssociation for Computational Linguistics: MainVolume, pages 3703\u20133714, Online.",
            "Association forComputational Linguistics.zero-shotWenpeng Yin, Jamaal Hay, and Dan Roth.",
            "2019.classi\ufb01cation:textBenchmarkingDatasets,evaluation and entailment approach.In Proceedings of the 2019 Conference on Empiri-cal Methods in Natural Language Processing andthe 9th International Joint Conference on NaturalLanguage Processing (EMNLP-IJCNLP), pages3914\u20133923, Hong Kong, China.",
            "Association forComputational Linguistics.Wenpeng Yin, Dragomir Radev, and Caiming Xiong.2021.",
            "DocNLI: A large-scale dataset for document-In Findings oflevel natural language inference.the Association for Computational Linguistics: ACL-IJCNLP 2021, pages 4913\u20134922, Online.",
            "Associa-tion for Computational Linguistics."
        ],
        "words": [
            "Embarrassingly",
            "Simple",
            "Performance",
            "Prediction",
            "for",
            "Abductive",
            "Natural",
            "Language",
            "Inference",
            "Em\u00af\u0131ls",
            "Kadik",
            ",",
            "is",
            ",",
            "Vaibhav",
            "Srivastav",
            ",",
            "and",
            "Roman",
            "Klinger",
            "Institut",
            "f\u00fcr",
            "Maschinelle",
            "Sprachverarbeitung",
            "University",
            "of",
            "Stuttgart",
            "Pfaffenwaldring",
            "5b",
            ",",
            "70569",
            "Stuttgart",
            "{",
            "emils.kadikis",
            ",",
            "vaibhav.srivastav",
            ",",
            "klinger",
            "@",
            "ims.uni-stuttgart.de",
            "}",
            "Abstract",
            "The",
            "task",
            "of",
            "abductive",
            "natural",
            "language",
            "infer-",
            "ence",
            "(",
            "\u03b1NLI",
            ")",
            ",",
            "to",
            "decide",
            "which",
            "hypothesis",
            "is",
            "the",
            "more",
            "likely",
            "explanation",
            "for",
            "a",
            "set",
            "of",
            "obser-",
            "vations",
            ",",
            "is",
            "a",
            "particularly",
            "dif\ufb01cult",
            "type",
            "of",
            "NLI",
            ".",
            "Instead",
            "of",
            "just",
            "determining",
            "a",
            "causal",
            "relation-",
            "ship",
            ",",
            "it",
            "requires",
            "common",
            "sense",
            "to",
            "also",
            "eval-",
            "uate",
            "how",
            "reasonable",
            "an",
            "explanation",
            "is",
            ".",
            "All",
            "recent",
            "competitive",
            "systems",
            "build",
            "on",
            "top",
            "of",
            "contextualized",
            "representations",
            "and",
            "make",
            "use",
            "of",
            "transformer",
            "architectures",
            "for",
            "learning",
            "an",
            "NLI",
            "model",
            ".",
            "When",
            "somebody",
            "is",
            "faced",
            "with",
            "a",
            "particular",
            "NLI",
            "task",
            ",",
            "they",
            "need",
            "to",
            "select",
            "the",
            "best",
            "model",
            "that",
            "is",
            "available",
            ".",
            "This",
            "is",
            "a",
            "time-consuming",
            "and",
            "resource-intense",
            "endeav-",
            "our",
            ".",
            "To",
            "solve",
            "this",
            "practical",
            "problem",
            ",",
            "we",
            "pro-",
            "pose",
            "a",
            "simple",
            "method",
            "for",
            "predicting",
            "the",
            "perfor-",
            "mance",
            "without",
            "actually",
            "\ufb01ne-tuning",
            "the",
            "model",
            ".",
            "We",
            "do",
            "this",
            "by",
            "testing",
            "how",
            "well",
            "the",
            "pre-trained",
            "models",
            "perform",
            "on",
            "the",
            "\u03b1NLI",
            "task",
            "when",
            "just",
            "comparing",
            "sentence",
            "embeddings",
            "with",
            "cosine",
            "is",
            "similarity",
            "to",
            "what",
            "achieved",
            "when",
            "training",
            "a",
            "classi\ufb01er",
            "on",
            "top",
            "of",
            "these",
            "embeddings",
            ".",
            "We",
            "show",
            "that",
            "the",
            "accu-",
            "racy",
            "of",
            "the",
            "cosine",
            "similarity",
            "approach",
            "corre-",
            "lates",
            "strongly",
            "with",
            "the",
            "accuracy",
            "of",
            "the",
            "classi-",
            "\ufb01cation",
            "approach",
            "with",
            "a",
            "Pearson",
            "correlation",
            "coef\ufb01cient",
            "of",
            "0.65",
            ".",
            "Since",
            "the",
            "similarity",
            "com-",
            "putation",
            "is",
            "orders",
            "of",
            "magnitude",
            "faster",
            "to",
            "com-",
            "pute",
            "on",
            "a",
            "given",
            "dataset",
            "(",
            "less",
            "than",
            "a",
            "minute",
            "vs.",
            "hours",
            ")",
            ",",
            "our",
            "method",
            "can",
            "lead",
            "to",
            "signi\ufb01cant",
            "time",
            "savings",
            "in",
            "the",
            "process",
            "of",
            "model",
            "selection",
            ".",
            "the",
            "performance",
            "that",
            "1",
            "Introduction",
            "Abduction",
            "is",
            "a",
            "type",
            "of",
            "reasoning",
            "that",
            "infers",
            "an",
            "ex-",
            "planation",
            "for",
            "some",
            "observations",
            "(",
            "Peirce",
            ",",
            "1931",
            ")",
            ".",
            "It",
            "is",
            "a",
            "particularly",
            "challenging",
            "type",
            "of",
            "inference",
            ";",
            "as",
            "opposed",
            "to",
            "deduction",
            "and",
            "induction",
            ",",
            "which",
            "derive",
            "the",
            "conclusion",
            "from",
            "only",
            "the",
            "information",
            "present",
            "in",
            "the",
            "observations",
            ",",
            "abduction",
            "requires",
            "making",
            "as-",
            "sumptions",
            "about",
            "an",
            "implicit",
            "context",
            "beyond",
            "just",
            "the",
            "given",
            "observations",
            ".",
            "Abductive",
            "reasoning",
            "is",
            "there-",
            "fore",
            "at",
            "the",
            "core",
            "of",
            "the",
            "way",
            "humans",
            "understand",
            "the",
            "world",
            "and",
            "how",
            "world",
            "knowledge",
            "is",
            "involved",
            ".",
            "Abductive",
            "reasoning",
            "in",
            "the",
            "natural",
            "language",
            "do-",
            "main",
            "has",
            "been",
            "introduced",
            "by",
            "Bhagavatula",
            "et",
            "al",
            ".",
            "(",
            "2020",
            ")",
            "who",
            "de\ufb01ned",
            "the",
            "abductive",
            "natural",
            "language",
            "inference",
            "(",
            "\u03b1NLI",
            ")",
            "task",
            ".",
            "In",
            "it",
            ",",
            "we",
            "are",
            "given",
            "four",
            "sentences",
            "\u2013",
            "two",
            "observations",
            "o1",
            "and",
            "o2",
            "and",
            "two",
            "hypotheses",
            "h1",
            "and",
            "h2",
            ",",
            "where",
            "we",
            "know",
            "that",
            "the",
            "se-",
            "quence",
            "of",
            "events",
            "was",
            "o1",
            "\u2192",
            "(",
            "h1|h2",
            ")",
            "\u2192",
            "o2",
            ".",
            "The",
            "task",
            "then",
            "is",
            "to",
            "decide",
            "which",
            "of",
            "the",
            "two",
            "hypotheses",
            "is",
            "the",
            "more",
            "plausible",
            "one",
            ".",
            "An",
            "example",
            "from",
            "Bhagavatula",
            "et",
            "al",
            ".",
            "(",
            "2020",
            ")",
            "is",
            "the",
            "following",
            ":",
            "o1",
            ":",
            "It",
            "was",
            "lunchtime",
            "and",
            "Kat",
            "was",
            "hungry",
            ".",
            "o2",
            ":",
            "Kat",
            "and",
            "her",
            "coworkers",
            "enjoyed",
            "a",
            "nice",
            "lunch",
            "outside",
            ".",
            "h1",
            ":",
            "Kat",
            "went",
            "to",
            "get",
            "a",
            "salad",
            ".",
            "h2",
            ":",
            "Kat",
            "decided",
            "to",
            "take",
            "a",
            "nap",
            "instead",
            "of",
            "eating",
            ".",
            "While",
            "it",
            "is",
            "not",
            "inconceivable",
            "that",
            "someone",
            "would",
            "decide",
            "to",
            "take",
            "a",
            "nap",
            "on",
            "their",
            "lunch",
            "break",
            "(",
            "h2",
            ")",
            ",",
            "given",
            "o2",
            "the",
            "\ufb01rst",
            "hypothesis",
            "becomes",
            "more",
            "likely",
            ".",
            "Currently",
            ",",
            "architectures",
            "transformer-based",
            "(",
            "Vaswani",
            "et",
            "al.",
            ",",
            "2017",
            ")",
            "are",
            "state",
            "of",
            "the",
            "art",
            "in",
            "a",
            "wide",
            "variety",
            "of",
            "natural",
            "language",
            "processing",
            "(",
            "NLP",
            ")",
            "tasks",
            "(",
            "Devlin",
            "et",
            "al.",
            ",",
            "2019",
            ";",
            "He",
            "et",
            "al.",
            ",",
            "2021",
            ";",
            "Li",
            "et",
            "al.",
            ",",
            "2021",
            ")",
            ",",
            "including",
            "\u03b1NLI",
            ".",
            "However",
            ",",
            "with",
            "an",
            "ever-changing",
            "landscape",
            "of",
            "transformer",
            "models",
            "and",
            "pre-training",
            "techniques",
            "(",
            "with",
            "over",
            "100001",
            "different",
            "\ufb01ne-tuned",
            "models",
            "available",
            "on",
            "the",
            "HuggingFace",
            "hub",
            "(",
            "Wolf",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            ")",
            ",",
            "\ufb01nding",
            "the",
            "best",
            "model",
            "for",
            "a",
            "given",
            "task",
            "has",
            "become",
            "a",
            "time-consuming",
            "process",
            "since",
            ",",
            "in",
            "order",
            "to",
            "compare",
            "multiple",
            "models",
            ",",
            "they",
            "each",
            "need",
            "to",
            "be",
            "separately",
            "\ufb01ne-tuned",
            "on",
            "the",
            "task",
            ".",
            "This",
            "model",
            "selection",
            "process",
            "might",
            "lead",
            "to",
            "a",
            "prohibitive",
            "runtime",
            ",",
            "which",
            "has",
            "led",
            "to",
            "research",
            "on",
            "performance",
            "prediction",
            ",",
            "namely",
            "to",
            "predict",
            "the",
            "ex-",
            "pected",
            "performance",
            "out",
            "of",
            "parameters",
            "of",
            "the",
            "model",
            "con\ufb01guration",
            ",",
            "without",
            "actually",
            "training",
            "the",
            "model",
            ".",
            "This",
            "procedure",
            "has",
            "been",
            "evaluated",
            "for",
            "a",
            "set",
            "of",
            "NLP",
            "tasks",
            ",",
            "including",
            "span",
            "prediction",
            "(",
            "Papay",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            "and",
            "language",
            "modelling",
            "(",
            "Chen",
            ",",
            "2009",
            ")",
            ".",
            "However",
            ",",
            "1https",
            ":",
            "//huggingface.co/models",
            "2",
            "2",
            "0",
            "2",
            "b",
            "e",
            "F",
            "1",
            "2",
            "]",
            "L",
            "C",
            ".",
            "s",
            "c",
            "[",
            "1",
            "v",
            "8",
            "0",
            "4",
            "0",
            "1",
            ".",
            "2",
            "0",
            "2",
            "2",
            ":",
            "v",
            "i",
            "X",
            "r",
            "a",
            "we",
            "are",
            "not",
            "aware",
            "of",
            "any",
            "previous",
            "work",
            "that",
            "per-",
            "formed",
            "performance",
            "prediction",
            "for",
            "\u03b1NLI",
            ".",
            "In",
            "this",
            "paper",
            ",",
            "we",
            "introduce",
            "a",
            "fast",
            "performance",
            "prediction",
            "method",
            "for",
            "the",
            "\u03b1NLI",
            "task",
            "that",
            "allows",
            "a",
            "more",
            "guided",
            "way",
            "of",
            "choosing",
            "which",
            "models",
            "to",
            "\ufb01ne-tune",
            ".",
            "We",
            "use",
            "various",
            "pre-trained",
            "transformer",
            "models",
            "to",
            "embed",
            "the",
            "observations",
            "and",
            "hypothe-",
            "ses",
            "with",
            "the",
            "approach",
            "introduced",
            "in",
            "Reimers",
            "and",
            "Gurevych",
            "(",
            "2019",
            ")",
            ",",
            "then",
            "compare",
            "which",
            "hypothesis",
            "is",
            "closer",
            "to",
            "the",
            "observations",
            "with",
            "cosine",
            "similar-",
            "ity",
            ".",
            "We",
            "\ufb01nd",
            "that",
            "the",
            "performance",
            "of",
            "the",
            "similarity-",
            "based",
            "approach",
            "is",
            "correlated",
            "to",
            "results",
            "obtained",
            "via",
            "\ufb01ne-tuning",
            ".",
            "Therefore",
            ",",
            "the",
            "similarity-based",
            "approach",
            "can",
            "serve",
            "as",
            "a",
            "performance",
            "prediction",
            "method",
            ".",
            "2",
            "Related",
            "work",
            "There",
            "are",
            "three",
            "research",
            "topics",
            "that",
            "need",
            "to",
            "be",
            "men-",
            "tioned",
            ".",
            "Approaches",
            "to",
            "abductive",
            "reasoning",
            ",",
            "pre-",
            "trained",
            "language",
            "models",
            ",",
            "and",
            "performance",
            "predic-",
            "tion",
            ".",
            "In",
            "this",
            "section",
            ",",
            "we",
            "explore",
            "them",
            "in",
            "detail",
            ".",
            "language",
            "inference",
            ".",
            "NLI",
            "Abductive",
            "natural",
            "has",
            "been",
            "proposed",
            "as",
            "the",
            "task",
            "of",
            "recognizing",
            "textual",
            "entailment",
            "by",
            "MacCartney",
            "and",
            "Manning",
            "(",
            "2008",
            ")",
            "and",
            "now",
            "constitutes",
            "a",
            "major",
            "challenge",
            "in",
            "NLP",
            "which",
            "has",
            "found",
            "application",
            "for",
            "other",
            "downstream",
            "tasks",
            ",",
            "including",
            "question",
            "answering",
            "or",
            "zero-shot",
            "classi\ufb01cation",
            "(",
            "Yin",
            "et",
            "al.",
            ",",
            "2019",
            ";",
            "Mishra",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            ".",
            "Based",
            "on",
            "the",
            "initial",
            "goal",
            "of",
            "establishing",
            "inference",
            "relations",
            "between",
            "two",
            "short",
            "texts",
            ",",
            "a",
            "myriad",
            "of",
            "vari-",
            "ants",
            "have",
            "been",
            "proposed",
            "(",
            "Yin",
            "et",
            "al.",
            ",",
            "2021",
            ";",
            "Williams",
            "et",
            "al.",
            ",",
            "2018",
            ";",
            "Bowman",
            "et",
            "al.",
            ",",
            "2015",
            ")",
            ".",
            "One",
            "such",
            "vari-",
            "ant",
            "is",
            "abductive",
            "NLI",
            "(",
            "\u03b1NLI",
            ",",
            "Bhagavatula",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            ".",
            "Transformer-based",
            "architectures",
            "dominate",
            "the",
            "\u03b1NLI",
            "leaderboard,2",
            "including",
            "RoBERTa-based",
            "models",
            "(",
            "Liu",
            "et",
            "al.",
            ",",
            "2020",
            ";",
            "Mitra",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            "which",
            "explore",
            "how",
            "additional",
            "knowledge",
            "can",
            "improve",
            "per-",
            "formance",
            "on",
            "reasoning",
            "tasks",
            ",",
            "and",
            "Zhu",
            "et",
            "al",
            ".",
            "(",
            "2020",
            ")",
            "who",
            "approach",
            "\u03b1NLI",
            "as",
            "a",
            "ranking",
            "task",
            ".",
            "The",
            "task",
            "authors",
            "improved",
            "upon",
            "their",
            "result",
            "in",
            "Lourie",
            "et",
            "al",
            ".",
            "(",
            "2021",
            ")",
            "by",
            "using",
            "a",
            "T5",
            "model",
            "(",
            "Raffel",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            "and",
            "experimenting",
            "with",
            "multi-task",
            "training",
            "and",
            "\ufb01ne-",
            "tuning",
            "over",
            "multiple",
            "reasoning",
            "tasks",
            ".",
            "Both",
            "the",
            "multi-task",
            "criteria",
            "and",
            "the",
            "Text-to-Text",
            "framework",
            "of",
            "T5",
            "help",
            "the",
            "model",
            "generalize",
            "and",
            "understand",
            "the",
            "context",
            "better",
            ".",
            "The",
            "second-best",
            "model",
            "on",
            "the",
            "leaderboard",
            "is",
            "a",
            "DeBERTa",
            "model",
            "(",
            "He",
            "et",
            "al.",
            ",",
            "2021",
            ")",
            ".",
            "The",
            "model",
            "re-",
            "2https",
            ":",
            "//leaderboard.allenai.org/anli/",
            "submissions/public",
            "places",
            "the",
            "masked",
            "language",
            "modelling",
            "task",
            "with",
            "a",
            "replaced-token",
            "detection",
            "task",
            ".",
            "It",
            "also",
            "uses",
            "a",
            "disen-",
            "tangled",
            "attention",
            "mechanism",
            "to",
            "encode",
            "the",
            "position",
            "and",
            "content",
            "information",
            ".",
            "The",
            "current",
            "state",
            "of",
            "the",
            "art",
            "shows",
            "an",
            "accuracy",
            "of",
            "91.18",
            "%",
            "using",
            "a",
            "new",
            "uni\ufb01ed-modal",
            "pre-training",
            "method",
            "to",
            "leverage",
            "multi-modal",
            "data",
            "for",
            "single-",
            "modal",
            "tasks",
            "(",
            "Li",
            "et",
            "al.",
            ",",
            "2021",
            ")",
            ".",
            "This",
            "result",
            "approaches",
            "the",
            "human",
            "baseline",
            "of",
            "92.9",
            "%",
            ".",
            "Pre-trained",
            "language",
            "models",
            ".",
            "The",
            "\u03b1NLI",
            "task",
            "requires",
            "the",
            "model",
            "to",
            "successfully",
            "\u201c",
            "understand",
            "\u201d",
            "the",
            "context",
            "of",
            "both",
            "the",
            "observations",
            "and",
            "use",
            "that",
            "un-",
            "derstanding",
            "to",
            "identify",
            "the",
            "more",
            "likely",
            "hypothe-",
            "sis",
            "entailing",
            "it",
            ".",
            "Most",
            "semantic",
            "representations",
            "in",
            "practical",
            "applications",
            "rely",
            "on",
            "distributional",
            "seman-",
            "tics",
            ".",
            "Such",
            "methods",
            "include",
            "the",
            "word-level",
            "embed-",
            "ding",
            "methods",
            "Word2Vec",
            "(",
            "Mikolov",
            "et",
            "al.",
            ",",
            "2013",
            ")",
            "and",
            "GloVe",
            "(",
            "Pennington",
            "et",
            "al.",
            ",",
            "2014",
            ")",
            "and",
            "language",
            "model-based",
            "word",
            "representation",
            "like",
            "ELMo",
            "(",
            "Pe-",
            "ters",
            "et",
            "al.",
            ",",
            "2018",
            ")",
            ",",
            "ULMFit",
            "(",
            "Howard",
            "and",
            "Ruder",
            ",",
            "2018",
            ")",
            ",",
            "and",
            "GPT",
            "(",
            "Radford",
            "et",
            "al.",
            ",",
            "2018",
            ")",
            ".",
            "The",
            "current",
            "state",
            "of",
            "the",
            "art",
            "are",
            "pre-trained",
            "trans-",
            "former",
            "architectures",
            "(",
            "Vaswani",
            "et",
            "al.",
            ",",
            "2017",
            ")",
            "like",
            "BERT",
            "(",
            "Devlin",
            "et",
            "al.",
            ",",
            "2019",
            ")",
            ",",
            "which",
            "use",
            "a",
            "masked",
            "language",
            "modelling",
            "and",
            "next",
            "sentence",
            "prediction",
            "objective",
            ".",
            "This",
            "not",
            "only",
            "helps",
            "the",
            "model",
            "under-",
            "stand",
            "the",
            "context",
            "within",
            "a",
            "sentence",
            "but",
            "also",
            "in-",
            "between",
            "consecutive",
            "sentences",
            ".",
            "There",
            "is",
            "however",
            "a",
            "trade-off",
            "in",
            "terms",
            "of",
            "the",
            "time",
            "it",
            "takes",
            "to",
            "train",
            "trans-",
            "former",
            "models",
            ".",
            "For",
            "example",
            ",",
            "a",
            "from-scratch",
            "train-",
            "ing",
            "of",
            "BERT",
            "takes",
            "6.4",
            "days",
            "on",
            "an",
            "8",
            "GPU",
            "Nvidia",
            "V100",
            "server3",
            ".",
            "Devlin",
            "et",
            "al",
            ".",
            "(",
            "2019",
            ")",
            "recommend",
            "\ufb01ne-",
            "tuning",
            "the",
            "language",
            "model",
            "between",
            "2-4",
            "epochs",
            "for",
            "a",
            "given",
            "task",
            ".",
            "However",
            ",",
            "in",
            "practice",
            ",",
            "multiple",
            "trials",
            "are",
            "required",
            "to",
            "\ufb01nd",
            "the",
            "optimal",
            "hyperparameters",
            ".",
            "These",
            "long",
            "training",
            "times",
            "and",
            "multiple",
            "\ufb01ne-tuning",
            "runs",
            "make",
            "model",
            "selection",
            "a",
            "time-intensive",
            "process",
            "(",
            "Liu",
            "and",
            "Wang",
            ",",
            "2021",
            ")",
            ".",
            "Performance",
            "prediction",
            ".",
            "The",
            "task",
            "of",
            "perfor-",
            "mance",
            "prediction",
            "is",
            "to",
            "estimate",
            "the",
            "performance",
            "of",
            "a",
            "speci\ufb01c",
            "system",
            "without",
            "explicitly",
            "running",
            "it",
            ".",
            "It",
            "helps",
            "in",
            "setting",
            "hyperparameters",
            ",",
            "\ufb01nding",
            "feature",
            "sets",
            ",",
            "or",
            "identifying",
            "candidate",
            "language",
            "models",
            "for",
            "a",
            "downstream",
            "NLP",
            "task",
            ".",
            "Chen",
            "(",
            "2009",
            ")",
            "develop",
            ",",
            "for",
            "instance",
            ",",
            "a",
            "generalized",
            "method",
            "for",
            "predicting",
            "the",
            "performance",
            "of",
            "exponential",
            "language",
            "models",
            ".",
            "They",
            "analyze",
            "the",
            "backoff",
            "features",
            "in",
            "an",
            "exponen-",
            "tial",
            "n-gram",
            "model",
            ".",
            "Papay",
            "et",
            "al",
            ".",
            "(",
            "2020",
            ")",
            "leverage",
            "3https",
            ":",
            "//aws.amazon.com/blogs/machine-",
            "learning/amazon-web-services-achieves-fastest-training-",
            "times-for-bert-and-mask-r-cnn/",
            "meta-learning",
            "to",
            "identify",
            "candidate",
            "model",
            "perfor-",
            "mance",
            "on",
            "the",
            "task",
            "of",
            "span",
            "identi\ufb01cation",
            ".",
            "They",
            "train",
            "a",
            "linear",
            "regressor",
            "as",
            "a",
            "meta-model",
            "to",
            "predict",
            "span",
            "ID",
            "performance",
            "based",
            "on",
            "model",
            "features",
            "and",
            "task",
            "metrics",
            "for",
            "an",
            "unseen",
            "task",
            ".",
            "Ye",
            "et",
            "al",
            ".",
            "(",
            "2021",
            ")",
            "pro-",
            "pose",
            "performance",
            "prediction",
            "methods",
            "particularly",
            "suited",
            "for",
            "\ufb01ne-grained",
            "evaluation",
            "metrics",
            ".",
            "They",
            "also",
            "develop",
            "methods",
            "for",
            "estimating",
            "the",
            "reliabil-",
            "ity",
            "of",
            "these",
            "performance",
            "predictions",
            ".",
            "Contrary",
            "to",
            "the",
            "previously",
            "mentioned",
            "papers",
            ",",
            "Xia",
            "et",
            "al",
            ".",
            "(",
            "2020",
            ")",
            "build",
            "regression",
            "models",
            "to",
            "predict",
            "the",
            "performance",
            "across",
            "a",
            "variety",
            "of",
            "NLP",
            "tasks",
            ",",
            "however",
            ",",
            "they",
            "do",
            "not",
            "consider",
            "NLI",
            "as",
            "one",
            "of",
            "them",
            ".",
            "In",
            "contrast",
            "to",
            "our",
            "work",
            ",",
            "all",
            "these",
            "previous",
            "meth-",
            "ods",
            "build",
            "on",
            "top",
            "of",
            "the",
            "idea",
            "to",
            "train",
            "a",
            "surrogate",
            "model",
            "for",
            "performance",
            "prediction",
            "and",
            "depend",
            "on",
            "the",
            "information",
            "about",
            "past",
            "runs",
            "of",
            "these",
            "models",
            ".",
            "Our",
            "approach",
            "focuses",
            "solely",
            "on",
            "the",
            "embeddings",
            "provided",
            "by",
            "the",
            "language",
            "model",
            "and",
            "leverages",
            "those",
            "as",
            "a",
            "predictor",
            "of",
            "performance",
            ".",
            "This",
            "particular",
            "setup",
            "is",
            "also",
            "motivated",
            "by",
            "the",
            "\u03b1NLI",
            "task",
            "itself",
            ",",
            "in",
            "which",
            "a",
            "sentence",
            "needs",
            "to",
            "be",
            "chosen",
            "for",
            "a",
            "given",
            "set",
            "of",
            "other",
            "sentences",
            ".",
            "3",
            "Methods",
            "Our",
            "paper",
            "investigates",
            "how",
            "well",
            "a",
            "\ufb01ne-tuned",
            "trans-",
            "former",
            "model",
            "\u2019",
            "s",
            "performance",
            "on",
            "the",
            "\u03b1NLI",
            "task",
            "(",
            "Bhagavatula",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            "is",
            "approximated",
            "by",
            "the",
            "cosine",
            "similarity",
            "of",
            "embeddings",
            "of",
            "the",
            "input",
            "sen-",
            "tences",
            "which",
            "we",
            "obtain",
            "from",
            "the",
            "pre-trained",
            "models",
            "before",
            "\ufb01ne-tuning",
            "them",
            ".",
            "Intuitively",
            ",",
            "if",
            "a",
            "model",
            "embeds",
            "the",
            "correct",
            "hypoth-",
            "esis",
            "close",
            "to",
            "the",
            "observations",
            "in",
            "some",
            "latent",
            "space",
            "(",
            "not",
            "necessarily",
            "a",
            "semantic",
            "similarity",
            "space",
            ")",
            ",",
            "then",
            "a",
            "classi\ufb01cation",
            "model",
            "built",
            "on",
            "top",
            "of",
            "that",
            "latent",
            "space",
            "should",
            "have",
            "an",
            "easier",
            "time",
            "discerning",
            "which",
            "is",
            "the",
            "correct",
            "hypothesis",
            ",",
            "because",
            "apparently",
            "that",
            "latent",
            "space",
            "captured",
            "some",
            "features",
            "that",
            "were",
            "salient",
            "for",
            "the",
            "\u03b1NLI",
            "task",
            ".",
            "3.1",
            "Sentence",
            "Embedding",
            "For",
            "both",
            "the",
            "similarity",
            "baseline",
            "and",
            "the",
            "\ufb01ne-tuned",
            "classi\ufb01cation",
            "model",
            ",",
            "the",
            "starting",
            "point",
            "is",
            "the",
            "pre-",
            "trained",
            "transformer",
            "model",
            "itself",
            ".",
            "We",
            "add",
            "a",
            "mean",
            "pooling",
            "layer",
            "to",
            "convert",
            "the",
            "token-by-token",
            "out-",
            "put",
            "of",
            "the",
            "model",
            "into",
            "a",
            "single",
            "sentence",
            "embed-",
            "ding",
            "(",
            "Reimers",
            "and",
            "Gurevych",
            ",",
            "2019",
            ")",
            ".",
            "Given",
            "some",
            "tokenized",
            "input",
            "x",
            "=",
            "[",
            "x1",
            ",",
            "x2",
            ",",
            ".",
            ".",
            ".",
            ",",
            "xn",
            "]",
            "and",
            "a",
            "pre-",
            "trained",
            "transformer",
            "model",
            "E",
            "which",
            "encodes",
            "each",
            "token",
            "E",
            "(",
            "xi",
            ")",
            ",",
            "we",
            "calculate",
            "the",
            "sentence",
            "embedding",
            "emb",
            "(",
            "x",
            ")",
            "=",
            "1",
            "n",
            "i=1",
            "E",
            "(",
            "xi",
            ")",
            ".",
            "(",
            "cid:80",
            ")",
            "n",
            "Al",
            "alternative",
            "to",
            "mean",
            "pooling",
            "would",
            "have",
            "been",
            "to",
            "use",
            "the",
            "embedding",
            "of",
            "the",
            "CLS",
            "token",
            ".",
            "We",
            "opted",
            "against",
            "that",
            "for",
            "three",
            "reasons",
            ".",
            "Firstly",
            ",",
            "Reimers",
            "and",
            "Gurevych",
            "(",
            "2019",
            ")",
            "show",
            "that",
            "mean",
            "pooling",
            "slightly",
            "outperforms",
            "using",
            "the",
            "CLS",
            "token",
            "in",
            "their",
            "seman-",
            "tic",
            "similarity",
            "models",
            ".",
            "Secondly",
            ",",
            "for",
            "some",
            "mod-",
            "els",
            ",",
            "the",
            "CLS",
            "token",
            "does",
            "not",
            "have",
            "any",
            "particular",
            "signi\ufb01cance",
            "before",
            "\ufb01ne-tuning",
            "on",
            "the",
            "downstream",
            "task",
            "due",
            "to",
            "the",
            "training",
            "objective",
            "they",
            "use",
            "(",
            "such",
            "as",
            "RoBERTa",
            "(",
            "Liu",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            ",",
            "which",
            "uses",
            "masked",
            "language",
            "modelling",
            ")",
            ".",
            "Thirdly",
            ",",
            "pooling",
            "is",
            "a",
            "general",
            "approach",
            "that",
            "can",
            "be",
            "adopted",
            "for",
            "any",
            "model",
            ",",
            "even",
            "if",
            "it",
            "does",
            "not",
            "output",
            "a",
            "CLS",
            "token",
            ".",
            "Since",
            "our",
            "goal",
            "was",
            "to",
            "avoid",
            "any",
            "model-speci\ufb01c",
            "enhancements",
            ",",
            "a",
            "universal",
            "blanket",
            "approach",
            "like",
            "this",
            "was",
            "preferable",
            ".",
            "3.2",
            "Similarity-based",
            "\u03b1NLI",
            "To",
            "perform",
            "\u03b1NLI",
            "on",
            "a",
            "validation",
            "instance",
            ",",
            "we",
            "ob-",
            "tain",
            "three",
            "sentence",
            "embeddings",
            "\u2013",
            "one",
            "for",
            "the",
            "com-",
            "bined",
            "observations",
            "o1",
            "+",
            "o2",
            "and",
            "one",
            "for",
            "each",
            "of",
            "the",
            "hypotheses",
            "h1",
            ",",
            "h2",
            ".",
            "To",
            "predict",
            "the",
            "more",
            "plausible",
            "hypothesis",
            ",",
            "we",
            "calculate",
            "which",
            "of",
            "them",
            "is",
            "closer",
            "to",
            "the",
            "observations",
            "with",
            "cosine",
            "similarity",
            ":",
            "\u02c6h",
            "=",
            "arg",
            "max",
            "h",
            "(",
            "cid:48",
            ")",
            "\u2208",
            "{",
            "h1",
            ",",
            "h2",
            "}",
            "cos",
            "(",
            "emb",
            "(",
            "o1",
            "+",
            "o2",
            ")",
            ",",
            "emb",
            "(",
            "h",
            "(",
            "cid:48",
            ")",
            ")",
            ")",
            "3.3",
            "Classi\ufb01cation-based",
            "\u03b1NLI",
            "For",
            "the",
            "classi\ufb01cation",
            "model",
            ",",
            "we",
            "add",
            "a",
            "classi\ufb01cation",
            "head",
            "on",
            "top",
            "of",
            "the",
            "pre-trained",
            "model",
            ",",
            "which",
            "con-",
            "sists",
            "of",
            "a",
            "mean",
            "pooling",
            "layer",
            "to",
            "get",
            "sentence",
            "embed-",
            "dings",
            ",",
            "then",
            "a",
            "fully-connected",
            "layer",
            "and",
            "a",
            "softmax",
            "output",
            "layer",
            ".",
            "For",
            "each",
            "instance",
            "of",
            "(",
            "o1",
            ",",
            "o2",
            ",",
            "h1",
            ",",
            "h2",
            ")",
            ",",
            "the",
            "model",
            "takes",
            "two",
            "different",
            "inputs",
            "which",
            "consist",
            "of",
            "both",
            "observations",
            "with",
            "each",
            "of",
            "the",
            "hypotheses",
            ",",
            "namely",
            "emb",
            "(",
            "o1",
            "+",
            "o2",
            "+",
            "h1",
            ")",
            "and",
            "emb",
            "(",
            "o1",
            "+",
            "o2",
            "+",
            "h2",
            ")",
            ".",
            "Both",
            "of",
            "these",
            "input",
            "representations",
            "are",
            "then",
            "used",
            "in",
            "a",
            "fully",
            "connected",
            "layer",
            "f",
            "with",
            "a",
            "softmax",
            "output",
            "layer",
            "to",
            "get",
            "the",
            "probability",
            "score",
            "for",
            "each",
            "input",
            ".",
            "The",
            "hypothesis",
            "that",
            "is",
            "assigned",
            "the",
            "largest",
            "proba-",
            "bility",
            "constitutes",
            "the",
            "prediction",
            ":",
            "\u02c6h",
            "(",
            "cid:48",
            ")",
            "=",
            "arg",
            "max",
            "h\u2208",
            "{",
            "h1",
            ",",
            "h2",
            "}",
            "softmax",
            "(",
            "f",
            "(",
            "emb",
            "(",
            "o1",
            "+",
            "o2",
            "+",
            "h",
            ")",
            ")",
            ")",
            "In",
            "our",
            "experiments",
            ",",
            "we",
            "\ufb01ne-tune",
            "the",
            "classi\ufb01ca-",
            "tion",
            "head",
            "on",
            "the",
            "\u03b1NLI",
            "training",
            "set",
            "without",
            "updating",
            "weights",
            "in",
            "the",
            "underlying",
            "language",
            "model",
            ".",
            "This",
            "is",
            "mostly",
            "due",
            "to",
            "time",
            "and",
            "resource",
            "constraints",
            ",",
            "how-",
            "ever",
            ",",
            "we",
            "believe",
            "that",
            "while",
            "\ufb01ne-tuning",
            "would",
            "im-",
            "prove",
            "classi\ufb01cation",
            "performance",
            "across",
            "the",
            "board",
            ",",
            "it",
            "would",
            "not",
            "affect",
            "the",
            "ranking",
            "as",
            "such",
            ".",
            "Since",
            "we",
            "are",
            "comparing",
            "models",
            "amongst",
            "themselves",
            ",",
            "the",
            "ranking",
            "is",
            "more",
            "important",
            ".",
            "Accuracy",
            "Run",
            "time",
            "Model",
            "albert-base-v2",
            "albert-large-v2",
            "bert-base-uncased",
            "bert-large-uncased",
            "distilbert-base-uncased",
            "squeezebert/squeezebert-uncased",
            "google/mobilebert-uncased",
            "google/canine-s",
            "google/electra-small-discriminator",
            "google/electra-base-discriminator",
            "google/electra-large-discriminator",
            "microsoft/mpnet-base",
            "roberta-base",
            "roberta-large",
            "google/bigbird-roberta-base",
            "kssteven/ibert-roberta-base",
            "distilroberta-base",
            "Citation",
            "Lan",
            "(",
            "2020",
            ")",
            "Lan",
            "(",
            "2020",
            ")",
            "Devlin",
            "(",
            "2019",
            ")",
            "Devlin",
            "(",
            "2019",
            ")",
            "Sanh",
            "(",
            "2019",
            ")",
            "Iandola",
            "(",
            "2020",
            ")",
            "Sun",
            "(",
            "2020",
            ")",
            "Clark",
            "(",
            "2021",
            ")",
            "Clark",
            "(",
            "2020",
            ")",
            "Clark",
            "(",
            "2020",
            ")",
            "Clark",
            "(",
            "2020",
            ")",
            "Song",
            "(",
            "2020",
            ")",
            "Liu",
            "(",
            "2020",
            ")",
            "Liu",
            "(",
            "2020",
            ")",
            "Zaheer",
            "(",
            "2020",
            ")",
            "Kim",
            "(",
            "2021",
            ")",
            "Sanh",
            "(",
            "2019",
            ")",
            "Sim",
            ".",
            "50.78",
            "%",
            "50.13",
            "%",
            "51.69",
            "%",
            "52.67",
            "%",
            "51.63",
            "%",
            "50.52",
            "%",
            "48.75",
            "%",
            "49.21",
            "%",
            "51.17",
            "%",
            "52.28",
            "%",
            "52.74",
            "%",
            "51.50",
            "%",
            "51.50",
            "%",
            "51.63",
            "%",
            "51.50",
            "%",
            "51.50",
            "%",
            "51.43",
            "%",
            "Class",
            ".",
            "65.34",
            "%",
            "69.71",
            "%",
            "65.99",
            "%",
            "67.04",
            "%",
            "62.60",
            "%",
            "61.95",
            "%",
            "61.68",
            "%",
            "58.09",
            "%",
            "63.51",
            "%",
            "78.07",
            "%",
            "88.51",
            "%",
            "74.87",
            "%",
            "74.15",
            "%",
            "84.14",
            "%",
            "71.02",
            "%",
            "73.63",
            "%",
            "65.99",
            "%",
            "Sim",
            ".",
            "5.68",
            "7.93",
            "2.69",
            "7.22",
            "1.63",
            "2.23",
            "4.29",
            "3.82",
            "1.69",
            "2.77",
            "7.23",
            "2.77",
            "2.70",
            "6.87",
            "5.74",
            "2.78",
            "1.67",
            "Class",
            ".",
            "0:55:58",
            "2:51:01",
            "1:13:28",
            "3:13:54",
            "0:26:36",
            "0:37:00",
            "0:36:20",
            "1:30:40",
            "0:12:27",
            "0:51:51",
            "3:09:35",
            "0:52:36",
            "0:52:28",
            "3:32:47",
            "1:02:08",
            "1:00:39",
            "0:29:08",
            "Table",
            "1",
            ":",
            "Accuracy",
            "on",
            "the",
            "\u03b1NLI",
            "validation",
            "set",
            "using",
            "similarity",
            "and",
            "a",
            "classi\ufb01cation",
            "model",
            ".",
            "The",
            "similarity",
            "runtime",
            "(",
            "how",
            "long",
            "it",
            "takes",
            "to",
            "evaluate",
            "the",
            "model",
            "since",
            "no",
            "training",
            "is",
            "required",
            ")",
            "is",
            "shown",
            "in",
            "seconds",
            ",",
            "the",
            "classi\ufb01cation",
            "runtime",
            "(",
            "how",
            "long",
            "it",
            "takes",
            "to",
            "\ufb01ne-tune",
            "and",
            "evaluate",
            "the",
            "model",
            ")",
            "in",
            "hours",
            ",",
            "minutes",
            ",",
            "and",
            "seconds",
            ".",
            "Note",
            "that",
            "the",
            "given",
            "training",
            "time",
            "is",
            "for",
            "a",
            "single",
            "set",
            "of",
            "hyperparameters",
            ".",
            "Identifying",
            "the",
            "best",
            "hyperparameters",
            "involved",
            "training",
            "each",
            "model",
            "multiple",
            "times",
            ".",
            "4",
            "Experiments",
            "We",
            "compare",
            "the",
            "similarity-prediction-based",
            "\u03b1NLI",
            "approach",
            "and",
            "the",
            "classi\ufb01cation-based",
            "\u03b1NLI",
            "ap-",
            "proach",
            "to",
            "evaluate",
            "if",
            "the",
            "\ufb01rst",
            "can",
            "act",
            "as",
            "an",
            "ap-",
            "proximation",
            "for",
            "the",
            "performance",
            "expected",
            "by",
            "the",
            "second",
            ".",
            "We",
            "use",
            "the",
            "pre-trained",
            "transformer",
            "mod-",
            "els",
            "which",
            "are",
            "available",
            "on",
            "the",
            "HuggingFace",
            "(",
            "Wolf",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            "hub",
            ".",
            "The",
            "full",
            "list",
            "of",
            "models",
            "we",
            "use",
            "is",
            "listed",
            "in",
            "Table",
            "1",
            ".",
            "The",
            "code",
            "for",
            "the",
            "experiments",
            "is",
            "available",
            "online.4",
            ".",
            "4.1",
            "Dataset",
            "All",
            "of",
            "our",
            "experiments",
            "were",
            "run",
            "on",
            "the",
            "train",
            "and",
            "validation",
            "split",
            "in",
            "the",
            "ART",
            "dataset",
            "provided",
            "for",
            "the",
            "\u03b1NLI",
            "challenge",
            "(",
            "Bhagavatula",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            ".",
            "It",
            "consists",
            "of",
            "169,654",
            "training",
            "and",
            "1,532",
            "validation",
            "samples",
            ",",
            "each",
            "consisting",
            "of",
            "two",
            "observations",
            "and",
            "two",
            "hypotheses",
            "obtained",
            "from",
            "a",
            "narrative",
            "short",
            "story",
            "corpus",
            "and",
            "augmented",
            "with",
            "wrong",
            "hypothe-",
            "ses",
            "written",
            "by",
            "crowd-sourced",
            "workers",
            ".",
            "The",
            "training",
            "data",
            "contains",
            "repetitions",
            "of",
            "the",
            "same",
            "(",
            "o1",
            ",",
            "o2",
            ")",
            "pairs",
            "with",
            "different",
            "sets",
            "of",
            "hypotheses",
            ",",
            "ranging",
            "from",
            "one",
            "plausible",
            "and",
            "one",
            "implausible",
            "hypothesis",
            "to",
            "two",
            "plausible",
            "hypotheses",
            "where",
            "one",
            "of",
            "them",
            "is",
            "more",
            "plausible",
            ".",
            "The",
            "validation",
            "set",
            "was",
            "constructed",
            "using",
            "adversarial",
            "\ufb01ltering",
            ",",
            "which",
            "se-",
            "lects",
            "one",
            "plausible",
            "and",
            "one",
            "implausible",
            "hypothesis",
            "4https",
            ":",
            "//github.com/Vaibhavs10/anli-performance-",
            "prediction",
            "for",
            "each",
            "set",
            "of",
            "observations",
            "that",
            "are",
            "hard",
            "to",
            "dis-",
            "tinguish",
            ".",
            "This",
            "increases",
            "the",
            "probability",
            "that",
            "the",
            "instances",
            "are",
            "free",
            "of",
            "annotation",
            "artifacts",
            ",",
            "which",
            "the",
            "authors",
            "de\ufb01ned",
            "as",
            "\u201c",
            "unintentional",
            "patterns",
            "in",
            "the",
            "data",
            "that",
            "leak",
            "information",
            "about",
            "the",
            "target",
            "label",
            "\u201d",
            "(",
            "Bhagavatula",
            "et",
            "al.",
            ",",
            "2020",
            ")",
            ".",
            "4.2",
            "Experimental",
            "Setup",
            "All",
            "of",
            "our",
            "classi\ufb01cation",
            "and",
            "similarity",
            "experiments",
            "were",
            "run",
            "on",
            "an",
            "Nvidia",
            "RTX",
            "2080",
            "GPU",
            ".",
            "For",
            "training",
            "the",
            "classi\ufb01er",
            "we",
            "used",
            "the",
            "maximum",
            "batch",
            "size",
            "that",
            "\ufb01t",
            "on",
            "the",
            "GPU",
            "(",
            "which",
            "is",
            "different",
            "for",
            "different",
            "sized",
            "models",
            ",",
            "ranging",
            "between",
            "12",
            "and",
            "128",
            ")",
            ".",
            "For",
            "similar-",
            "ity",
            "experiments",
            ",",
            "we",
            "only",
            "infer",
            "the",
            "embeddings",
            "from",
            "pre-trained",
            "models",
            ".",
            "For",
            "hyperparameter",
            "selection",
            ",",
            "to",
            "keep",
            "the",
            "comparison",
            "fair",
            ",",
            "we",
            "tuned",
            "the",
            "batch",
            "size",
            "and",
            "learning",
            "rate",
            "and",
            "considered",
            "the",
            "same",
            "set",
            "of",
            "possible",
            "combinations",
            "across",
            "all",
            "the",
            "models",
            ".",
            "The",
            "speci\ufb01c",
            "values",
            "used",
            "for",
            "each",
            "model",
            "are",
            "available",
            "in",
            "Table",
            "2",
            "in",
            "the",
            "appendix",
            ".",
            "We",
            "train",
            "for",
            "3",
            "epochs",
            "with",
            "learning",
            "rates",
            "ranging",
            "[",
            "10\u22125",
            ";",
            "9",
            "\u00b7",
            "10\u22125",
            "]",
            "and",
            "a",
            "weight",
            "decay",
            "of",
            "0.01",
            ".",
            "For",
            "each",
            "pre-trained",
            "model",
            ",",
            "we",
            "pick",
            "the",
            "one",
            "that",
            "achieved",
            "the",
            "highest",
            "accuracy",
            "on",
            "the",
            "validation",
            "set",
            ".",
            "4.3",
            "Evaluation",
            "and",
            "Results",
            "Table",
            "1",
            "shows",
            "the",
            "results",
            "as",
            "accuracy",
            "scores",
            ",",
            "ob-",
            "tained",
            "with",
            "each",
            "pre-trained",
            "model",
            "when",
            "using",
            "cosine",
            "similarity",
            "and",
            "when",
            "using",
            "a",
            "classi\ufb01er",
            "built",
            "on",
            "top",
            "of",
            "it",
            ".",
            "We",
            "also",
            "show",
            "the",
            "training",
            "runtimes",
            ".",
            "100",
            "80",
            "60",
            ".",
            "c",
            "c",
            "a",
            "n",
            "o",
            "i",
            "t",
            "a",
            "c",
            "\ufb01",
            "s",
            "s",
            "a",
            "c",
            "i",
            "l",
            "46",
            "48",
            "50",
            "52",
            "54",
            "similarity",
            "acc",
            ".",
            "Figure",
            "1",
            ":",
            "Relation",
            "between",
            "similarity",
            "and",
            "classi\ufb01cation",
            "accuracy",
            "scores",
            ".",
            "Note",
            "that",
            "the",
            "similarities",
            "are",
            "closer",
            "to",
            "each",
            "other",
            "than",
            "the",
            "classi\ufb01cation",
            "values",
            ",",
            "therefore",
            "we",
            "chose",
            "a",
            "different",
            "scale",
            ".",
            "The",
            "primary",
            "observation",
            "is",
            "that",
            "the",
            "accuracy",
            "scores",
            "of",
            "classi\ufb01cation",
            "and",
            "similarity",
            "are",
            "corre-",
            "lated",
            ".",
            "This",
            "can",
            "be",
            "seen",
            "in",
            "Figure",
            "1",
            ".",
            "The",
            "Pearson",
            "correlation",
            "coef\ufb01cient",
            "is",
            "r",
            "=",
            ".65",
            "(",
            "p",
            "=",
            "0.005",
            ")",
            ".",
            "The",
            "Spearman",
            "\u2019",
            "s",
            "correlation",
            "coef\ufb01cient",
            "is",
            "\u03c1",
            "=",
            ".67",
            "(",
            "p",
            "=",
            "0.003",
            ")",
            ",",
            "indicating",
            "that",
            "the",
            "ranking",
            "obtained",
            "with",
            "the",
            "similarity-based",
            "prediction",
            "is",
            "a",
            "reliable",
            "indicator",
            "that",
            "is",
            "helpful",
            "for",
            "model",
            "selection",
            ".",
            "Ad-",
            "ditionally",
            ",",
            "model",
            "\ufb01ne-tuning",
            "takes",
            "on",
            "average",
            "620",
            "times",
            "longer",
            "than",
            "the",
            "similarity-based",
            "estimate",
            ".",
            "Tuning",
            "the",
            "hyperparameters",
            "involved",
            "training",
            "each",
            "model",
            "multiple",
            "times",
            ".",
            "5",
            "Conclusions",
            "&",
            "Future",
            "Work",
            "In",
            "this",
            "paper",
            ",",
            "we",
            "have",
            "shown",
            "that",
            "similarity",
            "mea-",
            "sures",
            "based",
            "on",
            "the",
            "distributional",
            "semantic",
            "represen-",
            "tation",
            "in",
            "pre-trained",
            "transformer",
            "models",
            "serve",
            "as",
            "an",
            "effective",
            "proxy",
            "for",
            "\ufb01ne-tuned",
            "transformer-based",
            "classi\ufb01cation",
            "in",
            "\u03b1NLI",
            ".",
            "Since",
            "\ufb01ne-tuning",
            "a",
            "trans-",
            "former",
            "model",
            "takes",
            "notably",
            "more",
            "time",
            "than",
            "per-",
            "forming",
            "similarity",
            "comparisons",
            ",",
            "our",
            "approach",
            "sup-",
            "ports",
            "ef\ufb01cient",
            "model",
            "selection",
            "procedures",
            ".",
            "Future",
            "work",
            "should",
            "investigate",
            "the",
            "suitability",
            "of",
            "similarity-",
            "based",
            "performance",
            "prediction",
            "for",
            "other",
            "similar",
            "tasks",
            ",",
            "like",
            "next",
            "sentence",
            "prediction",
            ",",
            "question",
            "an-",
            "swering",
            ",",
            "summarization",
            ".",
            "References",
            "Samuel",
            "R.",
            "Bowman",
            ",",
            "Gabor",
            "Angeli",
            ",",
            "Christopher",
            "Potts",
            ",",
            "and",
            "Christopher",
            "D.",
            "Manning",
            ".",
            "2015",
            ".",
            "A",
            "large",
            "anno-",
            "tated",
            "corpus",
            "for",
            "learning",
            "natural",
            "language",
            "inference",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "2015",
            "Conference",
            "on",
            "Empiri-",
            "cal",
            "Methods",
            "in",
            "Natural",
            "Language",
            "Processing",
            ",",
            "pages",
            "632\u2013642",
            ",",
            "Lisbon",
            ",",
            "Portugal",
            ".",
            "Association",
            "for",
            "Compu-",
            "tational",
            "Linguistics",
            ".",
            "Stanley",
            "Chen",
            ".",
            "2009",
            ".",
            "Performance",
            "prediction",
            "for",
            "expo-",
            "nential",
            "language",
            "models",
            ".",
            "In",
            "Proceedings",
            "of",
            "Human",
            "Language",
            "Technologies",
            ":",
            "The",
            "2009",
            "Annual",
            "Confer-",
            "ence",
            "of",
            "the",
            "North",
            "American",
            "Chapter",
            "of",
            "the",
            "Associa-",
            "tion",
            "for",
            "Computational",
            "Linguistics",
            ",",
            "pages",
            "450\u2013458",
            ",",
            "Boulder",
            ",",
            "Colorado",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Jonathan",
            "H.",
            "Clark",
            ",",
            "Dan",
            "Garrette",
            ",",
            "Iulia",
            "Turc",
            ",",
            "and",
            "John",
            "Wieting",
            ".",
            "2021",
            ".",
            "CANINE",
            ":",
            "pre-training",
            "an",
            "ef\ufb01cient",
            "tokenization-free",
            "encoder",
            "for",
            "language",
            "representa-",
            "tion",
            ".",
            "CoRR",
            ",",
            "abs/2103.06874",
            ".",
            "Kevin",
            "Clark",
            ",",
            "Minh-Thang",
            "Luong",
            ",",
            "Quoc",
            "V.",
            "Le",
            ",",
            "and",
            "Christopher",
            "D.",
            "Manning",
            ".",
            "2020",
            ".",
            "Electra",
            ":",
            "Pre-",
            "training",
            "text",
            "encoders",
            "as",
            "discriminators",
            "rather",
            "than",
            "In",
            "International",
            "Conference",
            "on",
            "Learn-",
            "generators",
            ".",
            "ing",
            "Representations",
            ".",
            "Jacob",
            "Devlin",
            ",",
            "Ming-Wei",
            "Chang",
            ",",
            "Kenton",
            "Lee",
            ",",
            "and",
            "Kristina",
            "Toutanova",
            ".",
            "2019",
            ".",
            "BERT",
            ":",
            "Pre-training",
            "of",
            "deep",
            "bidirectional",
            "transformers",
            "for",
            "language",
            "under-",
            "In",
            "Proceedings",
            "of",
            "the",
            "2019",
            "Conference",
            "standing",
            ".",
            "of",
            "the",
            "North",
            "American",
            "Chapter",
            "of",
            "the",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ":",
            "Human",
            "Language",
            "Technologies",
            ",",
            "Volume",
            "1",
            "(",
            "Long",
            "and",
            "Short",
            "Papers",
            ")",
            ",",
            "pages",
            "4171\u20134186",
            ",",
            "Minneapolis",
            ",",
            "Minnesota",
            ".",
            "Associ-",
            "ation",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Pengcheng",
            "He",
            ",",
            "Xiaodong",
            "Liu",
            ",",
            "Jianfeng",
            "Gao",
            ",",
            "and",
            "Weizhu",
            "Chen",
            ".",
            "2021",
            ".",
            "Deberta",
            ":",
            "Decoding-enhanced",
            "In",
            "International",
            "bert",
            "with",
            "disentangled",
            "attention",
            ".",
            "Conference",
            "on",
            "Learning",
            "Representations",
            ".",
            "Jeremy",
            "Howard",
            "and",
            "Sebastian",
            "Ruder",
            ".",
            "2018",
            ".",
            "Universal",
            "language",
            "model",
            "\ufb01ne-tuning",
            "for",
            "text",
            "classi\ufb01cation",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "56th",
            "Annual",
            "Meeting",
            "of",
            "the",
            "As-",
            "sociation",
            "for",
            "Computational",
            "Linguistics",
            "(",
            "Volume",
            "1",
            ":",
            "Long",
            "Papers",
            ")",
            ",",
            "pages",
            "328\u2013339",
            ",",
            "Melbourne",
            ",",
            "Australia",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Forrest",
            "Iandola",
            ",",
            "Albert",
            "Shaw",
            ",",
            "Ravi",
            "Krishna",
            ",",
            "and",
            "Kurt",
            "Keutzer",
            ".",
            "2020",
            ".",
            "SqueezeBERT",
            ":",
            "What",
            "can",
            "computer",
            "vision",
            "teach",
            "NLP",
            "about",
            "ef\ufb01cient",
            "neural",
            "networks",
            "?",
            "In",
            "Proceedings",
            "of",
            "SustaiNLP",
            ":",
            "Workshop",
            "on",
            "Simple",
            "and",
            "Ef\ufb01cient",
            "Natural",
            "Language",
            "Processing",
            ",",
            "pages",
            "124\u2013135",
            ",",
            "Online",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Chandra",
            "Bhagavatula",
            ",",
            "Ronan",
            "Le",
            "Bras",
            ",",
            "Chaitanya",
            "Malaviya",
            ",",
            "Keisuke",
            "Sakaguchi",
            ",",
            "Ari",
            "Holtzman",
            ",",
            "Han-",
            "nah",
            "Rashkin",
            ",",
            "Doug",
            "Downey",
            ",",
            "Wen",
            "tau",
            "Yih",
            ",",
            "and",
            "Yejin",
            "Choi",
            ".",
            "2020",
            ".",
            "Abductive",
            "commonsense",
            "reasoning",
            ".",
            "In",
            "International",
            "Conference",
            "on",
            "Learning",
            "Representa-",
            "tions",
            ".",
            "Sehoon",
            "Kim",
            ",",
            "Amir",
            "Gholami",
            ",",
            "Zhewei",
            "Yao",
            ",",
            "Michael",
            "W.",
            "Mahoney",
            ",",
            "and",
            "Kurt",
            "Keutzer",
            ".",
            "2021",
            ".",
            "I-bert",
            ":",
            "Integer-",
            "only",
            "bert",
            "quantization",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "38th",
            "International",
            "Conference",
            "on",
            "Machine",
            "Learning",
            ",",
            "vol-",
            "ume",
            "139",
            "of",
            "Proceedings",
            "of",
            "Machine",
            "Learning",
            "Re-",
            "search",
            ",",
            "pages",
            "5506\u20135518",
            ".",
            "PMLR",
            ".",
            "Zhenzhong",
            "Lan",
            ",",
            "Mingda",
            "Chen",
            ",",
            "Sebastian",
            "Goodman",
            ",",
            "Kevin",
            "Gimpel",
            ",",
            "Piyush",
            "Sharma",
            ",",
            "and",
            "Radu",
            "Soricut",
            ".",
            "2020",
            ".",
            "ALBERT",
            ":",
            "A",
            "lite",
            "BERT",
            "for",
            "self-supervised",
            "In",
            "Proceed-",
            "learning",
            "of",
            "language",
            "representations",
            ".",
            "ings",
            "of",
            "the",
            "International",
            "Conference",
            "on",
            "Learning",
            "Representations",
            ".",
            "Wei",
            "Li",
            ",",
            "Can",
            "Gao",
            ",",
            "Guocheng",
            "Niu",
            ",",
            "Xinyan",
            "Xiao",
            ",",
            "Hao",
            "Liu",
            ",",
            "Jiachen",
            "Liu",
            ",",
            "Hua",
            "Wu",
            ",",
            "and",
            "Haifeng",
            "Wang",
            ".",
            "2021",
            ".",
            "UNIMO",
            ":",
            "Towards",
            "uni\ufb01ed-modal",
            "understanding",
            "and",
            "generation",
            "via",
            "cross-modal",
            "contrastive",
            "learning",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            "and",
            "the",
            "11th",
            "International",
            "Joint",
            "Conference",
            "on",
            "Natural",
            "Lan-",
            "guage",
            "Processing",
            "(",
            "Volume",
            "1",
            ":",
            "Long",
            "Papers",
            ")",
            ",",
            "pages",
            "2592\u20132607",
            ",",
            "Online",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "the",
            "59th",
            "Annual",
            "Meeting",
            "of",
            "Xueqing",
            "Liu",
            "and",
            "Chi",
            "Wang",
            ".",
            "2021",
            ".",
            "An",
            "empirical",
            "study",
            "on",
            "hyperparameter",
            "optimization",
            "for",
            "\ufb01ne-tuning",
            "pre-",
            "In",
            "Proceedings",
            "of",
            "the",
            "trained",
            "language",
            "models",
            ".",
            "59th",
            "Annual",
            "Meeting",
            "of",
            "the",
            "Association",
            "for",
            "Compu-",
            "tational",
            "Linguistics",
            "and",
            "the",
            "11th",
            "International",
            "Joint",
            "Conference",
            "on",
            "Natural",
            "Language",
            "Processing",
            "(",
            "Vol-",
            "ume",
            "1",
            ":",
            "Long",
            "Papers",
            ")",
            ",",
            "pages",
            "2286\u20132300",
            ",",
            "Online",
            ".",
            "As-",
            "sociation",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Yinhan",
            "Liu",
            ",",
            "Myle",
            "Ott",
            ",",
            "Naman",
            "Goyal",
            ",",
            "Jingfei",
            "Du",
            ",",
            "Man-",
            "dar",
            "Joshi",
            ",",
            "Danqi",
            "Chen",
            ",",
            "Omer",
            "Levy",
            ",",
            "Mike",
            "Lewis",
            ",",
            "Luke",
            "Zettlemoyer",
            ",",
            "and",
            "Veselin",
            "Stoyanov",
            ".",
            "2020",
            ".",
            "RoBERTa",
            ":",
            "A",
            "robustly",
            "optimized",
            "BERT",
            "pretraining",
            "approach",
            ".",
            "Nicholas",
            "Lourie",
            ",",
            "Ronan",
            "Le",
            "Bras",
            ",",
            "Chandra",
            "Bhagavat-",
            "ula",
            ",",
            "and",
            "Yejin",
            "Choi",
            ".",
            "2021",
            ".",
            "Unicorn",
            "on",
            "rainbow",
            ":",
            "A",
            "universal",
            "commonsense",
            "reasoning",
            "model",
            "on",
            "a",
            "new",
            "In",
            "Proceedings",
            "of",
            "the",
            "AAAI",
            "multitask",
            "benchmark",
            ".",
            "Conference",
            "on",
            "Arti\ufb01cial",
            "Intelligence",
            ",",
            "pages",
            "13480\u2013",
            "13488",
            ".",
            "Bill",
            "MacCartney",
            "and",
            "Christopher",
            "D.",
            "Manning",
            ".",
            "2008",
            ".",
            "Modeling",
            "semantic",
            "containment",
            "and",
            "exclusion",
            "in",
            "In",
            "Proceedings",
            "of",
            "the",
            "natural",
            "language",
            "inference",
            ".",
            "22nd",
            "International",
            "Conference",
            "on",
            "Computational",
            "Linguistics",
            "(",
            "Coling",
            "2008",
            ")",
            ",",
            "pages",
            "521\u2013528",
            ",",
            "Manch-",
            "ester",
            ",",
            "UK",
            ".",
            "Coling",
            "2008",
            "Organizing",
            "Committee",
            ".",
            "Tom\u00e1s",
            "Mikolov",
            ",",
            "Kai",
            "Chen",
            ",",
            "Greg",
            "Corrado",
            ",",
            "and",
            "Jeffrey",
            "Dean",
            ".",
            "2013",
            ".",
            "Ef\ufb01cient",
            "estimation",
            "of",
            "word",
            "represen-",
            "In",
            "1st",
            "International",
            "Con-",
            "tations",
            "in",
            "vector",
            "space",
            ".",
            "ference",
            "on",
            "Learning",
            "Representations",
            ",",
            "ICLR",
            "2013",
            ",",
            "Scottsdale",
            ",",
            "Arizona",
            ",",
            "USA",
            ",",
            "May",
            "2-4",
            ",",
            "2013",
            ",",
            "Workshop",
            "Track",
            "Proceedings",
            ".",
            "Anshuman",
            "Mishra",
            ",",
            "Dhruvesh",
            "Patel",
            ",",
            "Aparna",
            "Vijayaku-",
            "mar",
            ",",
            "Xiang",
            "Li",
            ",",
            "Pavan",
            "Kapanipathi",
            ",",
            "and",
            "Kartik",
            "Tala-",
            "madupula",
            ".",
            "2020",
            ".",
            "Reading",
            "comprehension",
            "as",
            "natural",
            "language",
            "inference",
            ":",
            "a",
            "semantic",
            "analysis",
            ".",
            "In",
            "Proceed-",
            "ings",
            "of",
            "the",
            "Ninth",
            "Joint",
            "Conference",
            "on",
            "Lexical",
            "and",
            "Computational",
            "Semantics",
            ",",
            "pages",
            "12\u201319",
            ",",
            "Barcelona",
            ",",
            "Spain",
            "(",
            "Online",
            ")",
            ".",
            "Association",
            "for",
            "Computational",
            "Lin-",
            "guistics",
            ".",
            "Arindam",
            "Mitra",
            ",",
            "Pratyay",
            "Banerjee",
            ",",
            "Kuntal",
            "Kumar",
            "Pal",
            ",",
            "Swaroop",
            "Mishra",
            ",",
            "and",
            "Chitta",
            "Baral",
            ".",
            "2020",
            ".",
            "How",
            "addi-",
            "tional",
            "knowledge",
            "can",
            "improve",
            "natural",
            "language",
            "com-",
            "monsense",
            "question",
            "answering",
            "?",
            "Sean",
            "Papay",
            ",",
            "Roman",
            "Klinger",
            ",",
            "and",
            "Sebastian",
            "Pad\u00f3",
            ".",
            "2020",
            ".",
            "Dissecting",
            "span",
            "identi\ufb01cation",
            "tasks",
            "with",
            "per-",
            "In",
            "Proceedings",
            "of",
            "the",
            "2020",
            "formance",
            "prediction",
            ".",
            "Conference",
            "on",
            "Empirical",
            "Methods",
            "in",
            "Natural",
            "Lan-",
            "guage",
            "Processing",
            "(",
            "EMNLP",
            ")",
            ",",
            "pages",
            "4881\u20134895",
            ",",
            "On-",
            "line",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Charles",
            "Sanders",
            "Peirce",
            ".",
            "1931",
            ".",
            "Collected",
            "papers",
            "of",
            "Charles",
            "Sanders",
            "Peirce",
            ".",
            "Harvard",
            "University",
            "Press",
            ".",
            "Jeffrey",
            "Pennington",
            ",",
            "Richard",
            "Socher",
            ",",
            "and",
            "Christopher",
            "Manning",
            ".",
            "2014",
            ".",
            "GloVe",
            ":",
            "Global",
            "vectors",
            "for",
            "word",
            "representation",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "2014",
            "Confer-",
            "ence",
            "on",
            "Empirical",
            "Methods",
            "in",
            "Natural",
            "Language",
            "Processing",
            "(",
            "EMNLP",
            ")",
            ",",
            "pages",
            "1532\u20131543",
            ",",
            "Doha",
            ",",
            "Qatar",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Matthew",
            "E.",
            "Peters",
            ",",
            "Mark",
            "Neumann",
            ",",
            "Mohit",
            "Iyyer",
            ",",
            "Matt",
            "Gardner",
            ",",
            "Christopher",
            "Clark",
            ",",
            "Kenton",
            "Lee",
            ",",
            "and",
            "Luke",
            "Zettlemoyer",
            ".",
            "2018",
            ".",
            "Deep",
            "contextualized",
            "word",
            "rep-",
            "In",
            "Proceedings",
            "of",
            "the",
            "2018",
            "Confer-",
            "resentations",
            ".",
            "ence",
            "of",
            "the",
            "North",
            "American",
            "Chapter",
            "of",
            "the",
            "Associ-",
            "ation",
            "for",
            "Computational",
            "Linguistics",
            ":",
            "Human",
            "Lan-",
            "guage",
            "Technologies",
            ",",
            "Volume",
            "1",
            "(",
            "Long",
            "Papers",
            ")",
            ",",
            "pages",
            "2227\u20132237",
            ",",
            "New",
            "Orleans",
            ",",
            "Louisiana",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Alec",
            "Radford",
            ",",
            "Karthik",
            "Narasimhan",
            ",",
            "Tim",
            "Salimans",
            ",",
            "and",
            "Improving",
            "language",
            "under-",
            "Ilya",
            "Sutskever",
            ".",
            "2018.",
            "standing",
            "by",
            "generative",
            "pre-training",
            ".",
            "Preprint",
            ".",
            "Colin",
            "Raffel",
            ",",
            "Noam",
            "Shazeer",
            ",",
            "Adam",
            "Roberts",
            ",",
            "Kather-",
            "ine",
            "Lee",
            ",",
            "Sharan",
            "Narang",
            ",",
            "Michael",
            "Matena",
            ",",
            "Yanqi",
            "Zhou",
            ",",
            "Wei",
            "Li",
            ",",
            "and",
            "Peter",
            "J.",
            "Liu",
            ".",
            "2020",
            ".",
            "Exploring",
            "the",
            "limits",
            "of",
            "transfer",
            "learning",
            "with",
            "a",
            "uni\ufb01ed",
            "text-to-",
            "text",
            "transformer",
            ".",
            "Journal",
            "of",
            "Machine",
            "Learning",
            "Re-",
            "search",
            ",",
            "21",
            "(",
            "140",
            ")",
            ":1\u201367",
            ".",
            "Nils",
            "Reimers",
            "and",
            "Iryna",
            "Gurevych",
            ".",
            "2019",
            ".",
            "Sentence-",
            "BERT",
            ":",
            "Sentence",
            "embeddings",
            "using",
            "Siamese",
            "BERT-",
            "networks",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "2019",
            "Conference",
            "on",
            "Empirical",
            "Methods",
            "in",
            "Natural",
            "Language",
            "Processing",
            "and",
            "the",
            "9th",
            "International",
            "Joint",
            "Conference",
            "on",
            "Natu-",
            "ral",
            "Language",
            "Processing",
            "(",
            "EMNLP-IJCNLP",
            ")",
            ",",
            "pages",
            "3982\u20133992",
            ",",
            "Hong",
            "Kong",
            ",",
            "China",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Victor",
            "Sanh",
            ",",
            "Lysandre",
            "Debut",
            ",",
            "Julien",
            "Chaumond",
            ",",
            "and",
            "Thomas",
            "Wolf",
            ".",
            "2019",
            ".",
            "Distilbert",
            ",",
            "a",
            "distilled",
            "version",
            "of",
            "bert",
            ":",
            "smaller",
            ",",
            "faster",
            ",",
            "cheaper",
            "and",
            "lighter",
            ".",
            "In",
            "NeurIPS",
            "EMC",
            "\u02c62",
            "Workshop",
            ".",
            "Kaitao",
            "Song",
            ",",
            "Xu",
            "Tan",
            ",",
            "Tao",
            "Qin",
            ",",
            "Jianfeng",
            "Lu",
            ",",
            "and",
            "Tie-",
            "Yan",
            "Liu",
            ".",
            "2020",
            ".",
            "Mpnet",
            ":",
            "Masked",
            "and",
            "permuted",
            "pre-",
            "training",
            "for",
            "language",
            "understanding",
            ".",
            "In",
            "Advances",
            "in",
            "Neural",
            "Information",
            "Processing",
            "Systems",
            ",",
            "volume",
            "33",
            ",",
            "pages",
            "16857\u201316867",
            ".",
            "Curran",
            "Associates",
            ",",
            "Inc.",
            "Zhiqing",
            "Sun",
            ",",
            "Hongkun",
            "Yu",
            ",",
            "Xiaodan",
            "Song",
            ",",
            "Renjie",
            "Liu",
            ",",
            "Yiming",
            "Yang",
            ",",
            "and",
            "Denny",
            "Zhou",
            ".",
            "2020",
            ".",
            "MobileBERT",
            ":",
            "a",
            "compact",
            "task-agnostic",
            "BERT",
            "for",
            "resource-limited",
            "In",
            "Proceedings",
            "of",
            "the",
            "58th",
            "Annual",
            "Meet-",
            "devices",
            ".",
            "ing",
            "of",
            "the",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ",",
            "Manzil",
            "Zaheer",
            ",",
            "Guru",
            "Guruganesh",
            ",",
            "Kumar",
            "Avinava",
            "Dubey",
            ",",
            "Joshua",
            "Ainslie",
            ",",
            "Chris",
            "Alberti",
            ",",
            "Santiago",
            "On-",
            "tanon",
            ",",
            "Philip",
            "Pham",
            ",",
            "Anirudh",
            "Ravula",
            ",",
            "Qifan",
            "Wang",
            ",",
            "Li",
            "Yang",
            ",",
            "et",
            "al",
            ".",
            "2020",
            ".",
            "Big",
            "bird",
            ":",
            "Transformers",
            "for",
            "longer",
            "sequences",
            ".",
            "Advances",
            "in",
            "Neural",
            "Information",
            "Processing",
            "Systems",
            ",",
            "33",
            ".",
            "Yunchang",
            "Zhu",
            ",",
            "Liang",
            "Pang",
            ",",
            "Yanyan",
            "Lan",
            ",",
            "and",
            "Xueqi",
            "Cheng",
            ".",
            "2020",
            ".",
            "L2r\u00b2",
            ":",
            "Leveraging",
            "ranking",
            "for",
            "abduc-",
            "tive",
            "reasoning",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "43rd",
            "Interna-",
            "tional",
            "ACM",
            "SIGIR",
            "Conference",
            "on",
            "Research",
            "and",
            "De-",
            "velopment",
            "in",
            "Information",
            "Retrieval",
            ",",
            "SIGIR",
            "\u2019",
            "20",
            ".",
            "A",
            "Model",
            "Hyperparameters",
            "All",
            "models",
            "were",
            "trained",
            "for",
            "3",
            "epochs",
            "with",
            "a",
            "weight",
            "decay",
            "of",
            "0.01",
            ".",
            "The",
            "batch",
            "size",
            "and",
            "learning",
            "rate",
            "used",
            "for",
            "each",
            "model",
            "can",
            "be",
            "seen",
            "in",
            "Table",
            "2",
            "Model",
            "Learning",
            "rate",
            "Batch",
            "size",
            "albert-base-v2",
            "albert-large-v2",
            "bert-base-uncased",
            "bert-large-uncased",
            "distilbert-base-unc",
            ".",
            "squeezebert/squeezebert-unc",
            ".",
            "google/mobilebert-unc",
            ".",
            "google/canine-s",
            "google/electra-small-discr",
            ".",
            "google/electra-base-discr",
            ".",
            "google/electra-large-discr",
            ".",
            "microsoft/mpnet-base",
            "roberta-base",
            "roberta-large",
            "google/bigbird-roberta-base",
            "kssteven/ibert-roberta-base",
            "distilroberta-base",
            "10\u22125",
            "10\u22125",
            "5",
            "\u00b7",
            "10\u22125",
            "10\u22125",
            "9",
            "\u00b7",
            "10\u22125",
            "7",
            "\u00b7",
            "10\u22125",
            "7",
            "\u00b7",
            "10\u22125",
            "10\u22125",
            "7",
            "\u00b7",
            "10\u22125",
            "3",
            "\u00b7",
            "10\u22125",
            "10\u22125",
            "3",
            "\u00b7",
            "10\u22125",
            "3",
            "\u00b7",
            "10\u22125",
            "10\u22125",
            "10\u22125",
            "3",
            "\u00b7",
            "10\u22125",
            "5",
            "\u00b7",
            "10\u22125",
            "60",
            "20",
            "32",
            "16",
            "128",
            "64",
            "100",
            "24",
            "128",
            "64",
            "16",
            "64",
            "60",
            "12",
            "40",
            "64",
            "80",
            "Table",
            "2",
            ":",
            "The",
            "learning",
            "rate",
            "and",
            "batch",
            "size",
            "that",
            "resulted",
            "in",
            "the",
            "best",
            "classi\ufb01cation",
            "accuracy",
            "for",
            "each",
            "model",
            ".",
            "pages",
            "2158\u20132170",
            ",",
            "Online",
            ".",
            "Association",
            "for",
            "Computa-",
            "tional",
            "Linguistics",
            ".",
            "Ashish",
            "Vaswani",
            ",",
            "Noam",
            "Shazeer",
            ",",
            "Niki",
            "Parmar",
            ",",
            "Jakob",
            "Uszkoreit",
            ",",
            "Llion",
            "Jones",
            ",",
            "Aidan",
            "N",
            "Gomez",
            ",",
            "\u0141",
            "ukasz",
            "Kaiser",
            ",",
            "and",
            "Illia",
            "Polosukhin",
            ".",
            "2017",
            ".",
            "Attention",
            "is",
            "all",
            "you",
            "need",
            ".",
            "In",
            "Advances",
            "in",
            "Neural",
            "Information",
            "Pro-",
            "cessing",
            "Systems",
            ",",
            "volume",
            "30",
            ".",
            "Curran",
            "Associates",
            ",",
            "Inc.",
            "Adina",
            "Williams",
            ",",
            "Nikita",
            "Nangia",
            ",",
            "and",
            "Samuel",
            "Bowman",
            ".",
            "2018",
            ".",
            "A",
            "broad-coverage",
            "challenge",
            "corpus",
            "for",
            "sen-",
            "tence",
            "understanding",
            "through",
            "inference",
            ".",
            "In",
            "Proceed-",
            "ings",
            "of",
            "the",
            "2018",
            "Conference",
            "of",
            "the",
            "North",
            "American",
            "Chapter",
            "of",
            "the",
            "Association",
            "for",
            "Computational",
            "Lin-",
            "guistics",
            ":",
            "Human",
            "Language",
            "Technologies",
            ",",
            "Volume",
            "1",
            "(",
            "Long",
            "Papers",
            ")",
            ",",
            "pages",
            "1112\u20131122",
            ",",
            "New",
            "Orleans",
            ",",
            "Louisiana",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguis-",
            "tics",
            ".",
            "Thomas",
            "Wolf",
            ",",
            "Lysandre",
            "Debut",
            ",",
            "Victor",
            "Sanh",
            ",",
            "Julien",
            "Chaumond",
            ",",
            "Clement",
            "Delangue",
            ",",
            "Anthony",
            "Moi",
            ",",
            "Pier-",
            "ric",
            "Cistac",
            ",",
            "Tim",
            "Rault",
            ",",
            "Remi",
            "Louf",
            ",",
            "Morgan",
            "Funtow-",
            "icz",
            ",",
            "Joe",
            "Davison",
            ",",
            "Sam",
            "Shleifer",
            ",",
            "Patrick",
            "von",
            "Platen",
            ",",
            "Clara",
            "Ma",
            ",",
            "Yacine",
            "Jernite",
            ",",
            "Julien",
            "Plu",
            ",",
            "Canwen",
            "Xu",
            ",",
            "Teven",
            "Le",
            "Scao",
            ",",
            "Sylvain",
            "Gugger",
            ",",
            "Mariama",
            "Drame",
            ",",
            "Quentin",
            "Lhoest",
            ",",
            "and",
            "Alexander",
            "Rush",
            ".",
            "2020",
            ".",
            "Hug-",
            "gingface",
            "\u2019",
            "s",
            "transformers",
            ":",
            "State-of-the-art",
            "natural",
            "lan-",
            "guage",
            "processing",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "2020",
            "Con-",
            "ference",
            "on",
            "Empirical",
            "Methods",
            "in",
            "Natural",
            "Language",
            "Processing",
            ":",
            "System",
            "Demonstrations",
            ",",
            "pages",
            "38\u201345",
            ",",
            "Online",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Mengzhou",
            "Xia",
            ",",
            "Antonios",
            "Anastasopoulos",
            ",",
            "Ruochen",
            "Xu",
            ",",
            "Yiming",
            "Yang",
            ",",
            "and",
            "Graham",
            "Neubig",
            ".",
            "2020",
            ".",
            "Pre-",
            "dicting",
            "performance",
            "for",
            "natural",
            "language",
            "process-",
            "ing",
            "tasks",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "58th",
            "Annual",
            "Meet-",
            "ing",
            "of",
            "the",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ",",
            "pages",
            "8625\u20138646",
            ",",
            "Online",
            ".",
            "Association",
            "for",
            "Computa-",
            "tional",
            "Linguistics",
            ".",
            "Zihuiwen",
            "Ye",
            ",",
            "Pengfei",
            "Liu",
            ",",
            "Jinlan",
            "Fu",
            ",",
            "and",
            "Graham",
            "Neu-",
            "big",
            ".",
            "2021",
            ".",
            "Towards",
            "more",
            "\ufb01ne-grained",
            "and",
            "reliable",
            "NLP",
            "performance",
            "prediction",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "16th",
            "Conference",
            "of",
            "the",
            "European",
            "Chapter",
            "of",
            "the",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ":",
            "Main",
            "Volume",
            ",",
            "pages",
            "3703\u20133714",
            ",",
            "Online",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "zero-shot",
            "Wenpeng",
            "Yin",
            ",",
            "Jamaal",
            "Hay",
            ",",
            "and",
            "Dan",
            "Roth",
            ".",
            "2019.",
            "classi\ufb01cation",
            ":",
            "text",
            "Benchmarking",
            "Datasets",
            ",",
            "evaluation",
            "and",
            "entailment",
            "approach",
            ".",
            "In",
            "Proceedings",
            "of",
            "the",
            "2019",
            "Conference",
            "on",
            "Empiri-",
            "cal",
            "Methods",
            "in",
            "Natural",
            "Language",
            "Processing",
            "and",
            "the",
            "9th",
            "International",
            "Joint",
            "Conference",
            "on",
            "Natural",
            "Language",
            "Processing",
            "(",
            "EMNLP-IJCNLP",
            ")",
            ",",
            "pages",
            "3914\u20133923",
            ",",
            "Hong",
            "Kong",
            ",",
            "China",
            ".",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ".",
            "Wenpeng",
            "Yin",
            ",",
            "Dragomir",
            "Radev",
            ",",
            "and",
            "Caiming",
            "Xiong",
            ".",
            "2021",
            ".",
            "DocNLI",
            ":",
            "A",
            "large-scale",
            "dataset",
            "for",
            "document-",
            "In",
            "Findings",
            "of",
            "level",
            "natural",
            "language",
            "inference",
            ".",
            "the",
            "Association",
            "for",
            "Computational",
            "Linguistics",
            ":",
            "ACL-",
            "IJCNLP",
            "2021",
            ",",
            "pages",
            "4913\u20134922",
            ",",
            "Online",
            ".",
            "Associa-",
            "tion",
            "for",
            "Computational",
            "Linguistics",
            "."
        ]
    },
    {
        "name": "xtandi_pi",
        "sentences": [
            "HIGHLIGHTS OF PRESCRIBING INFORMATION  These highlights do not include all the information needed to use XTANDI\u00ae safely and effectively.",
            "See full prescribing information for XTANDI.",
            "XTANDI\u00ae (enzalutamide) capsules, for oral use XTANDI\u00ae (enzalutamide) tablets, for oral use  Initial U.S. Approval: 2012  --------------------------  RECENT MAJOR CHANGES  --------------------------   Dosage and Administration  Dosing Information (2.1)                    10/2020   ---------------------------  INDICATIONS AND USAGE  --------------------------  XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with:  castration-resistant prostate cancer.",
            "(1)  metastatic castration-sensitive prostate cancer.",
            "(1)  ----------------------  DOSAGE AND ADMINISTRATION  ----------------------  XTANDI 160 mg (two 80 mg tablets or four 40 mg tablets or four 40 mg capsules) administered orally once daily.",
            "Swallow capsules or tablets whole.",
            "(2.1) Patients receiving XTANDI should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.",
            "(2.3)  ---------------------  DOSAGE FORMS AND STRENGTHS  --------------------  Capsule 40 mg (3) Tablet: 40 mg, 80 mg (3)  ------------------------------  CONTRAINDICATIONS  -----------------------------  None.",
            "(4)  -----------------------  WARNINGS AND PRECAUTIONS  ----------------------   Seizure occurred in 0.5% of patients receiving XTANDI.",
            "In patients with predisposing factors, seizures were reported in 2.2% of patients.",
            "Permanently discontinue XTANDI in patients who develop a seizure during treatment.",
            "(5.1)   Posterior reversible encephalopathy syndrome (PRES): Discontinue XTANDI.",
            "(5.2)  Hypersensitivity: Discontinue XTANDI.",
            "(5.3)  Ischemic Heart Disease: Optimize management of cardiovascular risk factors.",
            "Discontinue XTANDI for Grade 3-4 events.",
            "(5.4)  Falls and Fractures occurred in 11% and 10% of patients receiving XTANDI, respectively.",
            "Evaluate patients for fracture and fall risk, and treat patients with bone-targeted agents according to established guidelines.",
            "(5.5)  Embryo-Fetal Toxicity: XTANDI can cause fetal harm and loss of pregnancy.",
            "Advise males with female partners of reproductive potential to use effective contraception.",
            "(5.6, 8.1, 8.3)  ------------------------------  ADVERSE REACTIONS  -----------------------------  -treated patients are asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, and hypertension.",
            "(6.1)  To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",
            "------------------------------  DRUG INTERACTIONS  -----------------------------   Avoid strong CYP2C8 inhibitors, as they can increase the plasma exposure to XTANDI.",
            "If co-administration is necessary, reduce the dose of XTANDI.",
            "(2.2, 7.1)   Avoid strong CYP3A4 inducers as they can decrease the plasma exposure to XTANDI.",
            "If co-administration is necessary, increase the dose of XTANDI.",
            "(2.2, 7.2)  Avoid CYP3A4, CYP2C9 and CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the plasma exposures of these drugs.",
            "If XTANDI is co-administered with warfarin (CYP2C9 substrate), conduct additional INR monitoring.",
            "(7.3)  See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 07/2021  FULL PRESCRIBING INFORMATION: CONTENTS*1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information 2.2 Dose Modifications 2.3 Important Administration Instructions 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Seizure 5.2 Posterior Reversible Encephalopathy Syndrome (PRES) 5.3 Hypersensitivity 5.4 Ischemic Heart Disease 5.5 Falls and Fractures 5.6 Embryo-Fetal Toxicity 6 ADVERSE REACTIONS 6.1 Clinical Trial Experience 6.2 Post-Marketing Experience 7 DRUG INTERACTIONS 7.1 Drugs that Inhibit CYP2C8 7.2 Drugs that Induce CYP3A4 7.3 Effect of XTANDI on Drug Metabolizing Enzymes 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.3 Females and Males of Reproductive Potential 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Patients with Renal Impairment 8.7 Patients with Hepatic Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION  *Sections or subsections omitted from the full prescribing information are not listed.",
            "FULL PRESCRIBING INFORMATION  1 INDICATIONS AND USAGE XTANDI\u00ae is indicated for the treatment of patients with:  castration-resistant prostate cancer (CRPC)  metastatic castration-sensitive prostate cancer (mCSPC) 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information  The recommended dose of XTANDI is 160 mg (two 80 mg tablets or four 40 mg tablets or four 40 mg capsules) administered orally once daily.",
            "XTANDI can be taken with or without food [see Clinical Pharmacology (12.3)].",
            "Swallow capsules or tablets whole.",
            "Do not chew, dissolve, or open the capsules.",
            "Do not cut, crush, or chew the tablets [see How Supplied/Storage and Handling (16)].",
            "2.2 Dose Modifications  mg or 80 mg), if warranted [see Warnings and Precautions (5.1), (5.2)].",
            "Concomitant Strong CYP2C8 Inhibitors The concomitant use of strong CYP2C8 inhibitors should be avoided if possible.",
            "If patients must be co-administered a strong CYP2C8 inhibitor, reduce the XTANDI dose to 80 mg once daily.",
            "If co-administration of the strong inhibitor is discontinued, the XTANDI dose should be returned to the dose used prior to initiation of the strong CYP2C8 inhibitor [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].",
            "Concomitant Strong CYP3A4 Inducers The concomitant use of strong CYP3A4 inducers should be avoided if possible.",
            "If patients must be co-administered a strong CYP3A4 inducer, increase the XTANDI dose from 160 mg to 240 mg once daily.",
            "If co-administration of the strong CYP3A4 inducer is discontinued, the XTANDI dose should be returned to the dose used prior to initiation of the strong CYP3A4 inducer [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].",
            "2.3 Important Administration Instructions  Patients receiving XTANDI should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.",
            "3 DOSAGE FORMS AND STRENGTHS XTANDI 40 mg capsules are white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ.",
            "XTANDI 40 mg tablets are yellow, round, film-coated and debossed with E 40.",
            "XTANDI 80 mg tablets are yellow, oval, film-coated and debossed with E 80.",
            "4 CONTRAINDICATIONS None.",
            "5 WARNINGS AND PRECAUTIONS 5.1 Seizure Seizure occurred in 0.5% of patients receiving XTANDI in seven randomized clinical trials.",
            "In these trials, patients with predisposing factors for seizure were generally excluded.",
            "Seizure occurred from 13 to 1776 days after initiation of XTANDI.",
            "Patients experiencing seizure were permanently discontinued from therapy, and all seizure events resolved.",
            "In a single-arm trial designed to assess the risk of seizure in patients with pre-disposing factors for seizure, 8 of 366 (2.2%) XTANDI-treated patients experienced a seizure.",
            "Three of the 8 patients experienced a second seizure during continued treatment with XTANDI after their first seizure resolved.",
            "It is unknown whether anti-epileptic medications will prevent seizures with XTANDI.",
            "Patients in the study had one or more of the following pre-disposing factors: the use of medications that may lower the seizure threshold (~ 54%), history of traumatic brain or head injury (~ 28%), history of cerebrovascular accident or transient ischemic attack (~ disease from prostate cancer, unexplained loss of consciousness within the last 12 months, past history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection (all < 5%).",
            "Approximately 17% of patients had more than one risk factor.",
            "Advise patients of the risk of developing a seizure while receiving XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.",
            "Permanently discontinue XTANDI in patients who develop a seizure during treatment.",
            "5.2 Posterior Reversible Encephalopathy Syndrome (PRES)  There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving XTANDI [see Adverse Reactions (6.2)].",
            "PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension.",
            "A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI).",
            "Discontinue XTANDI in patients who develop PRES.",
            "5.3 Hypersensitivity  Hypersensitivity reactions, including edema of the face (0.5%), tongue (0.1%), or lip (0.1%) have been observed with enzalutamide in seven randomized clinical trials.",
            "Pharyngeal edema has been reported in post-marketing cases.",
            "Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue XTANDI and promptly seek medical care.",
            "Permanently discontinue XTANDI for serious hypersensitivity reactions.",
            "5.4 Ischemic Heart Disease  In the combined data of four randomized, placebo-controlled clinical studies, ischemic heart disease occurred more commonly in patients on the XTANDI arm compared to patients on the placebo arm (2.9% vs 1.3%).",
            "Grade 3-4 ischemic events occurred in 1.4% of patients on the XTANDI arm compared to 0.7% on the placebo arm.",
            "Ischemic events led to death in 0.4% of patients on the XTANDI arm compared to 0.1% on the placebo arm.",
            "Monitor for signs and symptoms of ischemic heart disease.",
            "Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia.",
            "Discontinue XTANDI for Grade 3-4 ischemic heart disease.",
            "5.5 Falls and Fractures  Falls and fractures occurred in patients receiving XTANDI.",
            "Evaluate patients for fracture and fall risk.",
            "Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents.",
            "In the combined data of four randomized, placebo-controlled clinical studies, falls occurred in 11% of patients treated with XTANDI compared to 4% of patients treated with placebo.",
            "Falls were not associated with loss of consciousness or seizure.",
            "Fractures occurred in 10% of patients treated with XTANDI and in 4% of patients treated with placebo.",
            "Grade 3-4 fractures occurred in 3% of patients treated with XTANDI and in 2% of patients treated with placebo.",
            "The median time to onset of fracture was 336 days (range: 2 to 1914 days) for patients treated with XTANDI.",
            "Routine bone density assessment and treatment of osteoporosis with bone-targeted agents were not performed in the studies.",
            "5.6 Embryo-Fetal Toxicity  The safety and efficacy of XTANDI have not been established in females.",
            "Based on animal reproductive studies and mechanism of action, XTANDI can cause fetal harm and loss of pregnancy when administered to a pregnant female.",
            "Advise males with female partners of reproductive potential to use effective contraception during treatment with XTANDI and for 3 months after the last dose of XTANDI [see Use in Specific Populations (8.1, 8.3)].",
            "6 ADVERSE REACTIONS The following is discussed in more detail in other sections of the labeling:  Seizure [see Warnings and Precautions (5.1)]  Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.2)]  Hypersensitivity [see Warnings and Precautions (5.3)]  Ischemic Heart Disease [see Warnings and Precautions (5.4)]  Falls and Fractures [see Warnings and Precautions (5.5)] 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",
            "The data in WARNINGS and PRECAUTIONS reflect seven randomized, controlled trials [AFFIRM, PREVAIL, TERRAIN, PROSPER, ARCHES, Asian PREVAIL (NCT02294461), and STRIVE (NCT01664923)] that were pooled to conduct safety analyses in patients with CRPC (N=3509) or mCSPC (N= 572) treated with XTANDI.",
            "Patients received XTANDI 160 mg (N= 4081) or placebo orally once daily (N= 2472) or bicalutamide 50 mg orally once daily (N= 387).",
            "All patients continued androgen deprivation therapy (ADT).",
            "In these seven trials, the median duration of treatment was 13.8 months (range: <0.1 to 87.6) in the XTANDI group.",
            "In four placebo-controlled trials (AFFIRM, PROSPER, PREVAIL, and ARCHES), the median duration of treatment was 14.3 months (range: <0.1 to 87.6) in the XTANDI group [see Clinical Studies (14)].",
            "In these four trials, the most common adverse rea 2% over placebo) in the XTANDI-treated patients were asthenia/fatigue, back pain, hot flush, constipation, arthralgia, decreased appetite, diarrhea, and hypertension.",
            "AFFIRM (NCT00974311): XTANDI versus Placebo in Metastatic CRPC Following Chemotherapy AFFIRM enrolled 1199 patients with metastatic CRPC who had previously received docetaxel.",
            "The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo.",
            "During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids.",
            "Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients.",
            "Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients.",
            "The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients.",
            "Table 1 shows adverse refrequency in the XTANDI arm compared to the placebo arm.",
            "Table 1.",
            "Adverse Reactions in AFFIRM  XTANDI (N = 800) Placebo (N = 399) Grade 1-41 (%) Grade 3-4 (%) Grade 1-4 (%) Grade 3-4 (%) General Disorders       Asthenic Conditions2 51 9.0 44 9.3       Peripheral Edema 15 1.0 13 0.8 Musculoskeletal and Connective Tissue Disorders       Back Pain 26 5.3 24 4.0       Arthralgia 21 2.5 17 1.8       Musculoskeletal Pain 15 1.3 12 0.3       Muscular Weakness 9.8 1.5 6.8 1.8       Musculoskeletal Stiffness 2.6 0.3 0.3 0.0 Gastrointestinal Disorders       Diarrhea 22 1.1 18 0.3 Vascular Disorders       Hot Flush 20 0.0 10 0.0       Hypertension 6.4 2.1 2.8 1.3 Nervous System Disorders       Headache 12 0.9 5.5 0.0       Dizziness3 9.5 0.5 7.5 0.5       Spinal Cord Compression and Cauda Equina Syndrome 7.4 6.6 4.5 3.8       Paresthesia 6.6 0.0 4.5 0.0       Mental Impairment Disorders4 4.3 0.3 1.8 0.0       Hypoesthesia 4.0 0.3 1.8 0.0 Infections and Infestations       Upper Respiratory Tract Infection5 11 0.0 6.5 0.3       Lower Respiratory Tract And Lung Infection6 8.5 2.4 4.8 1.3 Psychiatric Disorders       Insomnia 8.8 0.0 6.0 0.5       Anxiety 6.5 0.3 4.0 0.0 Renal and Urinary Disorders       Hematuria 6.9 1.8 4.5 1.0       Pollakiuria 4.8 0.0 2.5 0.0 Injury, Poisoning and Procedural Complications       Fall 4.6 0.3 1.3 0.0       Non-pathologic Fractures  4.0 1.4 0.8 0.3 Skin and Subcutaneous Tissue Disorders       Pruritus 3.8 0.0 1.3 0.0       Dry Skin 3.5 0.0 1.3 0.0 Respiratory Disorders       Epistaxis 3.3 0.1 1.3 0.3 1.",
            "CTCAE v4 2.",
            "Includes asthenia and fatigue.",
            "3.",
            "Includes dizziness and vertigo.",
            "4.",
            "Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.",
            "5.",
            "Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.",
            "6.",
            "Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.",
            "PREVAIL (NCT01212991): XTANDI versus Placebo in Chemotherapy-na\u00efve Metastatic CRPC PREVAIL enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 1715 received at least one dose of study drug.",
            "The median duration of treatment was 17.5 months with XTANDI and 4.6 months with placebo.",
            "Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of placebo-treated patients.",
            "Discontinuations due to adverse events were reported for 6% of XTANDI-treated patients.",
            "The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm.",
            "Table 2 frequency in the XTANDI arm compared to the placebo arm.",
            "Table 2.",
            "Adverse Reactions in PREVAIL  XTANDI (N = 871) Placebo (N = 844) Grade 1-41 (%) Grade 3-4 (%) Grade 1-4 (%) Grade 3-4 (%) General Disorders       Asthenic Conditions2 47 3.4 33 2.8       Peripheral Edema 12 0.2 8.2 0.4 Musculoskeletal and Connective Tissue Disorders       Back Pain 29 2.5 22 3.0       Arthralgia 21 1.6 16 1.1 Gastrointestinal Disorders       Constipation 23 0.7 17 0.4       Diarrhea 17 0.3 14 0.4 Vascular Disorders       Hot Flush 18 0.1 7.8 0.0       Hypertension 14 7.2 4.1 2.3 Nervous System Disorders       Dizziness3 11 0.3 7.1 0.0       Headache 11 0.2 7.0 0.4       Dysgeusia 7.6 0.1 3.7 0.0       Mental Impairment Disorders4 5.7 0.0 1.3 0.1       Restless Legs Syndrome 2.1 0.1 0.4 0.0 Respiratory Disorders       Dyspnea5 11 0.6 8.5 0.6 Infections and Infestations       Upper Respiratory Tract Infection6 16 0.0 11 0.0       Lower Respiratory Tract And Lung Infection7 7.9 1.5 4.7 1.1 Psychiatric Disorders       Insomnia 8.2 0.1 5.7 0.0 Renal and Urinary Disorders       Hematuria 8.8 1.3 5.8 1.3 Injury, Poisoning and Procedural Complications       Fall 13 1.6 5.3 0.7       Non-Pathological Fracture 8.8 2.1 3.0 1.1 Metabolism and Nutrition Disorders       Decreased Appetite 19 0.3 16 0.7 Investigations       Weight Decreased 12 0.8 8.5 0.2 Reproductive System and Breast Disorders       Gynecomastia 3.4 0.0 1.4 0.0 1.",
            "CTCAE v4 2.",
            "Includes asthenia and fatigue.",
            "3.",
            "Includes dizziness and vertigo.",
            "4.",
            "Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.",
            "5.",
            "Includes dyspnea, exertional dyspnea, and dyspnea at rest.",
            "6.",
            "Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.",
            "7.",
            "Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.",
            "TERRAIN (NCT01288911): XTANDI versus Bicalutamide in Chemotherapy-na\u00efve Metastatic CRPC TERRAIN enrolled 375 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 372 received at least one dose of study drug.",
            "The median duration of treatment was 11.6 months with XTANDI and 5.8 months with bicalutamide.",
            "Discontinuations with an adverse event as the primary reason were reported for 7.6% of XTANDI-treated patients and 6.3% of bicalutamide-treated patients.",
            "The most common adverse reactions leading to treatment discontinuation were back pain and pathological fracture, which occurred in 3.8% of XTANDI-treated patients for each event and in 2.1% and 1.6% of bicalutamide-treated patients, respectively.",
            "Table 3 shows overall and common XTANDI-treated patients.",
            "Table 3.",
            "Adverse Reactions in TERRAIN  XTANDI (N = 183) Bicalutamide (N = 189) Grade 1-41 (%) Grade 3-4 (%) Grade 1-4 (%) Grade 3-4 (%) Overall 94 39 94 38 General Disorders       Asthenic Conditions2 32 1.6 23 1.1 Musculoskeletal and Connective Tissue Disorders       Back Pain 19 2.7 18 1.6       Musculoskeletal Pain3 16 1.1 14 0.5 Vascular Disorders       Hot Flush 15 0 11 0       Hypertension 14 7.1 7.4 4.2 Gastrointestinal Disorders       Nausea 14 0 18 0       Constipation 13 1.1 13 0.5       Diarrhea 12 0 9.0 1.1 Infections and Infestations       Upper Respiratory Tract Infection4 12 0 6.3 0.5 Investigational       Weight Loss 11 0.5 7.9 0.5 1.",
            "CTCAE v 4 2.",
            "Including asthenia and fatigue.",
            "3.",
            "Including musculoskeletal pain and pain in extremity.",
            "4.",
            "Including nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.",
            "PROSPER (NCT02003924): XTANDI versus Placebo in Non-metastatic CRPC Patients PROSPER enrolled 1401 patients with non-metastatic CRPC, of whom 1395 received at least one dose of study drug.",
            "Patients were randomized 2:1 and received either XTANDI at a dose of 160 mg once daily (N = 930) or placebo (N = 465).",
            "The median duration of treatment at the time of analysis was 18.4 months (range: 0.0 to 42 months) with XTANDI and 11.1 months (range: 0.0 to 43 months) with placebo.",
            "Overall, 32 patients (3.4%) receivin 2 patients included coronary artery disorders (n = 7), sudden death (n = 2), cardiac arrhythmias (n = 2), general physical health deterioration (n = 2), stroke (n = 2), and secondary malignancy (n = 5; one each of acute myeloid leukemia, brain neoplasm, mesothelioma, small cell lung cancer, and malignant neoplasm of unknown primary site).",
            "Three patients (0.6%) receiving placebo died from adverse events of cardiac arrest (n = 1), left ventricular failure (n = 1), and pancreatic carcinoma (n = 1).",
            "Grade 3 or higher adverse reactions were reported among 31% of XTANDI-treated patients and 23% of placebo-treated patients.",
            "Discontinuations with an adverse event as the primary reason were reported for 9.4% of XTANDI-treated patients and 6.0% of placebo-treated patients.",
            "Of these, the most common adverse event leading to treatment discontinuation was fatigue, which occurred in 1.6% of the XTANDI-treated patients compared to none of the placebo-treated patients.",
            "Table 4 XTANDI arm than in the placebo arm.",
            "Table 4.",
            "Adverse Reactions in PROSPER  XTANDI (N = 930) Placebo (N = 465) Grade 1-41 (%) Grade 3-4 (%) Grade 1-4 (%) Grade 3-4 (%) Metabolism and Nutrition Disorders       Decreased Appetite 9.6 0.2 3.9 0.2 Nervous System Disorders       Dizziness2 12 0.5 5.2 0       Headache 9.1 0.2 4.5 0       Cognitive and Attention Disorders3 4.6 0.1 1.5 0 Vascular Disorders       Hot Flush 13 0.1 7.7 0       Hypertension 12 4.6 5.2 2.2 Gastrointestinal Disorders       Nausea 11 0.3 8.6 0       Constipation 9.1 0.2 6.9 0.4 General Disorders and Administration Site Conditions       Asthenic Conditions4 40 4.0 20 0.9 Investigations       Weight Decreased 5.9 0.2 1.5 0 Injury, Poisoning and Procedural Complications       Fall 11 1.3 4.1 0.6       Fractures5 9.8 2.0 4.9 1.7 Psychiatric Disorders       Anxiety 2.8 0.2 0.4 0 1.",
            "CTCAE v 4 2.",
            "Includes dizziness and vertigo.",
            "3.",
            "Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.",
            "4.",
            "Includes asthenia and fatigue.",
            "5.",
            "Includes all osseous fractures from all sites.",
            "ARCHES (NCT02677896): XTANDI versus Placebo in Metastatic CSPC Patients ARCHES randomized 1150 patients with mCSPC, of whom 1146 received at least one dose of study drug.",
            "All patients received either a gonadotropin-releasing hormone (GnRH) analogue concurrently or had bilateral orchiectomy.",
            "Patients received either XTANDI at a dose of 160 mg once daily (N=572) or placebo (N=574).",
            "The median duration of treatment was 12.8 months (range: 0.2 to 26.6 months) with XTANDI and 11.6 months (range: 0.2 to 24.6 months) with placebo.",
            "2 patients included heart disease (n=3), sepsis (n=2) and pulmonary embolism (n=2).",
            "Eight patients (1.4%) receiving placebo died from  2 patients included heart disease (n=2) and sudden death (n=2).",
            "Grade 3 or higher adverse events were reported in 24% of patients treated with XTANDI.",
            "Permanent discontinuation due to adverse events as the primary reason was reported in 4.9% of XTANDI-treated patients and 3.7% of placebo-treated patients.",
            "The most common adverse events resulting in permanent discontinuation in XTANDI-treated patients were alanine aminotransferase increased, aspartate aminotransferase elevation, and seizure, each in 0.3%.",
            "The most common adverse events leading to permanent discontinuation in placebo-treated patients were arthralgia, and fatigue, each in 0.3%.",
            "Dose reductions due to an adverse reaction occurred in 4.4% of patients who received XTANDI.",
            "Fatigue/asthenia was the most frequent adverse reaction requiring dose reduction in 2.1% of XTANDI-treated patients and 0.7% of placebo-treated patients.",
            "Table 5 in the placebo arm.",
            "Table 5.",
            "Adverse Reactions in ARCHES  XTANDI (N = 572) Placebo (N = 574) Grade 1-41 (%) Grade 3-4 (%) Grade 1-4 (%) Grade 3-4 (%) Metabolism and Nutrition Disorders Decreased Appetite 4.9 0.2 2.6 0 Nervous System Disorders Cognitive and Memory Impairment2 4.5 0.7 2.1 0 Restless Legs Syndrome 2.4 0 0.3 0 Vascular Disorders Hot Flush 27 0.3 22 0 Hypertension 8.0 3.3 5.6 1.7 General Disorders and Administration Site Conditions Asthenic conditions3 24 1.7 20 1.6 Musculoskeletal and Connective Tissue Disorders Musculoskeletal Pain 6.3 0.2 4.0 0.2 Injury, Poisoning and Procedural Complications Fractures4 6.5 1.0 4.2 1.0 1.",
            "CTCAE v 4.03.",
            "2.",
            "Includes memory impairment, amnesia, cognitive disorder, dementia, type, mental impairment, senile dementia and vascular dementia.",
            "3.",
            "Includes asthenia and fatigue.",
            "4.",
            "Includes Fracture related preferred terms under high level terms: fractures NEC; fractures and dislocations NEC; limb fractures and dislocations; pelvic fractures and dislocations; skull and brain therapeutic procedures; skull fractures, facial bone fractures and dislocations; spinal fractures and dislocations; thoracic cage fractures and dislocations.",
            "Laboratory Abnormalities  Table 6 sh 5% of patients, and more frequently (> 2%) in the XTANDI arm compared to placebo in the pooled, randomized, placebo-controlled studies.",
            "Table 6.",
            "Laboratory Abnormalities  XTANDI (N = 3173) Placebo (N = 2282) Grade 1-4 (%) Grade 3-4 (%) Grade 1-4 (%) Grade 3-4 (%) Hematology Neutrophil count decreased 20 0.9 17 0.4 White blood cell decreased 17 0.4 9.8 0.2 Chemistry  XTANDI (N = 3173) Placebo (N = 2282) Grade 1-4 (%) Grade 3-4 (%) Grade 1-4 (%) Grade 3-4 (%) Hyperglycemia 83 3.2 75 3.1 Hypermagnesemia 16 0.1 13 0 Hyponatremia 13 1.4 8.6 1.5 Hypercalcemia 6.8 0.1 4.5 0  Hypertension In the combined data from four randomized placebo-controlled clinical trials, hypertension was reported in 12% of patients receiving XTANDI and 5% of patients receiving placebo.",
            "Medical history of hypertension was balanced between arms.",
            "Hypertension led to study discontinuation in < 1% of patients in each arm.",
            "6.2 Post-Marketing Experience  The following additional adverse reactions have been identified during post-approval use of XTANDI.",
            "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.",
            "Gastrointestinal Disorders: vomiting Immune System Disorders: hypersensitivity (edema of the face, tongue, lip, or pharynx) Neurological Disorders: posterior reversible encephalopathy syndrome (PRES), dysgeusia Skin and Subcutaneous Tissue Disorders: rash, severe cutaneous adverse reactions (including Stevens-Johnson syndrome (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP)) 7 DRUG INTERACTIONS 7.1 Drugs that Inhibit CYP2C8 Co-administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the composite area under the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold.",
            "Co-administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible.",
            "If co-administration of XTANDI with a strong CYP2C8 inhibitor cannot be avoided, reduce the dose of XTANDI [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].",
            "7.2 Drugs that Induce CYP3A4 Co-administration of rifampin (strong CYP3A4 inducer and moderate CYP2C8 inducer) decreased the composite AUC of enzalutamide plus N-desmethyl enzalutamide by 37%.",
            "Co-administration of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) with XTANDI should be avoided if possible.",
            "St should be avoided.",
            "If co-administration of a strong CYP3A4 inducer with XTANDI cannot be avoided, increase the dose of XTANDI [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].",
            "7.3 Effect of XTANDI on Drug Metabolizing Enzymes Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans.",
            "At steady-state, XTANDI reduced the plasma exposure to midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate).",
            "Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin, clopidogrel) should be avoided, as enzalutamide may decrease their exposure.",
            "If co-administration with warfarin cannot be avoided, conduct additional INR monitoring [see Clinical Pharmacology (12.3)].",
            "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The safety and efficacy of XTANDI have not been established in females.",
            "Based on animal reproductive studies and mechanism of action, XTANDI can cause fetal harm and loss of pregnancy.",
            "There are no human data on the use of XTANDI in pregnant females.",
            "In animal reproduction studies, oral administration of enzalutamide in pregnant mice during organogenesis caused adverse developmental effects at doses lower than the maximum recommended human dose (see Data).",
            "Data Animal Data In an embryo-fetal developmental toxicity study in mice, enzalutamide caused developmental toxicity when administered at oral doses of 10 or 30 mg/kg/day throughout the period of organogenesis (gestational days 6-15).",
            "Findings included embryo-fetal lethality (increased post-implantation loss and resorptions) and decreased anogenital distance at  10 mg/kg/day, and cleft palate and absent palatine bone at 30 mg/kg/day.",
            "Doses of 30 mg/kg/day caused maternal toxicity.",
            "The doses tested in mice (1, 10 and 30 mg/kg/day) resulted in systemic exposures (AUC) approximately 0.04, 0.4 and 1.1 times, respectively, the exposures in patients.",
            "Enzalutamide did not cause developmental toxicity in rabbits when administered throughout the period of organogenesis (gestational days 6-18) at dose levels up to 10 mg/kg/day (approximately 0.4 times the exposures in patients based on AUC).",
            "In a pharmacokinetic study in pregnant rats with a single oral 30 mg/kg enzalutamide administration on gestation day 14, enzalutamide and/or its metabolites were present in the fetus at a Cmax that was approximately 0.3 times the concentration found in maternal plasma and occurred 4 hours after administration.",
            "8.2 Lactation Risk Summary The safety and efficacy of XTANDI have not been established in females.",
            "There is no information available on the presence of XTANDI in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.",
            "Enzalutamide and/or its metabolites were present in milk of lactating rats (see Data).",
            "Data Following a single oral administration in lactating rats on postnatal day 14, enzalutamide and/or its metabolites were present in milk at a Cmax that was 4 times higher than concentrations in the plasma and occurred 4 hours after administration.",
            "8.3 Females and Males of Reproductive Potential  Contraception Males Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of XTANDI [see Use in Specific Populations (8.1)].",
            "Infertility Males Based on animal studies, XTANDI may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].",
            "8.4 Pediatric Use Safety and effectiveness of XTANDI in pediatric patients have not been established.",
            "8.5 Geriatric Use Of 4081 patients who received XTANDI in seven randomized, controlled clinical trials, 78% were 65 and over, while 35% were 75 and over.",
            "No overall differences in safety or effectiveness were observed between these patients and younger patients.",
            "Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.",
            "8.6 Patients with Renal Impairment A dedicated renal impairment trial for XTANDI has not been conducted.",
            "Based on the population pharmacokinetic analysis using data from clinical trials in patients with metastatic CRPC and healthy volunteers, no significant difference in enzalutamide clearance was observed in patients with pre-existing mild to moderate renal impairment (30 mL/min  impairment.",
            "Severe renal impairment (CrCL < 30 mL/min) and end-stage renal disease have not been assessed [see Clinical Pharmacology (12.3)].",
            "8.7 Patients with Hepatic Impairment Dedicated hepatic impairment trials compared the composite systemic exposure of enzalutamide plus N-desmethyl enzalutamide in volunteers with baseline mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C, respectively) versus healthy controls with normal hepatic function.",
            "The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild, moderate, or severe baseline hepatic impairment compared to volunteers with normal hepatic function.",
            "No initial dosage adjustment is necessary for patients with baseline mild, moderate, or severe hepatic impairment [see Clinical Pharmacology (12.3)].",
            "10 OVERDOSAGE In the event of an overdose, stop treatment with XTANDI and initiate general supportive measures taking into consideration the half-life of 5.8 days.",
            "In a dose escalation study, no seizures were reported at < 240 mg daily, whereas 3 seizures were reported, 1 each at 360 mg, 480 mg, and 600 mg daily.",
            "Patients may be at increased risk of seizure following an overdose.",
            "11 DESCRIPTION Enzalutamide is an androgen receptor inhibitor.",
            "The chemical name is 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide.",
            "The molecular weight is 464.44 and molecular formula is C21H16F4N4O2S.",
            "The structural formula is:  Enzalutamide is a white crystalline non-hygroscopic solid.",
            "It is practically insoluble in water.",
            "XTANDI is available as liquid-filled soft gelatin capsules for oral administration.",
            "Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.",
            "The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.",
            "XTANDI is also available as film-coated tablets for oral administration.",
            "Each tablet contains 40 mg or 80 mg of enzalutamide.",
            "The inactive ingredients are hypromellose acetate succinate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, and magnesium stearate.",
            "The tablet film-coat contains hypromellose, talc, polyethylene glycol, titanium dioxide, and ferric oxide.",
            "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway.",
            "Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA.",
            "A major metabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide.",
            "Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.",
            "12.2 Pharmacodynamics  Cardiac Electrophysiology The effect of enzalutamide 160 mg/day at steady-state on the QTc interval was evaluated in 796 patients with metastatic CRPC.",
            "No large difference (i.e., greater than 20 ms) was observed between the mean QT interval change from baseline in patients treated with XTANDI and that in patients treated with placebo, based on the Fridericia correction method.",
            "However, small increases in the mean QTc interval (i.e., less than 10 ms) due to enzalutamide cannot be excluded due to limitations of the study design.",
            "12.3 Pharmacokinetics The pharmacokinetics of enzalutamide and its major active metabolite (N-desmethyl enzalutamide) were evaluated in patients with metastatic CRPC and healthy male volunteers.",
            "The plasma enzalutamide pharmacokinetics are adequately described by a linear two-compartment model with first-order absorption.",
            "Absorption Following oral administration of XTANDI capsules (160 mg daily) in patients with metastatic CRPC, the median time to reach maximum plasma enzalutamide concentrations (Cmax) is 1 hour (range 0.5 to 3 hours).",
            "At steady-state, the plasma mean Cmax values for enzalutamide and N-  CV) and 13.0 respectively.",
            "Following a single dose administration of 160 mg enzalutamide in healthy male volunteers, enzalutamide extent of absorption (AUC) was comparable between XTANDI tablet and XTANDI capsule, but the mean Cmax was 10%-28% lower than that of XTANDI capsules.",
            "The steady-state pharmacokinetic profiles (AUC and Cmax) of enzalutamide and N-desmethyl enzalutamide are similar for XTANDI tablet and XTANDI capsule.",
            "With the daily dosing regimen, enzalutamide steady-state is achieved by Day 28, and enzalutamide accumulates approximately 8.3-fold relative to a single dose.",
            "Daily fluctuations in enzalutamide plasma concentrations are low (mean peak-to-trough ratio of 1.25).",
            "At steady-state, enzalutamide showed approximately dose proportional pharmacokinetics over the daily dose range of 30 to 360 mg. A single 160 mg oral dose of XTANDI was administered to healthy volunteers with a high-fat meal or in the fasted condition.",
            "A high-fat meal did not alter the AUC to enzalutamide or N-desmethyl enzalutamide.",
            "The results are summarized in Figure 1.",
            "Distribution and Protein Binding The mean apparent volume of distribution (V/F) of enzalutamide in patients after a single oral dose is 110 L (29% CV).",
            "Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin.",
            "N-desmethyl enzalutamide is 95% bound to plasma proteins.",
            "In vitro, there was no protein binding displacement between enzalutamide and other highly protein bound drugs (warfarin, ibuprofen, and salicylic acid) at clinically relevant concentrations.",
            "Metabolism Following single oral administration of 14C-enzalutamide 160 mg, plasma samples were analyzed for enzalutamide and its metabolites up to 77 days post dose.",
            "Enzalutamide, N-desmethyl enzalutamide, and a major inactive carboxylic acid metabolite accounted for 88% of the 14C-radioactivity in plasma, representing 30%, 49%, and 10%, respectively, of the total 14C-AUC0-inf.",
            "In vitro, human CYP2C8 and CYP3A4 are responsible for the metabolism of enzalutamide.",
            "Based on in vivo and in vitro data, CYP2C8 is primarily responsible for the formation of the active metabolite (N-desmethyl enzalutamide).",
            "In vitro data suggest that carboxylesterase 1 metabolizes N-desmethyl enzalutamide and enzalutamide to the inactive carboxylic acid metabolite.",
            "In vitro, N-desmethyl enzalutamide is not a substrate of human CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5.",
            "Elimination  Enzalutamide is primarily eliminated by hepatic metabolism.",
            "Following single oral administration of 14C-enzalutamide 160 mg, 85% of the radioactivity is recovered by 77 days post dose: 71% is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).",
            "The mean apparent clearance (CL/F) of enzalutamide in patients after a single oral dose is 0.56 L/h (range 0.33 to 1.02 L/h).",
            "The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days).",
            "Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.",
            "Pharmacokinetics in Special Populations Renal Impairment: A population pharmacokinetic analysis (based on pre-existing renal function) was carried out with data from 59 healthy male volunteers and 926 patients with metastatic CRPC enrolled in clinical trials, including 512 with normal renal function (impairment (CrCL 30 to < 60 mL/min), and 1 with severe renal impairment (CrCL < 30 mL/min).",
            "The apparent clearance of enzalutamide was similar in patients with pre-existing mild and moderate renal impairment (CrCL 30 to < 90 mL/min) compared to patients and volunteers with normal renal function.",
            "The potential effect of severe renal impairment or end-stage renal disease on enzalutamide pharmacokinetics cannot be determined as clinical and pharmacokinetic data are available from only one patient [see Use in Specific Populations (8.6)].",
            "Hepatic Impairment: The plasma pharmacokinetics of enzalutamide and N-desmethyl enzalutamide were examined in volunteers with normal hepatic function (N = 22) and with pre-existing mild (N = 8, Child-Pugh Class A) moderate (N = 8, Child-Pugh Class B), or severe (N = 8, Child-Pugh Class C) hepatic impairment.",
            "XTANDI was administered as a single 160 mg dose.",
            "The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild, moderate, or severe baseline hepatic impairment compared to volunteers with normal hepatic function.",
            "The results are summarized in  Figure 1 [see Use in Specific Populations (8.7)].",
            "Body Weight and Age: Population pharmacokinetic analyses showed that weight (range: 46 to 163 kg) and age (range: 41 to 92 yrs.)",
            "do not have a clinically meaningful influence on the exposure to enzalutamide.",
            "Gender:  The effect of gender on the pharmacokinetics of enzalutamide has not been evaluated.",
            "Race:  The majority of XTANDI-treated patients in the randomized clinical trials were Caucasian (81%).",
            "Based on pharmacokinetic data from studies in Japanese and Chinese patients with prostate cancer, there were no clinically relevant differences in exposure among the populations.",
            "There are insufficient data to evaluate potential differences in the pharmacokinetics of enzalutamide in other races.",
            "Drug Interactions Effect of Other Drugs on XTANDI: In a drug-drug interaction trial in healthy volunteers, a single 160 mg oral dose of XTANDI was administered alone or after multiple oral doses of gemfibrozil (strong CYP2C8 inhibitor).",
            "Gemfibrozil increased the AUC0-inf of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold with minimal effect on Cmax.",
            "The results are summarized in Figure 1 [see Dosage and Administration (2.2) and Drug Interactions (7.1)].",
            "In a drug-drug interaction trial in healthy volunteers, a single 160 mg oral dose of XTANDI was administered alone or after multiple oral doses of rifampin (strong CYP3A4 and moderate CYP2C8 inducer).",
            "Rifampin decreased the AUC0-inf of enzalutamide plus N-desmethyl enzalutamide by 37% with no effect on Cmax.",
            "The results are summarized in  Figure 1 [see Dosage and Administration (2.2) and Drug Interactions (7.2)].",
            "In a drug-drug interaction trial in healthy volunteers, a single 160 mg oral dose of XTANDI was administered alone or after multiple oral doses of itraconazole (strong CYP3A4 inhibitor).",
            "Itraconazole increased the AUC0-inf of enzalutamide plus N-desmethyl enzalutamide by 1.3-fold with no effect on Cmax.",
            "The results are summarized in Figure 1.",
            "Figure 1.",
            "Effects of Other Drugs and Intrinsic/Extrinsic Factors on XTANDI  # PK parameters (Cmax and AUC0-inf) are for enzalutamide plus N-desmethyl enzalutamide, except in the food-effect trial, where they are for enzalutamide alone.",
            "* See Dosage and Administration (2.2).",
            "Effect of XTANDI on Other Drugs: In an in vivo phenotypic cocktail drug-drug interaction trial in patients with metastatic CRPC, a single oral dose of the CYP probe substrate cocktail (for CYP2C8, CYP2C9, CYP2C19, and CYP3A4) was administered before and concomitantly with XTANDI (following at least 55 days of dosing at 160 mg daily).",
            "The results are summarized in  Figure 2.",
            "Results showed that in vivo, at steady-state, XTANDI is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer [see Drug Interactions (7.3)].",
            "XTANDI did not cause clinically meaningful changes in exposure to the CYP2C8 substrate.",
            "In an in vivo phenotypic cocktail drug-drug interaction trial in patients with CRPC, a single oral dose of the CYP probe substrate cocktail for CYP1A2 and CYP2D6 was administered before and concomitantly with XTANDI (following at least 49 days of dosing at 160 mg daily).",
            "The results are summarized in Figure 2.",
            "Results showed that in vivo, at steady-state, XTANDI did not cause clinically meaningful changes in exposure to the CYP1A2 or CYP2D6 substrates.",
            "Figure 2.",
            "Effect of XTANDI on Other Drugs *See Drug Interactions (7.3).",
            "In vitro, enzalutamide, N-desmethyl enzalutamide, and the major inactive carboxylic acid metabolite caused direct inhibition of multiple CYP enzymes including CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5; however, subsequent clinical data showed that XTANDI is an inducer of CYP2C9, CYP2C19, and CYP3A4 and had no clinically meaningful effect on CYP2C8 (see Figure 2).",
            "In vitro, enzalutamide caused time-dependent inhibition of CYP1A2.",
            "In vitro studies showed that enzalutamide induces CYP2B6 and CYP3A4 and does not induce CYP1A2 at therapeutically relevant concentrations.",
            "In vitro, enzalutamide, N-desmethyl enzalutamide, and the major inactive carboxylic acid metabolite are not substrates for human P-glycoprotein.",
            "In vitro, enzalutamide and N-desmethyl enzalutamide are inhibitors of human P-glycoprotein, while the major inactive carboxylic acid metabolite is not.",
            "In vitro, enzalutamide and N-desmethyl enzalutamide do not appear to be substrates of human breast cancer resistance protein (BCRP); however, enzalutamide and N-desmethyl enzalutamide are inhibitors of human BCRP at clinically relevant concentrations.",
            "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A two-year carcinogenicity study was conducted in male and female rats at oral enzalutamide doses of 10, 30, and 100 mg/kg/day.",
            "Enzalutamide increased the incidence of benign Leydig cell tumors in the testes at all dose levels tested  0.3 times the human exposure based on AUC) and combined incidence of urothelial papilloma and carcinoma in the urinary bladder in male rats at 100 mg/kg/day (1.4 times the human exposure based on AUC).",
            "The findings in the testes are considered to be related to the pharmacological activity of enzalutamide.",
            "Rats are regarded as more sensitive than humans to developing interstitial cell tumors in the testes.",
            "Administration of enzalutamide to male and female rasH2 transgenic mice by oral gavage daily for 26 weeks did not result in increased incidence of neoplasms at doses up to 20 mg/kg/day.",
            "Enzalutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in either the in vitro mouse lymphoma thymidine kinase (Tk) gene mutation assay or the in vivo mouse micronucleus assay.",
            "Based on nonclinical findings in repeat-dose toxicology studies, which were consistent with the pharmacological activity of enzalutamide, male fertility may be impaired by treatment with XTANDI.",
            "In a 26-week study in rats, atrophy of the prostate -, 13-, and 39-week studies in dogs, hypospermatogenesis and atrophy of the prostate and epididymides were observed at  4 mg/kg/day (0.3 times the human exposure based on AUC).",
            "14 CLINICAL STUDIES The efficacy of XTANDI in patients with CRPC (N = 4692) or mCSPC (N = 1150) was demonstrated in five randomized, multicenter clinical trials.",
            "All patients received concomitant GnRH therapy or had prior bilateral orchiectomy.",
            "Patients were allowed, but not required, to continue or initiate glucocorticoids.",
            "AFFIRM (NCT00974311): XTANDI versus Placebo in Metastatic CRPC Following Chemotherapy  In AFFIRM, a total of 1199 patients who had received prior docetaxel-based chemotherapy were randomized 2:1 to receive either XTANDI orally at a dose of 160 mg once daily (N = 800) or placebo orally once daily (N = 399).",
            "Study treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression), initiation of new systemic antineoplastic treatment, unacceptable toxicity, or withdrawal.",
            "Patients with a previous history of seizure, taking medicines known to decrease the seizure threshold, or with other risk factors for seizure were not eligible [see Warnings and Precautions (5.1)].",
            "The following patient demographics and baseline disease characteristics were balanced between the treatment arms.",
            "The median age was 69 years (range 41-92) and the racial distribution was 92.7% Caucasian, 3.9% Black, 1.1% Asian, and 2.1% Other.",
            "Ninety-two percent of patients had an ECOG performance status score of 0-1 and 28% had a mean Brief Pain Inventory sco-one percent of patients had metastases in bone and 23% had visceral involvement in the lung and/or liver.",
            "Fifty-nine percent of patients had radiographic evidence of disease progression and 41% had PSA-only progression on study entry.",
            "All patients had received prior docetaxel-based therapy and 24% had received two cytotoxic chemotherapy regimens.",
            "During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids.",
            "A statistically significant improvement in overall survival was demonstrated at the pre-specified interim analysis at the time of 520 deaths in patients on the XTANDI arm compared to patients on the placebo arm (Table 7 and Figure 3).",
            "Table 7.",
            "Overall Survival of Patients Treated with Either XTANDI or Placebo in AFFIRM  XTANDI (N = 800) Placebo  (N = 399) Number of Deaths (%)  308 (38.5) 212 (53.1) Median Survival, months (95% CI) 18.4 (17.3, NR)  13.6 (11.3, 15.8)  P-value1 p < 0.0001  Hazard Ratio (95% CI)2 0.63 (0.53, 0.75)  NR = Not reached.",
            "1.",
            "P-value is derived from a log-rank test stratified by baseline ECOG performance status score (0-1 vs. 2) and mean baseline pain score (BPI- 2.",
            "Hazard Ratio is derived from a stratified proportional hazards model.",
            "Hazard Ratio < 1 favors XTANDI.",
            "Figure 3.",
            "Kaplan-Meier Curves of Overall Survival in AFFIRM  PREVAIL (NCT01212991): XTANDI versus Placebo in Chemotherapy-na\u00efve Metastatic CRPC In PREVAIL, 1717 chemotherapy-na\u00efve patients were randomized 1:1 to receive either XTANDI orally at a dose of 160 mg once daily (N = 872) or placebo orally once daily (N = 845).",
            "Patients with visceral metastases, patients with a history of mild to moderate heart failure (NYHA class I or II), and patients taking medications associated with lowering the seizure threshold were allowed.",
            "Patients with a previous history of seizure or a condition that might predispose to seizure and patients with moderate or severe pain from prostate cancer were excluded.",
            "Study treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.",
            "Overall survival and radiographic progression-free survival (rPFS) were assessed.",
            "Radiographic progression was assessed with the use of sequential imaging and was defined by bone scan identification of 2 or more new bone lesions with confirmation (Prostate Cancer Clinical Trials Working Group 2 criteria) and/or Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) criteria for progression of soft tissue lesions.",
            "The primary analysis of rPFS utilized centrally reviewed radiographic assessment of progression.",
            "Patient demographics and baseline disease characteristics were balanced between the treatment arms at entry.",
            "The median age was 71 years (range 42-93) and the racial distribution was 77% Caucasian, 10% Asian, 2% Black and 11% Other.",
            "The ECOG performance status score was 0 for 68% of patients, and 1 for 32% of patients.",
            "Baseline pain assessment was 0-1 (asymptomatic) in 67% of patients, and 2-3 (mildly symptomatic) in 32% of patients as defined by the Brief Pain Inventory Short Form (worst pain over past 24 hours at study entry).",
            "Fifty-four percent of patients had radiographic evidence of disease progression and 43% had PSA-only progression.",
            "Twelve percent of patients had visceral (lung and/or liver) disease involvement.",
            "During the study, 27% of patients on the XTANDI arm and 30% of patients on the placebo arm received glucocorticoids for varying reasons.",
            "A statistically significant improvement in overall survival was demonstrated at the pre-specified interim analysis, conducted after 540 deaths, in patients treated with XTANDI compared to those treated with placebo (Table 8).",
            "Forty percent of XTANDI-treated and 70% of placebo-treated patients received subsequent therapies for metastatic CRPC that may prolong overall survival.",
            "An updated survival analysis was conducted when 784 deaths were observed.",
            "The median follow-up time was 31 months.",
            "Results from this analysis were consistent with those from the pre-specified interim analysis (Table 8, Figure 4).",
            "At the updated analysis, 52% of XTANDI-treated and 81% of placebo-treated patients had received subsequent therapies that may prolong overall survival in metastatic CRPC.",
            "XTANDI was used as a subsequent therapy in 2% of XTANDI-treated patients and 29% of placebo-treated patients.",
            "Table 8.",
            "Overall Survival of Patients Treated with Either XTANDI or Placebo in PREVAIL  XTANDI  (N = 872) Placebo  (N = 845) Pre-specified Interim Analysis1       Number of Deaths (%)  241 (28) 299 (35)     Median Survival, months (95% CI) 32.4 (30.1, NR)  30.2 (28.0, NR)      P-value2 p < 0.0001      Hazard Ratio (95% CI)3 0.71 (0.60, 0.84)  Updated Survival Analysis4       Number of Deaths (%) 368 (42) 416 (49)     Median Survival, months (95% CI) 35.3 (32.2, NR) 31.3 (28.8, 34.2)     Hazard Ratio (95% CI)3 0.77 (0.67, 0.88) NR = Not reached.",
            "1.",
            "The data cut-off date is 16 Sep 2013.",
            "2.",
            "P-value is derived from an unstratified log-rank test.",
            "3.",
            "Hazard Ratio is derived from an unstratified proportional hazards model.",
            "Hazard Ratio < 1 favors XTANDI.",
            "4.",
            "The data cut- 765.",
            "Figure 4.",
            "Kaplan-Meier Curves of Overall Survival in PREVAIL  A statistically significant improvement in rPFS was demonstrated in patients treated with XTANDI compared to patients treated with placebo (Table 9, Figure 5).",
            "Table 9.",
            "Radiographic Progression-free Survival of Patients Treated with Either XTANDI or Placebo in PREVAIL  XTANDI (N = 832) Placebo  (N = 801) Number of Progression or Deaths (%)  118 (14) 320 (40) Median rPFS (months) (95% CI) NR (13.8, NR)  3.7 (3.6, 4.6)  P-value1 p < 0.0001  Hazard Ratio (95% CI)2 0.17 (0.14, 0.21)  NR = Not reached.",
            "Note: As of the cut-off date for the rPFS analysis, 1633 patients had been randomized.",
            "1.",
            "P-value is derived from an unstratified log-rank test.",
            "2.",
            "Hazard Ratio is derived from an unstratified proportional hazards model.",
            "Hazard Ratio < 1 favors XTANDI.",
            "Figure 5.",
            "Kaplan-Meier Curves of Radiographic Progression-free Survival in PREVAIL  Time to initiation of cytotoxic chemotherapy was prolonged after XTANDI treatment, with a median of 28.0 months for patients on the XTANDI arm versus a median of 10.8 months for patients on the placebo arm [HR = 0.35 (95% CI: 0.30, 0.40), p < 0.0001].",
            "The median time to first skeletal-related event was 31.1 months for patients on the XTANDI arm versus 31.3 months for patients on the placebo arm [HR = 0.72 (95% CI: 0.61, 0.84), p < 0.0001].",
            "A skeletal-related event was defined as radiation therapy or surgery to bone for prostate cancer, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain.",
            "TERRAIN (NCT01288911): XTANDI versus Bicalutamide in Chemotherapy-na\u00efve Metastatic CRPC TERRAIN was conducted in 375 chemotherapy-na\u00efve patients who were randomized 1:1 to receive either XTANDI orally at a dose of 160 mg once daily (N = 184) or bicalutamide orally at a dose of 50 mg once daily (N = 191).",
            "Patients with a previous history of seizure or a condition that might predispose to seizure and patients with moderate to severe pain from prostate cancer were excluded.",
            "Patients could have received prior bicalutamide, but those whose disease had progressed on prior antiandrogen therapy (e.g., bicalutamide) were excluded.",
            "Study treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event), the initiation of subsequent antineoplastic agent, unacceptable toxicity, or withdrawal.",
            "Radiographic disease progression was assessed by Independent Central Review (ICR) using the Prostate Cancer Clinical Trials Working Group 2 criteria and/or Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) criteria for progression of soft tissue lesions.",
            "Radiographic progression-free survival (rPFS) was defined as the time from randomization to the first objective evidence of radiographic progression as assessed by ICR or death, whichever occurred first.",
            "Patient demographics and baseline disease characteristics were balanced between the treatment arms at entry.",
            "The median age was 71 years (range 48-96) and the racial distribution was 93% Caucasian, 5% Black, 1% Asian and 1% Other.",
            "The ECOG performance status score was 0 for 74% of patients and 1 for 26% of patients.",
            "Baseline pain assessment was 0-1 (asymptomatic) in 58% of patients, and 2-3 (mildly symptomatic) in 36% of patients as defined by the Brief Pain Inventory Short Form Question 3 (worst pain over past 24 hours at study entry).",
            "Ninety-eight percent of patients had objective evidence of disease progression at study entry.",
            "Forty-six percent of patients had received prior treatment with bicalutamide while no patients received prior treatment with XTANDI.",
            "An improvement in rPFS was demonstrated in patients treated with XTANDI compared to patients treated with bicalutamide (Table 10, Figure 6).",
            "Table 10.",
            "Radiographic Progression-free Survival of Patients in TERRAIN  XTANDI  (N = 184) Bicalutamide (N = 191) Number of Progression or Deaths (%)  72 (39) 74 (39) Median rPFS (months) (95% CI) 19.5 (11.8, NR) 13.4 (8.2, 16.4) Hazard Ratio (95% CI)1 0.60 (0.43, 0.83) NR = Not reached.",
            "1.",
            "Hazard Ratio is derived from an unstratified proportional hazards model.",
            "Hazard Ratio < 1 favors XTANDI   Figure 6.",
            "Kaplan-Meier Curves of Radiographic Progression-free Survival in TERRAIN  PROSPER (NCT02003924): XTANDI versus Placebo in Non-metastatic CRPC PROSPER enrolled 1401 patients with non-metastatic CRPC who were randomized 2:1 to receive either XTANDI orally at a dose of 160 mg once daily (N = 933) or placebo orally once daily (N = 468).",
            "All patients in the PROSPER trial received a gonadotropin-releasing hormone (GnRH) analog or had a prior bilateral orchiectomy.",
            "Patients were stratified by Prostate Specific Antigen (PSA) Doubling Time (PSADT) and the use of bone-targeting agents.",
            "Patients were required   2 ng/mL, and confirmation of non-metastatic disease by blinded independent central review (BICR).",
            "PSA results were blinded and were not used for treatment discontinuation.",
            "Patients randomized to either arm discontinued treatment for radiographic disease progression confirmed by BICR, initiation of new treatment, unacceptable toxicity, or withdrawal.",
            "The following patient demographics and baseline characteristics were balanced between the two treatment arms.",
            "The median age at randomization was 74 years (range 50-95) and 23% were 80 years of age or older.",
            "The racial distribution was 71% Caucasian, 16% Asian, and 2% Black.",
            "A majority of patients had a Gleason score of 7 or higher (77%).",
            "The median PSADT was 3.7 months.",
            "Fifty-four percent (54%) of patients received prior treatment for prostate cancer with either surgery or radiation.",
            "Sixty-three percent (63%) of patients received prior treatment with an anti-androgen; 56% of patients received bicalutamide and 11% of patients received flutamide.",
            "All patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 at study entry.",
            "The major efficacy outcome of the study was metastasis-free survival (MFS), defined as the time from randomization to whichever of the following occurred first 1) loco-regional and/or distant radiographic progression per BICR or 2) death up to 112 days after treatment discontinuation without evidence of radiographic progression.",
            "A statistically significant improvement in MFS and OS was demonstrated in patients randomized to receive XTANDI compared with patients randomized to receive placebo.",
            "Consistent MFS results were observed when considering only distant radiographic progression events or deaths regardless of the cut-off date.",
            "Consistent MFS results were also observed in pre-specified and stratified patient sub--targeting agent (yes or no).",
            "The efficacy results from PROSPER are summarized in Table 11, Figure 7 and Figure 8.",
            "Table 11.",
            "Summary of Efficacy Results in PROSPER (Intent-to-treat Population)  XTANDI (N = 933) Placebo (N = 468) Metastasis-free survival       Number of Events (%) 219 (23.5) 228 (48.7)       Median, months (95% CI)1 36.6 (33.1, NR) 14.7 (14.2, 15.0)       Hazard Ratio (95% CI)2  0.29 (0.24, 0.35)       P-value2 p < 0.0001 Overall survival3       Number of Events (%) 288 (30.9) 178 (38.0)       Median, months (95% CI)1  67.0 (64.0, NR) 56.3 (54.4, 63.0)       Hazard Ratio (95% CI)2  0.73 (0.61, 0.88)       P-value2 p = 0.0011 NR = Not reached.",
            "1.",
            "Based on Kaplan-Meier estimates.",
            "2.",
            "Hazard ratio from a Cox regression model (with treatment as the only covariate) and p-value from a log-rank test are stratified by PSA doubling time and prior or concurrent use of a bone targeting agent.",
            "3.",
            "The pre-specified final analysis of OS occurred 27 months after the MFS analysis.",
            "Figure 7.",
            "Kaplan-Meier Curves of Metastasis-free Survival in PROSPER   Figure 8.",
            "Kaplan-Meier Curves of Overall Survival in PROSPER The primary efficacy outcome was also supported by a statistically significant delay in time to first use of new antineoplastic therapy (TTA) for patients in the XTANDI arm compared to those in the placebo arm.",
            "The median TTA was 39.6 months for patients on XTANDI and was 17.7 months for patients on placebo (HR = 0.21; 95% CI: [0.17, 0.26], p < 0.0001).",
            "ARCHES (NCT02677896): XTANDI versus Placebo in Metastatic CSPC ARCHES enrolled 1150 patients with mCSPC who were randomized 1:1 to receive XTANDI orally at a dose of 160 mg once daily (N=574) or placebo orally once daily (N=576).",
            "All patients in the trial received a GnRH analog or had a prior bilateral orchiectomy.",
            "Patients were stratified by volume of disease (low vs high) and prior docetaxel therapy for prostate cancer (no prior docetaxel, 1-5 cycles, or 6 prior cycles).",
            "High volume of disease is defined as metastases involving the viscera or, in the absence of visceral lesions, there must be 4 or more bone lesions, at least 1 of which must be in a bony structure beyond the vertebral column and pelvic bone.",
            "Treatment with concurrent docetaxel was not allowed.",
            "Patients continued treatment until radiographic disease progression, initiation of new treatment, unacceptable toxicity, or withdrawal.",
            "The following patient demographics and baseline characteristics were balanced between the two treatment arms.",
            "The median age at randomization was 70 years (range: 42-92) and 30% were 75 years of age or older.",
            "The racial distribution was 81% Caucasian, 14% Asian, and 1% Black.",
            "Sixty--seven percent (37%) of patients had a low volume of disease and 63% of patients had a high volume of disease.",
            "Eighty-two percent (82%) of patients had no prior docetaxel treatment; 2% of patients had 1 to 5 cycles of docetaxel and 16% of patients had 6 prior cycles of docetaxel treatment.",
            "Twelve percent (12%) of patients received concomitant bone-targeted agents (bisphosphonates or RANKL inhibitors) which included both prostate and non-prostate cancer indications.",
            "The Eastern Cooperative Oncology Group Performance Status (ECOG PS) score was 0 for 78% of patients and 1 for 22% of patients at study entry.",
            "The major efficacy outcome measure was radiographic progression-free survival (rPFS) based on blinded independent central review (BICR).",
            "Radiographic progression-free survival was defined as the time from randomization to radiographic disease progression at any time or death within 24 weeks after study drug discontinuation.",
            "Radiographic disease progression was defined by identification of 2 or more new bone lesions on a bone scan with confirmation (Prostate Cancer Working Group 2 criteria) and/or progression in soft tissue disease.",
            "Time to new antineoplastic therapy was an additional efficacy endpoint.",
            "XTANDI demonstrated a statistically significant improvement in rPFS compared to placebo.",
            "Consistent rPFS results were observed in patients with high or low volume of disease and patients with and without prior docetaxel therapy.",
            "Overall survival (OS) data were not mature at the time of rPFS analysis (7.3% deaths in the ITT population had been reported).",
            "Efficacy results for rPFS from ARCHES are summarized in Table 12 and Figure 9.",
            "Table 12.",
            "Efficacy Results in ARCHES based on BICR (Intent-to-Treat Analysis)  XTANDI (N = 574) Placebo  (N = 576) Radiographic Progression-free Survival      Number of events (%) 89 (15.5) 198 (34.4) Radiographic disease progression 77 (13.4) 185 (32.1) Death within 24 weeks after treatment discontinuation 12 (2.1) 13 (2.3)      Median, months (95% CI)1 NR 19.4 (16.6, NR)      Hazard ratio (95% CI)2 0.39 (0.30, 0.50)      P-value3 p < 0.0001 NR = Not reached 1.",
            "Based on Kaplan-Meier estimates.",
            "2.",
            "Hazard Ratio is based on a Cox regression model stratified by volume of disease (low vs high) and prior docetaxel use (yes vs no).",
            "3.",
            "P-value is based on a stratified log-rank test by volume of disease (low vs high) and prior docetaxel use (yes or no).",
            "Figure 9.",
            "Kaplan-Meier Curves of rPFS in ARCHES (Intent-to-Treat Analysis) A statistically significant improvement was also reported on the XTANDI arm compared to placebo in time to initiation of a new antineoplastic therapy (HR = 0.28 [95% CI: 0.20, 0.40]; p < 0.0001).",
            "16 HOW SUPPLIED/STORAGE AND HANDLING XTANDI (enzalutamide) 40 mg capsules are supplied as white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ and are available in the following package size:  Bottles of 120 capsules with child resistant closures (NDC 0469-0125-99)   XTANDI (enzalutamide) 40 mg tablets are supplied as yellow, round, film-coated tablets debossed with E 40, and are available in the following package size:   Bottles of 120 tablets with child resistant closures (NDC 0469-0625-99) XTANDI (enzalutamide) 80 mg tablets are supplied as yellow, oval, film-coated tablets debossed with E 80, and are available in the following package size:   Bottles of 60 tablets with child resistant closures (NDC 0469-0725-60) Recommended storage: Store XTANDI capsules and tablets at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) in a dry place and keep the container tightly closed.",
            "Excursions permitted from 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F).",
            "Swallow capsules or tablets whole.",
            "Do not chew, dissolve or open the capsules.",
            "Do not cut, crush, or chew the tablets.",
            "17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information).",
            "Seizure  Inform patients that XTANDI has been associated with an increased risk of seizure.",
            "Discuss conditions that may predispose to seizures and medications that may lower the seizure threshold.",
            "Advise patients of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.",
            "Inform patients to contact their healthcare provider right away if they have loss of consciousness or seizure [see Warnings and Precautions (5.1)].",
            "Posterior Reversible Encephalopathy Syndrome (PRES)  Inform patients to contact their healthcare provider right away if they experience rapidly worsening symptoms possibly indicative of PRES such as seizure, headache, decreased alertness, confusion, reduced eyesight, or blurred vision [see Warnings and Precautions (5.2)].",
            "Hypersensitivity  Inform patients that XTANDI may be associated with hypersensitivity reactions that include swelling of the face, lip, tongue, or throat [see Warnings and Precautions (5.3)].",
            "Advise patients who experience these types of symptoms of hypersensitivity to discontinue XTANDI and promptly contact their healthcare provider.",
            "Ischemic Heart Disease  Inform patients that XTANDI has been associated with an increased risk of ischemic heart disease.",
            "Advise patients to seek immediate medical attention if any symptoms suggestive of a cardiovascular event occur [see Warnings and Precautions (5.4)].",
            "Falls and Fractures  Inform patients that XTANDI is associated with an increased incidence of dizziness/vertigo, falls, and fractures.",
            "Advise patients to report these adverse reactions to their healthcare provider [see Warnings and Precautions (5.5)].",
            "Hypertension  Inform patients that XTANDI is associated with an increased incidence of hypertension [see Adverse Reactions (6.1)].",
            "Dosing and Administration  Inform patients who have not undergone bilateral orchiectomy and are receiving GnRH therapy that they need to maintain this treatment during the course of treatment with XTANDI.",
            "Instruct patients to take their dose at the same time each day (once daily).",
            "XTANDI can be taken with or without food.",
            "Each capsule or tablet should be swallowed whole.",
            "Do not chew, dissolve, or open the capsules.",
            "Do not cut, crush, or chew the tablets.",
            "Inform patients that they should not interrupt, modify the dose, or stop XTANDI without first consulting their healthcare provider.",
            "Inform patients that if they miss a dose, then they should take it as soon as they remember.",
            "If they forget to take the dose for the whole day, then they should take their normal dose the next day.",
            "They should not take more than their prescribed dose per day [see Dosage and Administration (2.1)].",
            "Embryo-Fetal Toxicity   Inform patients that XTANDI can be harmful to a developing fetus and can cause loss of pregnancy.",
            "Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of XTANDI.",
            "Advise male patients to use a condom if having sex with a pregnant woman [see Warnings and Precautions (5.6)].",
            "Infertility  Inform male patients that XTANDI may impair fertility [see Use in Specific Populations (8.3)].",
            "Manufactured for and Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062 Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062     Pfizer Inc., New York, NY 10017 316386-XTA-USA  Rx Only \u00a9 2020-21 Astellas Pharma US, Inc. XTANDI is a registered trademark of Astellas Pharma Inc.",
            "PATIENT INFORMATION XTANDI\u00ae (ex TAN dee) (enzalutamide) capsules and tablets What is XTANDI\u00ae?",
            "XTANDI is a prescription medicine used to treat men with prostate cancer that:  no longer responds to a hormone therapy or surgical treatment to lower testosterone OR  has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone.",
            "It is not known if XTANDI is safe and effective in females.",
            "It is not known if XTANDI is safe and effective in children.",
            "Before taking XTANDI, tell your healthcare provider about all your medical conditions, including if you:  have a history of seizures, brain injury, stroke, or brain tumors.",
            "have a history of heart disease.",
            "have high blood pressure.",
            "have abnormal amounts of fat or cholesterol in your blood (dyslipidemia).",
            "are pregnant or plan to become pregnant.",
            "XTANDI can cause harm to your unborn baby and loss of pregnancy (miscarriage).",
            "have a partner who is pregnant or may become pregnant.",
            "Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with XTANDI and for 3 months after the last dose of XTANDI.",
            "Males must use a condom during sex with a pregnant female.",
            "are breastfeeding or plan to breastfeed.",
            "It is not known if XTANDI passes into your breast milk.",
            "Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.",
            "XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works.",
            "You should not start or stop any medicine before you talk with the healthcare provider that prescribed XTANDI.",
            "Know the medicines you take.",
            "Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine.",
            "How should I take XTANDI?",
            "Take XTANDI exactly as your healthcare provider tells you.",
            "Take your prescribed dose of XTANDI 1 time a day, at the same time each day.",
            "Your healthcare provider may change your dose if needed.",
            "Do not change or stop taking your prescribed dose of XTANDI without talking with your healthcare provider first.",
            "XTANDI can be taken with or without food.",
            "Swallow XTANDI capsules or tablets whole.",
            "Do not chew, dissolve, or open the capsules.",
            "Do not cut, crush, or chew the tablets.",
            "If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment during your treatment with XTANDI unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).",
            "If you miss a dose of XTANDI, take your prescribed dose as soon as you remember that day.",
            "If you miss your daily dose, take your prescribed dose at your regular time the next day.",
            "Do not take more than your prescribed dose of XTANDI each day.",
            "If you take too much XTANDI, call your healthcare provider or go to the nearest emergency room right away.",
            "You may have an increased risk of seizure if you take too much XTANDI.",
            "What are the possible side effects of XTANDI?",
            "XTANDI may cause serious side effects including:  Seizure.",
            "If you take XTANDI you may be at risk of having a seizure.",
            "You should avoid activities where a sudden loss of consciousness could cause serious harm to yourself or others.",
            "Tell your healthcare provider right away if you have loss of consciousness or seizure.",
            "Posterior Reversible Encephalopathy Syndrome (PRES).",
            "If you take XTANDI you may be at risk of developing a condition involving the brain called PRES.",
            "Tell your healthcare provider right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision or other visual problems.",
            "Your healthcare provider will do a test to check for PRES.",
            "Allergic Reactions.",
            "Allergic reactions have happened in people who take XTANDI.",
            "Stop taking XTANDI and get medical help right away if you develop swelling of the face, tongue, lip or throat.",
            "Heart disease.",
            "Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with XTANDI.",
            "Your healthcare provider will monitor you for signs and symptoms of heart problems during your treatment with XTANDI.",
            "Call your healthcare provider or go to the nearest emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with XTANDI.",
            "Falls and fractures.",
            "XTANDI treatment may increase your risk for falls and fractures.",
            "Falls were not caused by loss of consciousness (fainting) or seizures.",
            "Your healthcare provider will monitor your risks for falls and fractures during treatment with XTANDI.",
            "Your healthcare provider will stop treatment with XTANDI if you have serious side effects.",
            "The most common side effects of XTANDI include:  weakness or feeling more tired than usual  back pain  hot flashes  constipation  joint pain  decreased appetite  diarrhea  high blood pressure XTANDI may cause fertility problems in males, which may affect the ability to father children.",
            "Talk to your healthcare provider if you have concerns about fertility.",
            "These are not all the possible side effects of XTANDI.",
            "Call your doctor for medical advice about side effects.",
            "You may report side effects to FDA at 1-800-FDA-1088.",
            "How should I store XTANDI?",
            "XTANDI capsules and tablets come in a child-resistant bottle.",
            "Store XTANDI capsules and tablets between 68\u00b0F to 77\u00b0F (20\u00b0C to 25\u00b0C).",
            "Keep XTANDI capsules and tablets dry and in a tightly closed container.",
            "Keep XTANDI and all medicines out of the reach of children.",
            "General information about the safe and effective use of XTANDI.",
            "Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.",
            "Do not use XTANDI for a condition for which it was not prescribed.",
            "Do not give XTANDI to other people, even if they have the same symptoms that you have.",
            "It may harm them.",
            "You can ask your healthcare provider or pharmacist for information about XTANDI that is written for health professionals.",
            "What are the ingredients in XTANDI?",
            "XTANDI capsules Active ingredient: enzalutamide Inactive ingredients: caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, black iron oxide.",
            "XTANDI tablets Active ingredient: enzalutamide Inactive ingredients: hypromellose acetate succinate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, and magnesium stearate.",
            "The tablet film-coat contains hypromellose, talc, polyethylene glycol, titanium dioxide, and ferric oxide.",
            "Manufactured for and Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062  Marketed by: Astellas Pharma US, Inc., Northbrook, IL 60062     Pfizer Inc., New York, NY 10017  316386-XTA-USA   \u00a9 2020-21 Astellas Pharma US, Inc.  XTANDI is a registered trademark of Astellas Pharma Inc.  For more information go to www.Xtandi.com or call 1-800-727-7003.",
            "This Patient Information has been approved by the U.S. Food and Drug Administration.",
            "Revised: October 2020"
        ],
        "words": [
            "HIGHLIGHTS",
            "OF",
            "PRESCRIBING",
            "INFORMATION",
            "These",
            "highlights",
            "do",
            "not",
            "include",
            "all",
            "the",
            "information",
            "needed",
            "to",
            "use",
            "XTANDI\u00ae",
            "safely",
            "and",
            "effectively",
            ".",
            "See",
            "full",
            "prescribing",
            "information",
            "for",
            "XTANDI",
            ".",
            "XTANDI\u00ae",
            "(",
            "enzalutamide",
            ")",
            "capsules",
            ",",
            "for",
            "oral",
            "use",
            "XTANDI\u00ae",
            "(",
            "enzalutamide",
            ")",
            "tablets",
            ",",
            "for",
            "oral",
            "use",
            "Initial",
            "U.S.",
            "Approval",
            ":",
            "2012",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "RECENT",
            "MAJOR",
            "CHANGES",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "Dosage",
            "and",
            "Administration",
            "Dosing",
            "Information",
            "(",
            "2.1",
            ")",
            "10/2020",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "-",
            "INDICATIONS",
            "AND",
            "USAGE",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "XTANDI",
            "is",
            "an",
            "androgen",
            "receptor",
            "inhibitor",
            "indicated",
            "for",
            "the",
            "treatment",
            "of",
            "patients",
            "with",
            ":",
            "castration-resistant",
            "prostate",
            "cancer",
            ".",
            "(",
            "1",
            ")",
            "metastatic",
            "castration-sensitive",
            "prostate",
            "cancer",
            ".",
            "(",
            "1",
            ")",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "DOSAGE",
            "AND",
            "ADMINISTRATION",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "XTANDI",
            "160",
            "mg",
            "(",
            "two",
            "80",
            "mg",
            "tablets",
            "or",
            "four",
            "40",
            "mg",
            "tablets",
            "or",
            "four",
            "40",
            "mg",
            "capsules",
            ")",
            "administered",
            "orally",
            "once",
            "daily",
            ".",
            "Swallow",
            "capsules",
            "or",
            "tablets",
            "whole",
            ".",
            "(",
            "2.1",
            ")",
            "Patients",
            "receiving",
            "XTANDI",
            "should",
            "also",
            "receive",
            "a",
            "gonadotropin-releasing",
            "hormone",
            "(",
            "GnRH",
            ")",
            "analog",
            "concurrently",
            "or",
            "should",
            "have",
            "had",
            "bilateral",
            "orchiectomy",
            ".",
            "(",
            "2.3",
            ")",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "-",
            "DOSAGE",
            "FORMS",
            "AND",
            "STRENGTHS",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "Capsule",
            "40",
            "mg",
            "(",
            "3",
            ")",
            "Tablet",
            ":",
            "40",
            "mg",
            ",",
            "80",
            "mg",
            "(",
            "3",
            ")",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "CONTRAINDICATIONS",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "-",
            "None",
            ".",
            "(",
            "4",
            ")",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "-",
            "WARNINGS",
            "AND",
            "PRECAUTIONS",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "Seizure",
            "occurred",
            "in",
            "0.5",
            "%",
            "of",
            "patients",
            "receiving",
            "XTANDI",
            ".",
            "In",
            "patients",
            "with",
            "predisposing",
            "factors",
            ",",
            "seizures",
            "were",
            "reported",
            "in",
            "2.2",
            "%",
            "of",
            "patients",
            ".",
            "Permanently",
            "discontinue",
            "XTANDI",
            "in",
            "patients",
            "who",
            "develop",
            "a",
            "seizure",
            "during",
            "treatment",
            ".",
            "(",
            "5.1",
            ")",
            "Posterior",
            "reversible",
            "encephalopathy",
            "syndrome",
            "(",
            "PRES",
            ")",
            ":",
            "Discontinue",
            "XTANDI",
            ".",
            "(",
            "5.2",
            ")",
            "Hypersensitivity",
            ":",
            "Discontinue",
            "XTANDI",
            ".",
            "(",
            "5.3",
            ")",
            "Ischemic",
            "Heart",
            "Disease",
            ":",
            "Optimize",
            "management",
            "of",
            "cardiovascular",
            "risk",
            "factors",
            ".",
            "Discontinue",
            "XTANDI",
            "for",
            "Grade",
            "3-4",
            "events",
            ".",
            "(",
            "5.4",
            ")",
            "Falls",
            "and",
            "Fractures",
            "occurred",
            "in",
            "11",
            "%",
            "and",
            "10",
            "%",
            "of",
            "patients",
            "receiving",
            "XTANDI",
            ",",
            "respectively",
            ".",
            "Evaluate",
            "patients",
            "for",
            "fracture",
            "and",
            "fall",
            "risk",
            ",",
            "and",
            "treat",
            "patients",
            "with",
            "bone-targeted",
            "agents",
            "according",
            "to",
            "established",
            "guidelines",
            ".",
            "(",
            "5.5",
            ")",
            "Embryo-Fetal",
            "Toxicity",
            ":",
            "XTANDI",
            "can",
            "cause",
            "fetal",
            "harm",
            "and",
            "loss",
            "of",
            "pregnancy",
            ".",
            "Advise",
            "males",
            "with",
            "female",
            "partners",
            "of",
            "reproductive",
            "potential",
            "to",
            "use",
            "effective",
            "contraception",
            ".",
            "(",
            "5.6",
            ",",
            "8.1",
            ",",
            "8.3",
            ")",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "ADVERSE",
            "REACTIONS",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "-",
            "-treated",
            "patients",
            "are",
            "asthenia/fatigue",
            ",",
            "back",
            "pain",
            ",",
            "hot",
            "flush",
            ",",
            "constipation",
            ",",
            "arthralgia",
            ",",
            "decreased",
            "appetite",
            ",",
            "diarrhea",
            ",",
            "and",
            "hypertension",
            ".",
            "(",
            "6.1",
            ")",
            "To",
            "report",
            "SUSPECTED",
            "ADVERSE",
            "REACTIONS",
            ",",
            "contact",
            "Astellas",
            "Pharma",
            "US",
            ",",
            "Inc.",
            "at",
            "1-800-727-7003",
            "or",
            "FDA",
            "at",
            "1-800-FDA-1088",
            "or",
            "www.fda.gov/medwatch",
            ".",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "DRUG",
            "INTERACTIONS",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "--",
            "-",
            "Avoid",
            "strong",
            "CYP2C8",
            "inhibitors",
            ",",
            "as",
            "they",
            "can",
            "increase",
            "the",
            "plasma",
            "exposure",
            "to",
            "XTANDI",
            ".",
            "If",
            "co-administration",
            "is",
            "necessary",
            ",",
            "reduce",
            "the",
            "dose",
            "of",
            "XTANDI",
            ".",
            "(",
            "2.2",
            ",",
            "7.1",
            ")",
            "Avoid",
            "strong",
            "CYP3A4",
            "inducers",
            "as",
            "they",
            "can",
            "decrease",
            "the",
            "plasma",
            "exposure",
            "to",
            "XTANDI",
            ".",
            "If",
            "co-administration",
            "is",
            "necessary",
            ",",
            "increase",
            "the",
            "dose",
            "of",
            "XTANDI",
            ".",
            "(",
            "2.2",
            ",",
            "7.2",
            ")",
            "Avoid",
            "CYP3A4",
            ",",
            "CYP2C9",
            "and",
            "CYP2C19",
            "substrates",
            "with",
            "a",
            "narrow",
            "therapeutic",
            "index",
            ",",
            "as",
            "XTANDI",
            "may",
            "decrease",
            "the",
            "plasma",
            "exposures",
            "of",
            "these",
            "drugs",
            ".",
            "If",
            "XTANDI",
            "is",
            "co-administered",
            "with",
            "warfarin",
            "(",
            "CYP2C9",
            "substrate",
            ")",
            ",",
            "conduct",
            "additional",
            "INR",
            "monitoring",
            ".",
            "(",
            "7.3",
            ")",
            "See",
            "17",
            "for",
            "PATIENT",
            "COUNSELING",
            "INFORMATION",
            "and",
            "FDA-approved",
            "patient",
            "labeling",
            "Revised",
            ":",
            "07/2021",
            "FULL",
            "PRESCRIBING",
            "INFORMATION",
            ":",
            "CONTENTS",
            "*",
            "1",
            "INDICATIONS",
            "AND",
            "USAGE",
            "2",
            "DOSAGE",
            "AND",
            "ADMINISTRATION",
            "2.1",
            "Dosing",
            "Information",
            "2.2",
            "Dose",
            "Modifications",
            "2.3",
            "Important",
            "Administration",
            "Instructions",
            "3",
            "DOSAGE",
            "FORMS",
            "AND",
            "STRENGTHS",
            "4",
            "CONTRAINDICATIONS",
            "5",
            "WARNINGS",
            "AND",
            "PRECAUTIONS",
            "5.1",
            "Seizure",
            "5.2",
            "Posterior",
            "Reversible",
            "Encephalopathy",
            "Syndrome",
            "(",
            "PRES",
            ")",
            "5.3",
            "Hypersensitivity",
            "5.4",
            "Ischemic",
            "Heart",
            "Disease",
            "5.5",
            "Falls",
            "and",
            "Fractures",
            "5.6",
            "Embryo-Fetal",
            "Toxicity",
            "6",
            "ADVERSE",
            "REACTIONS",
            "6.1",
            "Clinical",
            "Trial",
            "Experience",
            "6.2",
            "Post-Marketing",
            "Experience",
            "7",
            "DRUG",
            "INTERACTIONS",
            "7.1",
            "Drugs",
            "that",
            "Inhibit",
            "CYP2C8",
            "7.2",
            "Drugs",
            "that",
            "Induce",
            "CYP3A4",
            "7.3",
            "Effect",
            "of",
            "XTANDI",
            "on",
            "Drug",
            "Metabolizing",
            "Enzymes",
            "8",
            "USE",
            "IN",
            "SPECIFIC",
            "POPULATIONS",
            "8.1",
            "Pregnancy",
            "8.2",
            "Lactation",
            "8.3",
            "Females",
            "and",
            "Males",
            "of",
            "Reproductive",
            "Potential",
            "8.4",
            "Pediatric",
            "Use",
            "8.5",
            "Geriatric",
            "Use",
            "8.6",
            "Patients",
            "with",
            "Renal",
            "Impairment",
            "8.7",
            "Patients",
            "with",
            "Hepatic",
            "Impairment",
            "10",
            "OVERDOSAGE",
            "11",
            "DESCRIPTION",
            "12",
            "CLINICAL",
            "PHARMACOLOGY",
            "12.1",
            "Mechanism",
            "of",
            "Action",
            "12.2",
            "Pharmacodynamics",
            "12.3",
            "Pharmacokinetics",
            "13",
            "NONCLINICAL",
            "TOXICOLOGY",
            "13.1",
            "Carcinogenesis",
            ",",
            "Mutagenesis",
            ",",
            "Impairment",
            "of",
            "Fertility",
            "14",
            "CLINICAL",
            "STUDIES",
            "16",
            "HOW",
            "SUPPLIED/STORAGE",
            "AND",
            "HANDLING",
            "17",
            "PATIENT",
            "COUNSELING",
            "INFORMATION",
            "*",
            "Sections",
            "or",
            "subsections",
            "omitted",
            "from",
            "the",
            "full",
            "prescribing",
            "information",
            "are",
            "not",
            "listed",
            ".",
            "FULL",
            "PRESCRIBING",
            "INFORMATION",
            "1",
            "INDICATIONS",
            "AND",
            "USAGE",
            "XTANDI\u00ae",
            "is",
            "indicated",
            "for",
            "the",
            "treatment",
            "of",
            "patients",
            "with",
            ":",
            "castration-resistant",
            "prostate",
            "cancer",
            "(",
            "CRPC",
            ")",
            "metastatic",
            "castration-sensitive",
            "prostate",
            "cancer",
            "(",
            "mCSPC",
            ")",
            "2",
            "DOSAGE",
            "AND",
            "ADMINISTRATION",
            "2.1",
            "Dosing",
            "Information",
            "The",
            "recommended",
            "dose",
            "of",
            "XTANDI",
            "is",
            "160",
            "mg",
            "(",
            "two",
            "80",
            "mg",
            "tablets",
            "or",
            "four",
            "40",
            "mg",
            "tablets",
            "or",
            "four",
            "40",
            "mg",
            "capsules",
            ")",
            "administered",
            "orally",
            "once",
            "daily",
            ".",
            "XTANDI",
            "can",
            "be",
            "taken",
            "with",
            "or",
            "without",
            "food",
            "[",
            "see",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "Swallow",
            "capsules",
            "or",
            "tablets",
            "whole",
            ".",
            "Do",
            "not",
            "chew",
            ",",
            "dissolve",
            ",",
            "or",
            "open",
            "the",
            "capsules",
            ".",
            "Do",
            "not",
            "cut",
            ",",
            "crush",
            ",",
            "or",
            "chew",
            "the",
            "tablets",
            "[",
            "see",
            "How",
            "Supplied/Storage",
            "and",
            "Handling",
            "(",
            "16",
            ")",
            "]",
            ".",
            "2.2",
            "Dose",
            "Modifications",
            "mg",
            "or",
            "80",
            "mg",
            ")",
            ",",
            "if",
            "warranted",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.1",
            ")",
            ",",
            "(",
            "5.2",
            ")",
            "]",
            ".",
            "Concomitant",
            "Strong",
            "CYP2C8",
            "Inhibitors",
            "The",
            "concomitant",
            "use",
            "of",
            "strong",
            "CYP2C8",
            "inhibitors",
            "should",
            "be",
            "avoided",
            "if",
            "possible",
            ".",
            "If",
            "patients",
            "must",
            "be",
            "co-administered",
            "a",
            "strong",
            "CYP2C8",
            "inhibitor",
            ",",
            "reduce",
            "the",
            "XTANDI",
            "dose",
            "to",
            "80",
            "mg",
            "once",
            "daily",
            ".",
            "If",
            "co-administration",
            "of",
            "the",
            "strong",
            "inhibitor",
            "is",
            "discontinued",
            ",",
            "the",
            "XTANDI",
            "dose",
            "should",
            "be",
            "returned",
            "to",
            "the",
            "dose",
            "used",
            "prior",
            "to",
            "initiation",
            "of",
            "the",
            "strong",
            "CYP2C8",
            "inhibitor",
            "[",
            "see",
            "Drug",
            "Interactions",
            "(",
            "7.1",
            ")",
            "and",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "Concomitant",
            "Strong",
            "CYP3A4",
            "Inducers",
            "The",
            "concomitant",
            "use",
            "of",
            "strong",
            "CYP3A4",
            "inducers",
            "should",
            "be",
            "avoided",
            "if",
            "possible",
            ".",
            "If",
            "patients",
            "must",
            "be",
            "co-administered",
            "a",
            "strong",
            "CYP3A4",
            "inducer",
            ",",
            "increase",
            "the",
            "XTANDI",
            "dose",
            "from",
            "160",
            "mg",
            "to",
            "240",
            "mg",
            "once",
            "daily",
            ".",
            "If",
            "co-administration",
            "of",
            "the",
            "strong",
            "CYP3A4",
            "inducer",
            "is",
            "discontinued",
            ",",
            "the",
            "XTANDI",
            "dose",
            "should",
            "be",
            "returned",
            "to",
            "the",
            "dose",
            "used",
            "prior",
            "to",
            "initiation",
            "of",
            "the",
            "strong",
            "CYP3A4",
            "inducer",
            "[",
            "see",
            "Drug",
            "Interactions",
            "(",
            "7.2",
            ")",
            "and",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "2.3",
            "Important",
            "Administration",
            "Instructions",
            "Patients",
            "receiving",
            "XTANDI",
            "should",
            "also",
            "receive",
            "a",
            "gonadotropin-releasing",
            "hormone",
            "(",
            "GnRH",
            ")",
            "analog",
            "concurrently",
            "or",
            "should",
            "have",
            "had",
            "bilateral",
            "orchiectomy",
            ".",
            "3",
            "DOSAGE",
            "FORMS",
            "AND",
            "STRENGTHS",
            "XTANDI",
            "40",
            "mg",
            "capsules",
            "are",
            "white",
            "to",
            "off-white",
            "oblong",
            "soft",
            "gelatin",
            "capsules",
            "imprinted",
            "in",
            "black",
            "ink",
            "with",
            "ENZ",
            ".",
            "XTANDI",
            "40",
            "mg",
            "tablets",
            "are",
            "yellow",
            ",",
            "round",
            ",",
            "film-coated",
            "and",
            "debossed",
            "with",
            "E",
            "40",
            ".",
            "XTANDI",
            "80",
            "mg",
            "tablets",
            "are",
            "yellow",
            ",",
            "oval",
            ",",
            "film-coated",
            "and",
            "debossed",
            "with",
            "E",
            "80",
            ".",
            "4",
            "CONTRAINDICATIONS",
            "None",
            ".",
            "5",
            "WARNINGS",
            "AND",
            "PRECAUTIONS",
            "5.1",
            "Seizure",
            "Seizure",
            "occurred",
            "in",
            "0.5",
            "%",
            "of",
            "patients",
            "receiving",
            "XTANDI",
            "in",
            "seven",
            "randomized",
            "clinical",
            "trials",
            ".",
            "In",
            "these",
            "trials",
            ",",
            "patients",
            "with",
            "predisposing",
            "factors",
            "for",
            "seizure",
            "were",
            "generally",
            "excluded",
            ".",
            "Seizure",
            "occurred",
            "from",
            "13",
            "to",
            "1776",
            "days",
            "after",
            "initiation",
            "of",
            "XTANDI",
            ".",
            "Patients",
            "experiencing",
            "seizure",
            "were",
            "permanently",
            "discontinued",
            "from",
            "therapy",
            ",",
            "and",
            "all",
            "seizure",
            "events",
            "resolved",
            ".",
            "In",
            "a",
            "single-arm",
            "trial",
            "designed",
            "to",
            "assess",
            "the",
            "risk",
            "of",
            "seizure",
            "in",
            "patients",
            "with",
            "pre-disposing",
            "factors",
            "for",
            "seizure",
            ",",
            "8",
            "of",
            "366",
            "(",
            "2.2",
            "%",
            ")",
            "XTANDI-treated",
            "patients",
            "experienced",
            "a",
            "seizure",
            ".",
            "Three",
            "of",
            "the",
            "8",
            "patients",
            "experienced",
            "a",
            "second",
            "seizure",
            "during",
            "continued",
            "treatment",
            "with",
            "XTANDI",
            "after",
            "their",
            "first",
            "seizure",
            "resolved",
            ".",
            "It",
            "is",
            "unknown",
            "whether",
            "anti-epileptic",
            "medications",
            "will",
            "prevent",
            "seizures",
            "with",
            "XTANDI",
            ".",
            "Patients",
            "in",
            "the",
            "study",
            "had",
            "one",
            "or",
            "more",
            "of",
            "the",
            "following",
            "pre-disposing",
            "factors",
            ":",
            "the",
            "use",
            "of",
            "medications",
            "that",
            "may",
            "lower",
            "the",
            "seizure",
            "threshold",
            "(",
            "~",
            "54",
            "%",
            ")",
            ",",
            "history",
            "of",
            "traumatic",
            "brain",
            "or",
            "head",
            "injury",
            "(",
            "~",
            "28",
            "%",
            ")",
            ",",
            "history",
            "of",
            "cerebrovascular",
            "accident",
            "or",
            "transient",
            "ischemic",
            "attack",
            "(",
            "~",
            "disease",
            "from",
            "prostate",
            "cancer",
            ",",
            "unexplained",
            "loss",
            "of",
            "consciousness",
            "within",
            "the",
            "last",
            "12",
            "months",
            ",",
            "past",
            "history",
            "of",
            "seizure",
            ",",
            "presence",
            "of",
            "a",
            "space",
            "occupying",
            "lesion",
            "of",
            "the",
            "brain",
            ",",
            "history",
            "of",
            "arteriovenous",
            "malformation",
            ",",
            "or",
            "history",
            "of",
            "brain",
            "infection",
            "(",
            "all",
            "<",
            "5",
            "%",
            ")",
            ".",
            "Approximately",
            "17",
            "%",
            "of",
            "patients",
            "had",
            "more",
            "than",
            "one",
            "risk",
            "factor",
            ".",
            "Advise",
            "patients",
            "of",
            "the",
            "risk",
            "of",
            "developing",
            "a",
            "seizure",
            "while",
            "receiving",
            "XTANDI",
            "and",
            "of",
            "engaging",
            "in",
            "any",
            "activity",
            "where",
            "sudden",
            "loss",
            "of",
            "consciousness",
            "could",
            "cause",
            "serious",
            "harm",
            "to",
            "themselves",
            "or",
            "others",
            ".",
            "Permanently",
            "discontinue",
            "XTANDI",
            "in",
            "patients",
            "who",
            "develop",
            "a",
            "seizure",
            "during",
            "treatment",
            ".",
            "5.2",
            "Posterior",
            "Reversible",
            "Encephalopathy",
            "Syndrome",
            "(",
            "PRES",
            ")",
            "There",
            "have",
            "been",
            "reports",
            "of",
            "posterior",
            "reversible",
            "encephalopathy",
            "syndrome",
            "(",
            "PRES",
            ")",
            "in",
            "patients",
            "receiving",
            "XTANDI",
            "[",
            "see",
            "Adverse",
            "Reactions",
            "(",
            "6.2",
            ")",
            "]",
            ".",
            "PRES",
            "is",
            "a",
            "neurological",
            "disorder",
            "which",
            "can",
            "present",
            "with",
            "rapidly",
            "evolving",
            "symptoms",
            "including",
            "seizure",
            ",",
            "headache",
            ",",
            "lethargy",
            ",",
            "confusion",
            ",",
            "blindness",
            ",",
            "and",
            "other",
            "visual",
            "and",
            "neurological",
            "disturbances",
            ",",
            "with",
            "or",
            "without",
            "associated",
            "hypertension",
            ".",
            "A",
            "diagnosis",
            "of",
            "PRES",
            "requires",
            "confirmation",
            "by",
            "brain",
            "imaging",
            ",",
            "preferably",
            "magnetic",
            "resonance",
            "imaging",
            "(",
            "MRI",
            ")",
            ".",
            "Discontinue",
            "XTANDI",
            "in",
            "patients",
            "who",
            "develop",
            "PRES",
            ".",
            "5.3",
            "Hypersensitivity",
            "Hypersensitivity",
            "reactions",
            ",",
            "including",
            "edema",
            "of",
            "the",
            "face",
            "(",
            "0.5",
            "%",
            ")",
            ",",
            "tongue",
            "(",
            "0.1",
            "%",
            ")",
            ",",
            "or",
            "lip",
            "(",
            "0.1",
            "%",
            ")",
            "have",
            "been",
            "observed",
            "with",
            "enzalutamide",
            "in",
            "seven",
            "randomized",
            "clinical",
            "trials",
            ".",
            "Pharyngeal",
            "edema",
            "has",
            "been",
            "reported",
            "in",
            "post-marketing",
            "cases",
            ".",
            "Advise",
            "patients",
            "who",
            "experience",
            "any",
            "symptoms",
            "of",
            "hypersensitivity",
            "to",
            "temporarily",
            "discontinue",
            "XTANDI",
            "and",
            "promptly",
            "seek",
            "medical",
            "care",
            ".",
            "Permanently",
            "discontinue",
            "XTANDI",
            "for",
            "serious",
            "hypersensitivity",
            "reactions",
            ".",
            "5.4",
            "Ischemic",
            "Heart",
            "Disease",
            "In",
            "the",
            "combined",
            "data",
            "of",
            "four",
            "randomized",
            ",",
            "placebo-controlled",
            "clinical",
            "studies",
            ",",
            "ischemic",
            "heart",
            "disease",
            "occurred",
            "more",
            "commonly",
            "in",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "patients",
            "on",
            "the",
            "placebo",
            "arm",
            "(",
            "2.9",
            "%",
            "vs",
            "1.3",
            "%",
            ")",
            ".",
            "Grade",
            "3-4",
            "ischemic",
            "events",
            "occurred",
            "in",
            "1.4",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "0.7",
            "%",
            "on",
            "the",
            "placebo",
            "arm",
            ".",
            "Ischemic",
            "events",
            "led",
            "to",
            "death",
            "in",
            "0.4",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "0.1",
            "%",
            "on",
            "the",
            "placebo",
            "arm",
            ".",
            "Monitor",
            "for",
            "signs",
            "and",
            "symptoms",
            "of",
            "ischemic",
            "heart",
            "disease",
            ".",
            "Optimize",
            "management",
            "of",
            "cardiovascular",
            "risk",
            "factors",
            ",",
            "such",
            "as",
            "hypertension",
            ",",
            "diabetes",
            ",",
            "or",
            "dyslipidemia",
            ".",
            "Discontinue",
            "XTANDI",
            "for",
            "Grade",
            "3-4",
            "ischemic",
            "heart",
            "disease",
            ".",
            "5.5",
            "Falls",
            "and",
            "Fractures",
            "Falls",
            "and",
            "fractures",
            "occurred",
            "in",
            "patients",
            "receiving",
            "XTANDI",
            ".",
            "Evaluate",
            "patients",
            "for",
            "fracture",
            "and",
            "fall",
            "risk",
            ".",
            "Monitor",
            "and",
            "manage",
            "patients",
            "at",
            "risk",
            "for",
            "fractures",
            "according",
            "to",
            "established",
            "treatment",
            "guidelines",
            "and",
            "consider",
            "use",
            "of",
            "bone-targeted",
            "agents",
            ".",
            "In",
            "the",
            "combined",
            "data",
            "of",
            "four",
            "randomized",
            ",",
            "placebo-controlled",
            "clinical",
            "studies",
            ",",
            "falls",
            "occurred",
            "in",
            "11",
            "%",
            "of",
            "patients",
            "treated",
            "with",
            "XTANDI",
            "compared",
            "to",
            "4",
            "%",
            "of",
            "patients",
            "treated",
            "with",
            "placebo",
            ".",
            "Falls",
            "were",
            "not",
            "associated",
            "with",
            "loss",
            "of",
            "consciousness",
            "or",
            "seizure",
            ".",
            "Fractures",
            "occurred",
            "in",
            "10",
            "%",
            "of",
            "patients",
            "treated",
            "with",
            "XTANDI",
            "and",
            "in",
            "4",
            "%",
            "of",
            "patients",
            "treated",
            "with",
            "placebo",
            ".",
            "Grade",
            "3-4",
            "fractures",
            "occurred",
            "in",
            "3",
            "%",
            "of",
            "patients",
            "treated",
            "with",
            "XTANDI",
            "and",
            "in",
            "2",
            "%",
            "of",
            "patients",
            "treated",
            "with",
            "placebo",
            ".",
            "The",
            "median",
            "time",
            "to",
            "onset",
            "of",
            "fracture",
            "was",
            "336",
            "days",
            "(",
            "range",
            ":",
            "2",
            "to",
            "1914",
            "days",
            ")",
            "for",
            "patients",
            "treated",
            "with",
            "XTANDI",
            ".",
            "Routine",
            "bone",
            "density",
            "assessment",
            "and",
            "treatment",
            "of",
            "osteoporosis",
            "with",
            "bone-targeted",
            "agents",
            "were",
            "not",
            "performed",
            "in",
            "the",
            "studies",
            ".",
            "5.6",
            "Embryo-Fetal",
            "Toxicity",
            "The",
            "safety",
            "and",
            "efficacy",
            "of",
            "XTANDI",
            "have",
            "not",
            "been",
            "established",
            "in",
            "females",
            ".",
            "Based",
            "on",
            "animal",
            "reproductive",
            "studies",
            "and",
            "mechanism",
            "of",
            "action",
            ",",
            "XTANDI",
            "can",
            "cause",
            "fetal",
            "harm",
            "and",
            "loss",
            "of",
            "pregnancy",
            "when",
            "administered",
            "to",
            "a",
            "pregnant",
            "female",
            ".",
            "Advise",
            "males",
            "with",
            "female",
            "partners",
            "of",
            "reproductive",
            "potential",
            "to",
            "use",
            "effective",
            "contraception",
            "during",
            "treatment",
            "with",
            "XTANDI",
            "and",
            "for",
            "3",
            "months",
            "after",
            "the",
            "last",
            "dose",
            "of",
            "XTANDI",
            "[",
            "see",
            "Use",
            "in",
            "Specific",
            "Populations",
            "(",
            "8.1",
            ",",
            "8.3",
            ")",
            "]",
            ".",
            "6",
            "ADVERSE",
            "REACTIONS",
            "The",
            "following",
            "is",
            "discussed",
            "in",
            "more",
            "detail",
            "in",
            "other",
            "sections",
            "of",
            "the",
            "labeling",
            ":",
            "Seizure",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.1",
            ")",
            "]",
            "Posterior",
            "Reversible",
            "Encephalopathy",
            "Syndrome",
            "(",
            "PRES",
            ")",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.2",
            ")",
            "]",
            "Hypersensitivity",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.3",
            ")",
            "]",
            "Ischemic",
            "Heart",
            "Disease",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.4",
            ")",
            "]",
            "Falls",
            "and",
            "Fractures",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.5",
            ")",
            "]",
            "6.1",
            "Clinical",
            "Trial",
            "Experience",
            "Because",
            "clinical",
            "trials",
            "are",
            "conducted",
            "under",
            "widely",
            "varying",
            "conditions",
            ",",
            "adverse",
            "reaction",
            "rates",
            "observed",
            "in",
            "the",
            "clinical",
            "trials",
            "of",
            "a",
            "drug",
            "can",
            "not",
            "be",
            "directly",
            "compared",
            "to",
            "rates",
            "in",
            "the",
            "clinical",
            "trials",
            "of",
            "another",
            "drug",
            "and",
            "may",
            "not",
            "reflect",
            "the",
            "rates",
            "observed",
            "in",
            "practice",
            ".",
            "The",
            "data",
            "in",
            "WARNINGS",
            "and",
            "PRECAUTIONS",
            "reflect",
            "seven",
            "randomized",
            ",",
            "controlled",
            "trials",
            "[",
            "AFFIRM",
            ",",
            "PREVAIL",
            ",",
            "TERRAIN",
            ",",
            "PROSPER",
            ",",
            "ARCHES",
            ",",
            "Asian",
            "PREVAIL",
            "(",
            "NCT02294461",
            ")",
            ",",
            "and",
            "STRIVE",
            "(",
            "NCT01664923",
            ")",
            "]",
            "that",
            "were",
            "pooled",
            "to",
            "conduct",
            "safety",
            "analyses",
            "in",
            "patients",
            "with",
            "CRPC",
            "(",
            "N=3509",
            ")",
            "or",
            "mCSPC",
            "(",
            "N=",
            "572",
            ")",
            "treated",
            "with",
            "XTANDI",
            ".",
            "Patients",
            "received",
            "XTANDI",
            "160",
            "mg",
            "(",
            "N=",
            "4081",
            ")",
            "or",
            "placebo",
            "orally",
            "once",
            "daily",
            "(",
            "N=",
            "2472",
            ")",
            "or",
            "bicalutamide",
            "50",
            "mg",
            "orally",
            "once",
            "daily",
            "(",
            "N=",
            "387",
            ")",
            ".",
            "All",
            "patients",
            "continued",
            "androgen",
            "deprivation",
            "therapy",
            "(",
            "ADT",
            ")",
            ".",
            "In",
            "these",
            "seven",
            "trials",
            ",",
            "the",
            "median",
            "duration",
            "of",
            "treatment",
            "was",
            "13.8",
            "months",
            "(",
            "range",
            ":",
            "<",
            "0.1",
            "to",
            "87.6",
            ")",
            "in",
            "the",
            "XTANDI",
            "group",
            ".",
            "In",
            "four",
            "placebo-controlled",
            "trials",
            "(",
            "AFFIRM",
            ",",
            "PROSPER",
            ",",
            "PREVAIL",
            ",",
            "and",
            "ARCHES",
            ")",
            ",",
            "the",
            "median",
            "duration",
            "of",
            "treatment",
            "was",
            "14.3",
            "months",
            "(",
            "range",
            ":",
            "<",
            "0.1",
            "to",
            "87.6",
            ")",
            "in",
            "the",
            "XTANDI",
            "group",
            "[",
            "see",
            "Clinical",
            "Studies",
            "(",
            "14",
            ")",
            "]",
            ".",
            "In",
            "these",
            "four",
            "trials",
            ",",
            "the",
            "most",
            "common",
            "adverse",
            "rea",
            "2",
            "%",
            "over",
            "placebo",
            ")",
            "in",
            "the",
            "XTANDI-treated",
            "patients",
            "were",
            "asthenia/fatigue",
            ",",
            "back",
            "pain",
            ",",
            "hot",
            "flush",
            ",",
            "constipation",
            ",",
            "arthralgia",
            ",",
            "decreased",
            "appetite",
            ",",
            "diarrhea",
            ",",
            "and",
            "hypertension",
            ".",
            "AFFIRM",
            "(",
            "NCT00974311",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Metastatic",
            "CRPC",
            "Following",
            "Chemotherapy",
            "AFFIRM",
            "enrolled",
            "1199",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            "who",
            "had",
            "previously",
            "received",
            "docetaxel",
            ".",
            "The",
            "median",
            "duration",
            "of",
            "treatment",
            "was",
            "8.3",
            "months",
            "with",
            "XTANDI",
            "and",
            "3.0",
            "months",
            "with",
            "placebo",
            ".",
            "During",
            "the",
            "trial",
            ",",
            "48",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "and",
            "46",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "placebo",
            "arm",
            "received",
            "glucocorticoids",
            ".",
            "Grade",
            "3",
            "and",
            "higher",
            "adverse",
            "reactions",
            "were",
            "reported",
            "among",
            "47",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            ".",
            "Discontinuations",
            "due",
            "to",
            "adverse",
            "events",
            "were",
            "reported",
            "for",
            "16",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            ".",
            "The",
            "most",
            "common",
            "adverse",
            "reaction",
            "leading",
            "to",
            "treatment",
            "discontinuation",
            "was",
            "seizure",
            ",",
            "which",
            "occurred",
            "in",
            "0.9",
            "%",
            "of",
            "the",
            "XTANDI-treated",
            "patients",
            "compared",
            "to",
            "none",
            "(",
            "0",
            "%",
            ")",
            "of",
            "the",
            "placebo-treated",
            "patients",
            ".",
            "Table",
            "1",
            "shows",
            "adverse",
            "refrequency",
            "in",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "the",
            "placebo",
            "arm",
            ".",
            "Table",
            "1",
            ".",
            "Adverse",
            "Reactions",
            "in",
            "AFFIRM",
            "XTANDI",
            "(",
            "N",
            "=",
            "800",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "399",
            ")",
            "Grade",
            "1-41",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "General",
            "Disorders",
            "Asthenic",
            "Conditions2",
            "51",
            "9.0",
            "44",
            "9.3",
            "Peripheral",
            "Edema",
            "15",
            "1.0",
            "13",
            "0.8",
            "Musculoskeletal",
            "and",
            "Connective",
            "Tissue",
            "Disorders",
            "Back",
            "Pain",
            "26",
            "5.3",
            "24",
            "4.0",
            "Arthralgia",
            "21",
            "2.5",
            "17",
            "1.8",
            "Musculoskeletal",
            "Pain",
            "15",
            "1.3",
            "12",
            "0.3",
            "Muscular",
            "Weakness",
            "9.8",
            "1.5",
            "6.8",
            "1.8",
            "Musculoskeletal",
            "Stiffness",
            "2.6",
            "0.3",
            "0.3",
            "0.0",
            "Gastrointestinal",
            "Disorders",
            "Diarrhea",
            "22",
            "1.1",
            "18",
            "0.3",
            "Vascular",
            "Disorders",
            "Hot",
            "Flush",
            "20",
            "0.0",
            "10",
            "0.0",
            "Hypertension",
            "6.4",
            "2.1",
            "2.8",
            "1.3",
            "Nervous",
            "System",
            "Disorders",
            "Headache",
            "12",
            "0.9",
            "5.5",
            "0.0",
            "Dizziness3",
            "9.5",
            "0.5",
            "7.5",
            "0.5",
            "Spinal",
            "Cord",
            "Compression",
            "and",
            "Cauda",
            "Equina",
            "Syndrome",
            "7.4",
            "6.6",
            "4.5",
            "3.8",
            "Paresthesia",
            "6.6",
            "0.0",
            "4.5",
            "0.0",
            "Mental",
            "Impairment",
            "Disorders4",
            "4.3",
            "0.3",
            "1.8",
            "0.0",
            "Hypoesthesia",
            "4.0",
            "0.3",
            "1.8",
            "0.0",
            "Infections",
            "and",
            "Infestations",
            "Upper",
            "Respiratory",
            "Tract",
            "Infection5",
            "11",
            "0.0",
            "6.5",
            "0.3",
            "Lower",
            "Respiratory",
            "Tract",
            "And",
            "Lung",
            "Infection6",
            "8.5",
            "2.4",
            "4.8",
            "1.3",
            "Psychiatric",
            "Disorders",
            "Insomnia",
            "8.8",
            "0.0",
            "6.0",
            "0.5",
            "Anxiety",
            "6.5",
            "0.3",
            "4.0",
            "0.0",
            "Renal",
            "and",
            "Urinary",
            "Disorders",
            "Hematuria",
            "6.9",
            "1.8",
            "4.5",
            "1.0",
            "Pollakiuria",
            "4.8",
            "0.0",
            "2.5",
            "0.0",
            "Injury",
            ",",
            "Poisoning",
            "and",
            "Procedural",
            "Complications",
            "Fall",
            "4.6",
            "0.3",
            "1.3",
            "0.0",
            "Non-pathologic",
            "Fractures",
            "4.0",
            "1.4",
            "0.8",
            "0.3",
            "Skin",
            "and",
            "Subcutaneous",
            "Tissue",
            "Disorders",
            "Pruritus",
            "3.8",
            "0.0",
            "1.3",
            "0.0",
            "Dry",
            "Skin",
            "3.5",
            "0.0",
            "1.3",
            "0.0",
            "Respiratory",
            "Disorders",
            "Epistaxis",
            "3.3",
            "0.1",
            "1.3",
            "0.3",
            "1",
            ".",
            "CTCAE",
            "v4",
            "2",
            ".",
            "Includes",
            "asthenia",
            "and",
            "fatigue",
            ".",
            "3",
            ".",
            "Includes",
            "dizziness",
            "and",
            "vertigo",
            ".",
            "4",
            ".",
            "Includes",
            "amnesia",
            ",",
            "memory",
            "impairment",
            ",",
            "cognitive",
            "disorder",
            ",",
            "and",
            "disturbance",
            "in",
            "attention",
            ".",
            "5",
            ".",
            "Includes",
            "nasopharyngitis",
            ",",
            "upper",
            "respiratory",
            "tract",
            "infection",
            ",",
            "sinusitis",
            ",",
            "rhinitis",
            ",",
            "pharyngitis",
            ",",
            "and",
            "laryngitis",
            ".",
            "6",
            ".",
            "Includes",
            "pneumonia",
            ",",
            "lower",
            "respiratory",
            "tract",
            "infection",
            ",",
            "bronchitis",
            ",",
            "and",
            "lung",
            "infection",
            ".",
            "PREVAIL",
            "(",
            "NCT01212991",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Chemotherapy-na\u00efve",
            "Metastatic",
            "CRPC",
            "PREVAIL",
            "enrolled",
            "1717",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            "who",
            "had",
            "not",
            "received",
            "prior",
            "cytotoxic",
            "chemotherapy",
            ",",
            "of",
            "whom",
            "1715",
            "received",
            "at",
            "least",
            "one",
            "dose",
            "of",
            "study",
            "drug",
            ".",
            "The",
            "median",
            "duration",
            "of",
            "treatment",
            "was",
            "17.5",
            "months",
            "with",
            "XTANDI",
            "and",
            "4.6",
            "months",
            "with",
            "placebo",
            ".",
            "Grade",
            "3-4",
            "adverse",
            "reactions",
            "were",
            "reported",
            "in",
            "44",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "and",
            "37",
            "%",
            "of",
            "placebo-treated",
            "patients",
            ".",
            "Discontinuations",
            "due",
            "to",
            "adverse",
            "events",
            "were",
            "reported",
            "for",
            "6",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            ".",
            "The",
            "most",
            "common",
            "adverse",
            "reaction",
            "leading",
            "to",
            "treatment",
            "discontinuation",
            "was",
            "fatigue/asthenia",
            ",",
            "which",
            "occurred",
            "in",
            "1",
            "%",
            "of",
            "patients",
            "on",
            "each",
            "treatment",
            "arm",
            ".",
            "Table",
            "2",
            "frequency",
            "in",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "the",
            "placebo",
            "arm",
            ".",
            "Table",
            "2",
            ".",
            "Adverse",
            "Reactions",
            "in",
            "PREVAIL",
            "XTANDI",
            "(",
            "N",
            "=",
            "871",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "844",
            ")",
            "Grade",
            "1-41",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "General",
            "Disorders",
            "Asthenic",
            "Conditions2",
            "47",
            "3.4",
            "33",
            "2.8",
            "Peripheral",
            "Edema",
            "12",
            "0.2",
            "8.2",
            "0.4",
            "Musculoskeletal",
            "and",
            "Connective",
            "Tissue",
            "Disorders",
            "Back",
            "Pain",
            "29",
            "2.5",
            "22",
            "3.0",
            "Arthralgia",
            "21",
            "1.6",
            "16",
            "1.1",
            "Gastrointestinal",
            "Disorders",
            "Constipation",
            "23",
            "0.7",
            "17",
            "0.4",
            "Diarrhea",
            "17",
            "0.3",
            "14",
            "0.4",
            "Vascular",
            "Disorders",
            "Hot",
            "Flush",
            "18",
            "0.1",
            "7.8",
            "0.0",
            "Hypertension",
            "14",
            "7.2",
            "4.1",
            "2.3",
            "Nervous",
            "System",
            "Disorders",
            "Dizziness3",
            "11",
            "0.3",
            "7.1",
            "0.0",
            "Headache",
            "11",
            "0.2",
            "7.0",
            "0.4",
            "Dysgeusia",
            "7.6",
            "0.1",
            "3.7",
            "0.0",
            "Mental",
            "Impairment",
            "Disorders4",
            "5.7",
            "0.0",
            "1.3",
            "0.1",
            "Restless",
            "Legs",
            "Syndrome",
            "2.1",
            "0.1",
            "0.4",
            "0.0",
            "Respiratory",
            "Disorders",
            "Dyspnea5",
            "11",
            "0.6",
            "8.5",
            "0.6",
            "Infections",
            "and",
            "Infestations",
            "Upper",
            "Respiratory",
            "Tract",
            "Infection6",
            "16",
            "0.0",
            "11",
            "0.0",
            "Lower",
            "Respiratory",
            "Tract",
            "And",
            "Lung",
            "Infection7",
            "7.9",
            "1.5",
            "4.7",
            "1.1",
            "Psychiatric",
            "Disorders",
            "Insomnia",
            "8.2",
            "0.1",
            "5.7",
            "0.0",
            "Renal",
            "and",
            "Urinary",
            "Disorders",
            "Hematuria",
            "8.8",
            "1.3",
            "5.8",
            "1.3",
            "Injury",
            ",",
            "Poisoning",
            "and",
            "Procedural",
            "Complications",
            "Fall",
            "13",
            "1.6",
            "5.3",
            "0.7",
            "Non-Pathological",
            "Fracture",
            "8.8",
            "2.1",
            "3.0",
            "1.1",
            "Metabolism",
            "and",
            "Nutrition",
            "Disorders",
            "Decreased",
            "Appetite",
            "19",
            "0.3",
            "16",
            "0.7",
            "Investigations",
            "Weight",
            "Decreased",
            "12",
            "0.8",
            "8.5",
            "0.2",
            "Reproductive",
            "System",
            "and",
            "Breast",
            "Disorders",
            "Gynecomastia",
            "3.4",
            "0.0",
            "1.4",
            "0.0",
            "1",
            ".",
            "CTCAE",
            "v4",
            "2",
            ".",
            "Includes",
            "asthenia",
            "and",
            "fatigue",
            ".",
            "3",
            ".",
            "Includes",
            "dizziness",
            "and",
            "vertigo",
            ".",
            "4",
            ".",
            "Includes",
            "amnesia",
            ",",
            "memory",
            "impairment",
            ",",
            "cognitive",
            "disorder",
            ",",
            "and",
            "disturbance",
            "in",
            "attention",
            ".",
            "5",
            ".",
            "Includes",
            "dyspnea",
            ",",
            "exertional",
            "dyspnea",
            ",",
            "and",
            "dyspnea",
            "at",
            "rest",
            ".",
            "6",
            ".",
            "Includes",
            "nasopharyngitis",
            ",",
            "upper",
            "respiratory",
            "tract",
            "infection",
            ",",
            "sinusitis",
            ",",
            "rhinitis",
            ",",
            "pharyngitis",
            ",",
            "and",
            "laryngitis",
            ".",
            "7",
            ".",
            "Includes",
            "pneumonia",
            ",",
            "lower",
            "respiratory",
            "tract",
            "infection",
            ",",
            "bronchitis",
            ",",
            "and",
            "lung",
            "infection",
            ".",
            "TERRAIN",
            "(",
            "NCT01288911",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Bicalutamide",
            "in",
            "Chemotherapy-na\u00efve",
            "Metastatic",
            "CRPC",
            "TERRAIN",
            "enrolled",
            "375",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            "who",
            "had",
            "not",
            "received",
            "prior",
            "cytotoxic",
            "chemotherapy",
            ",",
            "of",
            "whom",
            "372",
            "received",
            "at",
            "least",
            "one",
            "dose",
            "of",
            "study",
            "drug",
            ".",
            "The",
            "median",
            "duration",
            "of",
            "treatment",
            "was",
            "11.6",
            "months",
            "with",
            "XTANDI",
            "and",
            "5.8",
            "months",
            "with",
            "bicalutamide",
            ".",
            "Discontinuations",
            "with",
            "an",
            "adverse",
            "event",
            "as",
            "the",
            "primary",
            "reason",
            "were",
            "reported",
            "for",
            "7.6",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "and",
            "6.3",
            "%",
            "of",
            "bicalutamide-treated",
            "patients",
            ".",
            "The",
            "most",
            "common",
            "adverse",
            "reactions",
            "leading",
            "to",
            "treatment",
            "discontinuation",
            "were",
            "back",
            "pain",
            "and",
            "pathological",
            "fracture",
            ",",
            "which",
            "occurred",
            "in",
            "3.8",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "for",
            "each",
            "event",
            "and",
            "in",
            "2.1",
            "%",
            "and",
            "1.6",
            "%",
            "of",
            "bicalutamide-treated",
            "patients",
            ",",
            "respectively",
            ".",
            "Table",
            "3",
            "shows",
            "overall",
            "and",
            "common",
            "XTANDI-treated",
            "patients",
            ".",
            "Table",
            "3",
            ".",
            "Adverse",
            "Reactions",
            "in",
            "TERRAIN",
            "XTANDI",
            "(",
            "N",
            "=",
            "183",
            ")",
            "Bicalutamide",
            "(",
            "N",
            "=",
            "189",
            ")",
            "Grade",
            "1-41",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Overall",
            "94",
            "39",
            "94",
            "38",
            "General",
            "Disorders",
            "Asthenic",
            "Conditions2",
            "32",
            "1.6",
            "23",
            "1.1",
            "Musculoskeletal",
            "and",
            "Connective",
            "Tissue",
            "Disorders",
            "Back",
            "Pain",
            "19",
            "2.7",
            "18",
            "1.6",
            "Musculoskeletal",
            "Pain3",
            "16",
            "1.1",
            "14",
            "0.5",
            "Vascular",
            "Disorders",
            "Hot",
            "Flush",
            "15",
            "0",
            "11",
            "0",
            "Hypertension",
            "14",
            "7.1",
            "7.4",
            "4.2",
            "Gastrointestinal",
            "Disorders",
            "Nausea",
            "14",
            "0",
            "18",
            "0",
            "Constipation",
            "13",
            "1.1",
            "13",
            "0.5",
            "Diarrhea",
            "12",
            "0",
            "9.0",
            "1.1",
            "Infections",
            "and",
            "Infestations",
            "Upper",
            "Respiratory",
            "Tract",
            "Infection4",
            "12",
            "0",
            "6.3",
            "0.5",
            "Investigational",
            "Weight",
            "Loss",
            "11",
            "0.5",
            "7.9",
            "0.5",
            "1",
            ".",
            "CTCAE",
            "v",
            "4",
            "2",
            ".",
            "Including",
            "asthenia",
            "and",
            "fatigue",
            ".",
            "3",
            ".",
            "Including",
            "musculoskeletal",
            "pain",
            "and",
            "pain",
            "in",
            "extremity",
            ".",
            "4",
            ".",
            "Including",
            "nasopharyngitis",
            ",",
            "upper",
            "respiratory",
            "tract",
            "infection",
            ",",
            "sinusitis",
            ",",
            "rhinitis",
            ",",
            "pharyngitis",
            ",",
            "and",
            "laryngitis",
            ".",
            "PROSPER",
            "(",
            "NCT02003924",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Non-metastatic",
            "CRPC",
            "Patients",
            "PROSPER",
            "enrolled",
            "1401",
            "patients",
            "with",
            "non-metastatic",
            "CRPC",
            ",",
            "of",
            "whom",
            "1395",
            "received",
            "at",
            "least",
            "one",
            "dose",
            "of",
            "study",
            "drug",
            ".",
            "Patients",
            "were",
            "randomized",
            "2:1",
            "and",
            "received",
            "either",
            "XTANDI",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "930",
            ")",
            "or",
            "placebo",
            "(",
            "N",
            "=",
            "465",
            ")",
            ".",
            "The",
            "median",
            "duration",
            "of",
            "treatment",
            "at",
            "the",
            "time",
            "of",
            "analysis",
            "was",
            "18.4",
            "months",
            "(",
            "range",
            ":",
            "0.0",
            "to",
            "42",
            "months",
            ")",
            "with",
            "XTANDI",
            "and",
            "11.1",
            "months",
            "(",
            "range",
            ":",
            "0.0",
            "to",
            "43",
            "months",
            ")",
            "with",
            "placebo",
            ".",
            "Overall",
            ",",
            "32",
            "patients",
            "(",
            "3.4",
            "%",
            ")",
            "receivin",
            "2",
            "patients",
            "included",
            "coronary",
            "artery",
            "disorders",
            "(",
            "n",
            "=",
            "7",
            ")",
            ",",
            "sudden",
            "death",
            "(",
            "n",
            "=",
            "2",
            ")",
            ",",
            "cardiac",
            "arrhythmias",
            "(",
            "n",
            "=",
            "2",
            ")",
            ",",
            "general",
            "physical",
            "health",
            "deterioration",
            "(",
            "n",
            "=",
            "2",
            ")",
            ",",
            "stroke",
            "(",
            "n",
            "=",
            "2",
            ")",
            ",",
            "and",
            "secondary",
            "malignancy",
            "(",
            "n",
            "=",
            "5",
            ";",
            "one",
            "each",
            "of",
            "acute",
            "myeloid",
            "leukemia",
            ",",
            "brain",
            "neoplasm",
            ",",
            "mesothelioma",
            ",",
            "small",
            "cell",
            "lung",
            "cancer",
            ",",
            "and",
            "malignant",
            "neoplasm",
            "of",
            "unknown",
            "primary",
            "site",
            ")",
            ".",
            "Three",
            "patients",
            "(",
            "0.6",
            "%",
            ")",
            "receiving",
            "placebo",
            "died",
            "from",
            "adverse",
            "events",
            "of",
            "cardiac",
            "arrest",
            "(",
            "n",
            "=",
            "1",
            ")",
            ",",
            "left",
            "ventricular",
            "failure",
            "(",
            "n",
            "=",
            "1",
            ")",
            ",",
            "and",
            "pancreatic",
            "carcinoma",
            "(",
            "n",
            "=",
            "1",
            ")",
            ".",
            "Grade",
            "3",
            "or",
            "higher",
            "adverse",
            "reactions",
            "were",
            "reported",
            "among",
            "31",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "and",
            "23",
            "%",
            "of",
            "placebo-treated",
            "patients",
            ".",
            "Discontinuations",
            "with",
            "an",
            "adverse",
            "event",
            "as",
            "the",
            "primary",
            "reason",
            "were",
            "reported",
            "for",
            "9.4",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "and",
            "6.0",
            "%",
            "of",
            "placebo-treated",
            "patients",
            ".",
            "Of",
            "these",
            ",",
            "the",
            "most",
            "common",
            "adverse",
            "event",
            "leading",
            "to",
            "treatment",
            "discontinuation",
            "was",
            "fatigue",
            ",",
            "which",
            "occurred",
            "in",
            "1.6",
            "%",
            "of",
            "the",
            "XTANDI-treated",
            "patients",
            "compared",
            "to",
            "none",
            "of",
            "the",
            "placebo-treated",
            "patients",
            ".",
            "Table",
            "4",
            "XTANDI",
            "arm",
            "than",
            "in",
            "the",
            "placebo",
            "arm",
            ".",
            "Table",
            "4",
            ".",
            "Adverse",
            "Reactions",
            "in",
            "PROSPER",
            "XTANDI",
            "(",
            "N",
            "=",
            "930",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "465",
            ")",
            "Grade",
            "1-41",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Metabolism",
            "and",
            "Nutrition",
            "Disorders",
            "Decreased",
            "Appetite",
            "9.6",
            "0.2",
            "3.9",
            "0.2",
            "Nervous",
            "System",
            "Disorders",
            "Dizziness2",
            "12",
            "0.5",
            "5.2",
            "0",
            "Headache",
            "9.1",
            "0.2",
            "4.5",
            "0",
            "Cognitive",
            "and",
            "Attention",
            "Disorders3",
            "4.6",
            "0.1",
            "1.5",
            "0",
            "Vascular",
            "Disorders",
            "Hot",
            "Flush",
            "13",
            "0.1",
            "7.7",
            "0",
            "Hypertension",
            "12",
            "4.6",
            "5.2",
            "2.2",
            "Gastrointestinal",
            "Disorders",
            "Nausea",
            "11",
            "0.3",
            "8.6",
            "0",
            "Constipation",
            "9.1",
            "0.2",
            "6.9",
            "0.4",
            "General",
            "Disorders",
            "and",
            "Administration",
            "Site",
            "Conditions",
            "Asthenic",
            "Conditions4",
            "40",
            "4.0",
            "20",
            "0.9",
            "Investigations",
            "Weight",
            "Decreased",
            "5.9",
            "0.2",
            "1.5",
            "0",
            "Injury",
            ",",
            "Poisoning",
            "and",
            "Procedural",
            "Complications",
            "Fall",
            "11",
            "1.3",
            "4.1",
            "0.6",
            "Fractures5",
            "9.8",
            "2.0",
            "4.9",
            "1.7",
            "Psychiatric",
            "Disorders",
            "Anxiety",
            "2.8",
            "0.2",
            "0.4",
            "0",
            "1",
            ".",
            "CTCAE",
            "v",
            "4",
            "2",
            ".",
            "Includes",
            "dizziness",
            "and",
            "vertigo",
            ".",
            "3",
            ".",
            "Includes",
            "amnesia",
            ",",
            "memory",
            "impairment",
            ",",
            "cognitive",
            "disorder",
            ",",
            "and",
            "disturbance",
            "in",
            "attention",
            ".",
            "4",
            ".",
            "Includes",
            "asthenia",
            "and",
            "fatigue",
            ".",
            "5",
            ".",
            "Includes",
            "all",
            "osseous",
            "fractures",
            "from",
            "all",
            "sites",
            ".",
            "ARCHES",
            "(",
            "NCT02677896",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Metastatic",
            "CSPC",
            "Patients",
            "ARCHES",
            "randomized",
            "1150",
            "patients",
            "with",
            "mCSPC",
            ",",
            "of",
            "whom",
            "1146",
            "received",
            "at",
            "least",
            "one",
            "dose",
            "of",
            "study",
            "drug",
            ".",
            "All",
            "patients",
            "received",
            "either",
            "a",
            "gonadotropin-releasing",
            "hormone",
            "(",
            "GnRH",
            ")",
            "analogue",
            "concurrently",
            "or",
            "had",
            "bilateral",
            "orchiectomy",
            ".",
            "Patients",
            "received",
            "either",
            "XTANDI",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "once",
            "daily",
            "(",
            "N=572",
            ")",
            "or",
            "placebo",
            "(",
            "N=574",
            ")",
            ".",
            "The",
            "median",
            "duration",
            "of",
            "treatment",
            "was",
            "12.8",
            "months",
            "(",
            "range",
            ":",
            "0.2",
            "to",
            "26.6",
            "months",
            ")",
            "with",
            "XTANDI",
            "and",
            "11.6",
            "months",
            "(",
            "range",
            ":",
            "0.2",
            "to",
            "24.6",
            "months",
            ")",
            "with",
            "placebo",
            ".",
            "2",
            "patients",
            "included",
            "heart",
            "disease",
            "(",
            "n=3",
            ")",
            ",",
            "sepsis",
            "(",
            "n=2",
            ")",
            "and",
            "pulmonary",
            "embolism",
            "(",
            "n=2",
            ")",
            ".",
            "Eight",
            "patients",
            "(",
            "1.4",
            "%",
            ")",
            "receiving",
            "placebo",
            "died",
            "from",
            "2",
            "patients",
            "included",
            "heart",
            "disease",
            "(",
            "n=2",
            ")",
            "and",
            "sudden",
            "death",
            "(",
            "n=2",
            ")",
            ".",
            "Grade",
            "3",
            "or",
            "higher",
            "adverse",
            "events",
            "were",
            "reported",
            "in",
            "24",
            "%",
            "of",
            "patients",
            "treated",
            "with",
            "XTANDI",
            ".",
            "Permanent",
            "discontinuation",
            "due",
            "to",
            "adverse",
            "events",
            "as",
            "the",
            "primary",
            "reason",
            "was",
            "reported",
            "in",
            "4.9",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "and",
            "3.7",
            "%",
            "of",
            "placebo-treated",
            "patients",
            ".",
            "The",
            "most",
            "common",
            "adverse",
            "events",
            "resulting",
            "in",
            "permanent",
            "discontinuation",
            "in",
            "XTANDI-treated",
            "patients",
            "were",
            "alanine",
            "aminotransferase",
            "increased",
            ",",
            "aspartate",
            "aminotransferase",
            "elevation",
            ",",
            "and",
            "seizure",
            ",",
            "each",
            "in",
            "0.3",
            "%",
            ".",
            "The",
            "most",
            "common",
            "adverse",
            "events",
            "leading",
            "to",
            "permanent",
            "discontinuation",
            "in",
            "placebo-treated",
            "patients",
            "were",
            "arthralgia",
            ",",
            "and",
            "fatigue",
            ",",
            "each",
            "in",
            "0.3",
            "%",
            ".",
            "Dose",
            "reductions",
            "due",
            "to",
            "an",
            "adverse",
            "reaction",
            "occurred",
            "in",
            "4.4",
            "%",
            "of",
            "patients",
            "who",
            "received",
            "XTANDI",
            ".",
            "Fatigue/asthenia",
            "was",
            "the",
            "most",
            "frequent",
            "adverse",
            "reaction",
            "requiring",
            "dose",
            "reduction",
            "in",
            "2.1",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "and",
            "0.7",
            "%",
            "of",
            "placebo-treated",
            "patients",
            ".",
            "Table",
            "5",
            "in",
            "the",
            "placebo",
            "arm",
            ".",
            "Table",
            "5",
            ".",
            "Adverse",
            "Reactions",
            "in",
            "ARCHES",
            "XTANDI",
            "(",
            "N",
            "=",
            "572",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "574",
            ")",
            "Grade",
            "1-41",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Metabolism",
            "and",
            "Nutrition",
            "Disorders",
            "Decreased",
            "Appetite",
            "4.9",
            "0.2",
            "2.6",
            "0",
            "Nervous",
            "System",
            "Disorders",
            "Cognitive",
            "and",
            "Memory",
            "Impairment2",
            "4.5",
            "0.7",
            "2.1",
            "0",
            "Restless",
            "Legs",
            "Syndrome",
            "2.4",
            "0",
            "0.3",
            "0",
            "Vascular",
            "Disorders",
            "Hot",
            "Flush",
            "27",
            "0.3",
            "22",
            "0",
            "Hypertension",
            "8.0",
            "3.3",
            "5.6",
            "1.7",
            "General",
            "Disorders",
            "and",
            "Administration",
            "Site",
            "Conditions",
            "Asthenic",
            "conditions3",
            "24",
            "1.7",
            "20",
            "1.6",
            "Musculoskeletal",
            "and",
            "Connective",
            "Tissue",
            "Disorders",
            "Musculoskeletal",
            "Pain",
            "6.3",
            "0.2",
            "4.0",
            "0.2",
            "Injury",
            ",",
            "Poisoning",
            "and",
            "Procedural",
            "Complications",
            "Fractures4",
            "6.5",
            "1.0",
            "4.2",
            "1.0",
            "1",
            ".",
            "CTCAE",
            "v",
            "4.03",
            ".",
            "2",
            ".",
            "Includes",
            "memory",
            "impairment",
            ",",
            "amnesia",
            ",",
            "cognitive",
            "disorder",
            ",",
            "dementia",
            ",",
            "type",
            ",",
            "mental",
            "impairment",
            ",",
            "senile",
            "dementia",
            "and",
            "vascular",
            "dementia",
            ".",
            "3",
            ".",
            "Includes",
            "asthenia",
            "and",
            "fatigue",
            ".",
            "4",
            ".",
            "Includes",
            "Fracture",
            "related",
            "preferred",
            "terms",
            "under",
            "high",
            "level",
            "terms",
            ":",
            "fractures",
            "NEC",
            ";",
            "fractures",
            "and",
            "dislocations",
            "NEC",
            ";",
            "limb",
            "fractures",
            "and",
            "dislocations",
            ";",
            "pelvic",
            "fractures",
            "and",
            "dislocations",
            ";",
            "skull",
            "and",
            "brain",
            "therapeutic",
            "procedures",
            ";",
            "skull",
            "fractures",
            ",",
            "facial",
            "bone",
            "fractures",
            "and",
            "dislocations",
            ";",
            "spinal",
            "fractures",
            "and",
            "dislocations",
            ";",
            "thoracic",
            "cage",
            "fractures",
            "and",
            "dislocations",
            ".",
            "Laboratory",
            "Abnormalities",
            "Table",
            "6",
            "sh",
            "5",
            "%",
            "of",
            "patients",
            ",",
            "and",
            "more",
            "frequently",
            "(",
            ">",
            "2",
            "%",
            ")",
            "in",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "placebo",
            "in",
            "the",
            "pooled",
            ",",
            "randomized",
            ",",
            "placebo-controlled",
            "studies",
            ".",
            "Table",
            "6",
            ".",
            "Laboratory",
            "Abnormalities",
            "XTANDI",
            "(",
            "N",
            "=",
            "3173",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "2282",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Hematology",
            "Neutrophil",
            "count",
            "decreased",
            "20",
            "0.9",
            "17",
            "0.4",
            "White",
            "blood",
            "cell",
            "decreased",
            "17",
            "0.4",
            "9.8",
            "0.2",
            "Chemistry",
            "XTANDI",
            "(",
            "N",
            "=",
            "3173",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "2282",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Grade",
            "1-4",
            "(",
            "%",
            ")",
            "Grade",
            "3-4",
            "(",
            "%",
            ")",
            "Hyperglycemia",
            "83",
            "3.2",
            "75",
            "3.1",
            "Hypermagnesemia",
            "16",
            "0.1",
            "13",
            "0",
            "Hyponatremia",
            "13",
            "1.4",
            "8.6",
            "1.5",
            "Hypercalcemia",
            "6.8",
            "0.1",
            "4.5",
            "0",
            "Hypertension",
            "In",
            "the",
            "combined",
            "data",
            "from",
            "four",
            "randomized",
            "placebo-controlled",
            "clinical",
            "trials",
            ",",
            "hypertension",
            "was",
            "reported",
            "in",
            "12",
            "%",
            "of",
            "patients",
            "receiving",
            "XTANDI",
            "and",
            "5",
            "%",
            "of",
            "patients",
            "receiving",
            "placebo",
            ".",
            "Medical",
            "history",
            "of",
            "hypertension",
            "was",
            "balanced",
            "between",
            "arms",
            ".",
            "Hypertension",
            "led",
            "to",
            "study",
            "discontinuation",
            "in",
            "<",
            "1",
            "%",
            "of",
            "patients",
            "in",
            "each",
            "arm",
            ".",
            "6.2",
            "Post-Marketing",
            "Experience",
            "The",
            "following",
            "additional",
            "adverse",
            "reactions",
            "have",
            "been",
            "identified",
            "during",
            "post-approval",
            "use",
            "of",
            "XTANDI",
            ".",
            "Because",
            "these",
            "reactions",
            "are",
            "reported",
            "voluntarily",
            "from",
            "a",
            "population",
            "of",
            "uncertain",
            "size",
            ",",
            "it",
            "is",
            "not",
            "always",
            "possible",
            "to",
            "reliably",
            "estimate",
            "the",
            "frequency",
            "or",
            "establish",
            "a",
            "causal",
            "relationship",
            "to",
            "drug",
            "exposure",
            ".",
            "Gastrointestinal",
            "Disorders",
            ":",
            "vomiting",
            "Immune",
            "System",
            "Disorders",
            ":",
            "hypersensitivity",
            "(",
            "edema",
            "of",
            "the",
            "face",
            ",",
            "tongue",
            ",",
            "lip",
            ",",
            "or",
            "pharynx",
            ")",
            "Neurological",
            "Disorders",
            ":",
            "posterior",
            "reversible",
            "encephalopathy",
            "syndrome",
            "(",
            "PRES",
            ")",
            ",",
            "dysgeusia",
            "Skin",
            "and",
            "Subcutaneous",
            "Tissue",
            "Disorders",
            ":",
            "rash",
            ",",
            "severe",
            "cutaneous",
            "adverse",
            "reactions",
            "(",
            "including",
            "Stevens-Johnson",
            "syndrome",
            "(",
            "SJS",
            ")",
            ",",
            "erythema",
            "multiforme",
            ",",
            "toxic",
            "epidermal",
            "necrolysis",
            "(",
            "TEN",
            ")",
            ",",
            "drug",
            "reaction",
            "with",
            "eosinophilia",
            "and",
            "systemic",
            "symptoms",
            "(",
            "DRESS",
            ")",
            "and",
            "acute",
            "generalized",
            "exanthematous",
            "pustulosis",
            "(",
            "AGEP",
            ")",
            ")",
            "7",
            "DRUG",
            "INTERACTIONS",
            "7.1",
            "Drugs",
            "that",
            "Inhibit",
            "CYP2C8",
            "Co-administration",
            "of",
            "a",
            "strong",
            "CYP2C8",
            "inhibitor",
            "(",
            "gemfibrozil",
            ")",
            "increased",
            "the",
            "composite",
            "area",
            "under",
            "the",
            "plasma",
            "concentration-time",
            "curve",
            "(",
            "AUC",
            ")",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "by",
            "2.2-fold",
            ".",
            "Co-administration",
            "of",
            "XTANDI",
            "with",
            "strong",
            "CYP2C8",
            "inhibitors",
            "should",
            "be",
            "avoided",
            "if",
            "possible",
            ".",
            "If",
            "co-administration",
            "of",
            "XTANDI",
            "with",
            "a",
            "strong",
            "CYP2C8",
            "inhibitor",
            "can",
            "not",
            "be",
            "avoided",
            ",",
            "reduce",
            "the",
            "dose",
            "of",
            "XTANDI",
            "[",
            "see",
            "Dosage",
            "and",
            "Administration",
            "(",
            "2.2",
            ")",
            "and",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "7.2",
            "Drugs",
            "that",
            "Induce",
            "CYP3A4",
            "Co-administration",
            "of",
            "rifampin",
            "(",
            "strong",
            "CYP3A4",
            "inducer",
            "and",
            "moderate",
            "CYP2C8",
            "inducer",
            ")",
            "decreased",
            "the",
            "composite",
            "AUC",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "by",
            "37",
            "%",
            ".",
            "Co-administration",
            "of",
            "strong",
            "CYP3A4",
            "inducers",
            "(",
            "e.g.",
            ",",
            "carbamazepine",
            ",",
            "phenobarbital",
            ",",
            "phenytoin",
            ",",
            "rifabutin",
            ",",
            "rifampin",
            ",",
            "rifapentine",
            ")",
            "with",
            "XTANDI",
            "should",
            "be",
            "avoided",
            "if",
            "possible",
            ".",
            "St",
            "should",
            "be",
            "avoided",
            ".",
            "If",
            "co-administration",
            "of",
            "a",
            "strong",
            "CYP3A4",
            "inducer",
            "with",
            "XTANDI",
            "can",
            "not",
            "be",
            "avoided",
            ",",
            "increase",
            "the",
            "dose",
            "of",
            "XTANDI",
            "[",
            "see",
            "Dosage",
            "and",
            "Administration",
            "(",
            "2.2",
            ")",
            "and",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "7.3",
            "Effect",
            "of",
            "XTANDI",
            "on",
            "Drug",
            "Metabolizing",
            "Enzymes",
            "Enzalutamide",
            "is",
            "a",
            "strong",
            "CYP3A4",
            "inducer",
            "and",
            "a",
            "moderate",
            "CYP2C9",
            "and",
            "CYP2C19",
            "inducer",
            "in",
            "humans",
            ".",
            "At",
            "steady-state",
            ",",
            "XTANDI",
            "reduced",
            "the",
            "plasma",
            "exposure",
            "to",
            "midazolam",
            "(",
            "CYP3A4",
            "substrate",
            ")",
            ",",
            "warfarin",
            "(",
            "CYP2C9",
            "substrate",
            ")",
            ",",
            "and",
            "omeprazole",
            "(",
            "CYP2C19",
            "substrate",
            ")",
            ".",
            "Concomitant",
            "use",
            "of",
            "XTANDI",
            "with",
            "narrow",
            "therapeutic",
            "index",
            "drugs",
            "that",
            "are",
            "metabolized",
            "by",
            "CYP3A4",
            "(",
            "e.g.",
            ",",
            "alfentanil",
            ",",
            "cyclosporine",
            ",",
            "dihydroergotamine",
            ",",
            "ergotamine",
            ",",
            "fentanyl",
            ",",
            "pimozide",
            ",",
            "quinidine",
            ",",
            "sirolimus",
            "and",
            "tacrolimus",
            ")",
            ",",
            "CYP2C9",
            "(",
            "e.g.",
            ",",
            "phenytoin",
            ",",
            "warfarin",
            ")",
            "and",
            "CYP2C19",
            "(",
            "e.g.",
            ",",
            "S-mephenytoin",
            ",",
            "clopidogrel",
            ")",
            "should",
            "be",
            "avoided",
            ",",
            "as",
            "enzalutamide",
            "may",
            "decrease",
            "their",
            "exposure",
            ".",
            "If",
            "co-administration",
            "with",
            "warfarin",
            "can",
            "not",
            "be",
            "avoided",
            ",",
            "conduct",
            "additional",
            "INR",
            "monitoring",
            "[",
            "see",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "8",
            "USE",
            "IN",
            "SPECIFIC",
            "POPULATIONS",
            "8.1",
            "Pregnancy",
            "Risk",
            "Summary",
            "The",
            "safety",
            "and",
            "efficacy",
            "of",
            "XTANDI",
            "have",
            "not",
            "been",
            "established",
            "in",
            "females",
            ".",
            "Based",
            "on",
            "animal",
            "reproductive",
            "studies",
            "and",
            "mechanism",
            "of",
            "action",
            ",",
            "XTANDI",
            "can",
            "cause",
            "fetal",
            "harm",
            "and",
            "loss",
            "of",
            "pregnancy",
            ".",
            "There",
            "are",
            "no",
            "human",
            "data",
            "on",
            "the",
            "use",
            "of",
            "XTANDI",
            "in",
            "pregnant",
            "females",
            ".",
            "In",
            "animal",
            "reproduction",
            "studies",
            ",",
            "oral",
            "administration",
            "of",
            "enzalutamide",
            "in",
            "pregnant",
            "mice",
            "during",
            "organogenesis",
            "caused",
            "adverse",
            "developmental",
            "effects",
            "at",
            "doses",
            "lower",
            "than",
            "the",
            "maximum",
            "recommended",
            "human",
            "dose",
            "(",
            "see",
            "Data",
            ")",
            ".",
            "Data",
            "Animal",
            "Data",
            "In",
            "an",
            "embryo-fetal",
            "developmental",
            "toxicity",
            "study",
            "in",
            "mice",
            ",",
            "enzalutamide",
            "caused",
            "developmental",
            "toxicity",
            "when",
            "administered",
            "at",
            "oral",
            "doses",
            "of",
            "10",
            "or",
            "30",
            "mg/kg/day",
            "throughout",
            "the",
            "period",
            "of",
            "organogenesis",
            "(",
            "gestational",
            "days",
            "6-15",
            ")",
            ".",
            "Findings",
            "included",
            "embryo-fetal",
            "lethality",
            "(",
            "increased",
            "post-implantation",
            "loss",
            "and",
            "resorptions",
            ")",
            "and",
            "decreased",
            "anogenital",
            "distance",
            "at",
            "10",
            "mg/kg/day",
            ",",
            "and",
            "cleft",
            "palate",
            "and",
            "absent",
            "palatine",
            "bone",
            "at",
            "30",
            "mg/kg/day",
            ".",
            "Doses",
            "of",
            "30",
            "mg/kg/day",
            "caused",
            "maternal",
            "toxicity",
            ".",
            "The",
            "doses",
            "tested",
            "in",
            "mice",
            "(",
            "1",
            ",",
            "10",
            "and",
            "30",
            "mg/kg/day",
            ")",
            "resulted",
            "in",
            "systemic",
            "exposures",
            "(",
            "AUC",
            ")",
            "approximately",
            "0.04",
            ",",
            "0.4",
            "and",
            "1.1",
            "times",
            ",",
            "respectively",
            ",",
            "the",
            "exposures",
            "in",
            "patients",
            ".",
            "Enzalutamide",
            "did",
            "not",
            "cause",
            "developmental",
            "toxicity",
            "in",
            "rabbits",
            "when",
            "administered",
            "throughout",
            "the",
            "period",
            "of",
            "organogenesis",
            "(",
            "gestational",
            "days",
            "6-18",
            ")",
            "at",
            "dose",
            "levels",
            "up",
            "to",
            "10",
            "mg/kg/day",
            "(",
            "approximately",
            "0.4",
            "times",
            "the",
            "exposures",
            "in",
            "patients",
            "based",
            "on",
            "AUC",
            ")",
            ".",
            "In",
            "a",
            "pharmacokinetic",
            "study",
            "in",
            "pregnant",
            "rats",
            "with",
            "a",
            "single",
            "oral",
            "30",
            "mg/kg",
            "enzalutamide",
            "administration",
            "on",
            "gestation",
            "day",
            "14",
            ",",
            "enzalutamide",
            "and/or",
            "its",
            "metabolites",
            "were",
            "present",
            "in",
            "the",
            "fetus",
            "at",
            "a",
            "Cmax",
            "that",
            "was",
            "approximately",
            "0.3",
            "times",
            "the",
            "concentration",
            "found",
            "in",
            "maternal",
            "plasma",
            "and",
            "occurred",
            "4",
            "hours",
            "after",
            "administration",
            ".",
            "8.2",
            "Lactation",
            "Risk",
            "Summary",
            "The",
            "safety",
            "and",
            "efficacy",
            "of",
            "XTANDI",
            "have",
            "not",
            "been",
            "established",
            "in",
            "females",
            ".",
            "There",
            "is",
            "no",
            "information",
            "available",
            "on",
            "the",
            "presence",
            "of",
            "XTANDI",
            "in",
            "human",
            "milk",
            ",",
            "the",
            "effects",
            "of",
            "the",
            "drug",
            "on",
            "the",
            "breastfed",
            "infant",
            ",",
            "or",
            "the",
            "effects",
            "of",
            "the",
            "drug",
            "on",
            "milk",
            "production",
            ".",
            "Enzalutamide",
            "and/or",
            "its",
            "metabolites",
            "were",
            "present",
            "in",
            "milk",
            "of",
            "lactating",
            "rats",
            "(",
            "see",
            "Data",
            ")",
            ".",
            "Data",
            "Following",
            "a",
            "single",
            "oral",
            "administration",
            "in",
            "lactating",
            "rats",
            "on",
            "postnatal",
            "day",
            "14",
            ",",
            "enzalutamide",
            "and/or",
            "its",
            "metabolites",
            "were",
            "present",
            "in",
            "milk",
            "at",
            "a",
            "Cmax",
            "that",
            "was",
            "4",
            "times",
            "higher",
            "than",
            "concentrations",
            "in",
            "the",
            "plasma",
            "and",
            "occurred",
            "4",
            "hours",
            "after",
            "administration",
            ".",
            "8.3",
            "Females",
            "and",
            "Males",
            "of",
            "Reproductive",
            "Potential",
            "Contraception",
            "Males",
            "Based",
            "on",
            "findings",
            "in",
            "animal",
            "reproduction",
            "studies",
            ",",
            "advise",
            "male",
            "patients",
            "with",
            "female",
            "partners",
            "of",
            "reproductive",
            "potential",
            "to",
            "use",
            "effective",
            "contraception",
            "during",
            "treatment",
            "and",
            "for",
            "3",
            "months",
            "after",
            "the",
            "last",
            "dose",
            "of",
            "XTANDI",
            "[",
            "see",
            "Use",
            "in",
            "Specific",
            "Populations",
            "(",
            "8.1",
            ")",
            "]",
            ".",
            "Infertility",
            "Males",
            "Based",
            "on",
            "animal",
            "studies",
            ",",
            "XTANDI",
            "may",
            "impair",
            "fertility",
            "in",
            "males",
            "of",
            "reproductive",
            "potential",
            "[",
            "see",
            "Nonclinical",
            "Toxicology",
            "(",
            "13.1",
            ")",
            "]",
            ".",
            "8.4",
            "Pediatric",
            "Use",
            "Safety",
            "and",
            "effectiveness",
            "of",
            "XTANDI",
            "in",
            "pediatric",
            "patients",
            "have",
            "not",
            "been",
            "established",
            ".",
            "8.5",
            "Geriatric",
            "Use",
            "Of",
            "4081",
            "patients",
            "who",
            "received",
            "XTANDI",
            "in",
            "seven",
            "randomized",
            ",",
            "controlled",
            "clinical",
            "trials",
            ",",
            "78",
            "%",
            "were",
            "65",
            "and",
            "over",
            ",",
            "while",
            "35",
            "%",
            "were",
            "75",
            "and",
            "over",
            ".",
            "No",
            "overall",
            "differences",
            "in",
            "safety",
            "or",
            "effectiveness",
            "were",
            "observed",
            "between",
            "these",
            "patients",
            "and",
            "younger",
            "patients",
            ".",
            "Other",
            "reported",
            "clinical",
            "experience",
            "has",
            "not",
            "identified",
            "differences",
            "in",
            "responses",
            "between",
            "the",
            "elderly",
            "and",
            "younger",
            "patients",
            ",",
            "but",
            "greater",
            "sensitivity",
            "of",
            "some",
            "older",
            "individuals",
            "can",
            "not",
            "be",
            "ruled",
            "out",
            ".",
            "8.6",
            "Patients",
            "with",
            "Renal",
            "Impairment",
            "A",
            "dedicated",
            "renal",
            "impairment",
            "trial",
            "for",
            "XTANDI",
            "has",
            "not",
            "been",
            "conducted",
            ".",
            "Based",
            "on",
            "the",
            "population",
            "pharmacokinetic",
            "analysis",
            "using",
            "data",
            "from",
            "clinical",
            "trials",
            "in",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            "and",
            "healthy",
            "volunteers",
            ",",
            "no",
            "significant",
            "difference",
            "in",
            "enzalutamide",
            "clearance",
            "was",
            "observed",
            "in",
            "patients",
            "with",
            "pre-existing",
            "mild",
            "to",
            "moderate",
            "renal",
            "impairment",
            "(",
            "30",
            "mL/min",
            "impairment",
            ".",
            "Severe",
            "renal",
            "impairment",
            "(",
            "CrCL",
            "<",
            "30",
            "mL/min",
            ")",
            "and",
            "end-stage",
            "renal",
            "disease",
            "have",
            "not",
            "been",
            "assessed",
            "[",
            "see",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "8.7",
            "Patients",
            "with",
            "Hepatic",
            "Impairment",
            "Dedicated",
            "hepatic",
            "impairment",
            "trials",
            "compared",
            "the",
            "composite",
            "systemic",
            "exposure",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "in",
            "volunteers",
            "with",
            "baseline",
            "mild",
            ",",
            "moderate",
            ",",
            "or",
            "severe",
            "hepatic",
            "impairment",
            "(",
            "Child-Pugh",
            "Class",
            "A",
            ",",
            "B",
            ",",
            "or",
            "C",
            ",",
            "respectively",
            ")",
            "versus",
            "healthy",
            "controls",
            "with",
            "normal",
            "hepatic",
            "function",
            ".",
            "The",
            "composite",
            "AUC",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "was",
            "similar",
            "in",
            "volunteers",
            "with",
            "mild",
            ",",
            "moderate",
            ",",
            "or",
            "severe",
            "baseline",
            "hepatic",
            "impairment",
            "compared",
            "to",
            "volunteers",
            "with",
            "normal",
            "hepatic",
            "function",
            ".",
            "No",
            "initial",
            "dosage",
            "adjustment",
            "is",
            "necessary",
            "for",
            "patients",
            "with",
            "baseline",
            "mild",
            ",",
            "moderate",
            ",",
            "or",
            "severe",
            "hepatic",
            "impairment",
            "[",
            "see",
            "Clinical",
            "Pharmacology",
            "(",
            "12.3",
            ")",
            "]",
            ".",
            "10",
            "OVERDOSAGE",
            "In",
            "the",
            "event",
            "of",
            "an",
            "overdose",
            ",",
            "stop",
            "treatment",
            "with",
            "XTANDI",
            "and",
            "initiate",
            "general",
            "supportive",
            "measures",
            "taking",
            "into",
            "consideration",
            "the",
            "half-life",
            "of",
            "5.8",
            "days",
            ".",
            "In",
            "a",
            "dose",
            "escalation",
            "study",
            ",",
            "no",
            "seizures",
            "were",
            "reported",
            "at",
            "<",
            "240",
            "mg",
            "daily",
            ",",
            "whereas",
            "3",
            "seizures",
            "were",
            "reported",
            ",",
            "1",
            "each",
            "at",
            "360",
            "mg",
            ",",
            "480",
            "mg",
            ",",
            "and",
            "600",
            "mg",
            "daily",
            ".",
            "Patients",
            "may",
            "be",
            "at",
            "increased",
            "risk",
            "of",
            "seizure",
            "following",
            "an",
            "overdose",
            ".",
            "11",
            "DESCRIPTION",
            "Enzalutamide",
            "is",
            "an",
            "androgen",
            "receptor",
            "inhibitor",
            ".",
            "The",
            "chemical",
            "name",
            "is",
            "4-",
            "{",
            "3-",
            "[",
            "4-cyano-3-",
            "(",
            "trifluoromethyl",
            ")",
            "phenyl",
            "]",
            "-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl",
            "}",
            "-2-fluoro-N-methylbenzamide",
            ".",
            "The",
            "molecular",
            "weight",
            "is",
            "464.44",
            "and",
            "molecular",
            "formula",
            "is",
            "C21H16F4N4O2S",
            ".",
            "The",
            "structural",
            "formula",
            "is",
            ":",
            "Enzalutamide",
            "is",
            "a",
            "white",
            "crystalline",
            "non-hygroscopic",
            "solid",
            ".",
            "It",
            "is",
            "practically",
            "insoluble",
            "in",
            "water",
            ".",
            "XTANDI",
            "is",
            "available",
            "as",
            "liquid-filled",
            "soft",
            "gelatin",
            "capsules",
            "for",
            "oral",
            "administration",
            ".",
            "Each",
            "capsule",
            "contains",
            "40",
            "mg",
            "of",
            "enzalutamide",
            "as",
            "a",
            "solution",
            "in",
            "caprylocaproyl",
            "polyoxylglycerides",
            ".",
            "The",
            "inactive",
            "ingredients",
            "are",
            "caprylocaproyl",
            "polyoxylglycerides",
            ",",
            "butylated",
            "hydroxyanisole",
            ",",
            "butylated",
            "hydroxytoluene",
            ",",
            "gelatin",
            ",",
            "sorbitol",
            "sorbitan",
            "solution",
            ",",
            "glycerin",
            ",",
            "purified",
            "water",
            ",",
            "titanium",
            "dioxide",
            ",",
            "and",
            "black",
            "iron",
            "oxide",
            ".",
            "XTANDI",
            "is",
            "also",
            "available",
            "as",
            "film-coated",
            "tablets",
            "for",
            "oral",
            "administration",
            ".",
            "Each",
            "tablet",
            "contains",
            "40",
            "mg",
            "or",
            "80",
            "mg",
            "of",
            "enzalutamide",
            ".",
            "The",
            "inactive",
            "ingredients",
            "are",
            "hypromellose",
            "acetate",
            "succinate",
            ",",
            "microcrystalline",
            "cellulose",
            ",",
            "colloidal",
            "silicon",
            "dioxide",
            ",",
            "croscarmellose",
            "sodium",
            ",",
            "and",
            "magnesium",
            "stearate",
            ".",
            "The",
            "tablet",
            "film-coat",
            "contains",
            "hypromellose",
            ",",
            "talc",
            ",",
            "polyethylene",
            "glycol",
            ",",
            "titanium",
            "dioxide",
            ",",
            "and",
            "ferric",
            "oxide",
            ".",
            "12",
            "CLINICAL",
            "PHARMACOLOGY",
            "12.1",
            "Mechanism",
            "of",
            "Action",
            "Enzalutamide",
            "is",
            "an",
            "androgen",
            "receptor",
            "inhibitor",
            "that",
            "acts",
            "on",
            "different",
            "steps",
            "in",
            "the",
            "androgen",
            "receptor",
            "signaling",
            "pathway",
            ".",
            "Enzalutamide",
            "has",
            "been",
            "shown",
            "to",
            "competitively",
            "inhibit",
            "androgen",
            "binding",
            "to",
            "androgen",
            "receptors",
            ";",
            "and",
            "consequently",
            ",",
            "inhibits",
            "nuclear",
            "translocation",
            "of",
            "androgen",
            "receptors",
            "and",
            "their",
            "interaction",
            "with",
            "DNA",
            ".",
            "A",
            "major",
            "metabolite",
            ",",
            "N-desmethyl",
            "enzalutamide",
            ",",
            "exhibited",
            "similar",
            "in",
            "vitro",
            "activity",
            "to",
            "enzalutamide",
            ".",
            "Enzalutamide",
            "decreased",
            "proliferation",
            "and",
            "induced",
            "cell",
            "death",
            "of",
            "prostate",
            "cancer",
            "cells",
            "in",
            "vitro",
            ",",
            "and",
            "decreased",
            "tumor",
            "volume",
            "in",
            "a",
            "mouse",
            "prostate",
            "cancer",
            "xenograft",
            "model",
            ".",
            "12.2",
            "Pharmacodynamics",
            "Cardiac",
            "Electrophysiology",
            "The",
            "effect",
            "of",
            "enzalutamide",
            "160",
            "mg/day",
            "at",
            "steady-state",
            "on",
            "the",
            "QTc",
            "interval",
            "was",
            "evaluated",
            "in",
            "796",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            ".",
            "No",
            "large",
            "difference",
            "(",
            "i.e.",
            ",",
            "greater",
            "than",
            "20",
            "ms",
            ")",
            "was",
            "observed",
            "between",
            "the",
            "mean",
            "QT",
            "interval",
            "change",
            "from",
            "baseline",
            "in",
            "patients",
            "treated",
            "with",
            "XTANDI",
            "and",
            "that",
            "in",
            "patients",
            "treated",
            "with",
            "placebo",
            ",",
            "based",
            "on",
            "the",
            "Fridericia",
            "correction",
            "method",
            ".",
            "However",
            ",",
            "small",
            "increases",
            "in",
            "the",
            "mean",
            "QTc",
            "interval",
            "(",
            "i.e.",
            ",",
            "less",
            "than",
            "10",
            "ms",
            ")",
            "due",
            "to",
            "enzalutamide",
            "can",
            "not",
            "be",
            "excluded",
            "due",
            "to",
            "limitations",
            "of",
            "the",
            "study",
            "design",
            ".",
            "12.3",
            "Pharmacokinetics",
            "The",
            "pharmacokinetics",
            "of",
            "enzalutamide",
            "and",
            "its",
            "major",
            "active",
            "metabolite",
            "(",
            "N-desmethyl",
            "enzalutamide",
            ")",
            "were",
            "evaluated",
            "in",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            "and",
            "healthy",
            "male",
            "volunteers",
            ".",
            "The",
            "plasma",
            "enzalutamide",
            "pharmacokinetics",
            "are",
            "adequately",
            "described",
            "by",
            "a",
            "linear",
            "two-compartment",
            "model",
            "with",
            "first-order",
            "absorption",
            ".",
            "Absorption",
            "Following",
            "oral",
            "administration",
            "of",
            "XTANDI",
            "capsules",
            "(",
            "160",
            "mg",
            "daily",
            ")",
            "in",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            ",",
            "the",
            "median",
            "time",
            "to",
            "reach",
            "maximum",
            "plasma",
            "enzalutamide",
            "concentrations",
            "(",
            "Cmax",
            ")",
            "is",
            "1",
            "hour",
            "(",
            "range",
            "0.5",
            "to",
            "3",
            "hours",
            ")",
            ".",
            "At",
            "steady-state",
            ",",
            "the",
            "plasma",
            "mean",
            "Cmax",
            "values",
            "for",
            "enzalutamide",
            "and",
            "N-",
            "CV",
            ")",
            "and",
            "13.0",
            "respectively",
            ".",
            "Following",
            "a",
            "single",
            "dose",
            "administration",
            "of",
            "160",
            "mg",
            "enzalutamide",
            "in",
            "healthy",
            "male",
            "volunteers",
            ",",
            "enzalutamide",
            "extent",
            "of",
            "absorption",
            "(",
            "AUC",
            ")",
            "was",
            "comparable",
            "between",
            "XTANDI",
            "tablet",
            "and",
            "XTANDI",
            "capsule",
            ",",
            "but",
            "the",
            "mean",
            "Cmax",
            "was",
            "10",
            "%",
            "-28",
            "%",
            "lower",
            "than",
            "that",
            "of",
            "XTANDI",
            "capsules",
            ".",
            "The",
            "steady-state",
            "pharmacokinetic",
            "profiles",
            "(",
            "AUC",
            "and",
            "Cmax",
            ")",
            "of",
            "enzalutamide",
            "and",
            "N-desmethyl",
            "enzalutamide",
            "are",
            "similar",
            "for",
            "XTANDI",
            "tablet",
            "and",
            "XTANDI",
            "capsule",
            ".",
            "With",
            "the",
            "daily",
            "dosing",
            "regimen",
            ",",
            "enzalutamide",
            "steady-state",
            "is",
            "achieved",
            "by",
            "Day",
            "28",
            ",",
            "and",
            "enzalutamide",
            "accumulates",
            "approximately",
            "8.3-fold",
            "relative",
            "to",
            "a",
            "single",
            "dose",
            ".",
            "Daily",
            "fluctuations",
            "in",
            "enzalutamide",
            "plasma",
            "concentrations",
            "are",
            "low",
            "(",
            "mean",
            "peak-to-trough",
            "ratio",
            "of",
            "1.25",
            ")",
            ".",
            "At",
            "steady-state",
            ",",
            "enzalutamide",
            "showed",
            "approximately",
            "dose",
            "proportional",
            "pharmacokinetics",
            "over",
            "the",
            "daily",
            "dose",
            "range",
            "of",
            "30",
            "to",
            "360",
            "mg.",
            "A",
            "single",
            "160",
            "mg",
            "oral",
            "dose",
            "of",
            "XTANDI",
            "was",
            "administered",
            "to",
            "healthy",
            "volunteers",
            "with",
            "a",
            "high-fat",
            "meal",
            "or",
            "in",
            "the",
            "fasted",
            "condition",
            ".",
            "A",
            "high-fat",
            "meal",
            "did",
            "not",
            "alter",
            "the",
            "AUC",
            "to",
            "enzalutamide",
            "or",
            "N-desmethyl",
            "enzalutamide",
            ".",
            "The",
            "results",
            "are",
            "summarized",
            "in",
            "Figure",
            "1",
            ".",
            "Distribution",
            "and",
            "Protein",
            "Binding",
            "The",
            "mean",
            "apparent",
            "volume",
            "of",
            "distribution",
            "(",
            "V/F",
            ")",
            "of",
            "enzalutamide",
            "in",
            "patients",
            "after",
            "a",
            "single",
            "oral",
            "dose",
            "is",
            "110",
            "L",
            "(",
            "29",
            "%",
            "CV",
            ")",
            ".",
            "Enzalutamide",
            "is",
            "97",
            "%",
            "to",
            "98",
            "%",
            "bound",
            "to",
            "plasma",
            "proteins",
            ",",
            "primarily",
            "albumin",
            ".",
            "N-desmethyl",
            "enzalutamide",
            "is",
            "95",
            "%",
            "bound",
            "to",
            "plasma",
            "proteins",
            ".",
            "In",
            "vitro",
            ",",
            "there",
            "was",
            "no",
            "protein",
            "binding",
            "displacement",
            "between",
            "enzalutamide",
            "and",
            "other",
            "highly",
            "protein",
            "bound",
            "drugs",
            "(",
            "warfarin",
            ",",
            "ibuprofen",
            ",",
            "and",
            "salicylic",
            "acid",
            ")",
            "at",
            "clinically",
            "relevant",
            "concentrations",
            ".",
            "Metabolism",
            "Following",
            "single",
            "oral",
            "administration",
            "of",
            "14C-enzalutamide",
            "160",
            "mg",
            ",",
            "plasma",
            "samples",
            "were",
            "analyzed",
            "for",
            "enzalutamide",
            "and",
            "its",
            "metabolites",
            "up",
            "to",
            "77",
            "days",
            "post",
            "dose",
            ".",
            "Enzalutamide",
            ",",
            "N-desmethyl",
            "enzalutamide",
            ",",
            "and",
            "a",
            "major",
            "inactive",
            "carboxylic",
            "acid",
            "metabolite",
            "accounted",
            "for",
            "88",
            "%",
            "of",
            "the",
            "14C-radioactivity",
            "in",
            "plasma",
            ",",
            "representing",
            "30",
            "%",
            ",",
            "49",
            "%",
            ",",
            "and",
            "10",
            "%",
            ",",
            "respectively",
            ",",
            "of",
            "the",
            "total",
            "14C-AUC0-inf",
            ".",
            "In",
            "vitro",
            ",",
            "human",
            "CYP2C8",
            "and",
            "CYP3A4",
            "are",
            "responsible",
            "for",
            "the",
            "metabolism",
            "of",
            "enzalutamide",
            ".",
            "Based",
            "on",
            "in",
            "vivo",
            "and",
            "in",
            "vitro",
            "data",
            ",",
            "CYP2C8",
            "is",
            "primarily",
            "responsible",
            "for",
            "the",
            "formation",
            "of",
            "the",
            "active",
            "metabolite",
            "(",
            "N-desmethyl",
            "enzalutamide",
            ")",
            ".",
            "In",
            "vitro",
            "data",
            "suggest",
            "that",
            "carboxylesterase",
            "1",
            "metabolizes",
            "N-desmethyl",
            "enzalutamide",
            "and",
            "enzalutamide",
            "to",
            "the",
            "inactive",
            "carboxylic",
            "acid",
            "metabolite",
            ".",
            "In",
            "vitro",
            ",",
            "N-desmethyl",
            "enzalutamide",
            "is",
            "not",
            "a",
            "substrate",
            "of",
            "human",
            "CYP1A1",
            ",",
            "CYP1A2",
            ",",
            "CYP2A6",
            ",",
            "CYP2B6",
            ",",
            "CYP2C8",
            ",",
            "CYP2C9",
            ",",
            "CYP2C18",
            ",",
            "CYP2C19",
            ",",
            "CYP2D6",
            ",",
            "CYP2E1",
            "and",
            "CYP3A4/5",
            ".",
            "Elimination",
            "Enzalutamide",
            "is",
            "primarily",
            "eliminated",
            "by",
            "hepatic",
            "metabolism",
            ".",
            "Following",
            "single",
            "oral",
            "administration",
            "of",
            "14C-enzalutamide",
            "160",
            "mg",
            ",",
            "85",
            "%",
            "of",
            "the",
            "radioactivity",
            "is",
            "recovered",
            "by",
            "77",
            "days",
            "post",
            "dose",
            ":",
            "71",
            "%",
            "is",
            "recovered",
            "in",
            "urine",
            "(",
            "including",
            "only",
            "trace",
            "amounts",
            "of",
            "enzalutamide",
            "and",
            "N-desmethyl",
            "enzalutamide",
            ")",
            ",",
            "and",
            "14",
            "%",
            "is",
            "recovered",
            "in",
            "feces",
            "(",
            "0.4",
            "%",
            "of",
            "dose",
            "as",
            "unchanged",
            "enzalutamide",
            "and",
            "1",
            "%",
            "as",
            "N-desmethyl",
            "enzalutamide",
            ")",
            ".",
            "The",
            "mean",
            "apparent",
            "clearance",
            "(",
            "CL/F",
            ")",
            "of",
            "enzalutamide",
            "in",
            "patients",
            "after",
            "a",
            "single",
            "oral",
            "dose",
            "is",
            "0.56",
            "L/h",
            "(",
            "range",
            "0.33",
            "to",
            "1.02",
            "L/h",
            ")",
            ".",
            "The",
            "mean",
            "terminal",
            "half-life",
            "(",
            "t1/2",
            ")",
            "for",
            "enzalutamide",
            "in",
            "patients",
            "after",
            "a",
            "single",
            "oral",
            "dose",
            "is",
            "5.8",
            "days",
            "(",
            "range",
            "2.8",
            "to",
            "10.2",
            "days",
            ")",
            ".",
            "Following",
            "a",
            "single",
            "160",
            "mg",
            "oral",
            "dose",
            "of",
            "enzalutamide",
            "in",
            "healthy",
            "volunteers",
            ",",
            "the",
            "mean",
            "terminal",
            "t1/2",
            "for",
            "N-desmethyl",
            "enzalutamide",
            "is",
            "approximately",
            "7.8",
            "to",
            "8.6",
            "days",
            ".",
            "Pharmacokinetics",
            "in",
            "Special",
            "Populations",
            "Renal",
            "Impairment",
            ":",
            "A",
            "population",
            "pharmacokinetic",
            "analysis",
            "(",
            "based",
            "on",
            "pre-existing",
            "renal",
            "function",
            ")",
            "was",
            "carried",
            "out",
            "with",
            "data",
            "from",
            "59",
            "healthy",
            "male",
            "volunteers",
            "and",
            "926",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            "enrolled",
            "in",
            "clinical",
            "trials",
            ",",
            "including",
            "512",
            "with",
            "normal",
            "renal",
            "function",
            "(",
            "impairment",
            "(",
            "CrCL",
            "30",
            "to",
            "<",
            "60",
            "mL/min",
            ")",
            ",",
            "and",
            "1",
            "with",
            "severe",
            "renal",
            "impairment",
            "(",
            "CrCL",
            "<",
            "30",
            "mL/min",
            ")",
            ".",
            "The",
            "apparent",
            "clearance",
            "of",
            "enzalutamide",
            "was",
            "similar",
            "in",
            "patients",
            "with",
            "pre-existing",
            "mild",
            "and",
            "moderate",
            "renal",
            "impairment",
            "(",
            "CrCL",
            "30",
            "to",
            "<",
            "90",
            "mL/min",
            ")",
            "compared",
            "to",
            "patients",
            "and",
            "volunteers",
            "with",
            "normal",
            "renal",
            "function",
            ".",
            "The",
            "potential",
            "effect",
            "of",
            "severe",
            "renal",
            "impairment",
            "or",
            "end-stage",
            "renal",
            "disease",
            "on",
            "enzalutamide",
            "pharmacokinetics",
            "can",
            "not",
            "be",
            "determined",
            "as",
            "clinical",
            "and",
            "pharmacokinetic",
            "data",
            "are",
            "available",
            "from",
            "only",
            "one",
            "patient",
            "[",
            "see",
            "Use",
            "in",
            "Specific",
            "Populations",
            "(",
            "8.6",
            ")",
            "]",
            ".",
            "Hepatic",
            "Impairment",
            ":",
            "The",
            "plasma",
            "pharmacokinetics",
            "of",
            "enzalutamide",
            "and",
            "N-desmethyl",
            "enzalutamide",
            "were",
            "examined",
            "in",
            "volunteers",
            "with",
            "normal",
            "hepatic",
            "function",
            "(",
            "N",
            "=",
            "22",
            ")",
            "and",
            "with",
            "pre-existing",
            "mild",
            "(",
            "N",
            "=",
            "8",
            ",",
            "Child-Pugh",
            "Class",
            "A",
            ")",
            "moderate",
            "(",
            "N",
            "=",
            "8",
            ",",
            "Child-Pugh",
            "Class",
            "B",
            ")",
            ",",
            "or",
            "severe",
            "(",
            "N",
            "=",
            "8",
            ",",
            "Child-Pugh",
            "Class",
            "C",
            ")",
            "hepatic",
            "impairment",
            ".",
            "XTANDI",
            "was",
            "administered",
            "as",
            "a",
            "single",
            "160",
            "mg",
            "dose",
            ".",
            "The",
            "composite",
            "AUC",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "was",
            "similar",
            "in",
            "volunteers",
            "with",
            "mild",
            ",",
            "moderate",
            ",",
            "or",
            "severe",
            "baseline",
            "hepatic",
            "impairment",
            "compared",
            "to",
            "volunteers",
            "with",
            "normal",
            "hepatic",
            "function",
            ".",
            "The",
            "results",
            "are",
            "summarized",
            "in",
            "Figure",
            "1",
            "[",
            "see",
            "Use",
            "in",
            "Specific",
            "Populations",
            "(",
            "8.7",
            ")",
            "]",
            ".",
            "Body",
            "Weight",
            "and",
            "Age",
            ":",
            "Population",
            "pharmacokinetic",
            "analyses",
            "showed",
            "that",
            "weight",
            "(",
            "range",
            ":",
            "46",
            "to",
            "163",
            "kg",
            ")",
            "and",
            "age",
            "(",
            "range",
            ":",
            "41",
            "to",
            "92",
            "yrs",
            ".",
            ")",
            "do",
            "not",
            "have",
            "a",
            "clinically",
            "meaningful",
            "influence",
            "on",
            "the",
            "exposure",
            "to",
            "enzalutamide",
            ".",
            "Gender",
            ":",
            "The",
            "effect",
            "of",
            "gender",
            "on",
            "the",
            "pharmacokinetics",
            "of",
            "enzalutamide",
            "has",
            "not",
            "been",
            "evaluated",
            ".",
            "Race",
            ":",
            "The",
            "majority",
            "of",
            "XTANDI-treated",
            "patients",
            "in",
            "the",
            "randomized",
            "clinical",
            "trials",
            "were",
            "Caucasian",
            "(",
            "81",
            "%",
            ")",
            ".",
            "Based",
            "on",
            "pharmacokinetic",
            "data",
            "from",
            "studies",
            "in",
            "Japanese",
            "and",
            "Chinese",
            "patients",
            "with",
            "prostate",
            "cancer",
            ",",
            "there",
            "were",
            "no",
            "clinically",
            "relevant",
            "differences",
            "in",
            "exposure",
            "among",
            "the",
            "populations",
            ".",
            "There",
            "are",
            "insufficient",
            "data",
            "to",
            "evaluate",
            "potential",
            "differences",
            "in",
            "the",
            "pharmacokinetics",
            "of",
            "enzalutamide",
            "in",
            "other",
            "races",
            ".",
            "Drug",
            "Interactions",
            "Effect",
            "of",
            "Other",
            "Drugs",
            "on",
            "XTANDI",
            ":",
            "In",
            "a",
            "drug-drug",
            "interaction",
            "trial",
            "in",
            "healthy",
            "volunteers",
            ",",
            "a",
            "single",
            "160",
            "mg",
            "oral",
            "dose",
            "of",
            "XTANDI",
            "was",
            "administered",
            "alone",
            "or",
            "after",
            "multiple",
            "oral",
            "doses",
            "of",
            "gemfibrozil",
            "(",
            "strong",
            "CYP2C8",
            "inhibitor",
            ")",
            ".",
            "Gemfibrozil",
            "increased",
            "the",
            "AUC0-inf",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "by",
            "2.2-fold",
            "with",
            "minimal",
            "effect",
            "on",
            "Cmax",
            ".",
            "The",
            "results",
            "are",
            "summarized",
            "in",
            "Figure",
            "1",
            "[",
            "see",
            "Dosage",
            "and",
            "Administration",
            "(",
            "2.2",
            ")",
            "and",
            "Drug",
            "Interactions",
            "(",
            "7.1",
            ")",
            "]",
            ".",
            "In",
            "a",
            "drug-drug",
            "interaction",
            "trial",
            "in",
            "healthy",
            "volunteers",
            ",",
            "a",
            "single",
            "160",
            "mg",
            "oral",
            "dose",
            "of",
            "XTANDI",
            "was",
            "administered",
            "alone",
            "or",
            "after",
            "multiple",
            "oral",
            "doses",
            "of",
            "rifampin",
            "(",
            "strong",
            "CYP3A4",
            "and",
            "moderate",
            "CYP2C8",
            "inducer",
            ")",
            ".",
            "Rifampin",
            "decreased",
            "the",
            "AUC0-inf",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "by",
            "37",
            "%",
            "with",
            "no",
            "effect",
            "on",
            "Cmax",
            ".",
            "The",
            "results",
            "are",
            "summarized",
            "in",
            "Figure",
            "1",
            "[",
            "see",
            "Dosage",
            "and",
            "Administration",
            "(",
            "2.2",
            ")",
            "and",
            "Drug",
            "Interactions",
            "(",
            "7.2",
            ")",
            "]",
            ".",
            "In",
            "a",
            "drug-drug",
            "interaction",
            "trial",
            "in",
            "healthy",
            "volunteers",
            ",",
            "a",
            "single",
            "160",
            "mg",
            "oral",
            "dose",
            "of",
            "XTANDI",
            "was",
            "administered",
            "alone",
            "or",
            "after",
            "multiple",
            "oral",
            "doses",
            "of",
            "itraconazole",
            "(",
            "strong",
            "CYP3A4",
            "inhibitor",
            ")",
            ".",
            "Itraconazole",
            "increased",
            "the",
            "AUC0-inf",
            "of",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            "by",
            "1.3-fold",
            "with",
            "no",
            "effect",
            "on",
            "Cmax",
            ".",
            "The",
            "results",
            "are",
            "summarized",
            "in",
            "Figure",
            "1",
            ".",
            "Figure",
            "1",
            ".",
            "Effects",
            "of",
            "Other",
            "Drugs",
            "and",
            "Intrinsic/Extrinsic",
            "Factors",
            "on",
            "XTANDI",
            "#",
            "PK",
            "parameters",
            "(",
            "Cmax",
            "and",
            "AUC0-inf",
            ")",
            "are",
            "for",
            "enzalutamide",
            "plus",
            "N-desmethyl",
            "enzalutamide",
            ",",
            "except",
            "in",
            "the",
            "food-effect",
            "trial",
            ",",
            "where",
            "they",
            "are",
            "for",
            "enzalutamide",
            "alone",
            ".",
            "*",
            "See",
            "Dosage",
            "and",
            "Administration",
            "(",
            "2.2",
            ")",
            ".",
            "Effect",
            "of",
            "XTANDI",
            "on",
            "Other",
            "Drugs",
            ":",
            "In",
            "an",
            "in",
            "vivo",
            "phenotypic",
            "cocktail",
            "drug-drug",
            "interaction",
            "trial",
            "in",
            "patients",
            "with",
            "metastatic",
            "CRPC",
            ",",
            "a",
            "single",
            "oral",
            "dose",
            "of",
            "the",
            "CYP",
            "probe",
            "substrate",
            "cocktail",
            "(",
            "for",
            "CYP2C8",
            ",",
            "CYP2C9",
            ",",
            "CYP2C19",
            ",",
            "and",
            "CYP3A4",
            ")",
            "was",
            "administered",
            "before",
            "and",
            "concomitantly",
            "with",
            "XTANDI",
            "(",
            "following",
            "at",
            "least",
            "55",
            "days",
            "of",
            "dosing",
            "at",
            "160",
            "mg",
            "daily",
            ")",
            ".",
            "The",
            "results",
            "are",
            "summarized",
            "in",
            "Figure",
            "2",
            ".",
            "Results",
            "showed",
            "that",
            "in",
            "vivo",
            ",",
            "at",
            "steady-state",
            ",",
            "XTANDI",
            "is",
            "a",
            "strong",
            "CYP3A4",
            "inducer",
            "and",
            "a",
            "moderate",
            "CYP2C9",
            "and",
            "CYP2C19",
            "inducer",
            "[",
            "see",
            "Drug",
            "Interactions",
            "(",
            "7.3",
            ")",
            "]",
            ".",
            "XTANDI",
            "did",
            "not",
            "cause",
            "clinically",
            "meaningful",
            "changes",
            "in",
            "exposure",
            "to",
            "the",
            "CYP2C8",
            "substrate",
            ".",
            "In",
            "an",
            "in",
            "vivo",
            "phenotypic",
            "cocktail",
            "drug-drug",
            "interaction",
            "trial",
            "in",
            "patients",
            "with",
            "CRPC",
            ",",
            "a",
            "single",
            "oral",
            "dose",
            "of",
            "the",
            "CYP",
            "probe",
            "substrate",
            "cocktail",
            "for",
            "CYP1A2",
            "and",
            "CYP2D6",
            "was",
            "administered",
            "before",
            "and",
            "concomitantly",
            "with",
            "XTANDI",
            "(",
            "following",
            "at",
            "least",
            "49",
            "days",
            "of",
            "dosing",
            "at",
            "160",
            "mg",
            "daily",
            ")",
            ".",
            "The",
            "results",
            "are",
            "summarized",
            "in",
            "Figure",
            "2",
            ".",
            "Results",
            "showed",
            "that",
            "in",
            "vivo",
            ",",
            "at",
            "steady-state",
            ",",
            "XTANDI",
            "did",
            "not",
            "cause",
            "clinically",
            "meaningful",
            "changes",
            "in",
            "exposure",
            "to",
            "the",
            "CYP1A2",
            "or",
            "CYP2D6",
            "substrates",
            ".",
            "Figure",
            "2",
            ".",
            "Effect",
            "of",
            "XTANDI",
            "on",
            "Other",
            "Drugs",
            "*",
            "See",
            "Drug",
            "Interactions",
            "(",
            "7.3",
            ")",
            ".",
            "In",
            "vitro",
            ",",
            "enzalutamide",
            ",",
            "N-desmethyl",
            "enzalutamide",
            ",",
            "and",
            "the",
            "major",
            "inactive",
            "carboxylic",
            "acid",
            "metabolite",
            "caused",
            "direct",
            "inhibition",
            "of",
            "multiple",
            "CYP",
            "enzymes",
            "including",
            "CYP2B6",
            ",",
            "CYP2C8",
            ",",
            "CYP2C9",
            ",",
            "CYP2C19",
            ",",
            "CYP2D6",
            ",",
            "and",
            "CYP3A4/5",
            ";",
            "however",
            ",",
            "subsequent",
            "clinical",
            "data",
            "showed",
            "that",
            "XTANDI",
            "is",
            "an",
            "inducer",
            "of",
            "CYP2C9",
            ",",
            "CYP2C19",
            ",",
            "and",
            "CYP3A4",
            "and",
            "had",
            "no",
            "clinically",
            "meaningful",
            "effect",
            "on",
            "CYP2C8",
            "(",
            "see",
            "Figure",
            "2",
            ")",
            ".",
            "In",
            "vitro",
            ",",
            "enzalutamide",
            "caused",
            "time-dependent",
            "inhibition",
            "of",
            "CYP1A2",
            ".",
            "In",
            "vitro",
            "studies",
            "showed",
            "that",
            "enzalutamide",
            "induces",
            "CYP2B6",
            "and",
            "CYP3A4",
            "and",
            "does",
            "not",
            "induce",
            "CYP1A2",
            "at",
            "therapeutically",
            "relevant",
            "concentrations",
            ".",
            "In",
            "vitro",
            ",",
            "enzalutamide",
            ",",
            "N-desmethyl",
            "enzalutamide",
            ",",
            "and",
            "the",
            "major",
            "inactive",
            "carboxylic",
            "acid",
            "metabolite",
            "are",
            "not",
            "substrates",
            "for",
            "human",
            "P-glycoprotein",
            ".",
            "In",
            "vitro",
            ",",
            "enzalutamide",
            "and",
            "N-desmethyl",
            "enzalutamide",
            "are",
            "inhibitors",
            "of",
            "human",
            "P-glycoprotein",
            ",",
            "while",
            "the",
            "major",
            "inactive",
            "carboxylic",
            "acid",
            "metabolite",
            "is",
            "not",
            ".",
            "In",
            "vitro",
            ",",
            "enzalutamide",
            "and",
            "N-desmethyl",
            "enzalutamide",
            "do",
            "not",
            "appear",
            "to",
            "be",
            "substrates",
            "of",
            "human",
            "breast",
            "cancer",
            "resistance",
            "protein",
            "(",
            "BCRP",
            ")",
            ";",
            "however",
            ",",
            "enzalutamide",
            "and",
            "N-desmethyl",
            "enzalutamide",
            "are",
            "inhibitors",
            "of",
            "human",
            "BCRP",
            "at",
            "clinically",
            "relevant",
            "concentrations",
            ".",
            "13",
            "NONCLINICAL",
            "TOXICOLOGY",
            "13.1",
            "Carcinogenesis",
            ",",
            "Mutagenesis",
            ",",
            "Impairment",
            "of",
            "Fertility",
            "A",
            "two-year",
            "carcinogenicity",
            "study",
            "was",
            "conducted",
            "in",
            "male",
            "and",
            "female",
            "rats",
            "at",
            "oral",
            "enzalutamide",
            "doses",
            "of",
            "10",
            ",",
            "30",
            ",",
            "and",
            "100",
            "mg/kg/day",
            ".",
            "Enzalutamide",
            "increased",
            "the",
            "incidence",
            "of",
            "benign",
            "Leydig",
            "cell",
            "tumors",
            "in",
            "the",
            "testes",
            "at",
            "all",
            "dose",
            "levels",
            "tested",
            "0.3",
            "times",
            "the",
            "human",
            "exposure",
            "based",
            "on",
            "AUC",
            ")",
            "and",
            "combined",
            "incidence",
            "of",
            "urothelial",
            "papilloma",
            "and",
            "carcinoma",
            "in",
            "the",
            "urinary",
            "bladder",
            "in",
            "male",
            "rats",
            "at",
            "100",
            "mg/kg/day",
            "(",
            "1.4",
            "times",
            "the",
            "human",
            "exposure",
            "based",
            "on",
            "AUC",
            ")",
            ".",
            "The",
            "findings",
            "in",
            "the",
            "testes",
            "are",
            "considered",
            "to",
            "be",
            "related",
            "to",
            "the",
            "pharmacological",
            "activity",
            "of",
            "enzalutamide",
            ".",
            "Rats",
            "are",
            "regarded",
            "as",
            "more",
            "sensitive",
            "than",
            "humans",
            "to",
            "developing",
            "interstitial",
            "cell",
            "tumors",
            "in",
            "the",
            "testes",
            ".",
            "Administration",
            "of",
            "enzalutamide",
            "to",
            "male",
            "and",
            "female",
            "rasH2",
            "transgenic",
            "mice",
            "by",
            "oral",
            "gavage",
            "daily",
            "for",
            "26",
            "weeks",
            "did",
            "not",
            "result",
            "in",
            "increased",
            "incidence",
            "of",
            "neoplasms",
            "at",
            "doses",
            "up",
            "to",
            "20",
            "mg/kg/day",
            ".",
            "Enzalutamide",
            "did",
            "not",
            "induce",
            "mutations",
            "in",
            "the",
            "bacterial",
            "reverse",
            "mutation",
            "(",
            "Ames",
            ")",
            "assay",
            "and",
            "was",
            "not",
            "genotoxic",
            "in",
            "either",
            "the",
            "in",
            "vitro",
            "mouse",
            "lymphoma",
            "thymidine",
            "kinase",
            "(",
            "Tk",
            ")",
            "gene",
            "mutation",
            "assay",
            "or",
            "the",
            "in",
            "vivo",
            "mouse",
            "micronucleus",
            "assay",
            ".",
            "Based",
            "on",
            "nonclinical",
            "findings",
            "in",
            "repeat-dose",
            "toxicology",
            "studies",
            ",",
            "which",
            "were",
            "consistent",
            "with",
            "the",
            "pharmacological",
            "activity",
            "of",
            "enzalutamide",
            ",",
            "male",
            "fertility",
            "may",
            "be",
            "impaired",
            "by",
            "treatment",
            "with",
            "XTANDI",
            ".",
            "In",
            "a",
            "26-week",
            "study",
            "in",
            "rats",
            ",",
            "atrophy",
            "of",
            "the",
            "prostate",
            "-",
            ",",
            "13-",
            ",",
            "and",
            "39-week",
            "studies",
            "in",
            "dogs",
            ",",
            "hypospermatogenesis",
            "and",
            "atrophy",
            "of",
            "the",
            "prostate",
            "and",
            "epididymides",
            "were",
            "observed",
            "at",
            "4",
            "mg/kg/day",
            "(",
            "0.3",
            "times",
            "the",
            "human",
            "exposure",
            "based",
            "on",
            "AUC",
            ")",
            ".",
            "14",
            "CLINICAL",
            "STUDIES",
            "The",
            "efficacy",
            "of",
            "XTANDI",
            "in",
            "patients",
            "with",
            "CRPC",
            "(",
            "N",
            "=",
            "4692",
            ")",
            "or",
            "mCSPC",
            "(",
            "N",
            "=",
            "1150",
            ")",
            "was",
            "demonstrated",
            "in",
            "five",
            "randomized",
            ",",
            "multicenter",
            "clinical",
            "trials",
            ".",
            "All",
            "patients",
            "received",
            "concomitant",
            "GnRH",
            "therapy",
            "or",
            "had",
            "prior",
            "bilateral",
            "orchiectomy",
            ".",
            "Patients",
            "were",
            "allowed",
            ",",
            "but",
            "not",
            "required",
            ",",
            "to",
            "continue",
            "or",
            "initiate",
            "glucocorticoids",
            ".",
            "AFFIRM",
            "(",
            "NCT00974311",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Metastatic",
            "CRPC",
            "Following",
            "Chemotherapy",
            "In",
            "AFFIRM",
            ",",
            "a",
            "total",
            "of",
            "1199",
            "patients",
            "who",
            "had",
            "received",
            "prior",
            "docetaxel-based",
            "chemotherapy",
            "were",
            "randomized",
            "2:1",
            "to",
            "receive",
            "either",
            "XTANDI",
            "orally",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "800",
            ")",
            "or",
            "placebo",
            "orally",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "399",
            ")",
            ".",
            "Study",
            "treatment",
            "continued",
            "until",
            "disease",
            "progression",
            "(",
            "evidence",
            "of",
            "radiographic",
            "progression",
            ",",
            "a",
            "skeletal-related",
            "event",
            ",",
            "or",
            "clinical",
            "progression",
            ")",
            ",",
            "initiation",
            "of",
            "new",
            "systemic",
            "antineoplastic",
            "treatment",
            ",",
            "unacceptable",
            "toxicity",
            ",",
            "or",
            "withdrawal",
            ".",
            "Patients",
            "with",
            "a",
            "previous",
            "history",
            "of",
            "seizure",
            ",",
            "taking",
            "medicines",
            "known",
            "to",
            "decrease",
            "the",
            "seizure",
            "threshold",
            ",",
            "or",
            "with",
            "other",
            "risk",
            "factors",
            "for",
            "seizure",
            "were",
            "not",
            "eligible",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.1",
            ")",
            "]",
            ".",
            "The",
            "following",
            "patient",
            "demographics",
            "and",
            "baseline",
            "disease",
            "characteristics",
            "were",
            "balanced",
            "between",
            "the",
            "treatment",
            "arms",
            ".",
            "The",
            "median",
            "age",
            "was",
            "69",
            "years",
            "(",
            "range",
            "41-92",
            ")",
            "and",
            "the",
            "racial",
            "distribution",
            "was",
            "92.7",
            "%",
            "Caucasian",
            ",",
            "3.9",
            "%",
            "Black",
            ",",
            "1.1",
            "%",
            "Asian",
            ",",
            "and",
            "2.1",
            "%",
            "Other",
            ".",
            "Ninety-two",
            "percent",
            "of",
            "patients",
            "had",
            "an",
            "ECOG",
            "performance",
            "status",
            "score",
            "of",
            "0-1",
            "and",
            "28",
            "%",
            "had",
            "a",
            "mean",
            "Brief",
            "Pain",
            "Inventory",
            "sco-one",
            "percent",
            "of",
            "patients",
            "had",
            "metastases",
            "in",
            "bone",
            "and",
            "23",
            "%",
            "had",
            "visceral",
            "involvement",
            "in",
            "the",
            "lung",
            "and/or",
            "liver",
            ".",
            "Fifty-nine",
            "percent",
            "of",
            "patients",
            "had",
            "radiographic",
            "evidence",
            "of",
            "disease",
            "progression",
            "and",
            "41",
            "%",
            "had",
            "PSA-only",
            "progression",
            "on",
            "study",
            "entry",
            ".",
            "All",
            "patients",
            "had",
            "received",
            "prior",
            "docetaxel-based",
            "therapy",
            "and",
            "24",
            "%",
            "had",
            "received",
            "two",
            "cytotoxic",
            "chemotherapy",
            "regimens",
            ".",
            "During",
            "the",
            "trial",
            ",",
            "48",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "and",
            "46",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "placebo",
            "arm",
            "received",
            "glucocorticoids",
            ".",
            "A",
            "statistically",
            "significant",
            "improvement",
            "in",
            "overall",
            "survival",
            "was",
            "demonstrated",
            "at",
            "the",
            "pre-specified",
            "interim",
            "analysis",
            "at",
            "the",
            "time",
            "of",
            "520",
            "deaths",
            "in",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "patients",
            "on",
            "the",
            "placebo",
            "arm",
            "(",
            "Table",
            "7",
            "and",
            "Figure",
            "3",
            ")",
            ".",
            "Table",
            "7",
            ".",
            "Overall",
            "Survival",
            "of",
            "Patients",
            "Treated",
            "with",
            "Either",
            "XTANDI",
            "or",
            "Placebo",
            "in",
            "AFFIRM",
            "XTANDI",
            "(",
            "N",
            "=",
            "800",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "399",
            ")",
            "Number",
            "of",
            "Deaths",
            "(",
            "%",
            ")",
            "308",
            "(",
            "38.5",
            ")",
            "212",
            "(",
            "53.1",
            ")",
            "Median",
            "Survival",
            ",",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "18.4",
            "(",
            "17.3",
            ",",
            "NR",
            ")",
            "13.6",
            "(",
            "11.3",
            ",",
            "15.8",
            ")",
            "P-value1",
            "p",
            "<",
            "0.0001",
            "Hazard",
            "Ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "2",
            "0.63",
            "(",
            "0.53",
            ",",
            "0.75",
            ")",
            "NR",
            "=",
            "Not",
            "reached",
            ".",
            "1",
            ".",
            "P-value",
            "is",
            "derived",
            "from",
            "a",
            "log-rank",
            "test",
            "stratified",
            "by",
            "baseline",
            "ECOG",
            "performance",
            "status",
            "score",
            "(",
            "0-1",
            "vs.",
            "2",
            ")",
            "and",
            "mean",
            "baseline",
            "pain",
            "score",
            "(",
            "BPI-",
            "2",
            ".",
            "Hazard",
            "Ratio",
            "is",
            "derived",
            "from",
            "a",
            "stratified",
            "proportional",
            "hazards",
            "model",
            ".",
            "Hazard",
            "Ratio",
            "<",
            "1",
            "favors",
            "XTANDI",
            ".",
            "Figure",
            "3",
            ".",
            "Kaplan-Meier",
            "Curves",
            "of",
            "Overall",
            "Survival",
            "in",
            "AFFIRM",
            "PREVAIL",
            "(",
            "NCT01212991",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Chemotherapy-na\u00efve",
            "Metastatic",
            "CRPC",
            "In",
            "PREVAIL",
            ",",
            "1717",
            "chemotherapy-na\u00efve",
            "patients",
            "were",
            "randomized",
            "1:1",
            "to",
            "receive",
            "either",
            "XTANDI",
            "orally",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "872",
            ")",
            "or",
            "placebo",
            "orally",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "845",
            ")",
            ".",
            "Patients",
            "with",
            "visceral",
            "metastases",
            ",",
            "patients",
            "with",
            "a",
            "history",
            "of",
            "mild",
            "to",
            "moderate",
            "heart",
            "failure",
            "(",
            "NYHA",
            "class",
            "I",
            "or",
            "II",
            ")",
            ",",
            "and",
            "patients",
            "taking",
            "medications",
            "associated",
            "with",
            "lowering",
            "the",
            "seizure",
            "threshold",
            "were",
            "allowed",
            ".",
            "Patients",
            "with",
            "a",
            "previous",
            "history",
            "of",
            "seizure",
            "or",
            "a",
            "condition",
            "that",
            "might",
            "predispose",
            "to",
            "seizure",
            "and",
            "patients",
            "with",
            "moderate",
            "or",
            "severe",
            "pain",
            "from",
            "prostate",
            "cancer",
            "were",
            "excluded",
            ".",
            "Study",
            "treatment",
            "continued",
            "until",
            "disease",
            "progression",
            "(",
            "evidence",
            "of",
            "radiographic",
            "progression",
            ",",
            "a",
            "skeletal-related",
            "event",
            ",",
            "or",
            "clinical",
            "progression",
            ")",
            "and",
            "the",
            "initiation",
            "of",
            "a",
            "cytotoxic",
            "chemotherapy",
            "or",
            "an",
            "investigational",
            "agent",
            ",",
            "unacceptable",
            "toxicity",
            ",",
            "or",
            "withdrawal",
            ".",
            "Overall",
            "survival",
            "and",
            "radiographic",
            "progression-free",
            "survival",
            "(",
            "rPFS",
            ")",
            "were",
            "assessed",
            ".",
            "Radiographic",
            "progression",
            "was",
            "assessed",
            "with",
            "the",
            "use",
            "of",
            "sequential",
            "imaging",
            "and",
            "was",
            "defined",
            "by",
            "bone",
            "scan",
            "identification",
            "of",
            "2",
            "or",
            "more",
            "new",
            "bone",
            "lesions",
            "with",
            "confirmation",
            "(",
            "Prostate",
            "Cancer",
            "Clinical",
            "Trials",
            "Working",
            "Group",
            "2",
            "criteria",
            ")",
            "and/or",
            "Response",
            "Evaluation",
            "Criteria",
            "in",
            "Solid",
            "Tumors",
            "(",
            "RECIST",
            "v",
            "1.1",
            ")",
            "criteria",
            "for",
            "progression",
            "of",
            "soft",
            "tissue",
            "lesions",
            ".",
            "The",
            "primary",
            "analysis",
            "of",
            "rPFS",
            "utilized",
            "centrally",
            "reviewed",
            "radiographic",
            "assessment",
            "of",
            "progression",
            ".",
            "Patient",
            "demographics",
            "and",
            "baseline",
            "disease",
            "characteristics",
            "were",
            "balanced",
            "between",
            "the",
            "treatment",
            "arms",
            "at",
            "entry",
            ".",
            "The",
            "median",
            "age",
            "was",
            "71",
            "years",
            "(",
            "range",
            "42-93",
            ")",
            "and",
            "the",
            "racial",
            "distribution",
            "was",
            "77",
            "%",
            "Caucasian",
            ",",
            "10",
            "%",
            "Asian",
            ",",
            "2",
            "%",
            "Black",
            "and",
            "11",
            "%",
            "Other",
            ".",
            "The",
            "ECOG",
            "performance",
            "status",
            "score",
            "was",
            "0",
            "for",
            "68",
            "%",
            "of",
            "patients",
            ",",
            "and",
            "1",
            "for",
            "32",
            "%",
            "of",
            "patients",
            ".",
            "Baseline",
            "pain",
            "assessment",
            "was",
            "0-1",
            "(",
            "asymptomatic",
            ")",
            "in",
            "67",
            "%",
            "of",
            "patients",
            ",",
            "and",
            "2-3",
            "(",
            "mildly",
            "symptomatic",
            ")",
            "in",
            "32",
            "%",
            "of",
            "patients",
            "as",
            "defined",
            "by",
            "the",
            "Brief",
            "Pain",
            "Inventory",
            "Short",
            "Form",
            "(",
            "worst",
            "pain",
            "over",
            "past",
            "24",
            "hours",
            "at",
            "study",
            "entry",
            ")",
            ".",
            "Fifty-four",
            "percent",
            "of",
            "patients",
            "had",
            "radiographic",
            "evidence",
            "of",
            "disease",
            "progression",
            "and",
            "43",
            "%",
            "had",
            "PSA-only",
            "progression",
            ".",
            "Twelve",
            "percent",
            "of",
            "patients",
            "had",
            "visceral",
            "(",
            "lung",
            "and/or",
            "liver",
            ")",
            "disease",
            "involvement",
            ".",
            "During",
            "the",
            "study",
            ",",
            "27",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "and",
            "30",
            "%",
            "of",
            "patients",
            "on",
            "the",
            "placebo",
            "arm",
            "received",
            "glucocorticoids",
            "for",
            "varying",
            "reasons",
            ".",
            "A",
            "statistically",
            "significant",
            "improvement",
            "in",
            "overall",
            "survival",
            "was",
            "demonstrated",
            "at",
            "the",
            "pre-specified",
            "interim",
            "analysis",
            ",",
            "conducted",
            "after",
            "540",
            "deaths",
            ",",
            "in",
            "patients",
            "treated",
            "with",
            "XTANDI",
            "compared",
            "to",
            "those",
            "treated",
            "with",
            "placebo",
            "(",
            "Table",
            "8",
            ")",
            ".",
            "Forty",
            "percent",
            "of",
            "XTANDI-treated",
            "and",
            "70",
            "%",
            "of",
            "placebo-treated",
            "patients",
            "received",
            "subsequent",
            "therapies",
            "for",
            "metastatic",
            "CRPC",
            "that",
            "may",
            "prolong",
            "overall",
            "survival",
            ".",
            "An",
            "updated",
            "survival",
            "analysis",
            "was",
            "conducted",
            "when",
            "784",
            "deaths",
            "were",
            "observed",
            ".",
            "The",
            "median",
            "follow-up",
            "time",
            "was",
            "31",
            "months",
            ".",
            "Results",
            "from",
            "this",
            "analysis",
            "were",
            "consistent",
            "with",
            "those",
            "from",
            "the",
            "pre-specified",
            "interim",
            "analysis",
            "(",
            "Table",
            "8",
            ",",
            "Figure",
            "4",
            ")",
            ".",
            "At",
            "the",
            "updated",
            "analysis",
            ",",
            "52",
            "%",
            "of",
            "XTANDI-treated",
            "and",
            "81",
            "%",
            "of",
            "placebo-treated",
            "patients",
            "had",
            "received",
            "subsequent",
            "therapies",
            "that",
            "may",
            "prolong",
            "overall",
            "survival",
            "in",
            "metastatic",
            "CRPC",
            ".",
            "XTANDI",
            "was",
            "used",
            "as",
            "a",
            "subsequent",
            "therapy",
            "in",
            "2",
            "%",
            "of",
            "XTANDI-treated",
            "patients",
            "and",
            "29",
            "%",
            "of",
            "placebo-treated",
            "patients",
            ".",
            "Table",
            "8",
            ".",
            "Overall",
            "Survival",
            "of",
            "Patients",
            "Treated",
            "with",
            "Either",
            "XTANDI",
            "or",
            "Placebo",
            "in",
            "PREVAIL",
            "XTANDI",
            "(",
            "N",
            "=",
            "872",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "845",
            ")",
            "Pre-specified",
            "Interim",
            "Analysis1",
            "Number",
            "of",
            "Deaths",
            "(",
            "%",
            ")",
            "241",
            "(",
            "28",
            ")",
            "299",
            "(",
            "35",
            ")",
            "Median",
            "Survival",
            ",",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "32.4",
            "(",
            "30.1",
            ",",
            "NR",
            ")",
            "30.2",
            "(",
            "28.0",
            ",",
            "NR",
            ")",
            "P-value2",
            "p",
            "<",
            "0.0001",
            "Hazard",
            "Ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "3",
            "0.71",
            "(",
            "0.60",
            ",",
            "0.84",
            ")",
            "Updated",
            "Survival",
            "Analysis4",
            "Number",
            "of",
            "Deaths",
            "(",
            "%",
            ")",
            "368",
            "(",
            "42",
            ")",
            "416",
            "(",
            "49",
            ")",
            "Median",
            "Survival",
            ",",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "35.3",
            "(",
            "32.2",
            ",",
            "NR",
            ")",
            "31.3",
            "(",
            "28.8",
            ",",
            "34.2",
            ")",
            "Hazard",
            "Ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "3",
            "0.77",
            "(",
            "0.67",
            ",",
            "0.88",
            ")",
            "NR",
            "=",
            "Not",
            "reached",
            ".",
            "1",
            ".",
            "The",
            "data",
            "cut-off",
            "date",
            "is",
            "16",
            "Sep",
            "2013",
            ".",
            "2",
            ".",
            "P-value",
            "is",
            "derived",
            "from",
            "an",
            "unstratified",
            "log-rank",
            "test",
            ".",
            "3",
            ".",
            "Hazard",
            "Ratio",
            "is",
            "derived",
            "from",
            "an",
            "unstratified",
            "proportional",
            "hazards",
            "model",
            ".",
            "Hazard",
            "Ratio",
            "<",
            "1",
            "favors",
            "XTANDI",
            ".",
            "4",
            ".",
            "The",
            "data",
            "cut-",
            "765",
            ".",
            "Figure",
            "4",
            ".",
            "Kaplan-Meier",
            "Curves",
            "of",
            "Overall",
            "Survival",
            "in",
            "PREVAIL",
            "A",
            "statistically",
            "significant",
            "improvement",
            "in",
            "rPFS",
            "was",
            "demonstrated",
            "in",
            "patients",
            "treated",
            "with",
            "XTANDI",
            "compared",
            "to",
            "patients",
            "treated",
            "with",
            "placebo",
            "(",
            "Table",
            "9",
            ",",
            "Figure",
            "5",
            ")",
            ".",
            "Table",
            "9",
            ".",
            "Radiographic",
            "Progression-free",
            "Survival",
            "of",
            "Patients",
            "Treated",
            "with",
            "Either",
            "XTANDI",
            "or",
            "Placebo",
            "in",
            "PREVAIL",
            "XTANDI",
            "(",
            "N",
            "=",
            "832",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "801",
            ")",
            "Number",
            "of",
            "Progression",
            "or",
            "Deaths",
            "(",
            "%",
            ")",
            "118",
            "(",
            "14",
            ")",
            "320",
            "(",
            "40",
            ")",
            "Median",
            "rPFS",
            "(",
            "months",
            ")",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "NR",
            "(",
            "13.8",
            ",",
            "NR",
            ")",
            "3.7",
            "(",
            "3.6",
            ",",
            "4.6",
            ")",
            "P-value1",
            "p",
            "<",
            "0.0001",
            "Hazard",
            "Ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "2",
            "0.17",
            "(",
            "0.14",
            ",",
            "0.21",
            ")",
            "NR",
            "=",
            "Not",
            "reached",
            ".",
            "Note",
            ":",
            "As",
            "of",
            "the",
            "cut-off",
            "date",
            "for",
            "the",
            "rPFS",
            "analysis",
            ",",
            "1633",
            "patients",
            "had",
            "been",
            "randomized",
            ".",
            "1",
            ".",
            "P-value",
            "is",
            "derived",
            "from",
            "an",
            "unstratified",
            "log-rank",
            "test",
            ".",
            "2",
            ".",
            "Hazard",
            "Ratio",
            "is",
            "derived",
            "from",
            "an",
            "unstratified",
            "proportional",
            "hazards",
            "model",
            ".",
            "Hazard",
            "Ratio",
            "<",
            "1",
            "favors",
            "XTANDI",
            ".",
            "Figure",
            "5",
            ".",
            "Kaplan-Meier",
            "Curves",
            "of",
            "Radiographic",
            "Progression-free",
            "Survival",
            "in",
            "PREVAIL",
            "Time",
            "to",
            "initiation",
            "of",
            "cytotoxic",
            "chemotherapy",
            "was",
            "prolonged",
            "after",
            "XTANDI",
            "treatment",
            ",",
            "with",
            "a",
            "median",
            "of",
            "28.0",
            "months",
            "for",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "versus",
            "a",
            "median",
            "of",
            "10.8",
            "months",
            "for",
            "patients",
            "on",
            "the",
            "placebo",
            "arm",
            "[",
            "HR",
            "=",
            "0.35",
            "(",
            "95",
            "%",
            "CI",
            ":",
            "0.30",
            ",",
            "0.40",
            ")",
            ",",
            "p",
            "<",
            "0.0001",
            "]",
            ".",
            "The",
            "median",
            "time",
            "to",
            "first",
            "skeletal-related",
            "event",
            "was",
            "31.1",
            "months",
            "for",
            "patients",
            "on",
            "the",
            "XTANDI",
            "arm",
            "versus",
            "31.3",
            "months",
            "for",
            "patients",
            "on",
            "the",
            "placebo",
            "arm",
            "[",
            "HR",
            "=",
            "0.72",
            "(",
            "95",
            "%",
            "CI",
            ":",
            "0.61",
            ",",
            "0.84",
            ")",
            ",",
            "p",
            "<",
            "0.0001",
            "]",
            ".",
            "A",
            "skeletal-related",
            "event",
            "was",
            "defined",
            "as",
            "radiation",
            "therapy",
            "or",
            "surgery",
            "to",
            "bone",
            "for",
            "prostate",
            "cancer",
            ",",
            "pathologic",
            "bone",
            "fracture",
            ",",
            "spinal",
            "cord",
            "compression",
            ",",
            "or",
            "change",
            "of",
            "antineoplastic",
            "therapy",
            "to",
            "treat",
            "bone",
            "pain",
            ".",
            "TERRAIN",
            "(",
            "NCT01288911",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Bicalutamide",
            "in",
            "Chemotherapy-na\u00efve",
            "Metastatic",
            "CRPC",
            "TERRAIN",
            "was",
            "conducted",
            "in",
            "375",
            "chemotherapy-na\u00efve",
            "patients",
            "who",
            "were",
            "randomized",
            "1:1",
            "to",
            "receive",
            "either",
            "XTANDI",
            "orally",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "184",
            ")",
            "or",
            "bicalutamide",
            "orally",
            "at",
            "a",
            "dose",
            "of",
            "50",
            "mg",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "191",
            ")",
            ".",
            "Patients",
            "with",
            "a",
            "previous",
            "history",
            "of",
            "seizure",
            "or",
            "a",
            "condition",
            "that",
            "might",
            "predispose",
            "to",
            "seizure",
            "and",
            "patients",
            "with",
            "moderate",
            "to",
            "severe",
            "pain",
            "from",
            "prostate",
            "cancer",
            "were",
            "excluded",
            ".",
            "Patients",
            "could",
            "have",
            "received",
            "prior",
            "bicalutamide",
            ",",
            "but",
            "those",
            "whose",
            "disease",
            "had",
            "progressed",
            "on",
            "prior",
            "antiandrogen",
            "therapy",
            "(",
            "e.g.",
            ",",
            "bicalutamide",
            ")",
            "were",
            "excluded",
            ".",
            "Study",
            "treatment",
            "continued",
            "until",
            "disease",
            "progression",
            "(",
            "evidence",
            "of",
            "radiographic",
            "progression",
            ",",
            "a",
            "skeletal-related",
            "event",
            ")",
            ",",
            "the",
            "initiation",
            "of",
            "subsequent",
            "antineoplastic",
            "agent",
            ",",
            "unacceptable",
            "toxicity",
            ",",
            "or",
            "withdrawal",
            ".",
            "Radiographic",
            "disease",
            "progression",
            "was",
            "assessed",
            "by",
            "Independent",
            "Central",
            "Review",
            "(",
            "ICR",
            ")",
            "using",
            "the",
            "Prostate",
            "Cancer",
            "Clinical",
            "Trials",
            "Working",
            "Group",
            "2",
            "criteria",
            "and/or",
            "Response",
            "Evaluation",
            "Criteria",
            "in",
            "Solid",
            "Tumors",
            "(",
            "RECIST",
            "v",
            "1.1",
            ")",
            "criteria",
            "for",
            "progression",
            "of",
            "soft",
            "tissue",
            "lesions",
            ".",
            "Radiographic",
            "progression-free",
            "survival",
            "(",
            "rPFS",
            ")",
            "was",
            "defined",
            "as",
            "the",
            "time",
            "from",
            "randomization",
            "to",
            "the",
            "first",
            "objective",
            "evidence",
            "of",
            "radiographic",
            "progression",
            "as",
            "assessed",
            "by",
            "ICR",
            "or",
            "death",
            ",",
            "whichever",
            "occurred",
            "first",
            ".",
            "Patient",
            "demographics",
            "and",
            "baseline",
            "disease",
            "characteristics",
            "were",
            "balanced",
            "between",
            "the",
            "treatment",
            "arms",
            "at",
            "entry",
            ".",
            "The",
            "median",
            "age",
            "was",
            "71",
            "years",
            "(",
            "range",
            "48-96",
            ")",
            "and",
            "the",
            "racial",
            "distribution",
            "was",
            "93",
            "%",
            "Caucasian",
            ",",
            "5",
            "%",
            "Black",
            ",",
            "1",
            "%",
            "Asian",
            "and",
            "1",
            "%",
            "Other",
            ".",
            "The",
            "ECOG",
            "performance",
            "status",
            "score",
            "was",
            "0",
            "for",
            "74",
            "%",
            "of",
            "patients",
            "and",
            "1",
            "for",
            "26",
            "%",
            "of",
            "patients",
            ".",
            "Baseline",
            "pain",
            "assessment",
            "was",
            "0-1",
            "(",
            "asymptomatic",
            ")",
            "in",
            "58",
            "%",
            "of",
            "patients",
            ",",
            "and",
            "2-3",
            "(",
            "mildly",
            "symptomatic",
            ")",
            "in",
            "36",
            "%",
            "of",
            "patients",
            "as",
            "defined",
            "by",
            "the",
            "Brief",
            "Pain",
            "Inventory",
            "Short",
            "Form",
            "Question",
            "3",
            "(",
            "worst",
            "pain",
            "over",
            "past",
            "24",
            "hours",
            "at",
            "study",
            "entry",
            ")",
            ".",
            "Ninety-eight",
            "percent",
            "of",
            "patients",
            "had",
            "objective",
            "evidence",
            "of",
            "disease",
            "progression",
            "at",
            "study",
            "entry",
            ".",
            "Forty-six",
            "percent",
            "of",
            "patients",
            "had",
            "received",
            "prior",
            "treatment",
            "with",
            "bicalutamide",
            "while",
            "no",
            "patients",
            "received",
            "prior",
            "treatment",
            "with",
            "XTANDI",
            ".",
            "An",
            "improvement",
            "in",
            "rPFS",
            "was",
            "demonstrated",
            "in",
            "patients",
            "treated",
            "with",
            "XTANDI",
            "compared",
            "to",
            "patients",
            "treated",
            "with",
            "bicalutamide",
            "(",
            "Table",
            "10",
            ",",
            "Figure",
            "6",
            ")",
            ".",
            "Table",
            "10",
            ".",
            "Radiographic",
            "Progression-free",
            "Survival",
            "of",
            "Patients",
            "in",
            "TERRAIN",
            "XTANDI",
            "(",
            "N",
            "=",
            "184",
            ")",
            "Bicalutamide",
            "(",
            "N",
            "=",
            "191",
            ")",
            "Number",
            "of",
            "Progression",
            "or",
            "Deaths",
            "(",
            "%",
            ")",
            "72",
            "(",
            "39",
            ")",
            "74",
            "(",
            "39",
            ")",
            "Median",
            "rPFS",
            "(",
            "months",
            ")",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "19.5",
            "(",
            "11.8",
            ",",
            "NR",
            ")",
            "13.4",
            "(",
            "8.2",
            ",",
            "16.4",
            ")",
            "Hazard",
            "Ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "1",
            "0.60",
            "(",
            "0.43",
            ",",
            "0.83",
            ")",
            "NR",
            "=",
            "Not",
            "reached",
            ".",
            "1",
            ".",
            "Hazard",
            "Ratio",
            "is",
            "derived",
            "from",
            "an",
            "unstratified",
            "proportional",
            "hazards",
            "model",
            ".",
            "Hazard",
            "Ratio",
            "<",
            "1",
            "favors",
            "XTANDI",
            "Figure",
            "6",
            ".",
            "Kaplan-Meier",
            "Curves",
            "of",
            "Radiographic",
            "Progression-free",
            "Survival",
            "in",
            "TERRAIN",
            "PROSPER",
            "(",
            "NCT02003924",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Non-metastatic",
            "CRPC",
            "PROSPER",
            "enrolled",
            "1401",
            "patients",
            "with",
            "non-metastatic",
            "CRPC",
            "who",
            "were",
            "randomized",
            "2:1",
            "to",
            "receive",
            "either",
            "XTANDI",
            "orally",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "933",
            ")",
            "or",
            "placebo",
            "orally",
            "once",
            "daily",
            "(",
            "N",
            "=",
            "468",
            ")",
            ".",
            "All",
            "patients",
            "in",
            "the",
            "PROSPER",
            "trial",
            "received",
            "a",
            "gonadotropin-releasing",
            "hormone",
            "(",
            "GnRH",
            ")",
            "analog",
            "or",
            "had",
            "a",
            "prior",
            "bilateral",
            "orchiectomy",
            ".",
            "Patients",
            "were",
            "stratified",
            "by",
            "Prostate",
            "Specific",
            "Antigen",
            "(",
            "PSA",
            ")",
            "Doubling",
            "Time",
            "(",
            "PSADT",
            ")",
            "and",
            "the",
            "use",
            "of",
            "bone-targeting",
            "agents",
            ".",
            "Patients",
            "were",
            "required",
            "2",
            "ng/mL",
            ",",
            "and",
            "confirmation",
            "of",
            "non-metastatic",
            "disease",
            "by",
            "blinded",
            "independent",
            "central",
            "review",
            "(",
            "BICR",
            ")",
            ".",
            "PSA",
            "results",
            "were",
            "blinded",
            "and",
            "were",
            "not",
            "used",
            "for",
            "treatment",
            "discontinuation",
            ".",
            "Patients",
            "randomized",
            "to",
            "either",
            "arm",
            "discontinued",
            "treatment",
            "for",
            "radiographic",
            "disease",
            "progression",
            "confirmed",
            "by",
            "BICR",
            ",",
            "initiation",
            "of",
            "new",
            "treatment",
            ",",
            "unacceptable",
            "toxicity",
            ",",
            "or",
            "withdrawal",
            ".",
            "The",
            "following",
            "patient",
            "demographics",
            "and",
            "baseline",
            "characteristics",
            "were",
            "balanced",
            "between",
            "the",
            "two",
            "treatment",
            "arms",
            ".",
            "The",
            "median",
            "age",
            "at",
            "randomization",
            "was",
            "74",
            "years",
            "(",
            "range",
            "50-95",
            ")",
            "and",
            "23",
            "%",
            "were",
            "80",
            "years",
            "of",
            "age",
            "or",
            "older",
            ".",
            "The",
            "racial",
            "distribution",
            "was",
            "71",
            "%",
            "Caucasian",
            ",",
            "16",
            "%",
            "Asian",
            ",",
            "and",
            "2",
            "%",
            "Black",
            ".",
            "A",
            "majority",
            "of",
            "patients",
            "had",
            "a",
            "Gleason",
            "score",
            "of",
            "7",
            "or",
            "higher",
            "(",
            "77",
            "%",
            ")",
            ".",
            "The",
            "median",
            "PSADT",
            "was",
            "3.7",
            "months",
            ".",
            "Fifty-four",
            "percent",
            "(",
            "54",
            "%",
            ")",
            "of",
            "patients",
            "received",
            "prior",
            "treatment",
            "for",
            "prostate",
            "cancer",
            "with",
            "either",
            "surgery",
            "or",
            "radiation",
            ".",
            "Sixty-three",
            "percent",
            "(",
            "63",
            "%",
            ")",
            "of",
            "patients",
            "received",
            "prior",
            "treatment",
            "with",
            "an",
            "anti-androgen",
            ";",
            "56",
            "%",
            "of",
            "patients",
            "received",
            "bicalutamide",
            "and",
            "11",
            "%",
            "of",
            "patients",
            "received",
            "flutamide",
            ".",
            "All",
            "patients",
            "had",
            "an",
            "Eastern",
            "Cooperative",
            "Oncology",
            "Group",
            "Performance",
            "Status",
            "(",
            "ECOG",
            "PS",
            ")",
            "score",
            "of",
            "0",
            "or",
            "1",
            "at",
            "study",
            "entry",
            ".",
            "The",
            "major",
            "efficacy",
            "outcome",
            "of",
            "the",
            "study",
            "was",
            "metastasis-free",
            "survival",
            "(",
            "MFS",
            ")",
            ",",
            "defined",
            "as",
            "the",
            "time",
            "from",
            "randomization",
            "to",
            "whichever",
            "of",
            "the",
            "following",
            "occurred",
            "first",
            "1",
            ")",
            "loco-regional",
            "and/or",
            "distant",
            "radiographic",
            "progression",
            "per",
            "BICR",
            "or",
            "2",
            ")",
            "death",
            "up",
            "to",
            "112",
            "days",
            "after",
            "treatment",
            "discontinuation",
            "without",
            "evidence",
            "of",
            "radiographic",
            "progression",
            ".",
            "A",
            "statistically",
            "significant",
            "improvement",
            "in",
            "MFS",
            "and",
            "OS",
            "was",
            "demonstrated",
            "in",
            "patients",
            "randomized",
            "to",
            "receive",
            "XTANDI",
            "compared",
            "with",
            "patients",
            "randomized",
            "to",
            "receive",
            "placebo",
            ".",
            "Consistent",
            "MFS",
            "results",
            "were",
            "observed",
            "when",
            "considering",
            "only",
            "distant",
            "radiographic",
            "progression",
            "events",
            "or",
            "deaths",
            "regardless",
            "of",
            "the",
            "cut-off",
            "date",
            ".",
            "Consistent",
            "MFS",
            "results",
            "were",
            "also",
            "observed",
            "in",
            "pre-specified",
            "and",
            "stratified",
            "patient",
            "sub",
            "--",
            "targeting",
            "agent",
            "(",
            "yes",
            "or",
            "no",
            ")",
            ".",
            "The",
            "efficacy",
            "results",
            "from",
            "PROSPER",
            "are",
            "summarized",
            "in",
            "Table",
            "11",
            ",",
            "Figure",
            "7",
            "and",
            "Figure",
            "8",
            ".",
            "Table",
            "11",
            ".",
            "Summary",
            "of",
            "Efficacy",
            "Results",
            "in",
            "PROSPER",
            "(",
            "Intent-to-treat",
            "Population",
            ")",
            "XTANDI",
            "(",
            "N",
            "=",
            "933",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "468",
            ")",
            "Metastasis-free",
            "survival",
            "Number",
            "of",
            "Events",
            "(",
            "%",
            ")",
            "219",
            "(",
            "23.5",
            ")",
            "228",
            "(",
            "48.7",
            ")",
            "Median",
            ",",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "1",
            "36.6",
            "(",
            "33.1",
            ",",
            "NR",
            ")",
            "14.7",
            "(",
            "14.2",
            ",",
            "15.0",
            ")",
            "Hazard",
            "Ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "2",
            "0.29",
            "(",
            "0.24",
            ",",
            "0.35",
            ")",
            "P-value2",
            "p",
            "<",
            "0.0001",
            "Overall",
            "survival3",
            "Number",
            "of",
            "Events",
            "(",
            "%",
            ")",
            "288",
            "(",
            "30.9",
            ")",
            "178",
            "(",
            "38.0",
            ")",
            "Median",
            ",",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "1",
            "67.0",
            "(",
            "64.0",
            ",",
            "NR",
            ")",
            "56.3",
            "(",
            "54.4",
            ",",
            "63.0",
            ")",
            "Hazard",
            "Ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "2",
            "0.73",
            "(",
            "0.61",
            ",",
            "0.88",
            ")",
            "P-value2",
            "p",
            "=",
            "0.0011",
            "NR",
            "=",
            "Not",
            "reached",
            ".",
            "1",
            ".",
            "Based",
            "on",
            "Kaplan-Meier",
            "estimates",
            ".",
            "2",
            ".",
            "Hazard",
            "ratio",
            "from",
            "a",
            "Cox",
            "regression",
            "model",
            "(",
            "with",
            "treatment",
            "as",
            "the",
            "only",
            "covariate",
            ")",
            "and",
            "p-value",
            "from",
            "a",
            "log-rank",
            "test",
            "are",
            "stratified",
            "by",
            "PSA",
            "doubling",
            "time",
            "and",
            "prior",
            "or",
            "concurrent",
            "use",
            "of",
            "a",
            "bone",
            "targeting",
            "agent",
            ".",
            "3",
            ".",
            "The",
            "pre-specified",
            "final",
            "analysis",
            "of",
            "OS",
            "occurred",
            "27",
            "months",
            "after",
            "the",
            "MFS",
            "analysis",
            ".",
            "Figure",
            "7",
            ".",
            "Kaplan-Meier",
            "Curves",
            "of",
            "Metastasis-free",
            "Survival",
            "in",
            "PROSPER",
            "Figure",
            "8",
            ".",
            "Kaplan-Meier",
            "Curves",
            "of",
            "Overall",
            "Survival",
            "in",
            "PROSPER",
            "The",
            "primary",
            "efficacy",
            "outcome",
            "was",
            "also",
            "supported",
            "by",
            "a",
            "statistically",
            "significant",
            "delay",
            "in",
            "time",
            "to",
            "first",
            "use",
            "of",
            "new",
            "antineoplastic",
            "therapy",
            "(",
            "TTA",
            ")",
            "for",
            "patients",
            "in",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "those",
            "in",
            "the",
            "placebo",
            "arm",
            ".",
            "The",
            "median",
            "TTA",
            "was",
            "39.6",
            "months",
            "for",
            "patients",
            "on",
            "XTANDI",
            "and",
            "was",
            "17.7",
            "months",
            "for",
            "patients",
            "on",
            "placebo",
            "(",
            "HR",
            "=",
            "0.21",
            ";",
            "95",
            "%",
            "CI",
            ":",
            "[",
            "0.17",
            ",",
            "0.26",
            "]",
            ",",
            "p",
            "<",
            "0.0001",
            ")",
            ".",
            "ARCHES",
            "(",
            "NCT02677896",
            ")",
            ":",
            "XTANDI",
            "versus",
            "Placebo",
            "in",
            "Metastatic",
            "CSPC",
            "ARCHES",
            "enrolled",
            "1150",
            "patients",
            "with",
            "mCSPC",
            "who",
            "were",
            "randomized",
            "1:1",
            "to",
            "receive",
            "XTANDI",
            "orally",
            "at",
            "a",
            "dose",
            "of",
            "160",
            "mg",
            "once",
            "daily",
            "(",
            "N=574",
            ")",
            "or",
            "placebo",
            "orally",
            "once",
            "daily",
            "(",
            "N=576",
            ")",
            ".",
            "All",
            "patients",
            "in",
            "the",
            "trial",
            "received",
            "a",
            "GnRH",
            "analog",
            "or",
            "had",
            "a",
            "prior",
            "bilateral",
            "orchiectomy",
            ".",
            "Patients",
            "were",
            "stratified",
            "by",
            "volume",
            "of",
            "disease",
            "(",
            "low",
            "vs",
            "high",
            ")",
            "and",
            "prior",
            "docetaxel",
            "therapy",
            "for",
            "prostate",
            "cancer",
            "(",
            "no",
            "prior",
            "docetaxel",
            ",",
            "1-5",
            "cycles",
            ",",
            "or",
            "6",
            "prior",
            "cycles",
            ")",
            ".",
            "High",
            "volume",
            "of",
            "disease",
            "is",
            "defined",
            "as",
            "metastases",
            "involving",
            "the",
            "viscera",
            "or",
            ",",
            "in",
            "the",
            "absence",
            "of",
            "visceral",
            "lesions",
            ",",
            "there",
            "must",
            "be",
            "4",
            "or",
            "more",
            "bone",
            "lesions",
            ",",
            "at",
            "least",
            "1",
            "of",
            "which",
            "must",
            "be",
            "in",
            "a",
            "bony",
            "structure",
            "beyond",
            "the",
            "vertebral",
            "column",
            "and",
            "pelvic",
            "bone",
            ".",
            "Treatment",
            "with",
            "concurrent",
            "docetaxel",
            "was",
            "not",
            "allowed",
            ".",
            "Patients",
            "continued",
            "treatment",
            "until",
            "radiographic",
            "disease",
            "progression",
            ",",
            "initiation",
            "of",
            "new",
            "treatment",
            ",",
            "unacceptable",
            "toxicity",
            ",",
            "or",
            "withdrawal",
            ".",
            "The",
            "following",
            "patient",
            "demographics",
            "and",
            "baseline",
            "characteristics",
            "were",
            "balanced",
            "between",
            "the",
            "two",
            "treatment",
            "arms",
            ".",
            "The",
            "median",
            "age",
            "at",
            "randomization",
            "was",
            "70",
            "years",
            "(",
            "range",
            ":",
            "42-92",
            ")",
            "and",
            "30",
            "%",
            "were",
            "75",
            "years",
            "of",
            "age",
            "or",
            "older",
            ".",
            "The",
            "racial",
            "distribution",
            "was",
            "81",
            "%",
            "Caucasian",
            ",",
            "14",
            "%",
            "Asian",
            ",",
            "and",
            "1",
            "%",
            "Black",
            ".",
            "Sixty",
            "--",
            "seven",
            "percent",
            "(",
            "37",
            "%",
            ")",
            "of",
            "patients",
            "had",
            "a",
            "low",
            "volume",
            "of",
            "disease",
            "and",
            "63",
            "%",
            "of",
            "patients",
            "had",
            "a",
            "high",
            "volume",
            "of",
            "disease",
            ".",
            "Eighty-two",
            "percent",
            "(",
            "82",
            "%",
            ")",
            "of",
            "patients",
            "had",
            "no",
            "prior",
            "docetaxel",
            "treatment",
            ";",
            "2",
            "%",
            "of",
            "patients",
            "had",
            "1",
            "to",
            "5",
            "cycles",
            "of",
            "docetaxel",
            "and",
            "16",
            "%",
            "of",
            "patients",
            "had",
            "6",
            "prior",
            "cycles",
            "of",
            "docetaxel",
            "treatment",
            ".",
            "Twelve",
            "percent",
            "(",
            "12",
            "%",
            ")",
            "of",
            "patients",
            "received",
            "concomitant",
            "bone-targeted",
            "agents",
            "(",
            "bisphosphonates",
            "or",
            "RANKL",
            "inhibitors",
            ")",
            "which",
            "included",
            "both",
            "prostate",
            "and",
            "non-prostate",
            "cancer",
            "indications",
            ".",
            "The",
            "Eastern",
            "Cooperative",
            "Oncology",
            "Group",
            "Performance",
            "Status",
            "(",
            "ECOG",
            "PS",
            ")",
            "score",
            "was",
            "0",
            "for",
            "78",
            "%",
            "of",
            "patients",
            "and",
            "1",
            "for",
            "22",
            "%",
            "of",
            "patients",
            "at",
            "study",
            "entry",
            ".",
            "The",
            "major",
            "efficacy",
            "outcome",
            "measure",
            "was",
            "radiographic",
            "progression-free",
            "survival",
            "(",
            "rPFS",
            ")",
            "based",
            "on",
            "blinded",
            "independent",
            "central",
            "review",
            "(",
            "BICR",
            ")",
            ".",
            "Radiographic",
            "progression-free",
            "survival",
            "was",
            "defined",
            "as",
            "the",
            "time",
            "from",
            "randomization",
            "to",
            "radiographic",
            "disease",
            "progression",
            "at",
            "any",
            "time",
            "or",
            "death",
            "within",
            "24",
            "weeks",
            "after",
            "study",
            "drug",
            "discontinuation",
            ".",
            "Radiographic",
            "disease",
            "progression",
            "was",
            "defined",
            "by",
            "identification",
            "of",
            "2",
            "or",
            "more",
            "new",
            "bone",
            "lesions",
            "on",
            "a",
            "bone",
            "scan",
            "with",
            "confirmation",
            "(",
            "Prostate",
            "Cancer",
            "Working",
            "Group",
            "2",
            "criteria",
            ")",
            "and/or",
            "progression",
            "in",
            "soft",
            "tissue",
            "disease",
            ".",
            "Time",
            "to",
            "new",
            "antineoplastic",
            "therapy",
            "was",
            "an",
            "additional",
            "efficacy",
            "endpoint",
            ".",
            "XTANDI",
            "demonstrated",
            "a",
            "statistically",
            "significant",
            "improvement",
            "in",
            "rPFS",
            "compared",
            "to",
            "placebo",
            ".",
            "Consistent",
            "rPFS",
            "results",
            "were",
            "observed",
            "in",
            "patients",
            "with",
            "high",
            "or",
            "low",
            "volume",
            "of",
            "disease",
            "and",
            "patients",
            "with",
            "and",
            "without",
            "prior",
            "docetaxel",
            "therapy",
            ".",
            "Overall",
            "survival",
            "(",
            "OS",
            ")",
            "data",
            "were",
            "not",
            "mature",
            "at",
            "the",
            "time",
            "of",
            "rPFS",
            "analysis",
            "(",
            "7.3",
            "%",
            "deaths",
            "in",
            "the",
            "ITT",
            "population",
            "had",
            "been",
            "reported",
            ")",
            ".",
            "Efficacy",
            "results",
            "for",
            "rPFS",
            "from",
            "ARCHES",
            "are",
            "summarized",
            "in",
            "Table",
            "12",
            "and",
            "Figure",
            "9",
            ".",
            "Table",
            "12",
            ".",
            "Efficacy",
            "Results",
            "in",
            "ARCHES",
            "based",
            "on",
            "BICR",
            "(",
            "Intent-to-Treat",
            "Analysis",
            ")",
            "XTANDI",
            "(",
            "N",
            "=",
            "574",
            ")",
            "Placebo",
            "(",
            "N",
            "=",
            "576",
            ")",
            "Radiographic",
            "Progression-free",
            "Survival",
            "Number",
            "of",
            "events",
            "(",
            "%",
            ")",
            "89",
            "(",
            "15.5",
            ")",
            "198",
            "(",
            "34.4",
            ")",
            "Radiographic",
            "disease",
            "progression",
            "77",
            "(",
            "13.4",
            ")",
            "185",
            "(",
            "32.1",
            ")",
            "Death",
            "within",
            "24",
            "weeks",
            "after",
            "treatment",
            "discontinuation",
            "12",
            "(",
            "2.1",
            ")",
            "13",
            "(",
            "2.3",
            ")",
            "Median",
            ",",
            "months",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "1",
            "NR",
            "19.4",
            "(",
            "16.6",
            ",",
            "NR",
            ")",
            "Hazard",
            "ratio",
            "(",
            "95",
            "%",
            "CI",
            ")",
            "2",
            "0.39",
            "(",
            "0.30",
            ",",
            "0.50",
            ")",
            "P-value3",
            "p",
            "<",
            "0.0001",
            "NR",
            "=",
            "Not",
            "reached",
            "1",
            ".",
            "Based",
            "on",
            "Kaplan-Meier",
            "estimates",
            ".",
            "2",
            ".",
            "Hazard",
            "Ratio",
            "is",
            "based",
            "on",
            "a",
            "Cox",
            "regression",
            "model",
            "stratified",
            "by",
            "volume",
            "of",
            "disease",
            "(",
            "low",
            "vs",
            "high",
            ")",
            "and",
            "prior",
            "docetaxel",
            "use",
            "(",
            "yes",
            "vs",
            "no",
            ")",
            ".",
            "3",
            ".",
            "P-value",
            "is",
            "based",
            "on",
            "a",
            "stratified",
            "log-rank",
            "test",
            "by",
            "volume",
            "of",
            "disease",
            "(",
            "low",
            "vs",
            "high",
            ")",
            "and",
            "prior",
            "docetaxel",
            "use",
            "(",
            "yes",
            "or",
            "no",
            ")",
            ".",
            "Figure",
            "9",
            ".",
            "Kaplan-Meier",
            "Curves",
            "of",
            "rPFS",
            "in",
            "ARCHES",
            "(",
            "Intent-to-Treat",
            "Analysis",
            ")",
            "A",
            "statistically",
            "significant",
            "improvement",
            "was",
            "also",
            "reported",
            "on",
            "the",
            "XTANDI",
            "arm",
            "compared",
            "to",
            "placebo",
            "in",
            "time",
            "to",
            "initiation",
            "of",
            "a",
            "new",
            "antineoplastic",
            "therapy",
            "(",
            "HR",
            "=",
            "0.28",
            "[",
            "95",
            "%",
            "CI",
            ":",
            "0.20",
            ",",
            "0.40",
            "]",
            ";",
            "p",
            "<",
            "0.0001",
            ")",
            ".",
            "16",
            "HOW",
            "SUPPLIED/STORAGE",
            "AND",
            "HANDLING",
            "XTANDI",
            "(",
            "enzalutamide",
            ")",
            "40",
            "mg",
            "capsules",
            "are",
            "supplied",
            "as",
            "white",
            "to",
            "off-white",
            "oblong",
            "soft",
            "gelatin",
            "capsules",
            "imprinted",
            "in",
            "black",
            "ink",
            "with",
            "ENZ",
            "and",
            "are",
            "available",
            "in",
            "the",
            "following",
            "package",
            "size",
            ":",
            "Bottles",
            "of",
            "120",
            "capsules",
            "with",
            "child",
            "resistant",
            "closures",
            "(",
            "NDC",
            "0469-0125-99",
            ")",
            "XTANDI",
            "(",
            "enzalutamide",
            ")",
            "40",
            "mg",
            "tablets",
            "are",
            "supplied",
            "as",
            "yellow",
            ",",
            "round",
            ",",
            "film-coated",
            "tablets",
            "debossed",
            "with",
            "E",
            "40",
            ",",
            "and",
            "are",
            "available",
            "in",
            "the",
            "following",
            "package",
            "size",
            ":",
            "Bottles",
            "of",
            "120",
            "tablets",
            "with",
            "child",
            "resistant",
            "closures",
            "(",
            "NDC",
            "0469-0625-99",
            ")",
            "XTANDI",
            "(",
            "enzalutamide",
            ")",
            "80",
            "mg",
            "tablets",
            "are",
            "supplied",
            "as",
            "yellow",
            ",",
            "oval",
            ",",
            "film-coated",
            "tablets",
            "debossed",
            "with",
            "E",
            "80",
            ",",
            "and",
            "are",
            "available",
            "in",
            "the",
            "following",
            "package",
            "size",
            ":",
            "Bottles",
            "of",
            "60",
            "tablets",
            "with",
            "child",
            "resistant",
            "closures",
            "(",
            "NDC",
            "0469-0725-60",
            ")",
            "Recommended",
            "storage",
            ":",
            "Store",
            "XTANDI",
            "capsules",
            "and",
            "tablets",
            "at",
            "20\u00b0C",
            "to",
            "25\u00b0C",
            "(",
            "68\u00b0F",
            "to",
            "77\u00b0F",
            ")",
            "in",
            "a",
            "dry",
            "place",
            "and",
            "keep",
            "the",
            "container",
            "tightly",
            "closed",
            ".",
            "Excursions",
            "permitted",
            "from",
            "15\u00b0C",
            "to",
            "30\u00b0C",
            "(",
            "59\u00b0F",
            "to",
            "86\u00b0F",
            ")",
            ".",
            "Swallow",
            "capsules",
            "or",
            "tablets",
            "whole",
            ".",
            "Do",
            "not",
            "chew",
            ",",
            "dissolve",
            "or",
            "open",
            "the",
            "capsules",
            ".",
            "Do",
            "not",
            "cut",
            ",",
            "crush",
            ",",
            "or",
            "chew",
            "the",
            "tablets",
            ".",
            "17",
            "PATIENT",
            "COUNSELING",
            "INFORMATION",
            "Advise",
            "the",
            "patient",
            "to",
            "read",
            "the",
            "FDA-approved",
            "patient",
            "labeling",
            "(",
            "Patient",
            "Information",
            ")",
            ".",
            "Seizure",
            "Inform",
            "patients",
            "that",
            "XTANDI",
            "has",
            "been",
            "associated",
            "with",
            "an",
            "increased",
            "risk",
            "of",
            "seizure",
            ".",
            "Discuss",
            "conditions",
            "that",
            "may",
            "predispose",
            "to",
            "seizures",
            "and",
            "medications",
            "that",
            "may",
            "lower",
            "the",
            "seizure",
            "threshold",
            ".",
            "Advise",
            "patients",
            "of",
            "the",
            "risk",
            "of",
            "engaging",
            "in",
            "any",
            "activity",
            "where",
            "sudden",
            "loss",
            "of",
            "consciousness",
            "could",
            "cause",
            "serious",
            "harm",
            "to",
            "themselves",
            "or",
            "others",
            ".",
            "Inform",
            "patients",
            "to",
            "contact",
            "their",
            "healthcare",
            "provider",
            "right",
            "away",
            "if",
            "they",
            "have",
            "loss",
            "of",
            "consciousness",
            "or",
            "seizure",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.1",
            ")",
            "]",
            ".",
            "Posterior",
            "Reversible",
            "Encephalopathy",
            "Syndrome",
            "(",
            "PRES",
            ")",
            "Inform",
            "patients",
            "to",
            "contact",
            "their",
            "healthcare",
            "provider",
            "right",
            "away",
            "if",
            "they",
            "experience",
            "rapidly",
            "worsening",
            "symptoms",
            "possibly",
            "indicative",
            "of",
            "PRES",
            "such",
            "as",
            "seizure",
            ",",
            "headache",
            ",",
            "decreased",
            "alertness",
            ",",
            "confusion",
            ",",
            "reduced",
            "eyesight",
            ",",
            "or",
            "blurred",
            "vision",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.2",
            ")",
            "]",
            ".",
            "Hypersensitivity",
            "Inform",
            "patients",
            "that",
            "XTANDI",
            "may",
            "be",
            "associated",
            "with",
            "hypersensitivity",
            "reactions",
            "that",
            "include",
            "swelling",
            "of",
            "the",
            "face",
            ",",
            "lip",
            ",",
            "tongue",
            ",",
            "or",
            "throat",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.3",
            ")",
            "]",
            ".",
            "Advise",
            "patients",
            "who",
            "experience",
            "these",
            "types",
            "of",
            "symptoms",
            "of",
            "hypersensitivity",
            "to",
            "discontinue",
            "XTANDI",
            "and",
            "promptly",
            "contact",
            "their",
            "healthcare",
            "provider",
            ".",
            "Ischemic",
            "Heart",
            "Disease",
            "Inform",
            "patients",
            "that",
            "XTANDI",
            "has",
            "been",
            "associated",
            "with",
            "an",
            "increased",
            "risk",
            "of",
            "ischemic",
            "heart",
            "disease",
            ".",
            "Advise",
            "patients",
            "to",
            "seek",
            "immediate",
            "medical",
            "attention",
            "if",
            "any",
            "symptoms",
            "suggestive",
            "of",
            "a",
            "cardiovascular",
            "event",
            "occur",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.4",
            ")",
            "]",
            ".",
            "Falls",
            "and",
            "Fractures",
            "Inform",
            "patients",
            "that",
            "XTANDI",
            "is",
            "associated",
            "with",
            "an",
            "increased",
            "incidence",
            "of",
            "dizziness/vertigo",
            ",",
            "falls",
            ",",
            "and",
            "fractures",
            ".",
            "Advise",
            "patients",
            "to",
            "report",
            "these",
            "adverse",
            "reactions",
            "to",
            "their",
            "healthcare",
            "provider",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.5",
            ")",
            "]",
            ".",
            "Hypertension",
            "Inform",
            "patients",
            "that",
            "XTANDI",
            "is",
            "associated",
            "with",
            "an",
            "increased",
            "incidence",
            "of",
            "hypertension",
            "[",
            "see",
            "Adverse",
            "Reactions",
            "(",
            "6.1",
            ")",
            "]",
            ".",
            "Dosing",
            "and",
            "Administration",
            "Inform",
            "patients",
            "who",
            "have",
            "not",
            "undergone",
            "bilateral",
            "orchiectomy",
            "and",
            "are",
            "receiving",
            "GnRH",
            "therapy",
            "that",
            "they",
            "need",
            "to",
            "maintain",
            "this",
            "treatment",
            "during",
            "the",
            "course",
            "of",
            "treatment",
            "with",
            "XTANDI",
            ".",
            "Instruct",
            "patients",
            "to",
            "take",
            "their",
            "dose",
            "at",
            "the",
            "same",
            "time",
            "each",
            "day",
            "(",
            "once",
            "daily",
            ")",
            ".",
            "XTANDI",
            "can",
            "be",
            "taken",
            "with",
            "or",
            "without",
            "food",
            ".",
            "Each",
            "capsule",
            "or",
            "tablet",
            "should",
            "be",
            "swallowed",
            "whole",
            ".",
            "Do",
            "not",
            "chew",
            ",",
            "dissolve",
            ",",
            "or",
            "open",
            "the",
            "capsules",
            ".",
            "Do",
            "not",
            "cut",
            ",",
            "crush",
            ",",
            "or",
            "chew",
            "the",
            "tablets",
            ".",
            "Inform",
            "patients",
            "that",
            "they",
            "should",
            "not",
            "interrupt",
            ",",
            "modify",
            "the",
            "dose",
            ",",
            "or",
            "stop",
            "XTANDI",
            "without",
            "first",
            "consulting",
            "their",
            "healthcare",
            "provider",
            ".",
            "Inform",
            "patients",
            "that",
            "if",
            "they",
            "miss",
            "a",
            "dose",
            ",",
            "then",
            "they",
            "should",
            "take",
            "it",
            "as",
            "soon",
            "as",
            "they",
            "remember",
            ".",
            "If",
            "they",
            "forget",
            "to",
            "take",
            "the",
            "dose",
            "for",
            "the",
            "whole",
            "day",
            ",",
            "then",
            "they",
            "should",
            "take",
            "their",
            "normal",
            "dose",
            "the",
            "next",
            "day",
            ".",
            "They",
            "should",
            "not",
            "take",
            "more",
            "than",
            "their",
            "prescribed",
            "dose",
            "per",
            "day",
            "[",
            "see",
            "Dosage",
            "and",
            "Administration",
            "(",
            "2.1",
            ")",
            "]",
            ".",
            "Embryo-Fetal",
            "Toxicity",
            "Inform",
            "patients",
            "that",
            "XTANDI",
            "can",
            "be",
            "harmful",
            "to",
            "a",
            "developing",
            "fetus",
            "and",
            "can",
            "cause",
            "loss",
            "of",
            "pregnancy",
            ".",
            "Advise",
            "male",
            "patients",
            "with",
            "female",
            "partners",
            "of",
            "reproductive",
            "potential",
            "to",
            "use",
            "effective",
            "contraception",
            "during",
            "treatment",
            "and",
            "for",
            "3",
            "months",
            "after",
            "the",
            "last",
            "dose",
            "of",
            "XTANDI",
            ".",
            "Advise",
            "male",
            "patients",
            "to",
            "use",
            "a",
            "condom",
            "if",
            "having",
            "sex",
            "with",
            "a",
            "pregnant",
            "woman",
            "[",
            "see",
            "Warnings",
            "and",
            "Precautions",
            "(",
            "5.6",
            ")",
            "]",
            ".",
            "Infertility",
            "Inform",
            "male",
            "patients",
            "that",
            "XTANDI",
            "may",
            "impair",
            "fertility",
            "[",
            "see",
            "Use",
            "in",
            "Specific",
            "Populations",
            "(",
            "8.3",
            ")",
            "]",
            ".",
            "Manufactured",
            "for",
            "and",
            "Distributed",
            "by",
            ":",
            "Astellas",
            "Pharma",
            "US",
            ",",
            "Inc.",
            ",",
            "Northbrook",
            ",",
            "IL",
            "60062",
            "Marketed",
            "by",
            ":",
            "Astellas",
            "Pharma",
            "US",
            ",",
            "Inc.",
            ",",
            "Northbrook",
            ",",
            "IL",
            "60062",
            "Pfizer",
            "Inc.",
            ",",
            "New",
            "York",
            ",",
            "NY",
            "10017",
            "316386-XTA-USA",
            "Rx",
            "Only",
            "\u00a9",
            "2020-21",
            "Astellas",
            "Pharma",
            "US",
            ",",
            "Inc.",
            "XTANDI",
            "is",
            "a",
            "registered",
            "trademark",
            "of",
            "Astellas",
            "Pharma",
            "Inc",
            ".",
            "PATIENT",
            "INFORMATION",
            "XTANDI\u00ae",
            "(",
            "ex",
            "TAN",
            "dee",
            ")",
            "(",
            "enzalutamide",
            ")",
            "capsules",
            "and",
            "tablets",
            "What",
            "is",
            "XTANDI\u00ae",
            "?",
            "XTANDI",
            "is",
            "a",
            "prescription",
            "medicine",
            "used",
            "to",
            "treat",
            "men",
            "with",
            "prostate",
            "cancer",
            "that",
            ":",
            "no",
            "longer",
            "responds",
            "to",
            "a",
            "hormone",
            "therapy",
            "or",
            "surgical",
            "treatment",
            "to",
            "lower",
            "testosterone",
            "OR",
            "has",
            "spread",
            "to",
            "other",
            "parts",
            "of",
            "the",
            "body",
            "and",
            "responds",
            "to",
            "a",
            "hormone",
            "therapy",
            "or",
            "surgical",
            "treatment",
            "to",
            "lower",
            "testosterone",
            ".",
            "It",
            "is",
            "not",
            "known",
            "if",
            "XTANDI",
            "is",
            "safe",
            "and",
            "effective",
            "in",
            "females",
            ".",
            "It",
            "is",
            "not",
            "known",
            "if",
            "XTANDI",
            "is",
            "safe",
            "and",
            "effective",
            "in",
            "children",
            ".",
            "Before",
            "taking",
            "XTANDI",
            ",",
            "tell",
            "your",
            "healthcare",
            "provider",
            "about",
            "all",
            "your",
            "medical",
            "conditions",
            ",",
            "including",
            "if",
            "you",
            ":",
            "have",
            "a",
            "history",
            "of",
            "seizures",
            ",",
            "brain",
            "injury",
            ",",
            "stroke",
            ",",
            "or",
            "brain",
            "tumors",
            ".",
            "have",
            "a",
            "history",
            "of",
            "heart",
            "disease",
            ".",
            "have",
            "high",
            "blood",
            "pressure",
            ".",
            "have",
            "abnormal",
            "amounts",
            "of",
            "fat",
            "or",
            "cholesterol",
            "in",
            "your",
            "blood",
            "(",
            "dyslipidemia",
            ")",
            ".",
            "are",
            "pregnant",
            "or",
            "plan",
            "to",
            "become",
            "pregnant",
            ".",
            "XTANDI",
            "can",
            "cause",
            "harm",
            "to",
            "your",
            "unborn",
            "baby",
            "and",
            "loss",
            "of",
            "pregnancy",
            "(",
            "miscarriage",
            ")",
            ".",
            "have",
            "a",
            "partner",
            "who",
            "is",
            "pregnant",
            "or",
            "may",
            "become",
            "pregnant",
            ".",
            "Males",
            "who",
            "have",
            "female",
            "partners",
            "who",
            "are",
            "able",
            "to",
            "become",
            "pregnant",
            "should",
            "use",
            "effective",
            "birth",
            "control",
            "(",
            "contraception",
            ")",
            "during",
            "treatment",
            "with",
            "XTANDI",
            "and",
            "for",
            "3",
            "months",
            "after",
            "the",
            "last",
            "dose",
            "of",
            "XTANDI",
            ".",
            "Males",
            "must",
            "use",
            "a",
            "condom",
            "during",
            "sex",
            "with",
            "a",
            "pregnant",
            "female",
            ".",
            "are",
            "breastfeeding",
            "or",
            "plan",
            "to",
            "breastfeed",
            ".",
            "It",
            "is",
            "not",
            "known",
            "if",
            "XTANDI",
            "passes",
            "into",
            "your",
            "breast",
            "milk",
            ".",
            "Tell",
            "your",
            "healthcare",
            "provider",
            "about",
            "all",
            "the",
            "medicines",
            "you",
            "take",
            ",",
            "including",
            "prescription",
            "and",
            "over-the-counter",
            "medicines",
            ",",
            "vitamins",
            ",",
            "and",
            "herbal",
            "supplements",
            ".",
            "XTANDI",
            "may",
            "affect",
            "the",
            "way",
            "other",
            "medicines",
            "work",
            ",",
            "and",
            "other",
            "medicines",
            "may",
            "affect",
            "how",
            "XTANDI",
            "works",
            ".",
            "You",
            "should",
            "not",
            "start",
            "or",
            "stop",
            "any",
            "medicine",
            "before",
            "you",
            "talk",
            "with",
            "the",
            "healthcare",
            "provider",
            "that",
            "prescribed",
            "XTANDI",
            ".",
            "Know",
            "the",
            "medicines",
            "you",
            "take",
            ".",
            "Keep",
            "a",
            "list",
            "of",
            "them",
            "with",
            "you",
            "to",
            "show",
            "your",
            "healthcare",
            "provider",
            "and",
            "pharmacist",
            "when",
            "you",
            "get",
            "a",
            "new",
            "medicine",
            ".",
            "How",
            "should",
            "I",
            "take",
            "XTANDI",
            "?",
            "Take",
            "XTANDI",
            "exactly",
            "as",
            "your",
            "healthcare",
            "provider",
            "tells",
            "you",
            ".",
            "Take",
            "your",
            "prescribed",
            "dose",
            "of",
            "XTANDI",
            "1",
            "time",
            "a",
            "day",
            ",",
            "at",
            "the",
            "same",
            "time",
            "each",
            "day",
            ".",
            "Your",
            "healthcare",
            "provider",
            "may",
            "change",
            "your",
            "dose",
            "if",
            "needed",
            ".",
            "Do",
            "not",
            "change",
            "or",
            "stop",
            "taking",
            "your",
            "prescribed",
            "dose",
            "of",
            "XTANDI",
            "without",
            "talking",
            "with",
            "your",
            "healthcare",
            "provider",
            "first",
            ".",
            "XTANDI",
            "can",
            "be",
            "taken",
            "with",
            "or",
            "without",
            "food",
            ".",
            "Swallow",
            "XTANDI",
            "capsules",
            "or",
            "tablets",
            "whole",
            ".",
            "Do",
            "not",
            "chew",
            ",",
            "dissolve",
            ",",
            "or",
            "open",
            "the",
            "capsules",
            ".",
            "Do",
            "not",
            "cut",
            ",",
            "crush",
            ",",
            "or",
            "chew",
            "the",
            "tablets",
            ".",
            "If",
            "you",
            "are",
            "receiving",
            "gonadotropin-releasing",
            "hormone",
            "(",
            "GnRH",
            ")",
            "therapy",
            ",",
            "you",
            "should",
            "continue",
            "with",
            "this",
            "treatment",
            "during",
            "your",
            "treatment",
            "with",
            "XTANDI",
            "unless",
            "you",
            "have",
            "had",
            "a",
            "surgery",
            "to",
            "lower",
            "the",
            "amount",
            "of",
            "testosterone",
            "in",
            "your",
            "body",
            "(",
            "surgical",
            "castration",
            ")",
            ".",
            "If",
            "you",
            "miss",
            "a",
            "dose",
            "of",
            "XTANDI",
            ",",
            "take",
            "your",
            "prescribed",
            "dose",
            "as",
            "soon",
            "as",
            "you",
            "remember",
            "that",
            "day",
            ".",
            "If",
            "you",
            "miss",
            "your",
            "daily",
            "dose",
            ",",
            "take",
            "your",
            "prescribed",
            "dose",
            "at",
            "your",
            "regular",
            "time",
            "the",
            "next",
            "day",
            ".",
            "Do",
            "not",
            "take",
            "more",
            "than",
            "your",
            "prescribed",
            "dose",
            "of",
            "XTANDI",
            "each",
            "day",
            ".",
            "If",
            "you",
            "take",
            "too",
            "much",
            "XTANDI",
            ",",
            "call",
            "your",
            "healthcare",
            "provider",
            "or",
            "go",
            "to",
            "the",
            "nearest",
            "emergency",
            "room",
            "right",
            "away",
            ".",
            "You",
            "may",
            "have",
            "an",
            "increased",
            "risk",
            "of",
            "seizure",
            "if",
            "you",
            "take",
            "too",
            "much",
            "XTANDI",
            ".",
            "What",
            "are",
            "the",
            "possible",
            "side",
            "effects",
            "of",
            "XTANDI",
            "?",
            "XTANDI",
            "may",
            "cause",
            "serious",
            "side",
            "effects",
            "including",
            ":",
            "Seizure",
            ".",
            "If",
            "you",
            "take",
            "XTANDI",
            "you",
            "may",
            "be",
            "at",
            "risk",
            "of",
            "having",
            "a",
            "seizure",
            ".",
            "You",
            "should",
            "avoid",
            "activities",
            "where",
            "a",
            "sudden",
            "loss",
            "of",
            "consciousness",
            "could",
            "cause",
            "serious",
            "harm",
            "to",
            "yourself",
            "or",
            "others",
            ".",
            "Tell",
            "your",
            "healthcare",
            "provider",
            "right",
            "away",
            "if",
            "you",
            "have",
            "loss",
            "of",
            "consciousness",
            "or",
            "seizure",
            ".",
            "Posterior",
            "Reversible",
            "Encephalopathy",
            "Syndrome",
            "(",
            "PRES",
            ")",
            ".",
            "If",
            "you",
            "take",
            "XTANDI",
            "you",
            "may",
            "be",
            "at",
            "risk",
            "of",
            "developing",
            "a",
            "condition",
            "involving",
            "the",
            "brain",
            "called",
            "PRES",
            ".",
            "Tell",
            "your",
            "healthcare",
            "provider",
            "right",
            "away",
            "if",
            "you",
            "have",
            "a",
            "seizure",
            "or",
            "quickly",
            "worsening",
            "symptoms",
            "such",
            "as",
            "headache",
            ",",
            "decreased",
            "alertness",
            ",",
            "confusion",
            ",",
            "reduced",
            "eyesight",
            ",",
            "blurred",
            "vision",
            "or",
            "other",
            "visual",
            "problems",
            ".",
            "Your",
            "healthcare",
            "provider",
            "will",
            "do",
            "a",
            "test",
            "to",
            "check",
            "for",
            "PRES",
            ".",
            "Allergic",
            "Reactions",
            ".",
            "Allergic",
            "reactions",
            "have",
            "happened",
            "in",
            "people",
            "who",
            "take",
            "XTANDI",
            ".",
            "Stop",
            "taking",
            "XTANDI",
            "and",
            "get",
            "medical",
            "help",
            "right",
            "away",
            "if",
            "you",
            "develop",
            "swelling",
            "of",
            "the",
            "face",
            ",",
            "tongue",
            ",",
            "lip",
            "or",
            "throat",
            ".",
            "Heart",
            "disease",
            ".",
            "Blockage",
            "of",
            "the",
            "arteries",
            "in",
            "the",
            "heart",
            "(",
            "ischemic",
            "heart",
            "disease",
            ")",
            "that",
            "can",
            "lead",
            "to",
            "death",
            "has",
            "happened",
            "in",
            "some",
            "people",
            "during",
            "treatment",
            "with",
            "XTANDI",
            ".",
            "Your",
            "healthcare",
            "provider",
            "will",
            "monitor",
            "you",
            "for",
            "signs",
            "and",
            "symptoms",
            "of",
            "heart",
            "problems",
            "during",
            "your",
            "treatment",
            "with",
            "XTANDI",
            ".",
            "Call",
            "your",
            "healthcare",
            "provider",
            "or",
            "go",
            "to",
            "the",
            "nearest",
            "emergency",
            "room",
            "right",
            "away",
            "if",
            "you",
            "get",
            "chest",
            "pain",
            "or",
            "discomfort",
            "at",
            "rest",
            "or",
            "with",
            "activity",
            "or",
            "shortness",
            "of",
            "breath",
            "during",
            "your",
            "treatment",
            "with",
            "XTANDI",
            ".",
            "Falls",
            "and",
            "fractures",
            ".",
            "XTANDI",
            "treatment",
            "may",
            "increase",
            "your",
            "risk",
            "for",
            "falls",
            "and",
            "fractures",
            ".",
            "Falls",
            "were",
            "not",
            "caused",
            "by",
            "loss",
            "of",
            "consciousness",
            "(",
            "fainting",
            ")",
            "or",
            "seizures",
            ".",
            "Your",
            "healthcare",
            "provider",
            "will",
            "monitor",
            "your",
            "risks",
            "for",
            "falls",
            "and",
            "fractures",
            "during",
            "treatment",
            "with",
            "XTANDI",
            ".",
            "Your",
            "healthcare",
            "provider",
            "will",
            "stop",
            "treatment",
            "with",
            "XTANDI",
            "if",
            "you",
            "have",
            "serious",
            "side",
            "effects",
            ".",
            "The",
            "most",
            "common",
            "side",
            "effects",
            "of",
            "XTANDI",
            "include",
            ":",
            "weakness",
            "or",
            "feeling",
            "more",
            "tired",
            "than",
            "usual",
            "back",
            "pain",
            "hot",
            "flashes",
            "constipation",
            "joint",
            "pain",
            "decreased",
            "appetite",
            "diarrhea",
            "high",
            "blood",
            "pressure",
            "XTANDI",
            "may",
            "cause",
            "fertility",
            "problems",
            "in",
            "males",
            ",",
            "which",
            "may",
            "affect",
            "the",
            "ability",
            "to",
            "father",
            "children",
            ".",
            "Talk",
            "to",
            "your",
            "healthcare",
            "provider",
            "if",
            "you",
            "have",
            "concerns",
            "about",
            "fertility",
            ".",
            "These",
            "are",
            "not",
            "all",
            "the",
            "possible",
            "side",
            "effects",
            "of",
            "XTANDI",
            ".",
            "Call",
            "your",
            "doctor",
            "for",
            "medical",
            "advice",
            "about",
            "side",
            "effects",
            ".",
            "You",
            "may",
            "report",
            "side",
            "effects",
            "to",
            "FDA",
            "at",
            "1-800-FDA-1088",
            ".",
            "How",
            "should",
            "I",
            "store",
            "XTANDI",
            "?",
            "XTANDI",
            "capsules",
            "and",
            "tablets",
            "come",
            "in",
            "a",
            "child-resistant",
            "bottle",
            ".",
            "Store",
            "XTANDI",
            "capsules",
            "and",
            "tablets",
            "between",
            "68\u00b0F",
            "to",
            "77\u00b0F",
            "(",
            "20\u00b0C",
            "to",
            "25\u00b0C",
            ")",
            ".",
            "Keep",
            "XTANDI",
            "capsules",
            "and",
            "tablets",
            "dry",
            "and",
            "in",
            "a",
            "tightly",
            "closed",
            "container",
            ".",
            "Keep",
            "XTANDI",
            "and",
            "all",
            "medicines",
            "out",
            "of",
            "the",
            "reach",
            "of",
            "children",
            ".",
            "General",
            "information",
            "about",
            "the",
            "safe",
            "and",
            "effective",
            "use",
            "of",
            "XTANDI",
            ".",
            "Medicines",
            "are",
            "sometimes",
            "prescribed",
            "for",
            "purposes",
            "other",
            "than",
            "those",
            "listed",
            "in",
            "a",
            "Patient",
            "Information",
            "leaflet",
            ".",
            "Do",
            "not",
            "use",
            "XTANDI",
            "for",
            "a",
            "condition",
            "for",
            "which",
            "it",
            "was",
            "not",
            "prescribed",
            ".",
            "Do",
            "not",
            "give",
            "XTANDI",
            "to",
            "other",
            "people",
            ",",
            "even",
            "if",
            "they",
            "have",
            "the",
            "same",
            "symptoms",
            "that",
            "you",
            "have",
            ".",
            "It",
            "may",
            "harm",
            "them",
            ".",
            "You",
            "can",
            "ask",
            "your",
            "healthcare",
            "provider",
            "or",
            "pharmacist",
            "for",
            "information",
            "about",
            "XTANDI",
            "that",
            "is",
            "written",
            "for",
            "health",
            "professionals",
            ".",
            "What",
            "are",
            "the",
            "ingredients",
            "in",
            "XTANDI",
            "?",
            "XTANDI",
            "capsules",
            "Active",
            "ingredient",
            ":",
            "enzalutamide",
            "Inactive",
            "ingredients",
            ":",
            "caprylocaproyl",
            "polyoxylglycerides",
            ",",
            "butylated",
            "hydroxyanisole",
            ",",
            "butylated",
            "hydroxytoluene",
            ",",
            "gelatin",
            ",",
            "sorbitol",
            "sorbitan",
            "solution",
            ",",
            "glycerin",
            ",",
            "purified",
            "water",
            ",",
            "titanium",
            "dioxide",
            ",",
            "black",
            "iron",
            "oxide",
            ".",
            "XTANDI",
            "tablets",
            "Active",
            "ingredient",
            ":",
            "enzalutamide",
            "Inactive",
            "ingredients",
            ":",
            "hypromellose",
            "acetate",
            "succinate",
            ",",
            "microcrystalline",
            "cellulose",
            ",",
            "colloidal",
            "silicon",
            "dioxide",
            ",",
            "croscarmellose",
            "sodium",
            ",",
            "and",
            "magnesium",
            "stearate",
            ".",
            "The",
            "tablet",
            "film-coat",
            "contains",
            "hypromellose",
            ",",
            "talc",
            ",",
            "polyethylene",
            "glycol",
            ",",
            "titanium",
            "dioxide",
            ",",
            "and",
            "ferric",
            "oxide",
            ".",
            "Manufactured",
            "for",
            "and",
            "Distributed",
            "by",
            ":",
            "Astellas",
            "Pharma",
            "US",
            ",",
            "Inc.",
            ",",
            "Northbrook",
            ",",
            "IL",
            "60062",
            "Marketed",
            "by",
            ":",
            "Astellas",
            "Pharma",
            "US",
            ",",
            "Inc.",
            ",",
            "Northbrook",
            ",",
            "IL",
            "60062",
            "Pfizer",
            "Inc.",
            ",",
            "New",
            "York",
            ",",
            "NY",
            "10017",
            "316386-XTA-USA",
            "\u00a9",
            "2020-21",
            "Astellas",
            "Pharma",
            "US",
            ",",
            "Inc.",
            "XTANDI",
            "is",
            "a",
            "registered",
            "trademark",
            "of",
            "Astellas",
            "Pharma",
            "Inc.",
            "For",
            "more",
            "information",
            "go",
            "to",
            "www.Xtandi.com",
            "or",
            "call",
            "1-800-727-7003",
            ".",
            "This",
            "Patient",
            "Information",
            "has",
            "been",
            "approved",
            "by",
            "the",
            "U.S.",
            "Food",
            "and",
            "Drug",
            "Administration",
            ".",
            "Revised",
            ":",
            "October",
            "2020"
        ]
    }
]